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Ageing is currently the inevitable consequence of human existence. The ageing process is a disease that 
internally imposes limitations and reductions in liberty through enfeeblement, frailty and pathology, 
leading to dramatic physiological and psychological suffering. Therefore, it is paramount we identify 
immediate strategies which defer the progression of age-associated diseases and compress morbidity.  
At present, calorie restriction (CR) offers the most feasible and robust intervention to decelerate ageing. 
However, despite the attractive pro-longevity effects of CR, several concerns surrounding the 
applicability, tolerability and safety have precluded its widespread adoption. Using the Connectivity Map 
to identify drugs with a similar transcriptome to CR, I sought to repurpose a clinically approved drug that 
demonstrated broad tolerability and safety whilst representing an easily translatable, potential calorie 
restriction mimetic. 
I identified rilmenidine: a widely-prescribed, centrally-acting antihypertensive that mimicked gene 
expression changes previously observed in CR. Furthermore, rilmenidine significantly opposed the 
transcriptional direction of ageing such that it rescued age-associated overexpression of genes enriched 
for immune-regulation, inflammation and ECM degradation.   
I validated the potential geroprotective properties of rilmenidine in the model organism C. elegans. 
Rilmenidine administration extended lifespan in WT worms, when commenced from early adulthood or 
only once the worm had aged. Furthermore, it decelerated the development of decrepitude, without 
altering developmental periods. Lifespan extension was not possible in genetic models of CR (eat-2), 
suggesting a longevity effect was induced through CR mimicry. Moreover, this was supported by 
rilmenidine-induced lifespan effects being dependent on 3 key CR nexuses: DAF-16, AMPK and TOR. 
In C. elegans, Rilmenidine elicited increases in ERK activity, typical of in-vitro imidazoline agonist 
exposure, which was abrogated following blockade of an imidazoline binding site. This effect was 
mimicked following the knockout of f13e9.1, which was characterised herein as the nematode ortholog 
of the human imidazoline type 1 receptor (IRAS). Indeed, rilmenidine also increased nematode 
thermotolerance as well as autophagy, both dependent on imidazoline binding, and demonstrated a 
capacity to attenuate the accumulation of polyQ aggregates. Autophagy was essential to the longevity 
effect of rilmenidine and was increased independent of the previously hypothesised cAMP pathway.  
Thus, this research presents a strong novel case for rilmenidine to be a CR mimetic that warrants 
substantial clinical investigation as to the auxiliary benefits of rilmenidine which may belie its overt 
purpose as an anti-hypertensive, such that it be preferentially prescribed to hypertensives which provides 
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1.1.  A Meditation on The Purpose of Ageing Research And The Acceptance of Death As a 
Postponable But Necessary Inevitability 
1.1.1. Immortality Quests To Buffer Mortality Salience  
The inevitability of death fascinates, haunts and compels human existence. Indeed, life itself must be 
defined by limitation to exist; the immutability of transience is inextricably woven into the fabric of reality. 
Hence, a sense of moribund impermanence has been ingrained into the human psyche and thus, not 
unsurprisingly, man has sought to soothe his mortal soul in the contemplation of immortality. 
Humanity’s oldest recorded tale, the Sumerian epic of “Gilgamesh”, written during the latter half of the 
third millennium, vicariously confronts transcendent immortality with all its desperation, greed and wisdom 
(Dalley, 2000).  Gilgamesh was a demi-god king who became tortured by the prospect of his own 
mortality. Initially told that he would be given rule over the city of Urak in lieu of immortality, he accepts 
his fate and seeks to become The Great Ruler, escribing his legacy into history to remain long after his 
physical departure. However, this joie-de-vivre soon evaporates, when his rampaging and narcissistic 
adventures, are punished by the Gods through the death of his good friend Enkidu. Petrified by cold 
reality of his impending fate, Gilgamesh revolts against death, denouncing it as an evil crime against the 
ordered and good universe (Mason, 1970.). He begs the Gods to let him live forever and is promised 
immortality upon the completion of two tasks: firstly, to remain awake for 6 days and 7 nights, and 
secondly to retrieve the flowers of life, from a river bed. Alas, encumbered by his earthly limitations, 
Gilgamesh falls woefully short and eventually resigns himself to his fate, proclaiming, “Only the gods live 
forever . . . As for mankind, numbered are their days; Whatever they achieve is but the wind!" (Starr, 
2010).  
The themes of this tale have been echoed throughout the ages, universally in all cultures: an imprudent 
quest for longevity, driven by an egocentric fear of death, fruitless in its conclusion. The desire for 
immortality, routinely presented in literature and mythology, is thought to tame and buffer our sense of 
vulnerability and impermanence. The human mind is remarkably complex in its self-awareness and thus 
the comprehension that life must end, when juxtaposed with the Darwinian predisposition for the 
continuation of life, provides Mankind with an unprecedented level of existential anxiety (Landau et al., 
2007).  As asserted in the Terror Management Theory, in order to avoid this continuous confrontation, 
society has constructed cultural worldviews that give meaning to life and enduring value and significance 
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unto themselves (Pyszczynski et al., 2015). Through the adoption of social roles and the consequent 
satisfaction of standards of value, one’s social and cultural worth is increased leading to a sense of self-
worth and esteem (Pyszczynski et al., 2004). In this instance, the contemplation of death is so costly, that 
the creation of literary, mythical and religious worlds is a necessity to provide a context of unceasing 
heroism. Likewise, participation in cultural values enables people to feel part of something larger, more 
significant, and more eternal than their mortal self, thereby imbuing the finitude of life with meaning 
(Pyszczynski et al., 1997). In turn their contribution and legacy may live on and offer symbolic immortality, 
as attempted by Gilgamesh in early parts of his epic. Belief systems, religions and stories that denied the 
finality of death may have evolved and grown in part due to their all-encompassing and compelling offer 
of literal immortality (Yetzer, Pyszczynski & Greenberg, 2018). Whilst such offers of immortality have 
been a mainstay in mythology and literature for most of humanity, the development of radical lifespan 
extension as a rational and diligently pursued narrative to off-set the final confrontation, has been 
prominent since the age of enlightenment (Cave, 2012). Such endeavours constitute the Elixir story of 
Cave’s four main death-denial mechanisms; the others comprising of resurrection, continuation of the 
soul and symbolic eternity in your legacy (Cave, 2012). Whilst most anti-aging interventions were literary 
and symbolic rather than plausible, as early as 1550, the paradigm had shifted to more conservative and 
achievable perceptions of lifespan extension: Luigi Comaro’s Art of Living Long, espoused sage advice 
on the importance of moderation in the maintenance of vitality into old age. Considered by some to be 
the first book of dieting, its popularity has had a profound influence on the modification of lifespan and 
only the Bible and the Koran have had more re-printings (Hayflick, 2006).  
Throughout the following centuries, concepts of fighting the ageing process matured, the prospects of 
entirely defeating the laws of entropy eroded, and the preservation of functionality in old age became 
paramount (Stambler, 2014). However, to dismiss all early meditations on radical longevity as charlatan 
whims, would serve to be blind to the wealth of biomedical contributions that the quest for lifespan 
extension has offered. Indeed, whilst the motivation was to find the elixir of youth, along the way pre 20th 
century life-extension attempts have produced the modern hormone replacement therapy or therapeutic 
endocrinology at large, the benefits of probiotic diets, and adjuvant-driven immunotherapy (Stambler, 
2014).  
During the early 20th century, rejuvenative anti-aging science became a well-established scientific field 
with hundreds of publications on the subject in the years preceding the 2nd World War (Stambler, 2014). 
But such research remained speculative and primarily academic: real changes in average lifespan were 
occurring through the direct treatment of disease. Often considered the greatest human accomplishment 
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of the last century, from the beginning of the 20th century, and the 110 years that followed, life expectancy 
in the Western world nearly doubled (Oeppen and Vaupel, 2002). This remarkable and indirect increase 
in lifespan expectancy came primarily through the reduction of childhood mortality mediated by 
improvements in basic public healthcare. In the first half of the 20th century, average life expectancy from 
birth, increased by nearly 20 years owing to improved sanitation and working conditions, better nutrition 
and housing, organized sewage disposal, improved animal and pest control, water chlorination, national 
vaccination programs, development of antibiotics and better medical practice (Fontana, 2009). Thus, the 
infectious disease model emerged for increasing lifespan. Quicker and more lucrative lifespan returns 
were possible via a whack-a-mole style treatment of emergent societal diseases. The epidemiological 
transition of life expectancy and an improved economic situation led to the replacement of infectious 
diseases with the chronic sequalae of non-communicable diseases (Omran, 2005). In this vein, the latter 
half of the 20th century saw more modest reductions in mid-life mortality through the curtailment of the 
emanating heart disease epidemic which was treated by advances in pharmaceutical cholesterol and 
hypertension control (Clarke et al., 2009).  Subsequently, this resulted in an increase in UK life 
expectancy of approximately 10 years between 1950 and 2000 (Office for National Statistics, 2019).  In 
the 21st century, earnest battles against cancer, Alzheimer’s Disease (AD) and other age-associated 
disease have been continuing with ongoing progress in reducing mortality rates. Life expectancy has 
grown linearly for nearly 100 years now, but the maximum achieved lifespan has entirely plateaued since 
the 1990s and the length of a healthy life span has remained unchanged (Vaupel, 2010; Robine and 
Cubaynes, 2017; Lakdawalla et al., 2004). A distribution shift has occurred and death  and morbidity have 
been concentrated at older ages: the failure of success (Gruenberg, 1977). Children born in this decade 
have an 85% chance of dying after 65 years from aged-related diseases far more complex, intertwined 
and chronic than previous models (Olshansky, 2015). Diminishing returns are inevitable as life 
expectancy approaches maximum lifespan and thus an emergent Faustian bargain has been proposed 
(Olshansky, 2017). 
Faust, the eponymous character of Goethe’s magnum opus, was a fictitious scholar, much loved by God. 
His virtuous quest for erudition attracted the attention of Mephistopheles, the Germanic folklore demon. 
Becoming increasingly unsatisfied and despairing at the vanity of scientific, humanitarian and religious 
learning, Faust turned to magic for the showering of infinite knowledge. Mephistopheles tempts Faust 
into unlimited knowledge and pleasure for a limited time in exchange for his soul, which he duly agrees. 
Comparatively, human desire for immortality appears insatiable, and such rapid and profitable returns in 
lifespan have of course been met with a Faustian-like price in the burden of disease, increased financial 
costs of care and pension schemes met with an aged and infirm population (Olshansky, 2017).  
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As discussed, previous gains in life expectancy were mostly due to reductions in mortality and as such 
the Cave’s elixir of life has remained elusive. Disease and death are still inescapable, merely in abeyance, 
in echo to Goethe’s tale. However, policy makers today continue to pursue the current medical model of 
disease treatment offering incrementally diminishing growth in life expectancy. The Department of Health 
and Social Care policy paper intends  to improve healthy life expectancy by an additional 5 years by 
2035, through preventative healthcare (Department of Health and Social Care, 2019). This is a noticeably 
conservative outlook formulated on a remodeling of cardiovascular disease prevention of the 70’s 
targeted to contemporary problems of obesity, alcohol consumption and sleep deprivation (Cheung, 
2018; Department of Health, 2016). Whilst this strategy has been excellent at improving quality of life for 
those at risk of premature disease, it offers little distraction from the salience of mortality and the fear of 
impending suffering and frailty which is a narrative not everyone is willing to follow (Fontana et al., 2014).  
As early as 1956, the concept of replacing the single disease model with an anti-aging model was being 
formalised as evidenced by McCay et al. concluding that treating ageing itself would be, “retarding the 
onset of certain chronic terminal illnesses” (McCay et al., 1956). Ageing represents a major risk factor for 
a  cluster of diseases with a conjoined causal process and delaying it could offset the co-morbidities of 
frailty (Niccoli and Partridge, 2012). Those willing to pursue this hypothesis over the last 25 years have 
been able to improve the health and lifespan of model organisms, from worms and flies, to rodents and 
fish, in turn increasing the length of disease-free life and postponing age-related disease (reviewed in: 
Bulterijs et al., 2015). But such remarkable results were met with cynicism within the gerontological 
community. The interspecies and even intraspecies ageing phenotype is complex and variable, with many 
considering ageing merely an unavoidable  culmination of stochastic damage (Martin, 2002; Finch and 
Kirkwood, 2000; Gems, 2015). As such, ageing is rendered intractable. Amelioration of the impact of one 
type of ageing-related damage would leave the majority unaffected and would therefore have little impact 
on overall ageing-related decline (Partridge, 2010). This sentiment is echoed to this day in approaches 
to geriatric medicine. Although care may be tailored towards old-age, geriatricians still focus their efforts 
on the treatment of individual ailments within the elderly with little holistic direction from gerontological 
research. This is at odds to other specialties such as oncology that routinely draw on basic translatable 
guidelines established from sizeable and well-funded research communities (Hayflick, 2004; Nikolich-
Žugich et al., 2016; Witham et al., 2019).  
Furthermore, a dichotomous perception of pro-longevity research has existed in the public. Bolstered by 
societal desires for immortality, research into the field of ageing can appear seductive and intriguing, 
whilst simultaneously, transgressive, suspicious, and even dangerous (Fishman et al., 2008) . If the public 
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were to contemplate such a field of research, it could spark anxieties and existential threats of 
inescapable death and fallibility (Martens et al., 2005). This, in line, with the continuously evolving 
complexities of ageing and an historical perception of transgressions and immorality has led geroscience 
into a form of “forbidden knowledge” (Kempner et al., 2005). As such the public have, until recently,  been 
largely unaware or unable to digest the benefits of prolongevity research and, in fact, misinterpretation 
and fear of radical societal change, through improper distillation of legitimate research has been a 
considerable challenge to gerontology (Sethe and de Magalhães, 2013). The truthful non-specialist 
communication of advances in geroscience is in constant conflict with mainstream demonization of old-
age and bashful boundary science (van Wijngaarden et al., 2018; Cole and Cole, 2014). As, succinctly 
expressed by Baars, society is experiencing an increasingly prevalent sense of “premature cultural 
senescing”, driven by an acceleration of information and compression of time (Baars, 2012). The 
dominant preference throughout modernity for the new or most advanced item has in late modernity come 
to include “young” (Baars, 2012). Such perception denigrates and undermines the utility and wisdom of 
ageing whilst wrongly glorifying the necessity of youth. Old age has become something to fear and avoid 
at all costs, a concept lapped up by a $42.51 billion anti-ageing industry (Orbis Research, 2018). On a 
background of paradoxically increasing chronic morbidity and decreasing mortality, the sufferance of 
ageing  has led to widespread public revulsion of growing old, and its association with loneliness, 
isolation, powerlessness and uselessness (Gilleard, 2018). Thus, it is that unsurprising the public often 
consider lifespan extension a Tithonian Error. 
1.1.2. The Tithonian Error: Healthspan As A Vital Component of Geroprotection  
In the Pio Monte della Misericordi, a Neapolitan church, hangs a baroque painting  by De Mura of the 
blonde female deity Eos, celestially poised and surrounded by love-putti, little angels, and maidens 
scattering flowers. Below, shielding his eyes is a withered and incongruous Tithonius, wearisomely 
slumped on a rock, for there he has been laid in solitude, burdening them both by his incapacity. Eos, 
had previously seduced the once young and vivacious son of Troy, Tithonius, and for years they had 
lived rapturously, but as the first grey hairs began to ripple from his comely head and noble chin, Eos 
was reminded of their disparate fates (Mordini, 2015). Despondent about Tithonus’s inevitable demise, 
Eos naively begged her father, Zeus, to accord Tithonius with immortality. However, perfidious Zeus 
displeased with his daughter’s infatuation with a mortal, deceivingly granted Tithonius eternality but not 
eternal youth. Thus, as the Homeric hymn goes, “when loathsome old age pressed full upon him, and he 
could not move nor lift his limbs, this seemed to her in her heart the best counsel: she laid him in a room 
and put to the shining doors. There he babbles endlessly, and no more has strength at all, such as once 
he had in his supple limbs” (Hine, 1970).  
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Tithonius’ folly represents the publicly perceived threat of lifespan extension: an ever-increasing lifespan, 
but at the cost of progressive enfeeblement, ill health and dementia. Whether such beliefs may be merely 
irrational responses to mortality salience or a media-manipulated perspective of valueless infirmity in old-
age, public ambivalence on the benefits of lifespan extension are apparent. A survey by the Pew 
Research Centre found a majority (57%) of individuals would refuse medical intervention to live to 120, 
with only 9% of participants wishing to live beyond 100 at all with current medical capabilities (Pew 
Research Centre, 2013). Freudian scepticism would argue this is more fear of infirmity than an honest 
wish for limited finitude: Freud viewed the discussion of death as lip-service and in reality, “our 
unconscious does not believe in its own death; it behaves as if immortal. At the bottom no one believes 
in his own death” (Furer and Walker, 2008). Against the former, research is repeatedly showing that 
lifespan extension offers more than just years of life, but life in years. Built into increases in lifespan can 
be a “compression of morbidity”: a phrase coined by James Fries in 1980 (Fries, 1980). The truth in this 
dichotomy is no better exemplified than in humans. Approximately 90% of centenarians are  functionally 
independent at the average age of 92 years, requiring no mobility support or daily intervention (Perls, 
2006). But not only those lucky enough to live naturally to 100 can enjoy the freedom of health in later 
life: a growing body of interventions can elicit even more spectacular pro-longevity morbidity 
compressions in model organisms.  
Using the term “healthspan”, scientists have used murine models to demonstrate how frequently 
prescribed pharmaceuticals can be used to extend the life of the animal in conjunction with increased 
disease-free survival and improved functionality into old age. Specifically, the administration of metformin, 
a first line treatment for diabetes, has the capacity to increase mean lifespan in female outbred mice by 
~40%, whilst also increasing healthspan by ~30% (Anisimov et al., 2008; Allard et al., 2016). This is 
reinforced by retrospective evidence in humans that type-2 diabetics treated with metformin had survival 
rates similar to (and, among those age > 70, even better than) their matched non-diabetic control group 
(Bannister et al., 2014). As follow-up, preliminary trials in healthy human beings to reduce morbidity and 
extend healthspan/lifespan using metformin are in process (Hall, 2015).  
Moreover, additional murine work has demonstrated that rapamycin, an immunosuppressive therapy for 
kidney transplant, has the capacity to increase median lifespan by up to ~30%, further thrusting the 
concept of pharmaceutical intervention for increased lifespan and disease compression into the limelight 
(Johnson et al., 2014). However, in this instance, the healthspan benefits have been less clear-cut. Whilst 
several laboratories have shown rapamycin to slow numerous physiologic metrics ofageing, including 
liver degeneration, myocardial abnormalities, endometrial hyperplasia and non-lethal adrenal tumours, 
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disturbingly, other labs have shown the adverse effect of increasing cataract formation and testicular 
degeneration in male mice (Wilkinson et al., 2012). Therein lies the first problem of directing interventions 
at ageing itself: the effects of targeting an upstream process as far-reaching as ageing, given its 
reconditeness and myriad nature, may lead to malapropos ancillary effects beyond mere survival. This is 
well-exemplified when considering the delicate balance of fecundity and lifespan. An established inverse 
correlation between the two exists, whereby, in nature, longer lifespans are associated with decreased 
fecundity (Read and Harvey, 1989; Partridge et al., 2005; Holmes et al., 2001). Furthermore, anti-ageing 
interventions, including rapamycin, that increase lifespan, tend to accentuate this trade-off (Reznick et 
al., 2000; Bjedov et al., 2010). Thus, when considering their applicability, in the knowledge of potential 
limitations, there exists a continued sense of circumspection and suspicion. However, it is important to 
note that as research continues into the underlying mechanisms of ageing, and relationships between 
other capacities are established, the accuracy of interventions are likely to improve. Yet, the relatively 
long lifespan of humans makes for unprecedented longitudinal study of efficacy and off-site target that 
would bring into question the justification of research costs and ethical conditions.     
Additionally, many of the most striking and unexpected interventions have been genetic, some through 
the manipulation of single genes (Kenyon et al., 1993). Of course, this raises clear, multi-disciplinary 
concerns surrounding the ethical pillars of medical research, and of course, such basic genetic 
manipulation is currently limited to animal models. With that said, the genetic tractability and malleability 
of the animal ageing process has spearheaded research over the last 30 years; genetic interventions 
have increased healthy lifespan across taxa including mammalian models. In particular, single mutations 
in nematodes have offered the most robust lifespan extension that has been recorded in a laboratory, 
with deletion of daf-2 doubling C. elegans lifespan, and homozygous nonsense mutations in the age‐1 
gene providing a near 10-fold increase (Kenyon et al., 1993; Ayyadevara et al., 2008). This is perhaps 
the greatest achievement of the gerontological field to date, and arguably the driving force behind the 
surge in popularity of ageing research. Kenyon excellently summarises this sense of hope: “which genes 
can extend lifespan? Can we augment their activities and live even longer? After centuries of wistful 
poetry and wild imagination, we are now getting answers, often unexpected ones, to these fundamental 
questions.” (Kenyon, 2010).   
1.1.3. Expediting The Cure For Ageing Through Bio-Tech Investment 
The devilish tangibility of truly modifying the ageing process, the end of mortality, has proved too tempting 
for the capitalist fist, and as such Mephistopheles has come to rear his head again. Some of the largest 
companies in the world, Google and Facebook, with limitless capital have set up shop firmly at the 
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forefront of biogerontology with profit in mind (Scott and DeFrancesco, 2015). Investment in longevity is 
by no means new; The National Institute of Ageing has existed since the 70’s: but the level of public and 
corporate interest is unprecedented, and the numbers are astonishing. In 2018, 145 anti-aging clinical 
trials were initiated and over $800 billion of private investment was pumped in longevity start-ups. In 
August 2018, Samumed raised $438 million in equity funding, a stunning investment for a company that, 
while promising, still has no approved drugs (CBS Insights, 2018.). Furthermore, Unity Biotech has 
received more than $300 million in funding with key investment from Amazon founder Jeff Bezos and 
PayPal co-founder Peter Thiel; they too have no clinically approved products (CBS Insights, 2018). It is 
undoubtable that recent advances in ageing research have accelerated the slurry of investment, but 
something more visceral must be at play as logic does not favour this sector. If history is anything to go 
by, longevity research is a terrible bet; there are no success stories.  It could be argued there exists little 
difference from the alchemists of the middle ages, or the gland grafters of the early twentieth century, or 
the hormone vendors now peddling their wares, to the modern practitioners of anti-aging medicine whom 
endeavour to convince the public the fountain of youth is near (Olshansky, 2017). No where is this more 
obvious than the collapse of Sirtis, a start-up company selling a resveratrol analogue which was 
purchased by GSK for $750 million, only to be shut down after clinical trials showed it caused unexpected 
safety concerns (Popat et al., 2013). Furthermore, Faustian-like prices are being paid for unproven 
cryonic preservation, as individuals pay over £100,000 for the distant possibility that in the future, science 
may have solved the currently unassailable task of bringing a frozen human back to life (Jones, 2013).   
But for Silicon Valley, the epicentre of death denial, no price is too high and furthermore, understanding 
isn’t a precondition for successful intervention. Whilst the desire for immortality or rather agelessness has 
long existed, a viable vehicle to realistically carry that desire is only recent; Ponce de Leon was merely 
too early. Death denial is no longer an abstract condition, but a mission statement for the resolution of a 
purely technological challenge which requires minor reprogramming of the “ageing bug”. Tech-prophets 
of Silicon Valley with their doctrines of immortality have inevitably appealed to a Western American 
society losing faith in religious notions of heavenly immortality, believing instead in the power of 
technology and science to save humanity. The San Francisco Bay Area is among the least religious areas 
of the US, according to the Pew Research Center, with only 42% of adults saying they believe in God 
with absolute certainty (Pew Research Center, 2018). Psychological research supports this idea: 
individuals with low religiosity exposed to indefinite lifespan extension propaganda measurably reduce 
their belief of an afterlife in favour of lifespan extension (Lifshin et al., 2018).  
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The denizens of Silicon Valley are no longer satisfied by the power of their legacy, their symbolic 
immortality; they secured symbolic immortality when their ideas became household names which 
revolutionised the Western World as we knew it. And seduced by the hubris of their success, some 
believe these technocrats take themselves seriously enough to consider their immortality or delayed 
death in humanity’s best interests (Begley, 2018). After all, the desire for immortality could be considered 
the ultimate expression of narcissism or perhaps for Silicon Valley to conquer death would be the ultimate 
humanitarian achievement.  
In the Western world, food is omnipresent, water systems are clean, vaccinations prevent disease and 
yet the problem of death remains unresolved. It is ironic therefore, whilst many third world countries still 
lack the basic necessities for civilised life, that Silicon Valley should pursue the luxurious concept of 
immortality: the final inequality. 
1.1.4. The Expedience of Anti-Aging Medicine As a Moral and Economic Obligation 
Importantly though, and despite commitment and appeal from leading scientists, any field looking to gain 
significant institutional and charitable momentum, must offer more than a narcissistic escape from the 
salience of mortality (Bulterijs et al., 2015). Thus, the reclassification of ageing as a disease that needs 
offsetting and which maintains focus on fundamental ageing mechanisms, rather than on “age-related 
disease” serves to resolve one’s scepticism on the medical utility of studying ageing. This dilemma has 
been fiercely debated in literature (Gladyshev and Gladyshev, 2016). Individuals, still dissatisfied with 
geroscience’s purpose, would argue that a disease must require pathology, and a deviation from the 
norm (Faragher, 2015). Given that ageing is inevitable in every individual, like puberty, maturation and 
fertilisation, it should be considered a normal and natural process and therefore not a disease that 
requires treatment (Caplan, 2005). If ageing is not a disease then anti-ageing is merely human 
enhancement and a selfish transgression from nature (Gems, 2011; Juengst et al., 2003; Rantanen, 
2014). However, the universality of ageing does not negate the consideration of ageing as a disease, 
rather it exaggerates it as a special type of disease (Gems, 2011a). The logic of medicine is predicated 
on the belief that disease is a state in which the limits of what is normal have been transgressed resulting 
in any abnormality of bodily structure or function, other than those arising directly from physical injury 
(Bulterijs et al., 2015; Caplan, 2005). Ageing is a process characterised by accumulative transgressions 
from the norm and broad spectrum of pathology which will inevitably lead to death, the ultimate pathology. 
Surely, ageing must have a prima facie claim to being counted as a disease? Moreover, the failure to 
define ageing as a disease is a dangerous one as it creates an intellectual barrier and disincentivises 
research (Faragher, 2015). Yet, some would argue that any attempt to counter the concept of ageing 
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would be fruitless and a waste of money. Specifically Gladyshev and Gladeyshev, fear a misallocation of 
economic and social resources to a futile cause, where the only result might be to prolong periods of 
illness and/or pain (Gladyshev and Gladyshev, 2016). Furthermore, normality and universality have an 
inescapable sense of benignancy, a naturalistic fallacy based on the consideration that all which is natural 
must be “good”. Ageing roots out the weak and makes way for the young and therefore it is in our best 
interest to grow old for the furtherance of mankind. Faragher equates this fallacious logic to the erroneous 
belief that avalanches, volcanoes and tsunamis must be good (because they are natural) whilst books, 
houses and clothing are bad (because they are not found in nature) (Faragher, 2015). Normality and 
universality does not mean harmlessness. Malignant neoplasms, viral infections, gingivitis, acne and 
hypertension are all ubiquitous phenomena, yet medicine does not reject these as untreatable. Even if 
one continues to rationalise these as separate entities to ageing, natural processes such as pregnancy, 
although not a “disease” per se, remain an accepted target for prevention in the form of contraception 
(Boorse, 1975). Lastly, the recategorization of ageing as a disease would at least offer some FDA-
approved regulation to prevent the swindling of anti-ageing products to the vulnerable elderly (Mehlman 
et al., 2004) .  
So, it follows that if ageing should be considered a disease which routinely imparts dramatic physiological 
and psychological suffering, is not the moral obligation of the medical community to do their utmost to 
reduce such consequences? It is strange that biogerontology has been forced to justify the ethics behind 
its endeavours when the ageing phenotype seamlessly moves between AD, cancer and macular 
degeneration, all areas of research which have never remotely required justification of their pursuit. The 
purpose of medicine must follow the universal moral principle that good is to be done and evil avoided 
(Andorno and Baffone, 2014). Suffering is an intrinsic evil and thus there is a moral duty to prevent human 
suffering. As stated by Karl Popper: “human suffering makes  a  direct  moral  appeal,  namely,  the  
appeal  for  help,  while  there  is  no  similar  call  to increase the happiness of a man who is doing well 
anyway” (Popper, 2003). Thus, provided biogerontological research continues to extend lifespan for the 
purpose of offsetting or compressing the physical and psychological suffering associated with 
senescence, and not for vain enhancement, there should be little moral objection.  
However, as expressed earlier in this chapter, deceleration of ageing that provides protection against the 
full spectrum of diseases of ageing thereby assuring late-life health extension does unfortunately come 
with an incidental corollary of increased lifespan, which as we have touched on, has thrown up some 
objection. This is not lifespan extension in the realms of medical immortality but a likely average lifespan 
of 112 years, and a maximum lifespan of 140 (Miller, 2002). Nonetheless, are these extra years simply a 
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postponement of the inevitable? Will people still die of the same diseases only a few decades later? Of 
course, they will. It would be foolish to assume that the deceleration of ageing would somehow provide a 
complete escape of age-associated disease. There is no such thing as life time protection against 
pathology, only deferral of pathology: a concept championed by Gems and Blagosklonny (Gems, 2015; 
Blagosklonny, 2006). But what is the alternative: the willful acceptance of premature suffering and death? 
Mankind is Inherently and genetically programmed to fear of death and will always choose life free from 
disease over death (de Magalhaes, 2018). I suspect, many would choose AD tomorrow rather than today. 
However, notably, the deceleration of ageing comes with no cure. Researchers are thus morally obliged 
to “continue on indefinitely, seeking ever greater decelerations of ageing, ever later postponements of 
illness and greater extensions of lifespan” (Gems, 2011a). But under the current model of disease and 
medicine this is the only prescription (Callahan, 2018). Ultimately, the success of any medical treatment 
is presently gauged in terms of the degree to which it extends a healthy lifespan (Gems, 2011b). To that 
end, finding a treatment that decelerates ageing is a path that must be followed.  
So if we now have a morally and medically advisable target to control the disease of ageing which if 
ameliorated can lead to moderate lifespan and healthspan extension and a reduction in suffering, how 
does one approach the funding and investigation of the subject? On the face of it, ageing should be 
considered the leading cause of death worldwide:  100,000 people globally die each day from age-related 
causes— a disease with a 100% mortality rate (De Grey and Rae, 2008). Once ageing is considered a 
disease, would it dwarf all competing claims for biomedical research funding because it affects every last 
one of us (Farrelly, 2008)? This is doubtful - the over-hyped propaganda of some gerontologists is unlikely 
to receive equal enthusiasm from investors and policy makers who quite frankly believe such research 
to be  utopian and unrealistic (Farrelly, 2008). Furthermore, the research of ageing would be considered 
a luxury to those who live in suffering. To divert funds away from research into poverty, infection and 
premature death associated diseases would be an insult to the 50% of all the individuals on this planet 
who died before they even got the chance to experience agedness (Ritchie, 2018). The equality-driven 
prioritarian viewpoint stipulates that investment imperative should always be weighted towards worse off 
individuals. To this end, the first-world elite would rarely qualify for funding (Clayton and Williams, 2000).  
However, the field should be wary not to undersell the potential gains any successful intervention on 
ageing would have on humanity. Some have projected that the effect of delayed ageing resulting in 2.2 
years additional life expectancy would yield US$7 trillion in savings over 50 years (de Magalhães et al., 
2017), whilst others claim that a modest retardation of human ageing by just seven years could confer 
benefits greater than those that could be achieved by the elimination of cancer (Farrelly, 2010).  It is also 
important that we are honest about the current limits to our understanding of the ageing process. Whilst, 
30 
 
as previously mentioned, understanding is not a prerequisite to treatment, blindly piling money in 
prospective fringe areas of the field would be inappropriate. Additionally, to request significant funding on 
false hopes and overstated presentiment, that fail to deliver, would also be greatly inappropriate. I an 
ideal world we need to find the middle ground between promising too much and promising too little 
(Farrelly, 2008). Significant costs into anti-ageing research would emerge upon the commencement of 
human clinical trials. It has been suggested that human trials into anti-ageing would cost at least $1 billion 
(Nikolich-Žugich et al., 2016; Paul et al., 2010) and that the reasonable amount which the NIH should be 
willing to commit to research has been estimated at $3 billion (Farrelly, 2010). Thus, ageing research, for 
now, should prioritise basic science with a translational, easily employable, clinical element, using 
resources already available to the scientist. For example, the utilisation of freely accessible, large, cross-
field “omics” databases and the repurposement of currently available drugs offers a cost-effective strategy 
to find implementable interventions for the ageing process without the need of an extensive drug 
development and testing pipeline (de Magalhães et al., 2017).   
Thus, this research thesis sets out to repurpose a drug for the deceleration of ageing and compression 
of morbidity mediated through currently studied pathways of ageing, enabling individuals to live a longer 
healthier life. It should serve to slow the manifestation of age-associated disease through the holistic 
retardation of the underlying causes of ageing leading to the reduction in geriatric suffering and 
emancipation of the ageing population. Freedom lies in the human capacity for self-determination. The 
ageing process internally imposes limitations and reductions in liberty through enfeeblement, frailty and 
pathology and thus, a failure to advocate and fund scientific research into ageing violates one’s right to 
health (Farrelly, 2019). Part and parcel of one’s physiological loss of liberty and capacity in old age is the 
inevitable psychological suffering that ensues, hastened by a societal revulsion of old age and a cultural 
narrative that prejudices the old. And whilst emancipatory efforts are made to reduce the suffering of 
ageing through the promotional ideal of “healthy ageing”, It leaves us with a sense of a widening gap 
between the fit and the frail. It is this frail, darker, lonelier side of ageing which society most fears driven 
by the physiological imprisonment of getting old.  
The provision of an intervention which can curb the progression of age-associated disease and compress 
morbidity so that it enables ageing individuals to continue their roles within society may help to remove 
the prejudices, segregation and isolation imposed upon the elderly. Such prejudice exists primarily 
because elderly people personify our inevitable demise (Martens et al., 2005). Furthermore, one’s 
animality is revealed in old age: a divulsion of physical vulnerability and basicness as systems fail and 
mind no longer controls body. This lack of evolutionary fitness is unattractive to those in polite society 
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unwilling to accept their own physical, animal nature (Martens et al., 2005). Lastly, the tribal mentality 
within human society demands a contribution from everyone and the incapacities of the aged has  
increased the tendency to regard them as non-contributing burdens, resulting in resentment and 
marginalisation (Wisdom et al., 2014). Whilst, intrinsically, such ageism will always exist towards those 
oldest old, when disease becomes an inevitability; such age-decelerating interventions should help to 
compress the period in which old age may feel like a personal and societal burden and help individuals 
continue to manifest their own symbolic immortality and continue to be fit and valued members of their 
community.   
In conclusion, this research, henceforth, does not search for the elixir of life, or the snake-oil of eternity: 
it is a reasonable, affordable, and rational approach to reduce the suffering of old-age and improve one’s 
wellbeing in later life, representing the moral obligation of the medical and scientific community. Beyond 
the individual, this research hopes that by slowing down the processes of ageing—even by a moderate 
amount— it could yield dramatic financial benefits to society and remove prejudices against old age, 
reducing fear of mortality and providing an increased sense of happiness and wellbeing. “For age is 
opportunity no less than youth itself, though in another dress. And as the evening twilight fades away the 
sky is filled with stars, invisible by day” (Longfellow, 1825).  
1.2.  Biology of Ageing 
1.2.1. Ageing As A Susceptibility to Death Which Encumbers Intervention Testing  
For ageing to be a viable target for intervention, it is advisable to present a clear understanding of its 
phenotype such that its outcomes may be monitored and measured appropriately. However, despite its 
universality, and clear perceptibility, it remains the most elusive and least well-understood aspect of 
human biology (Kirkwood, 2005). Simply put, humans, like all things on earth are subject to the inexorable 
forces of entropy where deterioration will always prevail over synthesis. Such deterioration, characterized 
by a progressive loss of physiological integrity, leading to impaired function, renders human beings 
progressively more likely to die (López-Otín et al., 2013; Medawar, 1952; Pedro De Magalhães, 2004) 
Thus, ageing is merely a time-dependent increase in disease susceptibility and mortality. But what does 
that look like and can interventions fundamentally defer susceptibility?  
First, mathematically, that answer is relatively homogenous and derived from the acceleration of mortality 
risk with age. This has culminated in various attempts to map rates of ageing with the Gompertz law 
perhaps being the most recognised (Finch and Pike, 1996). Gompertz’s actuarial work focused on 
quantifying the rate of ageing within a population but suggested that a law of individual ageing was 
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revealed through the net pattern of human mortality data (Milne, 2009). Therein he proposed that mortality 
rates increase exponentially with age, doubling approximately every eight years of age until there is death 
in an entire population or individual within a decade or two past the age of 100 (Kirkwood, 2015; Fries, 
2005). Almost all ageing animals and populations are subject to this model and as such, the ability to 
modulate this “rate of ageing” is a sine qua non of any anti-ageing intervention. Specifically researchers 
use the mortality rate doubling time, the amount of time it takes for the mortality rate to double for a given 
cohort, to define the decelerative success of any intervention (de Magalhães et al., 2005). Whilst, this 
method has its limitations, it serves as a practical metric of physical deterioration and health. Additionally, 
and used throughout this thesis, mean and maximum lifespan represents a broad and accessible metric 
to interpret the efficacy of an intervention and will be greatly referred to throughout this thesis.     
As introduced, there is a clear and supported relationship between population mortality and intrinsic 
biological senescence at the individual level (Gurven and Fenelon, 2009). However, what does disease 
susceptibility look like, and what physical deterioration is apparent?  Expectedly, the physiological 
manifestations of ageing are vast and heterogenous. The Digital Ageing Atlas, for example, a “one stop 
shop” for age-related changes  lists over 300 physiological changes, which include cellular, hormonal and 
changes at various scales (including organs and the whole organism); and psychological or cognitive 
changes (Craig et al., 2015). However, James Fries, reinforced by other researchers, posits that these 
changes are best considered within a collective decline in maximal function of the vital organs  (Atamna 
et al., 2018; Fries, 2005; Khan et al., 2017; Strehler, 1960; Strehler and Mildvan, 1960). The human body, 
and, specifically individual organs, strive to maintain homeostasis and express the capacity to endure 
recurrently stressful conditions. The young individual can withstand up to 7 to 11 times more physiological 
stress than the average quotidian demand (Manhapra, 2004). However, this fortitude and the subsequent 
ability to restore normal homeostatic balance and function in a relatively short recovery time becomes 
compromised in old age (Atamna et al., 2018).  Such functionality, termed “organ reserve”, progressively 
declines at a rate of 0.5% to 1.4% per year from the early twenties onwards and may further accelerate 
from the fifth decade (Bortz and Bortz, 1996; Sehl and Yates, 2001). Even in the absence of disease, 
one’s capacity will continue to erode, until ultimately, the most routine of daily perturbations, become 
unmanageable and culminate in mortality (Fries, 2005). Thus, “Death occurs when the rate at which an 
organism does work to restore the original state is less than that demanded to overcome the effects of a 
given challenge”, whether that challenge be acute disease, infection or trauma (Neustadt and Pieczenik, 
2008). To that end, the actuarial observations of Gompertz are indeed correlative to the decreased 
capacity of an organism (Fries, 2005).   
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The indicators of decline in reserve and homeostatic elasticity are organ specific. Furthermore, it is 
essential to remember that rates of organ or organismal decline are different for everyone, rarely linear, 
and may be hastened, modified or slowed by disease burden, lifestyle and nutritional status. That said, 
general patterns of age-change are common in certain tissue and moreover, such changes have been 
elucidated in most organ systems and serve as the source of many age-associated chronic diseases. 
Fries, again, considers these diseases, universal and inevitable manifestations of age that accelerate 
and can become symptomatic in line with functional decline, further compromising one’s stress resistance 
and vulnerability to death (Fries, 2005). The ability to compress the period of overt, symptomatic age-
associated disease, and maintain “healthy ageing” is one of the central tenants of anti-ageing research 
and a key target for pharmaceutical companies (Stefánsson, 2005).  
However, despite continued understanding of the associated pathologies of ageing, translating such 
“academic” knowledge into “anti-ageing” clinical trials with useful “hard” outcomes such as burden of 
chronic diseases, functional dependence, and/or mortality is poor (reference). Firstly, the complexity of 
human ageing that spans multiple physiological domains, cannot be accounted for in-vitro. Whilst organ 
function can be in part reconstituted in-vitro, the interconnected influence of human or animal systems 
on disease and age-related phenotypes often results in observations being invalid after mammalian 
follow-up (Artal-Sanz et al., 2006). 
Indeed, whilst there are movements towards using humans for longevity research, such clinical trials are 
extremely expensive and rare (Nikolich-Žugich et al., 2016; Paul et al., 2010). Specifically, the current 
NIH annual budget would cover no more than a couple of human clinical trials (Farrelly, 2010). Even if 
human clinical research applications were to overcome the significant ethical hurdles, human life spans 
are long, and chronic diseases of aging tend to manifest in the later decades of life. Thus, antiaging 
intervention trials targeting such chronic disease will require decades of follow-up before such “hard” 
outcomes could be measured. Indeed, these studies could be accelerated if reliable markers of the 
human ageing rate could quantify pretreatment baseline, during-treatment change, and posttreatment 
outcome of participants in randomized clinical trials of rejuvenation therapies, but these are yet to be 
sufficiently validated (Moffitt et al., 2017). 
Furthermore, human anti-ageing intervention trials face significant operational challenges which reduce 
the robustness of generated data. These include protocol adherence by study participants, drop-outs 
leading to incomplete and diminished data; result interpretation of the “intention to treat” analysis, where 
everyone in the treatment group is analysed together regardless of their adherence to the study 
intervention and the heterogeneity of participants (reviewed in: Newman et al., 2016). 
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Therefore, the de facto method to assess the effects of potential anti-ageing interventions is the utilisation 
of model organisms. Ideally researchers wish to use organisms that share similar physiology and 
functionality to humans and as such, mice and other rodents have dominated the anti-ageing intervention 
research field (Ingram and de Cabo, 2017; West et al., 2000). Unfortunately, however, mice often live 
more than 2 and half years. Despite a richness in phenotype scoring, they require continued housing and 
care, hence making rodent ageing study very laborious, expensive and time consuming (Maglioni et al., 
2016). These models are therefore commonly reserved for “end of pipeline” testing prior to preclinical 
study in humans. For example, from the discovery of rapamycin’s mechanism of action in 1995 a further 
14 years of study continued before it was successfully tested for complete lifespan effects in mice 
(Johnson et al., 2013). 
1.2.2. C. elegans as a model organism for anti-ageing intervention research  
However, in the early 1960s, ponderings by an academic called Sydney Brenner provided an alternate 
solution (Artal-Sanz et al., 2006; Nigon and Félix, 2017). Brenner utilised Caenorhabditis elegans as a 
model organism for evolutionary genetics study, legitimising its use by stating, “one would need the 
simplest differentiated organism, small enough to be handled in large numbers, easy to cultivate, with a 
short life cycle and amenable to genetic analysis” (Artal-Sanz et al., 2006). This, of course, has 
significant cross-over for ageing research.  
Indeed, it is simple and small: a ~1mm transparent body comprising 959 somatic cells in 
hermaphrodites (1031 for males) that form multiple distinct tissues observable by light and fluorescent 
microscopy (Mack et al., 2018). Worms have differentiated muscle cells, hypodermis, intestine, gonads, 
glands, an excretory system and nervous system. It was the fully mapped connectome of 302 neurons 
that so enticed Brenner, as it provided a unique balance of complexity and manageability (Mack et al., 
2018). The C. elegans intestine also provides an excellent platform for the analysis of drug absorption, 
distribution, metabolism, excretion and toxicity (ADMET), comparable to human gastroenterology and 
performing functions akin to mammalian  stomach, bowel, liver, pancreas and adipose tissue (Artal-
Sanz et al., 2006; Mcghee, 2007).  
The cultivation and maintenance of C. elegans is also relatively straightforward and inexpensive. They 
can be cultured on both solid and liquid media set in Petri dishes, tubes, or 6-, 12-, 24-, 96-, or 384-well 
plates (Leung et al., 2008). In laboratory conditions, C. elegans routinely subsist solely on a bacterial 
lawn of E.coli spread over NGM agar supplemented with cholesterol. Owing to their ability to enter a 
survival statsis known as Dauer, they can survive indefinitely in axenic conditions, deprived of E.coli, 
and are the only known multicellular organism than can be routinely cryo-preserved: this of course 
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permits the generation of archival libraries (Ma et al., 2018). Additionally, their hermaphroditism enables 
self-fertilisation and hence invariant progeny with a stable strain lineage which can be stored 
indefinitely.   Furthermore, self-fertilisation results in large-scale production of progeny (300 in just 3 
days) in the expected Mendelian ratios, which can be easily cultivated on single plates for high-
throughput screening. Such progeny is also primarily hermaphrodite although males can arise through 
spontaneous X-chromosome non-disjunction during meiosis (∼0.2%) (Mack et al., 2018). Thus, 
hermaphrodites are almost exclusively used for large-scale lifespan assays owing to their isogenic 
invariance. On the other hand, males allow the creation of new allele combinations through cross-
fertilisation, further facilitating the genetic amenability of C. elegans (Mack et al., 2018).  
As such, it is no surprise that C. elegans was the first animal to have its genome completely sequenced 
and it is likely to be the first animal with a library of loss-of-function mutations in every gene (Lai et al., 
2000; McDiarmid et al., 2018; The C. elegans Sequencing Consortium, 1998). From this, it has been 
estimated that, despite being 1/30 the size of a human genome, the number of protein coding genes 
between the two species is similar, and ∼40–80% (depending on similarity thresholds) of C. elegans 
proteins have been estimated to have orthologs in humans. Moreover, it is thought that 40% of genes 
known to be associated with human diseases have clear orthologs in the C. elegans genome (Mack et 
al., 2018) .  
Researchers use the wealth of genetic information surrounding the C. elegans genome to optimise both 
forward and reverse genetic approaches. In forward screens, worms with specific phenotypes are 
randomly mutagenized, often by EMS, to identify candidate genes which exacerbate or alleviate the 
trait of interest. This process has been greatly expediated in recent years following the economisation 
of NGS and also deep sequencing  (Sin et al., 2014). In reverse genetic approaches, the functionality of 
specific genes can be rapidly and easily explored. Not only does a phenomenally large library of cheap 
mutant strains already exist, but the worm community is extremely sharing of their own endeavours, 
making accessibility to various knockout models unprecedented.  Failing that, the knockout or 
knockdown of genes in C. elegans is quickly and cheaply accomplished. This is principally established 
through either the permanent deletion of a gene or  RNAi knockdown of gene function without altering 
the organism's DNA (Ahringer, 2006). First, in the creation of knockout mutants, a similar EMS 
mutagenesis library is created as in a forward genetic approach. However, this is followed by screening 
PCR to identify animals carrying lesions in the gene of interest and subsequent outcrossing to clean-up 
mutated DNA. In more recent years, since the implementation of CRISPR‐based genome engineering, 
targeted deletion or editing of any gene of interest in <1 month, is now possible, with far less offsite 
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mutation. Second, knockdown by RNAi in C. elegans has been available for over 15 years and is 
enacted principally through the feeding of bacteria carrying dsRNA-encoding plamids purchased from 
one of two libraries (Ahringer or Vidal) that collectively cover >90% of the worm genome. Importantly, 
this technique permits post-developmental gene knockdown which is particularly useful in separating 
developmental phenotypes from ageing phenotypes. Beyond the downregulation of specific gene 
function, the C. elegans genome is equally amenable to the fluorescent transgenesis of genes of 
interest as well as the expression of human genes to induce a disease-related phenotype in C. elegans.  
However, as briefly highlighted, perhaps the most relevant phenotype of C. elegans that lends itself to 
ageing research is its short life-cycle and lifespan (average approximately 17 days at 20 °C) which still 
permits the statistical identification of modest lifespan effects. As such, its efficacy as a 
pharmacological tool has been demonstrated by the recent documentation of small molecules with pro-
longevity effects, representing possible strategies to delay ageing and the onset of age-associated 
diseases in mammals.  
1.2.3. Cellular Manifestations of Ageing Influencing Universal Organismal Ageing 
As described, ageing is defined as an increasing risk of mortality caused by progressive deterioration of 
organ and tissue integrity (Fries, 1980). Whilst, the appearance of such deterioration, is for the moment 
unstoppable, its hinderance allows for the repression of chronic disease borne out of acceleration of the 
ageing phenotype. However, as shown, organs degenerate in their own manner and at their own rates, 
permitting or denying the ability for some tissue to manifest in disease. It would perhaps be more 
beneficial to consider “upstream” targets.  
At a cellular level, the inexorability of entropy is equally manifest as in the organism itself. Whilst the 
purpose is still questioned, damage accrued through endogenous fallibilities in metabolism and repair, or 
through exogenous inputs of environment and lifestyle are ultimately liable for ones ageing. It would be 
amiss to define the hallmarks of ageing through a lens other than that devised by Lopez-Otin et al. Their 
nine hallmarks of ageing can be clustered into 3 groups described by Aunan et al. as the primary 
hallmarks that cause damage to cellular functions; antagonistic hallmarks in the response to such 
damage; and, finally, integrative hallmarks that are the result of clinical phenotype, which ultimately 
contribute to the clinical effects of ageing as seen in physiological loss of reserve, organ decline and 
reduced function (Aunan et al., 2016; López-Otín et al., 2013) . For the purpose of this thesis, I have 
sought to categorise these hallmarks into three distinct aberrations: genomic related, proteomic and 
signalling. Whilst, other hallmarks are valid in their own right, their detailed discussion does not pertain 
to the changes in cellular ageing which this thesis serves to address.  
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1.2.3.1. Genomic, Epigenetic and Telomeric Aberrations  
Genome damage accrued through endogenous and exogenous sources is thought to precipitate much 
of the aged cell phenotype (Vijg and Montagna, 2017). Whilst mutagens are encountered throughout 
one’s lifespan, dysregulation of the mechanisms used to excise and repair such damage also 
accumulates which greatly accentuates the problem, leading to a viscous cycle. Furthermore, regulatory 
mechanisms to control the expression of genes at an epigenetic, telomeric and transcriptional level 
become aberrant, promoting cell cycle malfunction, carcinogenesis and senescence (Hoeijmakers, 
2009). 
One well-established theory of ageing denotes that direct damage to DNA is the formative and casual 
process of ageing itself (Alexander, 1967; Gensler and Bernstein, 1981). The genome is regularly 
exposed to insults which form various lesions along the DNA; it is proposed that as many as 100,000 
lesions are thought to occur daily in each somatic cell (Hoeijmakers, 2009). Such lesions comprise of 
base modifications, single-strand breaks (SSBs), double strand breaks (DSBs), and interstrand cross-
links (ICLs), which can manifest in point mutations, gene deletions and translocations alongside 
chromosomal changes and telomere shortening (Maynard et al., 2015). Research has elucidated a 
correlation between age and damage levels or mutation frequency, and consequent longevity  (Blokzijl 
et al., 2016; Pan et al., 2016). Whilst, accumulation of mutations is unavoidable with age, their frequency 
can be hastened through age-related decline in repair capacity (Vijg and Montagna, 2017). In 
juvenescence, an elaborate plethora of repair mechanisms exist to excise and replace damaged DNA, 
however, there is sufficient evidence that all pathways of DNA repair, mismatch, excision and double 
strand break repair, become less efficient with age, leading to accumulation of mutations and subsequent 
loss of genome stability  (Gorbunova et al., 2007).  Indeed, human diseases caused by inherited defects 
in DNA repair genes can closely recapitulate a premature ageing phenotype. Werner Syndrome patients, 
for example, defined by mutations in the DNA repair gene, WRN, exhibit hallmark symptoms of ageing 
including: premature greying of the hair and baldness, skin and muscular atrophy, hypogonadism, poor 
wound healing, atherosclerosis, osteoporosis, soft-tissue calcification, juvenile cataracts, a tendency 
towards diabetes, and an elevated cancer frequency (reviewed in Muftuoglu et al., 2008). Importantly, 
deficient DNA repair in Werner’s Syndrome culminate in significant chromosomal abnormalities, 
increased frequency of deleterious mutations and accumulation of DNA double-strand breaks (Ariyoshi 
et al., 2007; Freitas and de Magalhães, 2011). Conversely, however, long-lived animals appear to show 
upregulation of DNA repair. Specifically, the bowhead whales demonstrates duplications in genes linked 
to DNA damage repair and ageing, such as PCNA (proliferating cell nuclear antigen) (Keane et al., 2015). 
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Additionally, long-lived species of bat and rodents appear to show significant upregulation of DNA repair 
genes in comparison to their short lived counterparts (Conde-Pérezprina et al., 2012; Fang et al., 2014).  
With that said, it is important to note that, whilst direct DNA damage alone may contribute to ageing in its 
ability to self-disrupt transcription and its triggering of apoptosis or senescence, it is generally considered, 
the mutations generated from such damage, are the important factors driving genome instability and 
ageing (Vijg and Montagna, 2017). This is exemplified by the curved development of the ageing 
phenotype rather than a cliff, demonstrating a dominant role for stochastic events like somatic DNA 
damage causing ageing and the forming the mutational theory of ageing (Kenyon, 2010). 
Genomic instability refers to an increased tendency of alterations in the genome during the life cycle of 
cells driven by the accumulation of mutation (Vijg and Suh, 2013). For example, research estimates that 
through ageing, up to 10% of cells exhibit aneuploidy, and changes such as this are sufficient to drive 
age-related change through two primary mechanisms: induction of senescence and exhaustion of 
regenerative capacity (Macedo et al., 2018; Mukherjee and Thomas, 1997; Thomas and Fenech, 2008; 
Westra et al., 2008).  
Mack et al. (2018) recently published a review detailing changes in C. elegans ageing and evaluated 
their comparability to human hallmarks of ageing. Indeed C. elegans possess similar DNA repair 
machinery to that of humans, such that human segmental premature ageing syndromes, e.g. Werner, 
Bloom, and Cockayne syndromes may be elicited in worms (Babu et al., 2014; Lee et al., 2004; Wicky 
et al., 2004). Cellular responses to DNA damage appear conserved as well: transcriptional blocking 
DNA lesions provoke activation of a FOXO transcription factor in C. elegans and notably, age-1 and 
other long-lived mutants of the nematode C. elegans show increased DNA repair capacity (Mueller et 
al., 2014). However, the direct role of DNA damage towards C. elegans ageing is controversial and it is 
uncertain whether this animal is suitable for studying the contribution of spontaneously induced DNA 
damage to ageing (Lans et al., 2013). Whilst genotoxic levels of UV shorten C. elegans lifespan, 
genetic mutants that induce endogenous mutations do not consistently shorten lifespan and 
furthermore, exogenous DNA damage may extend lifespan in long-lived mutants potentially primed to 
tolerate such stress (Hyun et al., 2008). Importantly, C. elegans exist in a post-mitotic state with a 
definite number of steady post-mitotic cells and do not technically undergo cell senescence and 
lifespan or ageing appears unrelated to telomere length in worms (Lidzbarsky et al., 2018) . 
Nonetheless, C. elegans exhibit an increase in single-strand DNA breaks, 5-methylcytosine , and 
protein carbonyls accumulation with age (Back et al., 2012). Likewise, DR restriction appears to 
enhance SOD and catalase activity and oxidative stress resistance (Houthoofd et al., 2002a; Van 
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Raamsdonk and Hekimi, 2010). This apparent tolerance is not entirely mediated through IGF-1 
signalling in response to DR; specifically sod knockout has little or no effect on daf-2 strain longevity 
and in some cases, it even further increases lifespan of daf-2 (Zhou et al., 2011). That said, improved 
stress resistance to genotoxic agents forms one of the key assays used by biogerontologists to assess 
the ability of an intervention to affect ageing (Senchuk et al., 2017).  
1.2.3.2. Proteomic Aberrations  
Cellular ageing encompasses a labyrinth of processe which, whilst not uniformly manifested causes the, 
so far, ineluctable amassment of cellular damage leading to time dependent loss of cellular fitness. Loss 
of proteostasis is one such of those manifestation. Under normal and burgeoning conditions, the 
proteome is preserved via the stabilisation of folded proteins, management of efficient protein trafficking 
and controlled degradation, necessary to control the functional levels of proteins in their native state and 
minimize non-productive or harmful off-pathway reactions (reviewed in Hipp et al., 2019).  
First, deleterious genomic instability in ageing promotes the production of misfolded proteins (Kikis et al., 
2010). Furthermore, inherent polymorphisms, which occur at an incidence as high as two per coding 
sequence, can predispose individuals to misfolding: and the fallibility of translation machinery can lead 
to mutation in up to 18% of expressed proteins (Drummond and Wilke, 2008). Although no quantification 
of protein error levels in any ageing system exists, estimates in animals such as chick and rat have 
identified an age-related increase in protein error (Hipkiss, 2006; Holliday, 1996).  Extrinsically, this is 
compounded by exposure to ROS and other stressors, which further imparts proteotoxic stress and post-
translational modifications which can seemingly lock misfolded proteins in their position, thus preventing 
their degradation (reviewed in Krisko and Radman, 2019). Failure to rescue protein misfolding can result 
in aberrant aggregate formation, whose accumulation can eventually lead to characteristic age-related 
neuronal plaque formation and, in some instances, precipitate disease phenotypes (reviewed in Kikis et 
al., 2010).  
Thus it is essential that organisms possess sufficient mechanisms to remove and clear potentially toxic 
or aggregative proteins from the cell (Komatsu et al., 2006). This can be performed through three distinct 
processes: chaperone-mediated refolding and/or transport of proteins into non-toxic entities or 
intracellular inclusions, degradation by the ubiquitin protease system, or finally degraded via autophagy 
(each mechanism reviewed in Klaips et al., 2018). It is the latter of these processes that is most pertinent 
to this thesis and thus will receive a more detailed review. Furthermore, its modulation is one of the key 
targets of gerontological research and a pathway regularly affected by geroprotective drugs.  
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The discovery that middle aged mice fed rapamycin, an autophagic induction drug, displayed increased 
lifespan triggered vast research into the role upregulating autophagy may have in decelerating the ageing 
process (Kroemer and Levine, 2008). Furthermore, mitochondrial dysfunction, an additional hallmark of 
ageing, is characterised by loss of membrane potential and profligate leakage of respiratory electrons, 
toxic apoptotic mediators and ROS: autophagic processes are able to selectively remove such cellular 
contamination (Murrow and Debnath, 2013). In a similar pathway to toxic protein removal, cellular 
contaminants are quarantined within a double membraned vesicle known as an autophagosome and 
degraded via the autophagosome’s fusion with a lysosome (Ravikumar et al., 2010).  This is particularly 
important for post-mitotic cells such as cardiomyocytes and neural cells that must rely on homeostatic 
“cleansing” methods such as autophagy to maintain cell viability (L. Wang et al., 2015). 
Additionally, during inimical periods such as nutrient deprivation, growth factor withdrawal and oxidative 
stress, autophagy becomes an essential pro-survival pathway through its reproduction of amino acids 
and metabolic intermediates such as glutmaine (Altman and Rathmell, 2012; T. C. Lin et al., 2012). 
Furthermore, autophagy serves a mitigating role to degrade cellular pathogens, defective organelles, and 
more pernicious compounds such as aggregate-prone intracytoplasmic proteins associated with many 
neurodegenerative diseases (Fujikake et al., 2018).  Thus it would appear logical that any malfunction or 
cessation in a cell’s autophagic machinery would have deleterious consequences: indeed, autophagic 
inhibition of otherwise homeostatic mice precipitated the aggregation of morbific protein aggregates 
(Komatsu et al., 2006). Pertinently, autophagic malfunction, in a generalist view, would result in an 
accelerated accumulation of aberrant macromolecules and organelles mimicking a senescent phenotype, 
that compromises cellular and tissue integrity (Barbosa et al., 2019). Correlatively, literature 
demonstrates a reduced expression of autophagic proteins in aged tissues, whilst nematode autophagy 
mutants display reduced life span (Chang et al., 2017; Chapin et al., 2015). 
There appears to be a plethora of factors, morphologies and processes which contribute to the aged 
phenotype, many of which autophagy cannot avert. However, it is undeniable that the vast majority of 
cellular ageing interventions currently available not only rely on proficient autophagy, but require its 
upregulation (Hansen et al., 2018; Lapierre and Hansen, 2012).The prototypical and most robust example 
of longevity is often considered to be the manipulation of the highly conserved primordial insulin-like 
growth factor pathway (Junnila et al., 2013). Countless genetic, pharmacological and behavioural studies 
have elucidated that the downregulation of this pathway causes increased longevity in many animal and 
human models (Gelino and Hansen, 2012). In C. elegans, IGF-1 receptor (daf-2) mutants display a 
dramatically increased longevity, only when autophagic machinery is intact (Hansen et al., 2008). Equally, 
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loss of function mutations in key autophagic genes or RNAi attentuated the longevity effects of dietary 
restriction, rapamycin, spermidine and increased FOXO expression in nematodes, drosophilae and mice 
(Morselli et al., 2010). Similarly, Sirt-1 is able to prolong lifespan upon its transgenic overexpression, and 
reports suggest that this overexpression induces increased autophagy, whilst autophagy knockout 
abrogates its effect (Morselli et al., 2010).   
It would appear that controlled upregulation of autophagy delays the development of cellular ageing 
(Madeo et al., 2015). This is supported by studies in Drosophila, in which the upregulation of Atg8, an 
autophagy gene, increased longevity (Simonsen et al., 2008) Similarly, improving protein homeostasis 
through autophagy in C. elegans through expression of heat shock factor is sufficient to promote longevity 
(Kumsta et al., 2017). It is thus important to study any compounds which appear to be increasing 
autophagy and assess whether this attribute is transferrable to life extension. Conversely, any putative 
compounds that improve organismal longevity should be studied to assess whether this attribute is due 
to autophagy upregulation. 
Numerous reports have demonstrated a global reduction in C. elegans autophagy during ageing. Whole 
body extracts of worms show a reduction in autophagic activity, and an age-associated increase in 
uncleared autophagosomes can be observed in four major tissues (intestine, body-wall muscle, 
pharyngeal muscle and neurons), presumably caused by impaired autophagic activity or reductions in 
lysosomal protease activity (Chang et al., 2017; Sarkis et al., 1988; Wilhelm et al., 2017). Indeed, age-
related protein aggregation and misfolding is evident in C. elegans and precipitates a pronounced, 
widespread decline in proteostasis, which some argue is a programmed event (Labbadia and Morimoto, 
2014). Recent research has demonstrated that defective autophagy in ageing C. elegans affects 
lifespan and healthspan, and inhibition of autophagic machinery results in a significant lifespan increase 
and enhanced neural integrity (Medina and Richly, 2018; Wilhelm et al., 2017). As concluded by the 
authors, “Hence, by avoiding this detrimental autophagic deadlock in its early stages the toxic effects of 
dysfunctional autophagy are alleviated.” 
One important hallmark of neurodegenerative diseases is the accumulation of protein aggregates, 
which should typically be degraded via autophagy. As such, researchers have been continually using 
models of neurodegenerative diseases in C. elegans to elucidate their molecular mechanisms . Chronic 
exposure of misfolded proteins could interfere, block or over-utilise autophagic machinery, disturbing 
normal protein homeostasis (proteostasis) causing cellular dysfunction and death in neurodegenerative 
diseases. Indeed, expression of aggregation-prone proteins in various model systems was shown to 
interfere with cellular proteostasis which coincided with in age-dependent collapse of proteostasis 
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(Brignull et al., 2006; Shemesh et al., 2017). In this particular model, poly-Q expansions were 
expressed throughout the nervous system of the worm, mimicking a number a neurodegenerative 
diseases characterised by expansion of glutamine (Q, encoded by CAG) repeats within otherwise 
unrelated genes to cause misfolding, oligomerization, and aggregation. A model of poly-q disorders 
was first developed in 1999 in the laboratory of Anne Hart. However, subsequent developments by the 
Morimoto group were able to capitalise on the transparency of C. elegans to fuse Yellow Fluorescent 
Protein (YFP) to the polq locus, permitting the real-time in-vivo visualisation of aggregation akin to that 
observed in Huntington disease patients (Morley et al., 2002). This provides ease and convenience 
which has now been expanded to various promoters corresponding to neuronal or muscular 
expression. Similar models exist for other neurodegenerative diseases through the expression of 
human aggregative proteins in a number of different tissues fluorescence and phenotype induction 
read-outs. A popular AD model of the latter utilises the expression of the N-terminally truncated Aβ1–42 
peptide in C. elegans body wall muscle cells which causes paralysis when induced through temperature 
upshift (McColl et al., 2012). These models can be widely used for genetic or pharmocological screens 
to discover enhancers and/or suppressors of polyglutamine proteotoxicity and other neurodegenerative 
diseases (Sin et al., 2014). The inexorable tie between proteostatic collapse and ageing means many 
interventions that extend lifespan in worms also alleviate phenotypes of aggregative transgenic worms 
including poly-q expansion models (Devagi et al., 2018; Keowkase et al., 2018; Kim et al., 2019; 
Marcellino et al., 2018; Negi et al., 2017; Zhang et al., 2012). Moreover, researchers often demonstrate 
that potential pro-longevity compounds upregulate autophagy alongside a conferred amelioration of 
aggregation phenotypes in worms, whilst also increasing lifespan in wild-type worms (Boasquívis et al., 
2018; Denzel et al., 2014).  
1.2.3.3. Nutrient-Signalling Aberrations  
A fundamental challenge in the ageing field is to isolate the source of heterogeneity in the ageing process. 
As highlighted in Lopez-Otin et al., (2013)  the plethora of effects mediated through loss of genetic and 
protein homeostasis can often be consummately ameliorated or advanced by alterations in central 
signalling axes. Indeed, the loss of signalling regulation is arguably the most conserved and robustly 
mediated facet of ageing. Specifically, the method in which cells and organisms sense nutrients and 
signal such interpretation can dramatically influence organismal lifespan and ageing. In mammals, it is 
the somatotropic axis which influences three main signalling pathways (AMPK, mTOR and IGF-1) that 
has been the focus of much ageing research over the last few decades.  
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Inclusive of unicellular organisms, the ability to sense intra and extracellular nutrient availability and 
scarcity is a primordially conserved attribute across all taxa (Efeyan et al., 2015). Transmembrane 
chemoreceptors expressed by Escherichia coli (E.coli), sense local aspartate and malate availability and 
thus signal rotary motors to propel the cell via peritrichous flagella action closer to the energy source 
(Parkinson et al., 2015). Likewise, odour detection within terrestrial mammals senses the desirability of 
certain food quality, triggering positive feedback within the limbic area and promoting food consumption 
(Hoover, 2010).  
The dramatic divergence between prokaryotic and eukaryote evolution is thought to be driven by the 
engulfment of oxidative bacteria, the predecessors of mitochondria (Gray, 2012). This provided an 
abundant  source of ATP which could support the genomic capacity and regulation of hundreds of 
thousands-fold more genes (Lane and Martin, 2010). Thus, the conservation of ATP levels became 
paramount in the maintenance of cellular viability and moreover, the availability of ATP developed into a 
vital barometer of energy status within the cell. The hydrolysis of ATP to ADP and phosphate (or AMP 
and pyrophosphate) underpins the catalysis of enzymatic reactions and anabolic processes essential to 
cells, and therefore, the ratio between these three molecules can accurately determine and regulate the 
relative energy availability of a cell. This is governed through a heterotrimeric enzymatic complex called 
AMPK, considered the master regulator of metabolism within eukaryotes (Yuan et al., 2013). Both ADP 
and ATP willingly phosphorylate AMPK at residues T172 of the α and γ subunit respectively, whilst 
additionally promoting supplementary phosphorylation by liver kinase B1 (LKB1) allosterically activating 
AMPK 2-10 fold (Gowans et al., 2013). Conversely, ATP competitively inhibits the binding of both AMP 
and ADP to the γ-subunit during energy repletion (Jeon, 2016). The cellular effects of AMPK activation 
facilitate the catabolism of energy storage whilst inhibiting proliferative and anabolic capacities of the cell. 
AMPK promotes lipolysis of triglycerides whilst promoting the uptake of circulating free fatty acids and 
inhibiting the de novo synthesis of fatty acids or the storage of these molecules as triglycerides (Daval et 
al., 2005). This pattern is similarly mimicked in relation to glucose. AMPK actively inhibits glycogenosis 
and gluconeogenesis, whilst increasing the expression of GLUT transporters to increase glucose uptake 
into the cell for subsequent glycolysis (Jeon, 2016). 
In worms, aak-1 mutants have a shortened life and are unable to regulate metabolism effectively, 
whereas overexpression of AMPK units increases lifespan (Apfeld et al., 2004; Narbonne and Roy, 
2009). Additionally, the beneficial effects of metformin require the activity AAK-2 and its upstream 
kinase LKB1/PAR-4 (Onken and Driscoll, 2010). More recently, oxidative stress in C. elegans led to a 
constant activation of AMPK and consequent hyperactivation of autophagy (Kosztelnik et al., 2019). It is 
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also well established in worms, that AMPK activation, like in mammals leads to activation of key 
longevity transcription factors such as skn-1 and daf-16 (Templeman and Murphy, 2018). In fact, daf-2 
mutants display enhanced autophagy that is AMPK dependent and which contributes significantly to its 
effects on lifespan extension (Egan et al., 2011).  
Activated AMPK minimises energy expenditure through the inhibition of non-essential protein synthesis 
instead promoting the repurposement of proteins for energy substrates via autophagy (Kim et al., 2011; 
Wilson et al., 2015). This is regulated by AMPK inhibiting the activity of the anabolic mammalian target 
of rapamycin (mTOR), a signalling protein which upregulates protein synthesis and cell growth. 
Unsurprisingly, mTOR is an equally vital signalling molecule and among other processes, the mTOR 
pathway is central in amino-acid nutrient sensing. mTOR denotes a catalytic subunit of two distinct protein 
complexes, known as mTOR Complex 1 (mTORC1) and 2 (mTORC2), which are individually comprised 
of the following components: mTOR, mLST8, DEPTOR  and either Raptor for the mTOR1 complex or 
Rictor for the mTOR2 complex (Saxton and Sabatini, 2017).  
Mammalian lysosomes, orthologous to the storage vacuoles of yeast, in part function as amino acid pools 
in cells (Li and Kane, 2009). The observation that loading of lysosomes with amino-acids was sufficient 
to activate mTOR in-vitro, forged the way in the identification of SLC38A9, a lysosomal transmembrane 
protein with homology to amino acid transporters, as a positive regulator of the mTORC1 pathway (Zoncu 
et al., 2011). Further research pinpointed leucine and arginine levels as the specific amino acids that 
activate or inhibit mTOR (S. Wang et al., 2015; Wolfson et al., 2016).  Recent research, reviewed in  
Wolfson and Sabatini (2017), highlight the novel discoveries of  three amino acid sensors upstream of 
mTORC1 (SLC38A9, Sestrin1/2, and CASTOR1) which inhibit mTOR during shortages of leucine or 
arginine but in amino acid sufficiency activate mTOR consequently driving anabolic activities. 
Furthermore, mTOR can be activated by signalling from numerous growth factor receptors such as the 
insulin receptor or the epidermal growth factor (EGF) receptor which activate tyrosine kinase adaptor 
molecules at the cell membrane (Tanaka et al., 2011). This leads to the recruitment of the class I family 
of PI3K to the receptor complex, stimulating a phosphorylative cascade involving Akt and the successive 
activation of mTOR through the inhibition of its negative regulator TSC. Thus, in burgeoning conditions 
of high amino acid pools and circulating growth factors, mTOR will drive a number of anabolic activities, 
however, during homeostasis under non-proliferating conditions in vivo, most cells do not show active 
mTORC1 or mTORC2 signalling (Weichhart, 2018).     
Downstream of mTOR, key transcription factors are activated which increase protein synthesis, increase 
metabolism substrates and prohibit the catalysis of protein through autophagic or UPS systems. 
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mTORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 
Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). Activation of S6K1 causes binding to S6 ribosomal 
protein to support increased translation following the release of eukaryotic translation initiation factor 4E 
(eIF4E) from translation inhibitors eIF4E-binding protein 1 (4E-BP1) and 4E-BP2 by mTOR1. De novo 
lipid synthesis is increased by mTOR through the upregulation of sterol responsive element binding 
protein (SREBP) transcription factors which activates  lipogenic gene expression (Porstmann et al., 
2008). In carbohydrate metabolism, activated mTORC1 signalling stimulates glucose uptake and 
consequent glycolysis to provide carbon backbones for biosynthetic processes (Düvel et al., 2010). As 
previously discussed, AMPK stimulates autophagy in nutrient depleted environments. This is mediated 
through ULK-1 activation which phosphorylates a key autophagy protein beclin-1 (Russell et al., 2013). 
mTOR importantly, when activated, blocks the activation of ULK-1 by AMPK, whilst also inhibiting the 
expression of lysosomal biogenesis and the autophagy machinery (Kim et al., 2011; Saxton and Sabatini, 
2017). 
In similar concert to mammalian models, C. elegans AMPK appears to regulate the longevity pathways 
of mTOR. TOR in worms is coded for by let-363, and its deletion causes dauer-like larval arrest which 
limits its gerontological research utility (Jia et al., 2004). As such, downregulation of the TOR pathway 
and subsequent longevity, in C. elegans can be achieved through downstream rsks-1/S6K mutants: 
α/AAK-2 is required for this effect (Selman et al., 2009). Notably, the majority TORC1 components are 
conserved in C. elegans, although the TSC seems to be absent (Zhang and Mair, 2017). 
The TOR pathway in worms also controls growth and reproduction in response to the availability of 
amino acids and growth factors (Lapierre and Hansen, 2012). Key downstream factors of TOR: S6K, 
eIF2 and eIF4G, all increase lifespan in C. elegans when supressed (Hansen et al., 2007). The cellular 
mechanisms thought to be induced through TOR downregulation in C. elegans is: increased lipolysis, 
autophagy upregulation and overlapping transcriptional activation of DR induced transcripts (Lapierre 
and Hansen, 2012).  Lastly, the beneficial effects of rapamycin on C. elegans lifespan appear to be 
mediated through the TOR pathway (Robida-Stubbs et al., 2012). 
Upstream of mTOR and affecting AMPK activity is a complex interplay of three growth factor receptors 
and their associative signalling pathways. Three different mammalian insulin/IGF tyrosine kinase 
receptors have been identified: the insulin receptor (IR), IGF-1 receptor (IGF-1R), and the orphan IR 
related receptor (IRR), which all interact with three different ligands: insulin, IGF-1 and IGF-2. Upon 
increased endocrine signalling during anabolic and trophic states, increased growth hormone binding to 
insulin/IGF tyrosine kinase receptors converges onto insulin receptor substrate (IRS) which can initiate 
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signal transduction via two major branches: the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the 
Ras/MAPK pathway (Templeman and Murphy, 2018). The PI-3K- PKB/AKT pathway has been shown to 
regulate most of the metabolic effects of insulin/IGF-1 signalling, whereas the Ras-MAPK pathway had 
been shown to regulate most of the mitogenic effects of insulin/IGF-1 signalling (Taniguchi et al., 2006; 
van Heemst, 2010). The activation of Akt phosphorylates many targets, including the Forkhead box O 
(FOXO) transcription factor family and importantly TSC2, a regulator of mTOR activity (Saxton and 
Sabatini, 2017). Specifically, FOXO transcription factors are inhibited, through their exclusion from the 
nucleus  by the insulin/insulin‐like growth factor (IGF) signalling pathway (Kenyon, 2010). There exists 
four different members of the mammalian FoxO family (FOXO1A, FOXO3A, FOXO4 and FOXO6), which 
regulate an impressive array of gene expression targets related to cell cycle, stress resistance, and 
longevity (van der Horst and Burgering, 2007). Whilst direct targets of FOXO have been identified through 
CHIP-seq, precisely how FOXOs perform cell type‐specific functions remains unknown (Webb et al., 
2016). Nonetheless, FOXOs are often considered “master-switches” in the response to food shortage. 
When uninhibited by IGF signalling during low insulin/growth hormone drive, important transcriptional 
shifts initiated by FOXO promote cell survival through, improved nutrient uptake, lipid oxidation, cell cycle 
arrest and quiescence (van Heemst, 2010).  Conversely, during Insulin/GH-IRS-induced Akt activation, 
FOXOs become inhibited whilst mTOR becomes activated. This is thought to be mediated primarily 
through the phosphorylation of TSC and PRAS40. Akt directly phosphorylates TSC2 at two sites (S939 
and T1462 on the full length of the human protein) and possibly at two or three more sites (S981 and 
S1130/S1132), leading to inhibition of mTOR’s negative regulation (Yoon, 2017). PRAS40 has been also 
shown to interact with mTORC1, which negatively regulates mTORC1 signalling (Sancak et al., 2007). 
Phosphorylated PRAS40 binds to 14-3-3 proteins, which have been proposed to sequester PRAS40 
away from mTORC1 (Yoon, 2017). Furthermore, to compliment the anabolic state induced by growth 
hormone signalling, key cell survival starvation mechanism initiated by AMPK become inhibited. Again, 
the activation of AKT phosphorylates the AMPK α1-subunit (S487 in humans) but does not phosphorylate 
an equivalent site in the AMPK α2-subunit (S491), thus leading to inhibition of phosphorylation by 
upstream kinases at the activating site of AMPK, Thr172 (Hawley et al., 2014). 
To add a further layer of complexity to nutrient signalling within mammals, the mitogenic Ras-MAPK, 
activated by IRS signalling further regulates the PI3K/AKT pathway. Singularly, downstream targets of 
activated Ras-MAPK include the p90 ribosomal protein S6 kinase (RSK) and the transcription factor 
ELK1, which influence cell growth, proliferation, differentiation, and survival (Templeman and Murphy, 
2018). However, evidence suggests multiple levels of cross-talk between both Ras and AKT signalling 
(Aksamitiene et al., 2012). 
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The age-related decline in metabolic homeostasis of these pathways is likely an important contributing 
factor to general organismal ageing and has been demonstrated to potentiate the manifestation of aged 
phenotypes. Explicitly, sarcopenia, a central component of frailty in old age is thought to be associated 
with a decline in GH and IGF-1 levels. Functional loss of hypothalamic–pituitary axis presents with GH 
production reduction of 14% per decade after the age of 30 years, with a parallel decline in IGF-1 
secretion (Veldhuis et al., 1995). Importantly, IGF-1 is the primary mediator of muscle repair and growth 
by stimulating satellite cell proliferation and muscle protein synthesis, inhibiting proteolysis and 
counteracting inflammation and fibrosis (Vitale et al., 2016). Thus it is well represented in a number of 
cohort studies that reduced serum IGF-1 independently increases the risk of sarcopenia, whilst also 
reducing gait speed and muscle mass (Gielen et al., 2015; Tay et al., 2015; Volpato et al., 2014). 
It has been hypothesised that reduced IGF/GH signalling may serve a protective function aimed at 
minimizing cell growth and metabolism which would help to limit cancer development and also entropic 
damage during ageing (Junnila et al., 2013; López-Otín et al., 2013). However, paradoxically, senescent 
cells, another hallmark of the ageing phenotype, display constitutively activated mTOR. Senescent cells 
are highly metabolically active, and are often identified by their pro‐growth phenotypes such as an 
enlarged size, increased organelle content (including mitochondria and lysosomes), increased 
metabolism and the potent SASP (Carroll and Korolchuk, 2018). It has been shown that malapropic 
mTOR activation drives the transcription of SASP immune mediators (Laberge et al., 2015), whilst 
additionally increasing intracellular ROS upregulating a senescent-inducing DDR (Correia‐Melo et al., 
2016; Laberge et al., 2015). Likewise, AMPK activity is reduced in senescence, further permitting 
exaggerated metabolic and anabolic processes in senescent cells (Salminen et al., 2016). This pattern 
is represented across aged tissue: hyperactive mTOR is present in ovarian tissue and  sarcopenic muscle 
of aged donors, and also in the adipose tissue of aged mice (Baar et al., 2016; Bajwa et al., 2016; Joseph 
et al., 2019). Additionally, increased mTORC1 signalling is associated with numerous age‐related 
diseases and pathologies, including AD (An et al., 2003), diabetes (Inoki et al., 2011; Volkers et al., 2014), 
and cancer (Bar‐Peled et al., 2013; Grabiner et al., 2014).  
However, importantly, research demonstrates that changes in mTOR signalling are sex and tissue 
specific, and a more complex dysregulation in mTOR is apparent (Baar et al., 2016). Whilst, levels of 
mTOR activity do fluctuate between sex and tissues, the pattern of repression observed in some tissue, 
may still represent an inappropriately high level, and research has indicated that baseline fasted levels 
of mTOR activity are abnormally high in the liver of old mice (O. V Leontieva et al., 2014). However, as 
demonstrated above, age-changes in IGF/Insulin signalling upstream of mTOR show equivocal changes. 
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Moreover, an additional regulator of mTOR activity, AMPK, demonstrates a loss in signalling capacity 
with age to cope with both inherent and environmental stresses, highlighting a general loss of anabolic 
and metabolic homeostasis within the cell which could differentially affect mTOR signalling (Salminen et 
al., 2016). 
1.3. Calorie Restriction 
1.3.1. Calorie Restriction As a Means To Slow the Hallmarks of Ageing 
The field of age-related metabolic dysregulation has been largely driven by observations that reduced 
growth signalling confers improved longevity and healthspan. As early as the 1910s, it was shown that 
blunting the growth of female rats by decreasing their food intake led to life extension and the ability to 
reproduce at older ages than the rats that did not undergo a period of slow growth (Masoro, 2010; 
Osborne et al., 1917).  
Today, over a 100 years of research, across a multitude of model organism, has firmly established calorie 
restriction as the most robust and reliable geroprotective intervention (Liang et al., 2018). Two ground-
breaking and ongoing studies have managed to provide complete lifespan data for CR in Rhesus 
monkeys with 93% genetic homology to humans (Colman et al., 2009; Mattison et al., 2012). 
Unfortunately, whilst both promotive of CR, their conclusions are different: Colman et al. report 
healthspan and survival extension, whilst Mattison et al. report only healthspan extension.  Subsequent 
comparison and review has failed to ascertain which of the two studies is right, but instead, served to 
highlight firstly, the intricacies of defining the composite requirements for optimum calorie restriction, and 
secondly the wavering conservation of CR in line with evolution complexity  (Mattison et al., 2017; 
Vaughan et al., 2017). Significant calorie restriction induced lifespan extension is relatively 
straightforward to elicit in lower order species. At an invertebrate level, mere glucose depletion, the most 
common practice to mimic calorie restriction in yeast cultures, progressively increases the mean and 
maximum life span when glucose concentration drops from 2% up to 0.01% (Lee et al., 1999). Similarly, 
many studies have shown single amino acid depletion or the restriction of nitrogen availability is sufficient 
to increase lifespan in yeast (reviewed in Taormina and Mirisola, 2014). Again, in C. elegans, a non-
parasitic nematode worm,  unregulated and generic calorie restriction through feeding-defective mutants 
confers significant improvements in survival (Avery, 1993), whereas, in flies, diluted yet freely available 
diets with a fixed concentration of sugar can increase lifespan by 50% or more (Tatar, 2006). Whilst 
invertebrate models offer relative malleability in lifespan modulation by calorie restriction, they have also 
provided a vital insight into the importance of dietary ratios and nutrient content. Dietary restriction (DR),  
encompassing the depletion of specific nutrients, rather than the reduction of the overall energy intake, 
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with focus on protein-restriction, has been argued to be responsible for the increased longevity observed 
in fruit flies (Mair et al., 2005). Moreover, evidence continues to highlight the ratio between protein and 
carbohydrate as their most important regulator of lifespan (Carvalho et al., 2005; Fanson and Taylor, 
2012). During the Rhesus monkey trial that elicited lifespan extension, the animals were fed mainly once 
a day whilst twice in the other trial, which may have contributed to the 1.8 lower mortality compared to 
controls in the former. Thus, despite significant unravelling of the various modalities of DR, the molecular 
mechanisms coordinating this pro-longevity response remain obscure.  
There are numerous ways to induce DR/CR in the bacterivorous nematode (Zhang and Mair, 2017).  
Researchers discussing CR in worms are reluctant to use the term “calorie restriction”, instead 
preferring DR, given the variable mechanisms of food intake restriction which are not strictly defined by 
their calories (Zhang and Mair, 2017). DR was shown to increase lifespan in C. elegans are far back as 
1977 (Klass, 1977). In this first iteration, worms were grown in liquid S-medium with a limited bacterial 
food source determined by using a Petroff-Hauser counter and adjusted by serial dilution. This method 
was adopted by early investigators and was amenable to high-throughput study, permitting easy 
quantifiable definitions of food intake. Researchers have noted lifespan extension across ranges of 
dilution with correlative changes in fecundity (Panowski et al., 2007; Zhang and Mair, 2017). However, 
despite its early adoption, concerns regarding continuous swimming for worms and the consequent 
effects on metabolism and stress has led to other ways to induce DR using the standard agar plate-
based methods. The Brunet lab developed solid DR method by feeding animals with E.coli at different 
concentrations, but they were unable to elicit such empathic levels of lifespan extension as compared 
to liquid media, perhaps due to the DR initiation after development which was not the case in liquid 
media (Jianfeng et al., 2015). Indeed this also comes with its limitations, particularly in the 
standardisation of NGM media and peptone content, alongside the unregimented movement and 
bacterial consumption by C. elegans on the plate leading to great variability of DR effects between labs. 
As such, to bypass such variability axenic medium assays have been developed which confer lifespan 
extension, but unfortunately equally elicit a starvation response which is genetically and phenotypically 
separate to that of a DR response. 
Thus researchers have sought to utilise the vast mutant library to induce DR. The most popular of these 
is the eat-2 mutant, which lacks the encoded nicotinic acetyl-choline receptor and renders the 
pharyngeal muscle unresponsive. Animals are unable to efficiently grind the bacteria, inducing DR on 
regular media plates. These animals live around 30% longer than their WT counter parts in part due to 
downregulated TOR signalling, reduced phosphorylation of S6K and increased autophagy (Lakowski 
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and Hekimi, 1998). Importantly however, these animals are subject to DR during development, 
confounding longevity variables, and furthermore, due to the lethality of null mutants, the utilized alleles 
are typically hypomorphic mutations (Kapahi et al., 2017). In other papers, attempts to instead limit the 
uptake of nutrients in the gut have been made to induce DR. Fei et al. used RNAi to knockdown 
sodium-dicarboxylate cotransporters (NAC-2 – NAC-3), a key TCA intermediate transport protein in the 
gut, to reduce nutrient availability, and conferred significant lifespan extension (Fei et al., 2003).  
Whenever testing the efficacy of any DR model in worm, researchers tend to establish its connectivity 
and integration to ISS signalling. As described in other model organisms, downregulating the conserved 
Ins/IGF-1 pathway also significantly extends lifespan in C. elegans. In fact, genes acting on this 
pathway were the first genes to be directly linked to ageing and some of the genes in this pathway, 
including the FOXO transcription factor DAF-16 have been linked to DR (Kenyon, 2010). The IIS 
pathway is regulated by insulin-like peptide ligands that bind to the insulin/IGF-1 transmembrane 
receptor (IGFR) ortholog DAF-2. Activated DAF-2 results in recruitment and activation of the 
phosphoinositide 3-kinase AGE-1/PI3K. In turn, the serine/threonine kinases PDK-1, AKT-1, and AKT-2 
are activated, resulting in phosphorylation of the DAF-16/FoxO, and translocation to the nucleus and 
transcription of key longevity genes. Mutations in either age-1 or daf-2 almost double lifespan 
compared to wild-type worms and this prolonged lifespan phenotype is dependent on the FOXO-family 
transcription factor daf-16 (Kenyon, 2010; Kenyon et al., 1993). Importantly, downregulation of the ISS 
pathway elicits significant improvements to healthspan in C. elegans relevant to human ageing 
including sustained neuromuscular junction activity, learning and memory, supressed 
neurodegenerative protein aggregation, and pertinent to the limitations of  DR: an improved immune 
system (Cohen et al., 2006; Evans et al., 2008; Hsu et al., 2009; Kaletsky et al., 2016; Kauffman et al., 
2010). The necessity of various components of the ISS pathway for geroprotection in C. elegans is 
varied depending on the dietary regime, highlighting not only  the difficulty in homogenising DR regimes 
in worms, but also demonstrating that a single CR “master switch” is unlikely to exist. Specifically, daf-
16 is only indispensable for lifespan extension by dietary restriction on solid media, and notably this is 
mediated by AMPK, or in longevity mediated by CR in middle-aged organisms (Greer et al., 2007). 
Bacterial dietary restriction (bDR), liquid DR (lDR), modified solid DR (msDR) and anexic medium all 
extend lifespan independent of daf-16 (Jianfeng et al., 2015). Furthermore, dietary restriction by bDR, 
axenic mediums and chronic bacterial deprivation all extend the lifespan of daf-2 hypomorphic mutants 
(Zhang and Mair, 2017). Eat-2 mutants also seem to extend lifespan independent of daf-2:  eat-2;daf-2 
double mutant lived 20% longer than daf-2 alone and daf-2 on axenic medium live 274% longer than 
WT (Taormina and Mirisola, 2014). This non-linear complexity is furthered by the fact only 14 out of 17 
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eat mutants have increased mean and maximal lifespan, and therein they differ in their mechanisms of 
action: eat-2(ad1113) and eat-2(ad465) alleles require sir-2.1 to promote longevity whereas the eat-
2(ad1116) allele does not (Gao et al., 2018; Kapahi et al., 2017). Nonetheless, eat-2 mutants remain a 
favoured and versatile model of DR in worms, particularly given its amenability to bacterial RNAi.  
Supportively, rodent studies have demonstrated that CR without malnutrition, or DR through sole 
methionine restriction, suppresses circulating IGF-1 and insulin levels in proportion to the level of 
restriction (Vitale et al., 2019; Sanchez-Roman and Barja, 2013). This correlates with the observation 
that serum IGF-1 concentration is inversely correlated with median lifespan in 31, genetically-diverse, 
inbred mouse strains (Yuan et al., 2009). Thus, the downregulation of IGF-1/GH/Insulin signalling has 
been suggested to mediate some of the lifespan extension properties of CR. 
In humans, whilst IGF-1 levels have been correlated to lifespan, the data is inconclusive. Some studies 
report reduced IGF-1 in centenarians (Arai et al., 2001)  and long-lived individuals (Bonafè et al., 2003), 
whilst other research demonstrates an opposite relationship (Paolisso et al., 1997). Furthermore, in 
humans, calorie restriction does not reduce serum IGF-1 concentration, however a recent meta-analysis 
has challenged this (Lettieri-Barbato et al., 2016). Additionally, most recently, the CALORIE study group 
has  offered the first adequately powered research into the clinically controlled and reported effects of 
long term calorie restriction (Fontana et al., 2016). They designed a multicentre randomized controlled 
trial of calorie restriction lasting 2 years. Results again corroborate findings from shorter term (6 month- 
1 year) studies, demonstrating an inability of CR to reduce IGF-1. Researchers did nevertheless note a 
significant and persistent increase in serum IGFBP‐1, an inhibitory binding protein which should confer 
a reduction in IGF-1 potency. 
As highlighted earlier, the two most prominent downstream targets of IGF signalling is mTOR and AMPK, 
however inputs from other sources effect the activity of these enzymes. mTORC1 has for many years 
been considered a key nutrient sensor, fuelling speculation that the lifespan-enhancing effects of CR are 
at least partly mediated by decreased mTORC1 signalling. A role for reduced mTOR activity in ageing 
was first demonstrated in worms deficient in their mTOR ortholog let-363 which more than doubled its 
natural lifespan (Vellai et al., 2003). In flies, repression of mTOR activity through inhibition of upstream 
TSC complexes conferred a significant increase in lifespan (Kapahi et al., 2004). Given the essentiality 
of  mTOR in mammalian growth and development, knockout is lethal in mice and presumably in higher 
order species: mTOR mutant murine embryos lack forebrain development and body axis rotation, 
resulting in death at midgestation (12.5 days post) coitum (Hentges et al., 2001). That said, several 
mouse models of decreased mTOR signalling exist, with single allelic copy mTOR+/- mice demonstrating 
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a   14.4% increase in mean life span relative to wild type (Lamming et al., 2012). Likewise in flies, 
downstream of mTOR, caloric restriction up-regulates the Drosophila equivalent of 4E-BP (d4E-BP), and 
augmenting d4E-BP is sufficient to extend lifespan in this organism (Zid et al., 2009). Furthermore, the 
most robust pharmaceutical intervention that extends lifespan is rapamycin, an inhibitor of the mTOR that 
can improve longevity  in yeast, worms, flies, and even mice (Ehninger et al., 2014). 
Some researchers believe the anti-aging benefits of CR are solely and directly mediated by mTOR. 
Blagosklonny (2010), has stated that, “nutrients activate TOR, which is involved in ageing. By deactivating 
TOR, CR slows ageing. There is no aim, no selective advantage, no purpose. Simply: food activates TOR 
and TOR drives ageing.”  As discussed, stress resistance and homeostatic flexibility play a central role 
in preventing mortality with age.  Research in both kidney and liver has showed that, DR can improve 
resistance to multifactorial acute stress of ischaemia and reperfusion; however this protection is 
dependent on mTOR signalling (Harputlugil et al., 2014; Robertson et al., 2015). Further hepatic evidence 
suggest specific DR through amino acid restriction reduces mTOR phosphorylation and activity. Isocaloric 
restriction of protein markedly inhibits prostate and breast cancer growth in human xenograft animal 
models of neoplasia in part via a down-regulation of intratumor mTOR activity (Fontana et al., 2013). 
Given the amino acid specific signalling of mTOR, this research provides evidence that the proportion of 
lifespan extension of CR mediated by protein restriction may be elicited through reduced mTOR 
signalling. Whilst CR-like regimens do not addtively lengthen the lifespan of yeast or worms already 
exhibiting downregulated mTOR, this is not entirely replicated in higher order species or indeed other 
worm models (Hansen et al., 2007; Kaeberlein et al., 2005).  In flies, rapamycin fed to CR flies was able 
to additively increase maximal lifespan, suggesting CR may be more complex and affecting survival 
through pathways supplementary to mTOR. Furthermore, that RNAi knockdown of key downstream 
mTOR targets, S6K and translation initiation factors, yield an additive lifespan extension when combined 
with dietary restriction in C. elegans (Hansen et al., 2007). In mammalian models, the research is even 
more inconclusive as data suggests that mTOR signalling may only be reduced in specific tissues . 
Furthermore, rapamycin-induced inhibition of mTOR activity elicits significantly distinct and unique 
transcriptional and metabolomic profiles to that of CR (Wilson C Fok et al., 2014). However, in 
combination, DR mice given Rapa showed a significant change in many transcripts and metabolites, 
which were not changed significantly by DR or Rapa alone (Wilson C Fok et al., 2014). As the authors 
state, “These data suggest that feeding DR mice Rapa would increase lifespan over that observed in DR 
mice.” Recent evidence has shed some light on the possible reason behind the diversity of results, in that 
mTOR may not be constitutively downregulated at all times by CR/DR. In a very recent paper, Tulsian et 
al. demonstrate that the effect of CR on mTOR activity is entirely time-dependent (Tulsian et al., 2018). 
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CR induced mTORC1 activity at one time, reduced at two times and has no effect during other times, 
suggesting that the unification of feeding times across experiments may further research into the 
ambiguity of mTOR signalling and CR. Whilst a direct linear relationship between CR and mTOR activity 
may not hold true, owing in part to complex organ function, non-unified feeding regimes, and inconsistent  
quantification of mTOR signalling, there is broad consensus that reduced mTORC1 signalling probably 
contributes to longevity and health benefits as a result of dietary restriction, whether that be through 






Figure 1. Nutrient Sensing Pathways Associated with Ageing And The Geroprotective Effects of Calorie 
Restriction. Schematic illustration of three evolutionary conserved pathways which interlink to regulate the 
response to nutrient availability in multicellular eukaryotes. Decreased nutrient availability triggers a reduction in 
extracellular growth factors and intracellular ATP and amino acid levels. Downstream activation of AMPK and 
concomitant downregulation of ERK, AKT and TOR signalling in both mammalian and nematodal systems results 
in metabolic conservation and attenuation of anabolic activity. C.elegans orthologs are represented in red and 
proteins evolutionary and synonymously conserved in both mammalian and nemotodal systems are represented 




Of course, AMPK activation is the best-described intracellular trigger for mTOR inhibition, and 
unsurprisingly, CR is continually associated with AMPK activity. However, unfortunately the relationship 
is also complex. At a most basic level, glucose depletion in yeast causes an upregulation of AMPK activity 
and nuclear localisation (Turcotte et al., 2010). A collection of research has demonstrated that the sole 
overexpression of aak-2, a C. elegans AMPK ortholog, in worms can increase lifespan whilst its deletion 
reduces lifespan (reviewed in Cantó and Auwerx, 2011). Furthermore, aak-2 is increased during glucose 
restriction and calorie restriction demands the functional presence of aak-2. Similarly, in fruit flies, RNAi 
knockdown of the gamma subunit (AMPKγ) extended lifespan and abrogated any additive lifespan 
extension through starvation (Johnson et al., 2010). However, much like mTOR signalling, a linear 
relationship is not sufficient when approaching mammalian models: increased AMPK activity is not the 
sole reason for the benefits seen in calorie restriction. Indeed, some research suggests chronic AMPK 
activation may shorten lifespan (in yeast) and incur myopathies in mammals (Burwinkel et al., 2005). With 
that said, it is clear that AMPK relates to CR. Perhaps a more plausible explanation may be that AMPK 
may help coordinate some adaptions to CR through temporal and spatial changes in phosphorylation, 
rather than being the activated nexus of a single pathway.   
Ageing is the most universal contributors to the etiologies of metabolic decline and disease and given the 
role AMPK has in nutrient sensing, it is highly likely any relationship between AMPK and CR would exist 
through an improved sensitivity to insulin and response (Barzilai et al., 2012). Ageing commonly presents 
with insulin resistance, manifesting in unrestrained hepatic gluconeogenesis, adipose lipogenesis, and 
defective glycogen synthesis, glucose uptake in skeletal muscle and potential type-2 diabetes. This is 
progression is in part precipitated by increased age-associated adiposity which proliferates inflammatory 
signalling and free-fatty acid release, all of which can contribute to the pathogenesis the age-associated 
chronic condition. The CALERIE studies have clearly demonstrated that CR ameliorates adiposity and 
improves insulin sensitivity and reduced fasting insulin and lipid profiles (Larson-Meyer et al., 2006). The 
aforementioned CR Rhesus monkey trials both reported age-related divergence in fasting glucose levels, 
with increases more marked in control monkeys (Mattison et al., 2017).  Additionally, CR animals had 
lower incidence of glucoregulatory dysfunction than controls in both studies. Again, adiponectin is central 
to ageing with it not only being increased in young and CR individuals high circulating levels are found in 
several long-lived mouse mutants and human centenarians (Fontana et al., 2010). Unsurprisingly, 
adiponectin is an insulin sensitizer with anti-inflammatory properties and a potent activator of AMP-
activated protein kinase (AMPK). A further connection between the physiological effects of CR and AMPK 
is mitochondrial dysfunction. In brief, AMPK through ULK1 can increase mitophagy and can  
phosphorylate mitochondrial fission factor and promote mitochondrial fission upon energetic stress, 
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ensuring AMPK acts as a signal integration platform to maintain mitochondrial health (Herzig and Shaw, 
2018).  
However, the nexus of AMPK and indeed mTOR is not limited to an amelioration of insulin resistance 
and oxidative stress. CR is routinely cited as the most robust physiological inducer of autophagy and 
nutrient depletion is the gold-standard for autophagic induction in culture (Kroemer et al., 2010). In vivo, 
autophagic response to CR is oscillatory: autophagy is rapidly upregulated as early as 30 min after 
access to nutrients has been limited, before shortly being downregulated only to surge again after 10 
hours. It is suggested that this serves to prevent pathologically excessive autophagy and maintain 
proteostatsis (Zhang and Cuervo, 2008).   Thus, autophagy is a vital component of CR-induced 
longevity. Multiple models have demonstrated that the benefits of dietary restriction are abrogated 
following the knockdown of autophagic machinery (Rubinsztein et al., 2011). Regulation of this 
machinery is tightly controlled, as previously discussed, by mTOR and AMPK. Long-Term Calorie 
Restriction in humans not only increases the expression of AMPK, but also SIRT family transcripts, 
ULK1, ATG101, APG12, GAPRAP/GATE‐6, beclin‐1, autophagin‐1, and LC3 gene expression, as well 
as protein expression of FOXOs, PGC1α, beclin‐1, and LC3 (Yang et al., 2016). Murine work has 
explicitly shown CR to upregulate neuronal autophagy, limitingly in young mice, as effect of CR in older 
mice is less present (Alirezaei et al., 2010). Thus, in application, an AD mouse model fasted for three 
months caused significant autophagic induction however was unable to significantly clear aggregates 
(Chen et al., 2015) . This is at odds to other research using specific autophagic activators such as 
rapamycin that attentuate cognitive deficits and reduces amyloid-beta level (Spilman et al., 2010). With 
that said, a plethora of studies have highlighted the effects of CR on hepatic and sarcoplasmic 
autophagy which can be reviewed in Bagherniya et al., 2018. Of most interest is the observation that 
mild CR could attenuate the age-related sarcopenic impairment of autophagy in rodent skeletal muscle, 
which might be one of the mechanisms by which CR attenuates age-related cellular damage and cell 
death in skeletal muscle in vivo (Wohlgemuth et al., 2010). 
In summary, CR should serve to attenuate the anabolic signal of insulin and overnutrition which send 
positive growth and proliferative signals, pushing cellular balance toward growth and cell division. 
“Increased metabolism will produce ROS from mitochondria as well as shortening the time in which cells 
repair or replace old or damaged molecules. Although enough energy is present to produce daughter 
cells, these rapid rates of cell division may be harmful. Therefore, CR may promote increased lifespan 
by decreasing rates of cell division and favouring repair and maintenance” (Gillespie et al., 2016). 
57 
 
1.3.2. Concerns and Pitfalls of Calorie Restriction 
Despite the seemingly beneficial profile of CR, there has of course been significant concerns and pitfalls 
highlighted by critics. On a purely practical level, defining CR is difficult, and no unified composition and 
intake has been established. In terms of total caloric intake, it is apparent that severe rather than 
mild/moderate CR in humans results in the same metabolic and molecular adaptations typical of long-
lived CR animals, whilst improving overall health and reducing multiple metabolic factors implicated in 
the pathogenesis of the most common chronic diseases typical of Western countries (Most et al., 2017). 
For many though, severe CR with adequate micronutrition is not an option. Primarily, intentional CR in 
elderly populations would contribute to significantly higher risk of functional impairment and incident 
disability (Coker and Wolfe, 2018). In an exhaustive review of dietary interventions in the elderly it was 
concluded that caloric restriction or “dietary alone”–induced weight loss contributed to the development 
of sarcopenia and bone loss, and likely precipitated the genesis of frailty in vulnerable individuals (Batsis 
et al., 2015). These concerns are mirrored in a recent review by Ingram and de Cabo, who describe the 
limited utility of CR in aged rodents, and the potential implications for humans (Ingram and de Cabo, 
2017). Both mice and rats initiated on CR in late-life often results in negligible effects or indeed reductions 
in longevity (Forster et al., 2003; Lipman et al., 1998, 1995; Ross, 2009). Research into the latest 
beneficial initiation point is ongoing, however Dhahbi et al. initiated CR (~40%) in 19-mo old male C3B6F1 
mice and reported significant increases in lifespan accompanied by reduced tumour rates as well as a 
global gene transcriptional profile that resembled life-long CR (Dhahbi et al., 2004).  
However, responsiveness to CR is not a ubiquitous phenomenon, and its ineffectiveness is not limited to 
the elderly. This is at odds to the attractive paradigm of longevity prolongation by CR being universal 
among animals. If the applicability of CR to human longevity is not upheld through evolutionary 
conservation, it is critical to the rationale of its implementation. This is particularly concerning given the 
apparent unresponsiveness of Colman’s Rhesus monkeys, who despite demonstrating reduced 
morbidity,  failed to live any longer (Colman et al., 2009). Subsequent discussion has indeed highlighted 
the possibility that CR is genotype sensitive, and optimum food intake is genotype and sex-specific, 
explaining the disparity of responsiveness between the two rhesus monkey trials (Mattison et al., 2017). 
This idea has been explored further in rodents. Research at two separate sites  showed that the effects 
of 40% CR were very dissimilar in different ILSXISS recombinant inbred strains of mice, with some strains 
exhibited an adverse response (Liao et al., 2010; Rikke et al., 2010). This has been reciprocated in short 
lived DBA/2J mice that exhibit a genotype-specific variability in CR responsiveness ranging from a slight 
reduction to a greater than 60 % increase in mean lifespan (Ingram and de Cabo, 2017). Researchers 
suspect that stringent CR regimes of ~40% may be too aggressive for certain strains, which would result 
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in undernutrition. Thus, some strains would maybe exhibit increased lifespan if they were tested at a 
lower level of dietary restriction. Furthermore, it may be that longevity-extending effect of CR is only 
evident when animals have been housed in laboratory conditions for several generations, evidenced by 
an inability to extend lifespan in wild caught mice (Harper et al., 2006).  
 
Figure 2 Concerns and pitfalls regarding the clinical applicability of calorie restriction for geroprotection 









The modulation of dietary intake to test optimal dosages is achievable in rodent models due to the 
administration of a fixed and regulated simple diet. This is extremely difficult and is succinctly expressed 
in a recent review, “Randomized controlled trials for single micronutrients or bioactive ingredients are 
much easier to accomplish than macronutrient, whole food, or dietary pattern studies. The more complex 
the design of menus; the procurement, storage, and transfer of the intervention to the participant; and the 
participant’s ability to handle receipt of the intervention, including storage, preparation, and protocol 
compliance, can be daunting” (Weaver and Miller, 2017) . One of the largest obstacles to CR in human 
populations is undoubtedly compliance and this can be greatly improved if the regime is tolerable. 
However, research has continually raised the psychological problems induced by CR, mostly pertaining 
to mental challenge of reduced food intake.  Active participants have reported an increased desire to eat 
and a decreased satisfaction of appetite (Anton et al., 2009). This has been tied to pressing concerns 
following the development of eating disorders such as binge eating, anorexia and bulimia in CR trials 
(Redman and Ravussin, 2011). Reassuringly, however, well-controlled studies such as CALORIE have 
reported no adverse effects of CR on mood, cognitive performance, memory, attention and health-related 
quality of life after 2 years of CR (Martin et al., 2016; Velthuis-te Wierik et al., 1994). The effects of 
decades of CR are still unknown and furthermore, the effects of long-term CR on cognition and 
neurodegeneration in humans will remain unknown for years to come. Little research on cognition has 
emerged from the rhesus monkey studies. That said, a pertinent study in non-human primates using 
lemurs noted that, whilst cognitive and behavioural performances were  not modulated by CR, a 
significant acceleration atrophy of grey matter occurred following CR (Pifferi et al., 2018). This reinforces 
potential concerns regarding the long-term administration of CR on brain integrity in human populations.  
Concerns have also been raised regarding the immunological function of animals under CR. Gardner et 
al. (2005; 2011) in a series of papers first provided experimental evidence that CR mice exhibited CR 
impaired responses to the influenza virus resulting in a much higher risk of mortality. These concerns 
were compounded by increased colonisation by various nematode infections following inoculation in CR 
mouse strains, which additionally proliferated an aberrant t-cell response (Kristan, 2007; Shi et al., 1998). 
Furthermore, infection with Helicobacter hepaticus induced greater colitis and resultant mortality in CR 
SMAD3−/−mice vs control SMAD3−/−mice (McCaskey et al., 2012). Conversely, many papers have 
associated CR with improved immune function. This stems from research suggesting mice injected with 
influenza faired significantly better than their controls (Effros et al., 1991). Kristen has since reviewed the 
relationship between CR and infection and concluded that despite an enhanced immune function, “CR 
hosts are more susceptible to infection by intact pathogens than their fully fed counterparts”(Kristan, 
2008). It is likely, that the metabolic demands required to mount an appropriate immune response may 
60 
 
not be met in CR rodents. This reflects similar concerns of slower wound healing in CR rodents which 
may translate to reduced reserve function in humans. For some decades, a continuous flow of research 
has amounted. As early as 1988, studies reported that mice, and then later, that rats on CR had slower 
rate of wound healing measured by in vivo assays (Harrison and Archer, 1987; Hunt et al., 2012; Reed 
et al., 1996). This is supported by mechanistic studies elucidating that CR mice have affected collagen 
production, extracellular matrix deposition and neovascularisation (Otranto et al., 2009; Spanheimer et 
al., 1991). It is thought that CR does not diminish the ability to heal wounds but rather preserves one’s 
proliferative capacity, and upon the reinstating of sufficient nutrient reserve, wound healing is actually 
enhanced (Dirks and Leeuwenburgh, 2006). This theory is bolstered by murine work showing that upon 
ad libitum refeeding of CR mice 4 weeks prior to injury, resulted in improved wound healing compared to 
controls (Reed et al., 1996). In humans, results again lack long term inference. Mild leukopenia has been 
observed in the CALORIE-2 CR population but there is a negligible impact on immunity (Contreras et al., 
2018). In non-human primates and mice, the number of naive t-cells in CR populations is higher and 
unchanged in human populations undergoing over a decade of CR (Messaoudi et al., 2006; Meydani et 
al., 2016; Tomiyama et al., 2017). Thus CR must be approached with caution in those who are immune-
deficient or indeed vulnerable to infection, and more work must be done to establish CR dosages that do 
not significantly impinge on immune function. 
Critics also highlight the danger of reduced musculoskeletal integrity associated with CR (Larson-Meyer 
et al., 2010; Velthuis-te Wierik et al., 1994). Additionally, reduced muscle mass and energy reserve, as a 
result, have been shown to reduce physical performance in humans and model organisms. Short-term 
CR studies in humans demonstrate a shortened time to exhaustion and reduced strength and aerobic 
fitness (Larson-Meyer et al., 2010; Velthuis-te Wierik et al., 1994).   Undoubtedly, human trials have 
demonstrated that CR produces favourable body compositions. CR participants experience reductions in 
fat mass with a higher lean skeletal muscle mass-to-fat mass ratio (Das et al., 2017; Mercken et al., 
2013). There is of course a concomitant reduction in free-fat mass and obviously muscle mass (Das et 
al., 2017). This was initially concerning; however, it is now apparent that upon nutritional equilibrium to 
muscle mass, skeletal muscle declines plateau (Dirks and Leeuwenburgh, 2006). From thereon, research 
suggest that muscle strength actually increases relative to body mass in CR participants (Racette et al., 
2017). However, whilst participants remained relatively strong, the objective sarcopenia must be 
tempered with thermogenesis and protective concerns. Individuals with less muscle mass may have a 
reduced ability to generate heat, manifesting in increased cold sensitivity in participants (Dirks and 
Leeuwenburgh, 2006). This of course endangers individuals with comprised thermoregulation or indeed 
reduced stress resistance.  Importantly, reduced body weight, insulation and muscle mass may lead to 
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increased exposure of potentially weakened muscles to trauma. Long term calorie restriction has been 
shown to significantly decrease bone mass and mineralisation in both mice and humans (Ingram and de 
Cabo, 2017; Villareal et al., 2016). Concerningly in humans, this bone loss was found to be at clinically 
important sites of osteoporotic fractures such as the hip and femoral neck and the lumbar spine (Villareal 
et al., 2011). This is compounded by mouse studies showing that mid-life CR resulted in detrimental 
effects to bone architecture and strength (Banu et al., 2001; Colman et al., 2007). Clinical trials in humans 
have challenged the effects of reduced bone mass. Indeed, members of the CR society actually show no 
change in the rate of bone turnover (Villareal et al., 2011). Furthermore, trabecular bone architecture, (a 
major determinant of bone strength and a good predictor of the risk of developing fragility fracture) was 
not significantly different between the CR and control groups, despite the CR-mediated low bone mineral 
density (Most et al., 2017; Villareal et al., 2011). It has been suggested that although bone density may 
decrease, bone quality and strength is improved through a reduction of bone turnover and a prevention 
of secondary hyperparathyroidism (Most et al., 2017; Villareal et al., 2011). As suspected, CR does have 
a proclivity to affect bone quality and mass, however these appear to be dose and site-dependent. In 
dosage tested in mice, only 30-40% CR induced negative effects on bone architecture  (Berrigan et al., 
2002). This reinforces concerns regarding the appropriate composition and dosage of CR for humans to 
maintain appropriate body composition and musculoskeletal integrity. Moreover, the significant reduction 
in fat mass seen from CR, can lead to sexual dysfunction, infertility and menstrual irregularities in women 
(Dirks and Leeuwenburgh, 2006). Imperatively, women with low BMI are at greater risk for pre-term 
delivery and birth of low birth-weight infants (Allen et al., 1994). These associations detail more broader 
concerns of CR on reproduction in animals and humans.    
Fecundity concerns of CR centre around the disposable soma theory: the reallocation of resources away 
from reproduction to somatic maintenance (and thus survival) to increase the chance of surviving the 
period of resource limitation. Thus, calorie restriction should, in theory, result in reduced reproductive 
capacity. Simply, reproductive output is negatively associated with lifespan in humans (Tabatabaie et al., 
2011). However direct evidence in humans is limited. In mice, long lived species tend to have a markedly 
reduced reproductive capacity and CR indeed supresses fecundity (Partridge et al., 2005; Soultoukis and 
Partridge, 2016). Mice on CR, additionally, produce offspring with low birth weight and multiple metabolic 
defects, including early life adiposity, altered pancreatic function and progressive glucose intolerance 
(Ingram and de Cabo, 2017). A recent meta-analysis looking at the effect of reproduction and CR in 26 
studies on over 20 different species, based on 1096 control and 1132 treatment subjects drew three 
conclusions (Moatt et al., 2016). First and foremost, and in agreement with other research by Nakagawa 
et al., CR does lead to a reduction in reproduction but, in line with longevity (Nakagawa et al., 2012). 
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Second, reproduction declines linearly with increasing CR, at odds with both current evolutionary theories 
of CR. However, they were uncertain of the reliability of this pattern given the paucity of data at the tails 
of distribution. Lastly, they noted a sexually dimorphic effect of CR, with a greater effect in females. The 
authors primary concern regarding all three conclusions hinged on a selection bias towards routinely 
used model organisms. Indeed they highlighted the citation bias towards 3 studies using drosophila and 
rats that may be shaping false assertions between fecundity and CR. The meta-analyses found the rate 
of decline of reproduction with increasing CR was steeper in model than non-model species. This could 
be due to two contributing factors. Frist, laboratory animals have been in nutrient rich environments for 
many generations, putting selective pressure towards fecundity rather than longevity. Thus, CR model 
organisms respond more plastically to food availability. Second, it may be that after decades of research, 
the dosages required to elicit efficacious CR in these model organisms has been well established 
compared to other animals, such that effect of CR on fecundity is further unmasked.  
In monkeys however, the effects of moderate CR on reproductive function is less apparent. Female 
rhesus monkeys undergoing 30% CR displayed no adverse effects (Sitzmann et al., 2008). In males, CR 
appears to have little impact on testicular function or sperm parameters, however ejaculate osmolality 
and pH were benignly changed in response to nutritional status (Sitzmann et al., 2010).  
In conclusion, CR is clearly not appropriate for certain sub-populations, such as women of child-bearing 
age, developing children and adolescents, and elderly or infirmed populations. Furthermore, until an 
appropriate dosage of CR can be established the risks posed by inappropriate levels of CR remain a 
large obstacle. Even with appropriate dosage and composition, the window of opportunity to prescribe 
CR is small and may be ineffective. Taking females for example, their childhood and adolescence would 
prohibit CR. Then during their twenties there may be a small window to incorporate CR. Then throughout 
child-bearing ages of 30, CR again becomes inappropriate. Then, provided they remain free from illness, 
which is unlikely, there may be a period to implement CR from 40-60. From 60 onwards, particularly in 
menopausal woman, concerns over musculoskeletal integrity may prohibit CR. Would this be a big 
enough period of implementation? 
1.3.3. Calorie Restriction Mimetics 
There is a clear moral and economic obligation to rapidly provide an intervention to decelerate the 
ageing process. At present, calorie restriction offers the most feasible and robust intervention.  
However, as highlighted, several concerns surrounding the applicability, tolerability and safety of calorie 
restriction currently precludes its adoption. Thus, the search for a viable alternative that could 
recapitulate the phenotype of calorie restriction without dietary implementation has greatly accelerated 
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in the last decade. In 1998, the discovery that feeding 2-‐Deoxy‐d‐glucose to rats mimicked the 
physiological effects of calorie restriction, led to the coining of the term “calorie restriction mimetic” 
(CRM) (Lane et al., 1998). Since then, the number of citations associated with the term has grown from 
21 citations in 2006, to 75 citations in 2015 (Ingram and Roth, 2015).  
A number of recent reviews on CRM state the main limiting factor which justifies the use of CRMs is a 
poor compliance to the demands of a CR lifestyle, likely explaining some failures in observational 
clinical studies (Madeo et al., 2019; Picca et al., 2017; Redman et al., 2018; Shintani et al., 2018). 
Indeed, the overarching benefit of CRMs lies in the fact one may have their cake and eat it. In fact, 
according to Ingram and Roth, CRMs by definition, must not exert their benefit through a reduction in 
food intake and any doing so would constitute an induction of CR rather than a de facto mimicry 
(Ingram and Roth, 2015). Key here is the ease of implementation. CRMs, manifest normally as 
pharmacological intervention, and offer users the hormonal, metabolic or physiological effects of CR 
without a substantial change in diet or caloric intake. Thus, the compliance to such a regime is far more 
likely to persist for the requisite duration that CR demands. Furthermore, given the vital caveats 
surrounding the daily implementation of CR in terms of dietary composition and timing, CRMs should 
fare better. A single CRM would require tailoring only in its dosage and timing. This expediates trials in 
model organisms as researchers need to account for less factors. Consequently, an optimum dose and 
regime should be found sooner, and if translatable to humans, offers a routine and followable 
prescription.  
The oft-cited unsuitability of CR in many subpopulations is in part driven by the pleiotropic nature of CR 
that induces a catalogue of physiological effects. The numerous and largely undefined pathways which 
mediate the ageing process, do of course, also involve themselves in the regulation of immunity, tissue 
repair, thermoregulation and reproduction (Le Couteur et al., 2012). Ideally CRMs would bypass the 
pleiotropy of CR and provide a more targeted approach. Indeed, this distinction prefaces the duality of 
CRM research: those that search to provide upstream substrates that fully recapitulates CR and those 
that wish to elicit certain cellular responses of CR through downstream activation of key pathways.  
Some researchers propose that the effects of CR can only result from upstream processes as rather than 
being driven through a single or a few vital genetic pathways, ageing is manifested through the actions 
of multiple pathways. Thus a screen for identifying candidate CRM should focus on direct manipulation 
of metabolic and energy sensing systems (Ingram et al., 2006). As briefly mentioned, 2-‐Deoxy‐d‐glucose 
was the first example of an upstream CRM and exerts its prolongevity effect through the suppression of 
glycolytic activity (Roth et al., 2005). Consequently, metabolism is shifted to mitochondrially-based 
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oxidation of fat and an increased formation of ROS. This is represented by a reduction in metabolic rate, 
manifested as a reduction in locomotory activity, heart rate, and blood pressure similar to CR (Wan et al., 
2003). Elegant C. elegans study demonstrated that the likely longevity benefit of 2-deoxy-d-glucose was 
derived from “mito-hormesis”: a mild stress response  from low dose free radical toxicity that encourages 
cell survival and preservation (Schulz et al., 2007). It follows on from the more general concept of 
“hormesis” which stipulates that low-dose stress on an organism can improve healthspan and lifespan. 
A similar compound, d-Glucosamine, also demonstrates glycolytic inhibition which upregulates the 
mitohormetic response and improves longevity in model organisms (Weimer et al., 2014). Subsequent 
work shed some light on the mechanisms of this metabolic shift, showing that glucosamine upregulated 
autophagy in an mTOR independent manner, and this upregulation was essential for increased lifespan 
(Shintani et al., 2010). Many compounds, including amino acids and metabolic intermediates like βHB 
and α-ketoglutarate are upstream CRMs (Chin et al., 2014; Kim et al., 2018a). Notably, pharmacologically 
induced glucose restriction mediated by a number of compounds, such as 2-Deoxy‐d‐glucose, 
glucosamine and d-allulose extends healthy lifespan in worms (Schulz et al., 2007; Shintani et al., 2017).  
Another technique that has been employed to directly inhibit the utilization of ingested calories is 
through the blockade or retardation of fat digestion or absorption. The two most well-studied candidates 
are chitosan and orlistat (Ingram and Roth, 2015). Chitoson is a supplement purported to bind to or 
“trap” dietary fat, preventing fat absorption and causing fat excretion. These reports are based on 
rodent assessment, however human analysis has revealed little change in faecal fat excretion (Gades 
and Stern, 2005). Orlistat, a commonly prescribed anti-obesity medication, similarly works by slowing 
fat breakdown through the inhibition of pancreatic lipases (Hollywood and Ogden, 2011; Zhi et al., 
1995). Undoubtedly, these compounds have elicited significant physiological changes suggestive of CR 
such as weight loss and favourable changes in lipid profile and glycaemic control  in overweight 
individuals (Jacob et al., 2009; Jull et al., 2008; Rucker et al., 2007). However, there have been no 
studies demonstrating any effect of these compounds on lifespan or indeed healthspan and it is unlikely 
efforts have not previously been made. Thus, at present glycolytic inhibition appears the most 
recapitulative upstream mechanism to mimic CR longevity. Importantly though the main limitation to 
upstream energy targeting lies in the precise holistic mimicry of CR. Whilst their activation of anti-aging 
pathways may be undifferentiated, they will of course also lack orthogonality, which CRMs were 
intended to epitomise.   
As such, researchers have looked to modulate specific downstream pathways of CR in a hope it might 
provide a more precise and directed evocation of the beneficial aspects of CR without any adverse 
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associations. Indeed, the most successful interventions have focussed on the 3 main age-associated 
pathways: mTOR, AMPK and IGF-1. When assessing the validity of a compound as a CRM beyond its 
inability to alter food intake, researchers propose that they must also activate stress response 
pathways, provide protection against stressors and lead to a preservation of healthspan (Ingram et al., 
2006). Two major drugs have emerged as leaders of the race to define the first bone-fide prescriptible 
CRM. 
Firstly, pharmacological interventions aimed at activating the AMPK nexus have been developed or 
repurposed to mimic CR downstream. These substances include some FDA-approved drugs including 
biguanides, resveratrol, thiazolidinediones, salicylates and glucagon-like peptide-1 receptor agonists  
(Vaiserman et al., 2016). Biguanides represent a class of compounds that include phenformin, 
buformin, and the modern-day metformin and have been used since the 1950s as major anti-diabetic 
treatments due to their robust ability to reduce hyperglycaemia, insulin, gluconeogenesis, 
intestinal glucose absorption, serum lipids and somatomedin (Ingram and Roth, 2015). However, in 
response to safety concerns over lactic acidosis development in many patients on forerunner 
biguanides (phenformin and buformin), metformin has since become the most widely used biguanide 
drug to treat type 2 diabetes mellitus (T2DM) and metabolic syndrome with over 120 million 
prescriptions worldwide (Anisimov, 2003; Lushchak et al., 2017).  
The ubiquitous and long-term clinical use of metformin has provided data for the thousands of 
publications and precipitated over 2000 metformin clinical trials  (Balasubramanian et al., 2017). 
Moreover, this has provided a platform for key epidemiological study and meta-analyses linking 
metformin usage to improved survival outcomes and ageing in general.  Early studies by Scarpello 
(2003) and also Eurich et al., (2005) noted increased survival from all-cause mortality in diabetic and 
heart-failure patients. At a similar time, concordant research observed a reduction in cardiovascular risk 
in individuals with diabetes treated with metformin (Johnson et al., 2005). This has since been 
supported by recent work demonstrating a 6% reduction in CV risk and also carotid artery intima-media 
thickness (a surrogate marker of CVD) in metformin treated diabetics (Petrie et al., 2017; Wang et al., 
2017). Meta-analyses have revealed conflicting evidence with the first suggesting reported no 
significant over-all mortality benefit of metformin whilst the more recent, and arguably more fastidious, 
revealing that diabetics taking the drug had lower all-cause mortality and age-associated diseases than 
non-diabetics (Campbell et al., 2017). Nonetheless, a multitude of research has indicated that 
metformin seems to be beneficial against a number of other age-related diseases, including cancer, 
cardiovascular disorders and chronic kidney disease (reviewed in Valencia et al., 2017).  
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In light of these compelling findings, research on the geroprotective properties of metformin has been 
rapidly developing in model organisms to determine dose effectiveness and safety, 
physiological/metabolic effects, and mechanisms. 2008 was the first time metformin, and moreover, any 
pharmacological agent, had been proven to extend lifespan in a rodent model (Anisimov et al., 2008).  
Admittedly, this model, the outbred Swiss-derived female mice, is rarely used outside Russia, however 
it led the way for further, somewhat conflicting publications. Numerous lifespan studies, including the 
former, have now assessed metformin in different genetic backgrounds. The most cited paper (586 
citations as of April 2019), by de Cabo’s lab, tested two doses of metformin (0.1% and 1%) in regular 
C57BL/6 mice initiated at 12 months of age. A clear and contrasting dose response was observed with 
the 0.1% w/w male group showing increased the mean life span (6%), whilst lifespan was significantly 
reduced at the higher dose (Martin-Montalvo et al., 2013). However, the 0.1% dosage was 
subsequently tested by ITP using their UM-HET3 mouse model: they found that when initiated at 9 
months of age, metformin did not significantly increase the life span of either male or female mice 
(Strong et al., 2016). Despite the somewhat indeterminacies of these studies on lifespan, metformin 
has repeatedly demonstrated a proclivity to improve healthspan in rodent models. In the de Cabo lab 
experiments, the lower dose increased healthspan as indicated by a number of parameters measured 
at older ages, including improved glucose tolerance, increased treadmill endurance, better rotarod 
performance, higher levels of locomotor activity, and reduced incidence of cataracts (Martin-Montalvo et 
al., 2013). Furthermore, other reports have noted improved mitochondrial function, reduced 
inflammation, cognitive performance and estrous function (Allard et al., 2016; Anisimov et al., 2011). 
Similar difficulties in eliciting lifespan extension has been observed in drosophilae. Administration of 
metformin to flies did reduce adiposity in line with rodent models, but ultimately failed to prolong 
lifespan; higher does were actually toxic (Slack et al., 2012). Interestingly however, metformin does 
robustly activate AMPK, the kinase which is thought to mediate the majority of metabolic actions by 
metformin (Viollet et al., 2012). Indeed AMPK activity is significantly upregulated in mice and C. elegans  
treated with metformin (Martin-Montalvo et al., 2013; Onken and Driscoll, 2010). It has been proposed 
that the changes in cell signalling from the activation of AMPK, occur from an AMP:ATP shift 
precipitated by the inhibition of electron transport chain complex I (Foretz et al., 2014; Owen et al., 
2000). Activated AMPK can then drive the catabolic and insulin sensitising effects associated with 
improved physiological integrity such as cellular uptake of glucose, β-oxidation of fatty acids, 
increased glucose transporter 4 (GLUT4) expression, and mitochondrial biogenesis (Solon-Biet et al., 
2015). However, some of the physiological benefits of metformin cannot be accounted for by AMPK 
activation alone. For example, reduced gluconeogenesis, a process central to the anti-diabetic 
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response to metformin, occurs through non-competitively inhibiting the redox shuttle enzyme 
mitochondrial glycerophosphate dehydrogenase to produce an altered hepatocellular redox state that 
reduces the conversion of lactate and glycerol to glucose (Madiraju et al., 2014). Furthermore, evidence 
also exists that the prolongevity effects of metformin may occur independently of AMPK through target 
of rapamycin complex 1 (TORC1) inhibition. It was shown that metformin inhibits Ras-
related GTP binding (Rag) GTPases, thus directly regulating mTORC1 activity (Kalender et al., 2010). 
Secondly, the downstream targets of mTOR, S6K1 and 4E-BP1 are directly inhibited by metformin 
(Dowling et al., 2007). Other hypothesis for metformin’s geroprotection are alterations in microbial folic 
acid and methionine metabolism as well as induction of mitohormesis via H2O2 regulated by 
the peroxiredoxin PRDX-2 pathway (Cabreiro et al., 2013; De Haes et al., 2014). 
Beyond evident modulation of key stress pathways altered by CR, alongside increased lifespan and 
healthspan, metformin demonstrates key candidacy as a CRM through its similarity of transcriptome: 
microarray analysis showed marked overlap between gene expression patterns induced by both 
metformin and CR (Dhahbi et al., 2005). Whilst further mechanisms remain elusive, it is likely that 
metformin suffers from the same pleiotropy as CR. Research is beginning to highlight key flaws in the 
utility of metformin including a propensity to reduce visual acuity and spatial memory of aged male mice 
and also the exacerbation of damage caused to sciatic nerve fibers and incidence of porcelain 
gallbladder (Ciric et al., 2018; Dorvash et al., 2018; Thangthaeng et al., 2017). Nonetheless, funding 
has been granted to begin “the first-in-class study enrolling patients who have been diagnosed with one 
single age-associated condition and designed to detect the capacity of metformin to delay the 
manifestation of a second, equally age-associated disorder” (Palliyaguru et al., 2019). At present, 
metformin is a well-tolerated intervention in humans, including the elderly and non-diabetic which has 
expedited this clinical trial. However, the doses used to induce lifespan extension in rodents generally 
exceed the recommended daily metformin therapy in patients with type 2 diabetes, and may correlate 
to an increased risk, putting into question the worthwhileness of metformin treatment given its relatively 
modest effects on lifespan in rodents.  
Metformin is the only potential CRM to date that has been enrolled in a clinical trial with the sole 
intention of decelerating ageing. However, rapamycin, the other CRM candidate discussed in this 
thesis, correspondingly has approved efficacy in clinical trials. Rapamycin, also known as sirolimus, is a 
complex macrolide antibiotic, produced by Streptomyces hygroscopicus strain isolated on Easter Island 
in 1972 (Seghal et al., 1975). It was initially developed as an antifungal agent, but is now used in clinic 
by reason of its immunosuppressive effects to prevent renal transplantation rejection and to treat 
68 
 
autoimmune disorders (Lamming et al., 2013).  The primary mechanism for this indication is due to the 
inhibition of interleukin-2 signalling and other cytokine-receptor-dependent signalling pathways by 
acting on mTOR and preventing the activation of T and B cells (Thomson et al., 2009).  
Upon the discovery the TOR pathway as an important regulator of ageing in yeast and C. elegans, the 
potential anti-aging properties of rapamycin began to be seriously explored (Arriola Apelo and 
Lamming, 2016). Interest was further spiked following research  in 2009 by the National Institute on 
Ageing Interventions Testing Program reporting that dietary supplementation with rapamycin increased 
mean lifespan 28–38% compared to control animals and also maximum lifespan in heterogeneous mice 
(Harrison et al., 2009). Importantly, and in contrast to metformin, treatment was initiated at 20 months of 
age, corresponding to approximately 60 years of age in humans. This late-life prolongevity effect can 
also be elicited in mice when initiated at 9 months or 19 months as well (Miller et al., 2011; Zhang et al., 
2014). Since the initial discovery, numerous other rodent studies have replicated the pro-longevity 
effect of rapamycin supplementation, even when combined with poor diet (Leontieva et al., 2014). 
Research has shown rapamycin to also delay ageing-related changes in mice, including tendon 
stiffening, accumulation of sub-cellular alterations in the myocardium, endometrial hyperplasia, liver 
degeneration, and decline in physical activity (Wilkinson et al., 2012). Moreover, Rapamycin has been 
shown to ameliorate morbidity and mortality in mouse models of several neurodegenerative diseases 
and also progeroid syndromes (reviewed in Lee et al., 2019). 
With that said, research has not been unequivocal. Neff et al., although inducing lifespan extension, 
failed to successfully manipulate most healthspan parameters of aged mice (Neff et al., 2013). In fact, 
they noted that the putatively age-related traits improved by rapamycin are similarly affected in both 
young and old mice. This has brought into question the benefit of rapamycin in humans, and led many 
to suggest that rapamycin is not an anti-aging intervention per se (Richardson, 2013). This is view is in 
part driven by parallel oncological research indicating rapamycin to extend lifespan through a reduction 
in cancer mortality rather than a deceleration of ageing (Ciuffreda et al., 2010). Indeed, rapamycin has 
significantly improved survival in cancer-prone strains of mice and its analogues are clinically used to 
treat a number of cancers such as: follicular lymphoma or mantle cell lymphoma, pancreatic 
neuroendocrine tumours, soft-tissue sarcomas, B-cell non-Hodgkin lymphoma, advanced hepatocellular 
carcinoma, paediatric solid or central nervous system tumours (Kopeina et al., 2017). However, the 
mechanisms modulating the anti-tumour and anti-ageing aspects of rapamycin are thought to both be 
due to the direct inhibition of the mTOR pathway which upregulates autophagy (Perluigi et al., 2015), as 
well as immune-modulating and anti-inflammatory activity beyond that of tumour suppression (Araki et 
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al., 2009). Furthermore, the inhibition of mTOR can be thought to mimic at least some of the aspects of 
calorie restriction.  
Firstly, as in CR, rapamycin precipitates similar FOXO-mediated apoptotic effect in human cancer cell 
lines, however in healthy human cells, the apoptosis-promoting properties of FOXO are attenuated by 
SIRT1 promoting cell survival rather than death (Giannakou and Partridge, 2004; Gillespie et al., 2016). 
Equally, as stipulated in Ingram and Roth’s prerequisites, rapamycin upregulates key stress pathway 
genes associated with CR that protect against oxidative stress: SOD1, glutathione reductase, δ-
aminolevulinate dehydratase (Kofman et al., 2012). Also, rapamycin appears to attenuate the 
production of ROS in-vitro (Shin et al., 2011). Physiologically, similarities between CR and rapamycin 
can be observed: rapamycin leads to decreased body weight and adiposity and in turn induced 
improved endocrine function as measured by reduced serum leptin (Arriola Apelo et al., 2016; Carter et 
al., 2016; Miller et al., 2011). 
Rapamycin is the only CRM that has reproduced a similar lifespan increase to that of CR (Arriola Apelo 
and Lamming, 2016). Unquestionably, rapamycin is a powerful inducer of cellular change and as 
mechanisms are still being elucidated, numerous safety concerns have emerged. Oncological use of 
rapamycin in humans comes with significant risk of metabolic complications such as hyperglycaemia, 
hypercholesterolaemia and hypertriglyceridemia (Sivendran et al., 2014). This adverse metabolic profile 
is equally present during lifespan studies in mice treated with rapamycin. Numerous authors have 
reported insulin resistance, hyperlipidaemia and glucose intolerance (Neff et al., 2013; Wilkinson et al., 
2012). Further research suggests this is likely due to dysfunctional  hepatic gluconeogenesis induced by 
chronic rapamycin treatment eventually inhibiting mTORC2 (Lamming et al., 2012). Of note though, 
rapamycin-induced metabolic impairments appear to be fully reversible in both lean and obese mice, 
raising possibilities and indeed successes in intermittent dosing (Arriola Apelo and Lamming, 2016; Liu 
et al., 2014).  
More concerning though in lifespan studies with rapamycin is the repeated observation of testicular 
degeneration and increased incidence of cataracts (Richardson, 2013). Additionally, the 
immunosuppressive properties of rapamycin will continue to raise concerns on its applicability in 
vulnerable populations. These issues, particularly metabolic ones may resolve as rapalogs more 
specific for mTORC1 are developed, and indeed rapamycin remains a key candidate to become a bone 
fide CRM. However, clinical applicability of rapamycin remains uncertain especially as no long-term 
studies have been conducted in large non-human primates. Following on from concerns that rapamycin 
may not actually slow ageing alongside research also showing a longevity selection bias towards 
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female mice. Moreover, acute rapamycin treatment in humans cells induces a far more aggressive 
transcriptional change than in mice indicating that rapamycin may not be as beneficial to humans as it 
is to lower order species (Fok et al., 2014; Gillespie et al., 2015). Thus, a rational approach to 
rapamycin must be made beyond the hype.  
Both rapamycin and metformin have shown promise and at least demonstrated potential in mimicking 
the geroprotective properties of CR. However, they both come with substantial criticism. Metformin may 
provide a still unsubstantiated pleotropic effect whilst rapamycin appears to aggressively over-
downregulate one pathway associated with CR. Thus, much work is still required to identify compounds 
which provide a safe and tolerable profile that extends lifespan and healthspan in a manner similar to 
CR.  
1.4. Allantoin and Other Imidazoline Receptor Agonists as Pro-longevity Calorie Restriction 
Mimetics 
Expediated by recent advances in genomic and transcriptomic sequencing, alongside high throughput 
genetic and compound screens, a wealth of public data is available to researchers to assist in 
understanding the discrete complexities of calorie restriction on a genomic, transcriptomic and proteomic 
level. This has empowered researchers to greatly improve the reverse pharmacological screening 
process to find and test direct targets of calorie restriction. Efforts have been made in the past to identify 
a CR gene signature that overlapped relevant compounds but this did not seek to identify novel 
compounds (Dhahbi et al., 2005). Despite this research, and encouragement from Spindler and Mote, 
(2007), little has been done to capitalise on this potential.  
However,  In 2015, our lab exploited Gene Expression Omnibus (GEO), a public database of gene 
expression files, to isolate an in-vitro transcriptome of calorie restriction, derived from rat cell lines 
exposed to rhesus monkey sera from CR states (Calvert et al., 2016). This transcriptome was then 
uploaded to a now-outdated Connectivity Map to isolate drugs with an overlapping gene signature (Lamb 
et al., 2006). Following up these potential drug hits to assess in-vivo effects was essential.  
Calvert’s connectivity map results revealed 5 compounds with a high similarity to the CR gene signature 
and these were subsequently screened in C. elegans for lifespan and healthspan effects. Reassuringly, 
this method returned an internal control, rapamycin, which duly extended lifespan in a solid media lifespan 
assay. One particular compound, allantoin, which prior to this study, had not been studied in the context 
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of ageing, extended lifespan by 21.9%, in a CR dependent way, and significantly improved healthspan 
defined by pharyngeal pumping.  
Calvert et al. speculated that allantoin, as a product of free-radical uric acid oxidation, may exert its 
lifespan extension through upregulating stress responses in reaction to perceived changes in oxidative 
stress (Artyukin, 2013). Like humans, C. elegans lacks uricase, an enzyme responsible for oxidation of 
uric acid to allantoin (Ramazzina et al., 2006). Furthermore, in nematodes nitrogen excretion occurs  only 
in the form of ammonia and amino acids, while no significant amounts of urea, uric acid, allantoin, or 
creatinine have been recorded (Rothstein, 1963). Thus, it is unlikely, allantoin remains as the final step 
in uric acid metabolism. The oxidative stress feedback hypothesis proposed by Calvert et al. becomes 
even more untenable when considering that allantion levels are negatively correlated to lifespan with high 
urate:allantoin ratio being observed among long-lived species (Ma and Gladyshev, 2017). Moreover 
naked mole rats have a particularly low expression level of uricase, corresponding to lower production of 
allantoin, and interestingly, humans, as the longest-lived primates have the highest serum urate level 
(Cutler, 1984; Ma et al., 2015). 
Another hypothesis explaining the prolongevity effect of allantoin involves its affinity to the imidazoline 
type 1 receptor (I1R). This receptor is part of a broader family of imidazoline receptors discovered by 
Bousquet and Schwartz in 1983, who demonstrated that clonidine, a hypotensive agent, depressed 
sympathetic tone independently of the canonical adrenoreceptor (Bousquet and Schwartz, 1983). Unlike 
α2 adrenoreceptors, imidazoline receptors do not show affinity towards catecholamines, but instead bind 
imidazoline and guanidinium compounds of which clonidine and allantoin are derivatives of the latter 
(Dardonville and Rozas, 2004). 
Yang et al., (2012) discovered that allantoin was able to activate I1Rs in animal models and cell lines.  
Furthermore, 5mg/kg intraperitoneal injections of allantoin significantly reduces body weight of high-fat 
diet (HFD) mice in comparison to control HFD; however, this effect was abrogated following antagonism 
of IR1s by efaroxan (Chung et al., 2013). Other research has demarcated allantoin to exert anti-asthmatic 
(Lee et al., 2010), antidiabetic (Niu et al., 2010), antihypertensive activities (Chen et al., 2014), as well as 
memory-enhancing effects in AD  (Ahn et al., 2014). Furthermore, allantoin appears to upregulate key 
genes associated with CR-induced longevity and, recent research has highlighted a transcriptional 
similarity between metformin and allantoin, including increased AMPK activation (K.-C. Lin et al., 2012; 
J. Ma et al., 2018). Lastly, recent studies, profiting from our lab group’s initial studies have since confirmed 
increases in C. elegans lifespan in response to allantoin (Admasu et al., 2018). 
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Unfortunately, allantoin lacks convenient translatability. Allantoin is degraded by the microbial flora of the 
GI tract, and orally administered allantoin fails to be metabolised and excreted in the urine (Kahn and 
Nolan, 2000). Thus, allantoin requires intravenous or intraperitoneal administration which would 
significantly disincentivise its use in humans; furthermore, rodent lifespan studies would become 
inconvenient and expensive owing to regulated daily/weekly injections. Perhaps more concerningly, F344 
rats fed rat chow with (n=20) and without 0.2% (n=24) allantoin (2,000 ppm) demonstrated no difference 
in lifespan when the experiment was aborted after 106 weeks (Lijinsky, 1984).  
Given that allantoin has a relatively weak affinity to I1Rs, it is possible that more specific I1R agonists 
may be able to confer an improved geroprotection from oral administration (Dardonville and Rozas, 
2004). Notably, Ye et al., found guanfacine hydrochloride and guanbenz acetate, both guanidium-based 
I1Rs agonists  to extend mean lifespan in C. elegans by 15 and 12% respectively (Ye et al., 2014). In a 
separate paper, the endogenously produced imidazoline receptor ligand agmatine was able to extend 
lifespan in C. elegans by 16% at concentrations of 1mM (Edwards et al., 2015a). Despite its endogeneity, 
agmatine has the same antihypertensive properties as centrally acting hypertensives, mediated through 
the imidazoline binding site. Finally, another endogenous imidazoline receptor agonist known as harmane 
has the propensity to extend mean lifespan in C. elegans bred in pathogenic environments by an average 
of 13 days (Jakobsen et al., 2013). However, neither rilmenidine nor moxonidine, both clinically approved 
anti-hypertensives, imidazolines with high affinities to I1Rs, have ever been tested in nematodes at all, 
and in other model organisms for longevity effects.  
With this in mind, It was prudent to capitalise on an important opportunity to firstly examine whether the 
repurposement of clinically approved, more specific imidazoline receptor agonists such as rilmenidine, 
may be able to extend healthy lifespan in C. elegans through the safe mimicry of calorie restriction; and 
secondly establish through which molecular mechanisms and pathways this longevity effect may occur. 
Such repurposement and screening represents a reasonable and low-cost identification of easily 
implementable and translatable CRMs for anti-ageing clinical trials which should serve to reduce the 
suffering of old-age and improve wellbeing in later life: a moral obligation of the medical and scientific 
community.  By establishing whether this potential CRM could slow down the processes of ageing in C. 
elegans—even by a moderate amount— would instigate a pipeline of research that could expediate the 
current ageing field and yield dramatic financial and societal  benefits to society. 
In order to do this, publicly available transcriptomes of cell lines exposed to rilmenidine and other I1Rs 
need to be mined to indicate whether rilmenidine may affect ageing pathways. If so, these bioinformatic 
results will require rapid high-throughput screening in C. elegans to assess for longevity affects. I will 
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then dissect the signalling pathway of rilmenidine in C. elegans to ascertain whether any longevity effects 
are mediated via two common ageing pathways associated with calorie restriction: mTOR and AMPK. 
Then finally it is important to assess the translatability of any longevity effects onto common chronic 






2.1.1. Probing the Connectivity Map with Age-associated Transcripts 
Representative non-tissue specific ageing transcription signatures were gathered from two sources. 
First, we used a gene signature generated from a meta-analyses of 127 multi-tissue datasets using 
previously described methods (de Magalhães et al., 2009; Fabris et al., 2018). This is the largest known 
meta-analysis of multi-publication datasets, and includes datasets used in de Magalhães et al., (2009) 
and Voutetakis et al., (2015). A sub-analysis was performed using just brain tissue samples within the 
selected datasets.  Notably, this meta-analysis did not include any data generated by the Genotype 
Tissue Expression Project. There is a similar meta-analysis of differential expression that tackles this 
data (Mele et al., 2015). They too used a linear regression model. We combined these two sets to 
establish a consensus gene list of DEGs from both analyses which could then be used to probe the 
connectivity map. 
As performed in other research, the touchstone L100 Gene Expression cMap (Subramanian et al., 
2017) was individually queried with each signatures using up to the top 150 recognised protein-coding 
overexpressed genes and top 150 recognised protein-coding underexpressed genes (Dönertaş et al., 
2018). All genes were converted to Entrez IDs.  The mean tau score and rank of each perturbagen 
across each signature was recorded. Tau scores over 90 or -90 were considered significant (Broad 
Institute, 2017).  
For the list of DEGs in the Rostral Ventral Lateral Medulla of young and old F344 rats (Balivada et al., 
2017), data was fetched from GSE90956 and the top 250 DEGs (as defined by log-fold change) were 
calculated using GEO2R R script which utilises GEO query and  limma topTable function (Barrett et al., 
2012) 
2.1.2. Meta-analyses of Transcriptional Profiles and Functional Enrichment 
Meta-analyses of the rilmenidine treated cell lines was conducted using .GCT files of normalised gene 
expression from the NIH LINCS Common Fund Programme. Cell line data was filtered to contain only 57 
cell lines exposed to rilmenidine at a concentration of 10 µM for 24h. For the meta-analyses of combined 
imidazoline receptor agonists, the same criteria was applied, using 9 drugs against a total of 221 cell line 
arrays, producing 2,940,626 gene scores. Thresholds for differential expression values (robust z-ratios 
calculated by comparing the gene’s expression value in the given sample to that same gene’s expression 
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values in all other samples in the cohort and then collapsed replicate samples) were set at >2/-2 as 
previously defined (Koido et al., 2018). Whilst only 991 landmark genes have been arrayed, a further 
12,000 genes have been assigned two levels of inference confidence: well-inferred and inferred.  All 
inferred genes were included in the analysis as in (Wilson et al., 2015). Meta-analyses was done following 
methods described in de Magalhães et al., (2009). To identify genes consistently under/over expressed 
in response to rilmenidine and/or imidazoline receptor agonists, I calculated the number of times a gene 
exceeded the differential gene expression thresholds in each direction for every tested cell line. This tally 
was then subject to cumulative binomial distribution analysis and Benjamini–Hochberg correction to 
ascertain the probability of observing an equal or higher under or overexpression by chance; FDR of 
<0.05 was considered significant (Benjamini and Hochberg, 1995). Transcriptional signature pairwise 
comparisons were made between relevant gene lists using Fisher’s Exact Test and p-values were 
subsequently adjusted for multiplicity using the Bonferroni correction which was represented by Venn 
Diagrams created using EuLerr (Larsson, 2018).  
Gene ontology (GO) enrichment analysis on DEG lists was carried out using the R package ‘topGO’ 
(Alexa and Rahnenfuhrer, 2016) using the weight01 algorithm and Fisher’s exact test, to identify enriched 
Biological Process GO terms. This method accounts for the hierarchical structure of the GO terms and 
so gives more specific terms than a simple enrichment analysis would. The resultant list of significant 
Gene Ontology IDs and their respective p-values as derived from ‘topGO’, were inputted into REViGO 
(Supek et al., 2011). A similarity threshold of 0.5 was set against a UniProt default background and 
SimRel semantic similarity.    
2.1.3. C. elegans Microarray Analysis 
6 Gene expression .SOFT file datasets were downloaded from GEO: GSE8058, GSE16753, GSE54024, 
GSE34113, GSE32521, GSE39252 
Datasets were chosen if they contained at least 3 replicates of NT worms no older than 3 days into 
adulthood and provided gene expression data had already been normalised.  
WT  transcriptomes were extracted and mean expression for each probe was calculated for each dataset. 
Given the wide variability in expression units, including some negative values, data was normalised for 
each probe so that it is between 0 and 1 for all datasets. This is represented as:  
𝑍𝑖 = 𝑋𝑖 −𝑚𝑖𝑛(𝑋)max(𝑥) − min⁡(𝑥) 
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Where 𝑍𝑖  is the normalised expression value for probe i, 𝑋𝑖 is the raw expression value for probe i, and 
x is all the expression values. Probes were then ranked according to expression and plotted against 
expression using the R package “ggplot2”. Probes targeted to f13e9.1 are labelled on the graph to 






2.2.1. C. elegans Strains 
Table 1. C. elegans strains. 
 
Strain  Genotype Outcrossed Source Reference Use 
AM141 rmIs133 [unc-54p::Q40::YFP] x5 CGC 
(Morley et al., 
2002) PolyQ Protein Aggregation Assay 
DA1116 eat-2(ad1116) II x2 CGC (Avery, 1993) Dietary Restriction 
GR1307 daf-16(mgDf50) I x3 CGC (Ogg et al., 1997) Lifespan Analysis 
KWN190 rnyEx109 [nhx-2p::D3cpv + pha-1(+)] x0 CGC 
(Coburn et al., 
2013) Calcium Signalling 
WT  
Bristol WT  N/A CGC (Brenner, 1974) Control Strain 
PHX116 sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry] 0 SUNYBioTech This Thesis Phenotyping 
PHX117 sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry] 0 SUNYBioTech This Thesis Phenotyping 
PHX893  F13E9.1(syb767)IV x4 SUNYBioTech This Thesis Phenotyping 
PHX945 
F13E9.1 (syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+) + myo-
2p::mCherry] x4 SUNYBioTech This Thesis Phenotyping 
PHX946 
F13E9.1 (syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-
2::mCherry] x4 SUNYBioTech This Thesis Phenotyping 
TG38 aak-2(gt33) X x3 CGC (Lee et al., 2008) Lifespan Analysis 
VK1093 vkEx1093 [nhx-2p::mCherry::lgg-1] x0 CGC 
(Gosai et al., 
2010) Autophagy Measurement 
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2.2.2. Reagents and Media 
 Table 2. Reagents and media 
Compound Name In-Text Abbr Supplier Cat. No 
Working  
Concentrations Storage Use 
2',5'-Dideoxyadenosine DDE Enzo Life Sciences CN110 1mM in ddH2O 100mM in DMSO at -20°C cAMP Decrease 
5-Fluoro-2'-deoxyuridine FUDR Alfa Aeasar L16497  100µg/ml in dH2O 10mg/ml in dH20 at 4°C Lifespan Assays 
Agarose Molecular Grade Agarose Bioline BIO-41026 N/A RT Gel Electrophoresis 
Allantoin Allantoin Sigma 05670  250µM in DMSO 25mM in DMSO at -20°C Tested Compound 
BAPTA AM BAPTA AM TOCRIS 2787 100µM in DMSO 10mM in DMSO at -20°C Calcium Measurements 
Carbenicillin .Disodium salt Carbenicillin  Enzo Life Sciences M250 100-500µg/ml in dH20 100mg/ml in dH2O at -20°C Autophagy Measurement  
Chloroquine Diphosphate Salt Chloroquine Alfa Aeasar J64459 20mM in dH20 100mM in dH20 at -20°C Autophagy Measurement  
Cyclic AMP Sodium Salt cAMP Santa Cruz 37839-81-9 5mM in dH2O 100mM in ddH2O at -20°C cAMP Increase 
Dimethyl Sulfoxide DMSO Sigma D8418  1% RT Solvent 
Efaroxan Hydrochloride Efaroxan Sigma E3263 2mM in ddH20 66mM in ddH2O at -20 Imidazoline Receptor 
Antagonist 
Ethidium Bromide Ethidium Bromide Sigma E1510  38mg/100ml 10mg/ml at RT Gel Electrophoresis 
Forskolin Forskolin Alfa Aeasar J63292  500µM in DMSO 50mM in DMSO at -20°C cAMP Increase 
Hydrogen Peroxide H2O2 Sigma 88597 1mM to 5mM 3% at RT in dark Oxidative Stress 
Ionomycin Ionomycin Caymen Chemicals CAY10004974 10µM in DMSO 100µM in DMSO at -20°C Calcium Measurements 
Isopropyl-beta-D-thiogalactopyranoside IPTG Thermo Fisher R0392 100µM in dH2O 10mM in dH2O at -20°C Autophagy Measurement  
Loading Dye Loading Dye Thermo Fisher R0611 x1 x6 Single Worm PCR 
L-Proline Proline Sigma P0380  5mM in dH2O 500mM in H2O at -20°C Thermotolerance 
Moxonidine hydrochloride Moxonidine Tocris 2282 200µM in DMSO 20mM in DMSO at -20°C Tested Compound 
N-Acetyl-L-cysteine NAC Sigma A7250  5-10mM in dH20 1M in dH2O at -20°C Oxidative Stress 
Nuclease Free Water Nuclease Free Water Qiagen 129115 N/A RT Single Worm PCR 
Nystatin Suspension Nystatin Sigma N1638 50IU/mL in DPBS 10,000 unit/mL in DPBS at 20°C C. elegans Culture 
Penicillin-Streptomycin Penicillin-Streptomycin Sigma P4333 50IU/mL  citrate buffer at -20⁰C C. elegans Culture 
Phusion HF Buffer Phusion HF Buffer New England Biolabs B0518 x1 x5 at -20°C Protein Extraction 
Protease Inhibitor Cocktail Protease Inhibitor Cocktail Sigma COEDTAF-RO 1 tablet per 12mL RIPA Solid tablets at 4°C Protein Extraction 
Proteinase K Solution Proteinase K Solution Ambion AM2548 700µg/ml 20mg/ml at -20°C Protein Extraction 
Radioimmunoprecipitation assay buffer RIPA Buffer Cell Signalling 9806 x1 x10 at -20°C Protein Extraction 
Rapamycin Rapamycin Alfa Aeasar J62473  100µM in DMSO 10mM in DMSO at -20°C Autophagy Measurement  
Resveratrol  Resveratrol Alfa Aeasar J60790  100µM in DMSO 10mM in DMSO at -20°C Lifespan Assays 
Rilmenidine Hemifumarate Rilmenidine Tocris 790 100-400µM in DMSO 40mM in DMSO at -20°C Tested Compound 
Tetracycline Tetracycline Sigma 87128  12.5µg/ml in EtOH 5mg/ml in EtOH at -20°C Autophagy Measurement  
Tetramisole Hydrochloride Tetramisole Hydrochloride Sigma T1512  20mM in dH20 100mM in dH20 at 4°C Microscopy  
Thapsagarin  Thapsigargin Sigma T9033  1-5µM in DMSO Solid Film at -20°C Calcium Measurements 
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Nutrient Growth Medium Agar (NGM) 
17mg/mL Agar 
3mg/mL NaCl 
2.5mg/mL Bacterial Peptone 
100µM CaCl2 
5mg/mL Cholesterol  
100µM MgSO4 
25µM potassium phosphate buffer (pH6) 
 
LB Agar 
37g/L LB Broth with agar (Lennox) 
 
LB Broth 







2.3. Bacterial Preparation 
2.3.1. Generation of Live E.coli Stocks 
A starter culture of E. coli OP50 obtained from the CGC (https://cgc.umn.edu/strain/OP50), as advised 
(Stiernagle, 2006), arrived on NGM agar (see section 2.2.2) and was stored at 4°C for no more than 
one week. This culture was aseptically streaked onto LB Agar plates and incubated at 37⁰C overnight. 
The following day, 200mL of Lennox LB broth per single colony was inoculated and further incubated at 
37°C for no more than 20 hours. Resultant OP50 E.coli cultures were aliquoted into 50ml falcon tubes 
and centrifuged for 10 minutes at 3000rpm: 90% of the supernatant was then discarded to yield a x10 
concentrate (Sutphin and Kaeberlein, 2009). These stocks were stored at 4⁰C for no more than one 
month (Stiernagle, 2006). 
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For RNAi experiments, sequence verified HT115 E.coli strains transformed with either the plasmids 
CUUkp3301P034Q (lgg-1) or CUUkp3303WT 02Q (bec-1) were purchased from the Ahringer RNAi 
feeding library available at SourceBioscience (Kamath et al., 2003): an empty HT115 vector strain was  
also purchased from CGC https://cgc.umn.edu/strain/HT115(DE3). Upon receipt, the strain was stored 
for no more than one week at 4°C before being streaked onto LB agar plates containing 100µg/ml 
carbenicillin (Enzo Life Sciences # M250) and 12.5µg/ml tetracycline (Sigma #87128), to prevent plasmid 
loss as outlined by Maher et al. (2013). Plates were then incubated at 37⁰C in the dark overnight.  The 
following day, isolated single colonies were grown up in Lennox LB Broth containing 500µg/ml 
carbenicillin for no more than 16 hours (Kamath et al., 2001). Resultant stocks were centrifuged at 
3000rpm for 10 minutes and supernatant lessened to yield x10 concentrate. These stocks were then 
stored at 4⁰C for no more than one month. 
A stab culture of the E.coli strain EPI300 carrying a sequenced validated WRM0616C_F02 (f13e9.1) 
clone was purchased from C. elegans TransgeneOme Resource (Sarov et al., 2012) and shipped to 
SUNYBiotech (https://transgeneome.mpi-cbg.de/transgeneomics/public/clone.html?wellId=32643519). 
The culture was inoculated onto  LB agar w/ 12.5µg/mL chloramphenicol and 50 µg/mL nourseothricin, 
and incubated at 37⁰C overnight. A stable, low copy number culture was cultured in LB broth and 
subsequently induced with Fosmid Autoinduction Solution (Epicentre #AIS107F) before DNA extraction 
and purification by SUNYBiotech. 
2.3.2. Freezing of E.coli Stocks 
All stocks were frozen as described in (Gott, 2004). Single colonies of E.coli were picked and 
inoculated into 2.5 ml Lennox LB broth, with the addition of 12.5µg/mL of tetracycline and 100µg/ml 
carbenicillin for HT115 strains and left to grow overnight  for ~18 hours at 37⁰C. 0.25 ml 80% glycerol 
and 0.75 ml of overnight culture were combined per screw-cap freezer tube and stored at -80°C.  
2.3.3. Generation of UV-Killed OP50 E.coli 
Unconcentrated live OP50 E.coli cultures were generated as described in section 2.3.1. 32 mL of 
culture were aliquoted to each 50mL falcon tubes, mixed with absolute ethanol (8mL) to yield a 20% 
ethanol solution as described (Calvert et al., 2016) and pipetted into T160 flasks to a volume of 150ml. 
Flasks were transferred to a UV-Linker machine (CL-1000 Ultraviolet crosslinker UVP) and irradiated 
for 120 minutes at 999,900 microjoules/cm2. 50ml aliquots of UV-killed E.coli-ethanol solution was 
pelleted at 3000rpm for 10 minutes and resuspended to a x10 concentrate in 5mL Lennox LB broth.     
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2.4. C. elegans Husbandry 
2.4.1. Culture and Stock Maintenance 
All worms were cultured on NGM agar supplemented with 50IU/mL penicillin (Sigma #P4333), 50µg/ml 
streptomycin (#P4333), and 50IU/mL Nystatin ( Sigma #1638) to prevent contamination as previously 
described (Stiernagle, 2006). Worm populations are routinely cultured in such an antimicrobial 
environment, which as corroborated by my own experiences, did not affect OP50 growth nor 
development of worms (Garcia et al., 2007; Ludewig et al., 2013; Savion et al., 2018; Scott et al., 
2017). The N2 bristol strain was selected as WT for all experiments and any reference to WT C. 
elegans, unless otherwise stated, refers to this strain henceforth. Worms were grown on 60mm NGM 
plates seeded with x10 Live OP50 E.coli for at least 4 generations to minimise transgenerational effects 
of antecedent starvation or contamination (Greer et al., 2011; Jobson et al., 2015; Rechavi et al., 2014).   
All worms were grown on laboratory table tops during cultivation at RT and exposed to artificial light; 
however they were transferred to 20⁰C incubators and kept in the dark during assay preparation and 
execution to mitigate the effects of varying light on worm phenotypes (De Magalhaes Filho et al., 2018). 
No generations that had undergone bleach synchronisation or a previous assay were reused for 
population propagation. Stock worms were not cultivated for more than 1 month before being replaced 
by a thawed central stock. Before any assay, worms were grown in well-fed uncontaminated conditions 
and any assays or populations that developed contaminations were abandoned.    
2.4.2. Freezing and Thawing of C. elegans Strains 
Upon receipt, strains were picked onto NGM plates seeded with x10 live OP50 E.coli. They were then 
grown on those plates for 4 days before being picked onto 4 fresh 60mm NGM plates again seeded 
with x10 live E.coli. Strains were then left to populate the plates and consume all food inducing acute 
and mild starvation such that L1 arrest occurred in recently hatched eggs. At this point, worms were 
collected in M9, pelleted at 1500rpm and resuspended in 3mL M9 solution. The worm suspension was 
mixed with equal volume sterile freezing solution (5.8g/L NaCl, 50mM KH2PO4 (pH 6.0), 25% (w.v) 
glycerol, 300mM MgSO4,) and aliquoted into 1.5mL freezing vials. Worms were immediately transferred 
to -80⁰C for indefinite storage. Vials could be thawed at room temperature, emptied directly onto an 
NGM plate surface and allowed to dry for 30 minutes in a tissue culture hood. Plates were then seeded 
with a small amount of x10 concentrated OP50 and left overnight. Surviving worms were picked onto 
fresh agar plates and cultured as in Section 2.4.1. 
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2.4.3. Drug Treatments 
All drug treatments, unless otherwise stated, were administered to C. elegans via the addition of the 
respective compound to NGM, which was then spotted with UV-killed OP50. Whilst, different routes of 
administration are available, it has been established that dissolution of drugs in NGM agar offers the 
best subsequent bioavailability and accumulation in nematodes which peaks at 24h (Zheng et al., 
2013).  
Drugs were dissolved upon receipt into aliquoted stock concentration in their relevant solvents and 
appropriately stored for no more than one month before use (see 2.2.2). Drugs that were dissolved in 
DMSO, were stored in concentrations such that the final volume of drug solution requiring addition to 
the NGM plates did not exceed 1% DMSO. DMSO in concentrations other than 1% have been shown 
to significantly alter lifespan and other ageing markers (Wang et al., 2010). All plates, unless otherwise 
stated, were prepared one day before use in sterile conditions. NGM agar was cooled to below 65°C 
after same-day autoclaving, and respective drugs were concomitantly added to the plates as 3mL NGM 
was pipetted into 35mm petri dishes. Plates were gently swirled to homogenise the solution and left to 
dry for 1 hour in a hood. 60µl of x10 concentrated OP50 E.coli  was then added to the centre of the 
plate and again the plates were left to dry for 30 minutes in a hood. Plates were wrapped in parafilm 
and stored at 20°C before use.  
2.4.4. Alkaline Hypochlorite-Based Synchronisation of Gravid Hermaphrodites 
All worm populations were synchronised using an alkaline hypochlorite treatment based on methods 
described by Porta-de-la-Riva et al. (2012). For each population, well-fed gravid hermaphrodites were 
recovered and pooled in M9 buffer from at least 3 confluent 100mm NGM agar plates previously seeded 
with live x10 concentrated E.coli OP50. Worms were pelleted by centrifuging at 1500rpm for 2 minutes 
at room-temperature in 15ml falcon tubes and supernatant was discarded. 2ml of alkaline hypochlorite 
solution (NaOH 1 M, NaOCl ~1.6%) was added and tubes were agitated for around 10 minutes until only 
embryos remained visible in the solution. The reaction was stopped by addition of 12ml M9 solution and 
centrifuged at 1500rpm for 2 minutes at room-temperature. The supernatant was discarded and the pellet 
was rewashed a further 3 times in M9 buffer before being incubated overnight with gentle rocking in 2ml 
M9 solution. The following day, synchronised L1 nematodes were recovered by centrifugation and left to 
develop for requisite times on NGM plates seeded with x10 concentrated live OP50 E.coli.   
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2.5. Nematode Transgenesis  
The f13e9.1 locus was viewed using WormBase with the protein motifs tracker enabled to allow 
visualisation of protein domain regions to be excised (Sigrist et al., 2010; Zerbino et al., 2018). 
Homozygous PHX893 (F13E9.1(syb767)IV) strains were created using CRISPR/Cas9 technology and 
performed by SunyBiotech. The 3rd exon, 4th exon and part of 5th exon was deleted and replaced by a 
splice site and stop codon that terminated transcription and resulted in mutant strain carrying an 873bp 
homozygous deletion in the f13e9.1 gene. This strain was subsequently outcrossed four times against 
an WT  background using PCR screening at each stage and the final outcrossed strain was confirmed 
by sequencing. 
Second, the transgenic strains PHX117 sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry] 
and PHX116 sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry] containing and integrated 
full-length rescue of the f13e9.1 locus within the fosmid were generated on WT  backgrounds and created 
by SUNYBiotech. Specifically, the integrated rescue contained the WRM0616C_F02(pRedFlp-
Hgr)(F13E9.1[33366]::S0001_pR6K_Amp_2xTY1ce_EGFP_FRT_rpsl_neo_FRT_3xFlag)dFRT::unc-
119-Nat) fosmid construct derived from the copy-number inducible vector pCC1Fos grown up in E.coli 
strain EPI300 (See section 1.3.1) .  Fosmid DNA was extracted and added to a 20ng/µL DNA mixture 
containing both the purified fosmid and pCFJ90 Pmyo-2::mcherry. The solution was microfinjected into 
10-30 adult WT  worm gonads to generate a line of extrachromosomal transgenic arrays. Stable lines 
were then irradiated with γ ray dose of 40 GRAY to produce two lines of the same genotype. The 
previously produced, PHX893 (F13E9.1(syb767)IV) was then crossed 4 times with PX116 to generate 
the two rescue lines: PHX945 and PHX946 F13E9.1 (syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, unc-
119(+) + myo-2p::mCherry].  
2.6. Biochemical Methods 
2.6.1. Protein Extraction 
Whole worm protein lysates were prepared as in Hu et al. (2017) . ~500 day 1 adult worms per condition 
and genotype were transferred to either empty NGM plates to induce starvation (+ve control) or to UV-
killed OP50 E.coli NGM plates containing requisite drugs or vehicle (1% DMSO). After 24 hours, worms 
were suspended in M9 buffer and centrifuged at 1000rpm for 2 minutes to yield a wet pellet. Worms were 
then re-suspended on ice in 50µl of RIPA buffer with added phosphatase inhibitors (Cell Signalling 
Technologies  #9806) and cOmplete EDTA-free protease inhibitor cocktail (Roche # 04693159001) 
before sonication: 10 sec ON/1 minute OFF, 14% amplitude 3 times until the vast majority of animals 
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were dissolved. Lysates were then spun down twice at 13,000g/20minutes 4o C and immediately frozen 
at -20oC for no more than one week before use. 
2.6.2. Western Blot Analysis 
Total protein lysate concentrations were quantified using a bicinchoninic acid (BCA) assay (BioRAD) 
according to the manufacturer’s protocol.  
Protein lysates were heated for 5 minutes at 95°C, cooled on ice for 2 minutes and pelleted for 3 minutes 
at 13,000g. 25µg of protein was loaded per well into an 18 well 10% TGX™ Precast Gel (BioRad), 
submerged in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) and separated at 300V 
for approximately 30 minutes. Gels were transferred via Trans-Blot® Turbo™ Transfer System to 
nitrocellulose membranes and blocked for 60 minutes in blocking buffer (Licor Odyssey® Blocking Buffer 
#P/N 927-40100). Blots were incubated overnight with the primary antibody Phospho‐ERK (Cell 
Signalling Technology, Catalogue number: 9101) at 1:1000 in blocking buffer (Licor Odyssey® Blocking 
Buffer #P/N 927-40100) (Gee et al., 2013) with gentle rocking. The following morning, blots were washed 
three times in TBST before being incubated for 1 hour with the secondary antibody IRDye® 800CW Goat 
anti-Rabbit IgG at a concentration of 1:10,00 in blocking buffer w/ 0.1% tween.  This process was then 
repeated for the loading control, α-tubulin, using anti- alpha Tubulin (ab72910) and IRDye® 680RD Goat 
anti-Mouse IgG. Changes in ERK phosphorylation are often calculated using phospho-ERK:Total ERK 
ratios (Kao et al., 2004; Nykamp et al., 2008). However, given the frequent use of ERK as a loading 
control (H. Huang et al., 2004; Hwang et al., 2005), we followed previous examples in both worms (Chen 
et al., 2008; Villanueva-Chimal et al., 2017) and other models (Redshaw and Loughna, 2012; Zhou et al., 
2015) and calculated changes in phospho-ERK via the surrogate loading control α-tubulin. In a subset of 
experiments, executed by Shanghai Model Organisms, lysates from PHX945 and PHX946 strains were 
probed with monoclonal FLAG-tag antibodies (Sigma #F1804) to verify for fosmid F13E9.1 rescue. 
Bound antibody was detected using Odyssey® CLx Imaging System. For all immunoblotting, three 
independent trials for each genotype and/or condition was completed and mean densiometric ratios 
between loading control and pERK or FLAG minus local median background were calculated using Image 
Studio Lite as per software guidelines (Licor Biosciences, 2013) . Results were considered significant if 
the magnitude of the %change exceeded the CV by at least x1.5. 
2.6.3. Genomic DNA Extraction 
Single worms were picked and dropped into individual PCR tubes on ice containing 10µl of freshly 
aliquoted proteinase K (400µg/ml) in Phusion HF Buffer. Tubes were immediately transferred to -80⁰C 
overnight. The following morning, tubes were thawed on ice before being added to a thermocycler set to 
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the following: 65⁰C for 90 minutes and 90⁰C for 15 minutes. Crude DNA extract was then stored for no 
more than one week at 4⁰C before use in PCR.   
2.6.4. Single Worm PCR 
Single Worm Polymerase Chain Reactions were made using Phusion® High-Fidelity PCR Master Mix 
(New England Biolads #M0531S) to a final volume of 50ul per reaction made up of the following: 3ul 
template (crude DNA extraction), 5µl of 10µM primer mix 1:1, 17µl of nuclease-free water (Qiagen), and 
25µl of Phusion® High-Fidelity PCR Master Mix with HF Buffer. Reaction mixtures were then added to a 
thermocycler to undergo the following cycles: 
All primers (40nM synthesis scale) were designed using PrimerBlast (Ye et al., 2012) and ApE v2.0.55 
for genotyping WT  and f13e9.1 -/- worms. Primer were purchased from Eurogentec Ltd at a 100µM stock 
concentration in nuclease-free H2O. 10µM aliquots were stored at -20⁰C until use.  
The primers used were as follows: 
 
2.6.5. Gel Electrophoresis 
1g agarose (Bioline # BIO-41026) was dissolved in 100µl x1 TAE buffer (2mM Tris HCl, 50mM EDTA, 
pH 8.0) and microwaved for 1 minute until solution was clear. After cooling, 0.03mg ethidium bromide 
was added (Sigma Aldrich #E1510) and cast into a mould for electrophoresis. 10ul of x6 DNA Gel Loading 
Dye (Thermo Fisher #R0611) was added to each PCR tube and then 10ul of PCR product was loaded 
into each well. Gels were submerged in x1 TAE buffer and ran at 100v for 40 minutes before being 
visualized under UV on a ChemiDoc XRS+ (BioRad). Images were analysed and inverted in Image Studio 
Lite. 
F: 5’-AGGACCACCAGGAGCTACAT-3’




R: 5’- TTACGAAGGGCCATTCGTAC- 3’
F: 5’- GAGCGGCAGAAGTAATCCGT-3’
R: 5’- AGTGAACGACAAGACGACGAA- 3’
F: 5’- TCCTATCAGAAAACTGGTCG -3’















2.7. Lifespan Analyses 
For all strains and each assay, worms were cultured in the same conditions as described in Section 2.4.1. 
Well-fed gravid hermaphrodites were recovered and pooled in M9 buffer from at least 3 confluent 100mm 
plates and bleach syncronised as described in Section 2.4.4. Larval crowding is well known to influence 
development rate and lifespan (Ludewig et al., 2017), such that wet worm pellets never exceeded 500µL 
and remained comparable between groups. Resultant hatched embryos were halted at L1 overnight in 
M9 buffer to maximise time-synchrony, before being added to NGM seeded with x10 OP50 E.coli 
concentrate and left to develop for 52 hours at 20°C until late L4/adult. One day prior to L4 molt, 6-well 
plates containing 3ml of NGM per well were made up in a sterile hood, with the addition of requisite test 
compounds when required as in section 2.4.3. Furthermore,100µg/ml FUDR was also added  as in 
Calvert et al., (2016) at recommended concentrations (Gruber et al., 2009; Sutphin and Kaeberlein, 
2009), to circumvent confounding issues of egg-laying and subsequent worm development. Despite 
research extoling the negligible effect of FUDR on lifespan (Gandhi et al., 1980; Hosono et al., 1982), 
studies have noted FUDR to influence lifespan in a number of mutants (Kato et al., 2016; Van Raamsdonk 
and Hekimi, 2011). The seemingly scant evidence for the effect of FUDR on the lifespan of strains used 
and generated herein combined with the ubiquity of FUDR in C. elegans research permitted its use in 
this thesis. 
At L4/adult molt, worms were transferred to previously made 6-well lifespan assay plates and maintained 
at 20°C in the dark, wrapped in parafilm to moderate humidity. Worms were counted every 2 to 3 days 
and dead worms (failure to respond to no more than 3 "prods" with a platinum worm pick) were removed 
at each inspection. 60 μL of UV-killed OP50 was added three times a week to all plates until day 15 of 
the assay by which point low-food consumption negated the need for additional E.coli (Calvert et al., 
2016). 
For late administration lifespan assays, worms were prepared and added to lifespan assay plates as 
described in this section. At day 12, requisite worms were washed of lifespan assay plates with M9 and 
carefully pipetted onto new drug plates prepared on day 11, seeded with UV-killed E.coli, and contained 
freshly prepared test compounds and 100µg/ml FUDR. 
Survival results attained during this research were verified by automated lifespan assessment using the 
lifespan machine at Ewald lab in the Swiss Federal Institute of Technology (Stroustrup et al., 2013). 
Additionally, a small proportion of lifespan assays, indicated where necessary, were conducted by 
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Shanghai Model (Cuong et al., 2018; Fei et al., 2017; Hou et al., 2009; Weidong et al., 2018; Yang et al., 
2013; Ying et al., 2015; Zhu et al., 2015)  
For all lifespan assays, unless otherwise stated, at least 150 worms per genotype and/or condition were 
used across at least 3 independent trials. Worms that crawled into the agar, or experienced matricidal 
events were removed from the assay and not included in the lifespan calculations as in previous 
research (Bridi et al., 2015; Fleckenstein, 2014; Gusarov et al., 2017; Hsu et al., 2009; Schulz et al., 
2007; Slaughter, 2013). The biases accrued by the removal of censored animals from lifespan is well 
documented, and indeed the Kaplan-Meir survival curve was designed as a nonparametric method for 
estimating survival curves that considers the contribution of these worms (Kaplan and Meier, 1958). That 
said, such events occurred rarely (less than 1%) across treatment and genotype. Furthermore, the 
unchanging incidence of matricide and desiccation across groups suggests that the lifetime (age at death) 
of each worm was independent of the potential loss time of censorship and would contribute little to the 
final analyses as evidenced in Petrascheck and Miller, (2017). For each condition and/or genotype, 
survival results were pooled. Lifespan statistics were calculated using the OASIS2 online tool (Han et al., 
2016). Specifically, mean lifespan was measured as the no. days when survivorship reached 50%. 
Furthermore, maximum lifespan was defined as the mean lifespan of the final 10% of survivors in a given 
population.  P-values relating to survival difference between populations were calculated using log-rank 
(Mantel-Cox method) test.  
2.8. Autophagy Studies in C. elegans 
2.8.1. Measurement of Autophagy in-vivo 
The vKEx1093 reporter strain generated by Gosai et al.  (2010) was purchased from the CGC 
(https://cgc.umn.edu/transgene/23476) and frozen upon receipt. One week before each trial, aliquots of 
vkEx1093 worms were thawed and selectively picked on uncontaminated NGM agar seeded with live 
OP50 for 7 days to establish a stabilised line. Gravid hermaphrodites were then bleach synchronised as 
in section 2.4.4. and resultant embryos were left to grow for 52 hours at 20°C on NGM plates seeded 
with live OP50 E.coli (Papandreou and Tavernarakis, 2017). At late-L4 stage, worms were transferred to 
either empty NGM plates to induce starvation (+ve control) or to UV-killed OP50 E.coli NGM plates 
containing requisite drugs or vehicle (1% DMSO). Worms were then incubated at 20°C for 24 hours to 
maximise drug absorption and efficacy(Zheng et al., 2013). As described in previous assays (Burkewitz 
et al., 2012; Chapin et al., 2015), 20mM chloroquine was also added to the NGM for the drug incubation 
period when measuring autophagic flux. After 24 hours, day 1 adult worms were immobilized and 
mounted onto glass slides in 20mM solution of tetramisole hydrochloride.  Approximately 10 worms per 
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condition were imaged at a x10 objective on a Zeiss Axio Observer using a 150ms exposure time. Each 
worm was imaged within 5 minutes as tetramisole is known to induce puncta accrual after this time (Zhang 
et al., 2015). In total, at least 25 images across 3 independent trials were collected and pooled for each 
condition, in line with previous measurements of autophagy (Eisenberg et al., 2009; Morselli et al., 2010). 
Levels of autophagy induction were quantified based on a previously used technique (Martinez et al., 
2015). Using Zen software, three 1mm2 boxes were sequentially assigned to the most fluorescent areas 
of posterior intestine for each animal. With set histogramic parameters (black: 0 gamma:1.0 white: 1000 
or 5000 for highly fluorescent animals), the total number of visible puncta were manually counted in each 
box, and a mean number of puncta calculated per mm2 of animal intestine. Limiting measurement to 
fluorescent areas of the posterior intestine reduces the mosaic effect of extrachromosomal expression 
in-vivo and using three individual boxes limits the accumulation of subjective counting disparity.  Median 
number of puncta per mm2 posterior intestine for all animals in each condition was calculated and 
compared using one-factor (ANOVA) variance analysis corrected by the post hoc Bonferroni test. 
2.8.2. RNAi Autophagy Knockdown Lifespan Analysis and Validation 
For RNAi lifespan analyses, F1 synchronised WT  C. elegans were grown on live OP50 E.coli until late 
L4-stage. Nematodes were then transferred to NGM plates (penicillin-streptomycin omitted) containing 
100µM IPTG, 400µM FUDR and 50µg/ml carbenicillin with either 200µM rilmenidine hemifumrate or 1% 
DMSO Vehicle. Plates had previously been seeded with live E.coli (HT115) expressing an empty vector, 
bec-1 dsRNA or lgg-1 dsRNA (section) and incubated for 1–2 days at room temperature prior to induce 
dsRNA expression. 
Worms were maintained on the same drug plates for the entirety of their lifespan and scored for survival 
every 2-3 days as previously described (Seo et al., 2018) with the addition of requisite E.coli as and when 
it was consumed. Fresh strains were prepared for each assay.  A caveat must be noted that Hansen et 
al., (2008) initially used FUDR on single plates during autophagy knockdown assays but stopped 
following a failure to induce the requisite phenotype with bec-1. Nonetheless, this was not experienced 
during our assays, and moreover, researchers have continued to use FUDR with bec-1 RNAi (Edwards 
et al., 2015b; Hashimoto et al., 2009a; Seo et al., 2018). A total of over 100 worms per condition were 
assayed across 3 independent trials and analysed as in section 2.7.1.  
Knockdown was validated by measuring autophagy inhibition of vKEx1093(nhx-2::mCherry::lgg-1) worms 
rather than RT-PCR; a decision based on previous methods (Miedel et al., 2012; Pietrocola et al., 2018; 
Schipanski et al., 2013). Autophagy was pharmacologically upregulated in  F1 day-1 adult vKEx1093 
worms by the addition of rapamycin 100µM to RNAi feeding plates  and incubated at 20oC (Ikenaka et 
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al., 2013). After 3 days the worms were observed for autophagy knockdown and images were acquired 
as described in previous sections (section 2.81). At least 12 images across 3 independent trials were 
collected for each condition.  The number of visible puncta per mm2 posterior intestine of each animal 
was manually counted and calculated. Given the variable penetrance of RNAi in C. elegans (Kamath et 
al., 2001) and consequent non-normal data distribution, a Krushal test was performed across all 
conditions (Han et al., 2017). 
2.9. Stress Assays 
2.9.1. Oxidative Stress (H2O2) Resistance Assay on Solid Media 
Survival of day-1 worms exposed to varying concentrations of hydrogen peroxide (H2O2) was assessed 
as an index of oxidative stress resistance based on methods previously employed using solid media 
(Ludewig et al., 2013; Oláhová and Veal, 2015). Well-fed gravid hermaphrodites were bleach 
synchronised as in section 2.4.4. and resultant embryos were left to grow for 52 hours at 20°C on NGM 
plates seeded with live OP50 E.coli.  Bleach treatment has not been proven to affect survival rates in 
oxidative stress conditions and as such this protocol has previously been used in a number of similar C. 
elegans assays (Bou Dib et al., 2014; Izumikawa et al., 2016; Smith et al., 2014). At late-L4 stage, worms 
were transferred to seeded UV-killed OP50 E.coli NGM plates containing 200µM-400µM rilmenidine 
hemifumarate, or 5-10mM NAC (+ve control) or vehicle (1% DMSO) for 24h. Such concentrations of NAC 
have previously been used to reduce oxidative stress in C. elegans (Yang and Hekimi, 2010) and also 
NAC has been used to ameliorate superoxide-induced phenotypes (Sha et al., 2017). After 24h, worms 
were transferred to freshly prepared 3ml NGM plates containing requisite drugs (rilmenidine, NAC, 1% 
DMSO) and 1mM, 2mM or 5mM H2O2 (made from 3% stock H2O2 purchased the same week to prevent 
degradation (Sigma # 88597)). A subset of worms were removed from drug exposure whilst incubated 
on H2O2 plates in order to account for any confounding external reactivities of H2O2, rilmenidine and NAC, 
not related to endogenous superoxide scavenging. Survival of at least 60 worms per condition across 3 
independent trials was scored every 2 hours for 10 hours based on published guidelines (Senchuk et al., 
2017) and previous methods (Jansen et al., 2002).  Death of each animal was assessed at the indicated 
times by microscopic examination of ability to respond to no more than 3 "prods" with a platinum worm 
pick. Survival and mean lifespan was estimated from a Kaplan-Meir plot for each condition using OASIS2 
(Han et al., 2016), and statistical differences between populations compared by way of log rank test and 
Bonferroni correction.  
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2.9.2. Thermotolerance and Recovery Assay 
Survival of day-1 adult worms exposed to an acute bout of temperature up-shift  while exposed to varying 
drugs was assessed as an index of thermotolerance resistance based on published guidelines (Zevian 
and Yanowitz, 2014). Well-fed gravid hermaphrodites were bleach synchronised as in section 2.4.4. and 
resultant embryos were left to grow for 52 hours at 20°C on NGM plates seeded with live OP50 E.coli. 
Whilst, Zevian and Yanowitz, (2014) advise against the bleach syncronisation of worms due to the 
acquired increase in basal stress resistance, this technique has been widely for such assays (Kumsta et 
al., 2017; Raynes et al., 2012). At late-L4 stage, worms were transferred to seeded UV-killed OP50 E.coli 
NGM plates containing 200µM-400µM rilmenidine hemifumarate, or 5mM L-proline (+ve control) or 
vehicle (1% DMSO) for 24h. Proline has been shown to improve thermotolerance by ~30% in C. elegans 
through the improvement of protein stabilisation and membrane integrity (Edwards et al., 2015b). The 
thermotolerance assay was started at day 1 adulthood, to avoid premature age-related proteostastic 
collapse (Ben-Zvi et al., 2009) and to negate the need for FUDR which has been shown to interfere with 
thermotolerance and proteotoxic stress (Angeli et al., 2013) . After 24h of respective drug exposure, 
worms were added to an incubator preset to 37⁰C to induce heat-shock whilst still exposed to the 
respective drugs (Zevian and Yanowitz, 2014). After 3 hours, worms were removed from the incubator 
and being kept on the same drug plates, shifted to 20⁰C  and scored for survival after a ~20h “recovery 
period” (Kumsta et al., 2017). This period prevents false categorization of worms as visual inspection of 
worms immediately after heat shock is not a reliable determinant of their ultimate survival (Zevian and 
Yanowitz, 2014). At least 100 worms per condition across 3 identically designed independent trials were 
scored as either dead or alive by their ability to respond to no more than 3 "prods" with a platinum worm 
pick. Percentage survival was calculated and populations compared by one-way ANOVA of variance with 
Tukey post-hoc correction.  
Rilmenidine increases thermotolerance but not oxidative stress resistance dependent on f13e9.1. 
Survival of WT (WT,WT ), f13e9.1 (-/-) mutants, and two f13e9.1 rescue mutants (PHX945 and PHX946) 
in the presence or absence of rilmenidine following exposure to either heat-stress or oxidative stress.  
2.9.3. Assessment of F13E9.1::eGFP localisation 
The strains WT , PHX893, PHX945 and PHX946 were synchronized to adulthood (day 1) and exposed 
to drugs as in section 2.4.3. No less than 10 worms per genotype were immobilised in 20mM tetramisole 
pipetted into a glass-bottomed dish and observed under a Zeiss 710 confocal microscope at 20 °C with 
a Fluar 20x/0.75 lens. Images were acquired as in Teuscher and Ewald, (2018) which recommends a 
super-thin bandpass green filter (520 +/- 20nm) to overcome inherent autofluorescence within worms.  
91 
 
2.9.4. PolyQ Protein Aggregation Assay 
The C. elegans strain AM141 {rmIs133[P(unc-54)Q40::YFP]} (Morley et al., 2002)  was purchased from 
the CGC (https://cgc.umn.edu/transgene/23476) and frozen upon receipt. One week before each trial, 
aliquots of AM141 worms were thawed and picked on uncontaminated NGM agar seeded with live OP50. 
Strains were cultured for one week before being used for the polyQ aggregation assay, of which is  based 
on previously employed methodologies (Xiao et al., 2014; Zhang et al., 2012). Gravid hermaphrodites 
were bleached synchronized and the yielded eggs were incubated overnight in M9 medium. Syncronised 
L1 nematodes were then transferred to NGM plates containing 200µM-400µM rilmenidine 
hemifumuarate concentrations or a 1% DMSO vehicle. After incubation for the indicated periods of time, 
the nematodes were collected and immobilized in 10µl of 20mM tetramisole hydrochloride onto 
microscope slides.  Approximately 30 animals per condition across 3 trials were imaged under a Zeiss 
Axio Observer microscope at either a x10 and x20 objective. The number of polyQ40::YFP aggregates 
in body wall muscle was counted using ZenBlue software with set histogramic parameters (black: 500 
gamma:1.0 white: 5000). Approximately 50 animals across 3 independent trials were randomly selected 
for each treatment group and scored for number of aggregates. Groups were compared by two-factor 
repeated measures ANOVA and Tukey post-hoc correction. 
2.10. Body Size and Developmental Phenotyping 
2.10.1. Body Size Phenotyping  
Synchronised day 1 hermaphrodite worms cultured on live E.coli NGM plates were measured for body 
length and width in brightfield at x10 objective on a Zeiss Axio Observer following paralysis in 20mM 
tetramisole. It is well  established that in C. elegans, prolonged exposure to tetramisole induces acute 
shrinkage and changes in the skin elasticity (Galimov et al., 2018; Glenn et al., 2004; Woodruff et al., 
2018), however, the attainment of images that provide accurate determination of the body size change is 
difficult. As such, the acute use of tetramisole is still commonplace when imaging worms for body length 
measurement (Lant et al., 2015; Li et al., 2018; Mörck and Pilon, 2006; Shaohe Wang et al., 2015).  
Between 10-20 worms per data point were used in line with previous body length analyses (Bar et al., 
2016). Due to the significant transparency and animation of the tails obscuring the tail end-point, animal 
length was measured from head (most visibly anterior buccal line) to a position where the tail tapered to 
a 10-μm ±0.5μm diameter (Petzold et al., 2011). Body width measurements were taken from the 
posterior vulval peak to the corresponding outer edge of the intestinal cuticle (Mörck and Pilon, 2006). 
Measurements was made using the segmented lines function on Image J software (Collins, 2007) 
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normalised to the scale bar as implemented in previous work (Bar et al., 2016; Dineen and Gaudet, 2014; 
Mörck and Pilon, 2006). 
2.10.2. Developmental Measurements 
Bleach synchronised worms that had been halted in L1 starvation for 24h were measured for 
development following exposure to food source as described in (Schindler et al., 2014). ~ 500 worms per 
genotype and condition were placed onto NGM plates containing requisite test compounds and spotted 
with live OP50 E.coli. It is well established that live E.coli often metabolises drugs dissolved in NGM, 
reducing their efficacy (Zheng et al., 2013); however we were unable to elicit reliable and measurable 
development in worms grown on dead OP50 E.coli, which is in line previous observations (Lenaerts et 
al., 2008) . Worms were added to a 20⁰C incubator and left to develop. After 24 hours, measurement of 
worm development was conducted within another 24 hour window loosely based on previous reports 
(Schindler et al., 2014): 0 hours (24 hours exposure to food source), 3 hours, 6 hours, and then 24 hours 
(48 hours exposure to food source). Per trial and timepoint, 10 worms were immobilized and mounted 
onto glass slides in 20mM solution of tetramisole hydrochloride. Animals were then imaged at a x10 
objective for body length and x60 objective for vulval development in brightfield on a Zeiss Axio Observer. 
Vulval development was scored using visual identification of late larval stage vulval checkpoints detailed 
by Schindler, Baugh and Sherwood, (2014). Statistical significance of differences in vulval development 
was determined by 2 way ANOVA.  
2.11. “Healthspan Measurements” 
2.11.1. Age-related autofluorescence  
Autofluorescence of the intestine was measured as an index of healthspan based on previously published 
guidelines (Bansal et al., 2015). Well-fed gravid hermaphrodites were bleach synchronised and resultant 
embryos were left to grow for 52 hours at 20°C on NGM plates seeded with live OP50 E.coli. At late-L4 
stage, WT or mutant worms were transferred to NGM plates containing requisite drugs or vehicle (1% 
DMSO) spotted with UV-killed OP50 E.coli and left for either 1 day or 10 days at 20⁰C to age, based on 
previously used time points (Pluskota et al., 2009). 10 animals per data point were immobilized and 
mounted onto glass slides in 20mM solution of tetramisole hydrochloride (Yan et al., 2017) before being 
imaged through both brightfield and DAPI filter using a Zeiss Axio Observer (300ms exposure, x10 
objective) (Bansal et al., 2015). A total of at least 30 worms per condition were imaged across 3 
independent trials.  
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Intestinal florescence was quantified using mean pixel intensity. Intestinal areas from pharyngeal-
intestinal valve to rectum were traced using the spline mode in Zen Blue v2.3 and raw mean pixel intensity 
was calculated (Hill et al., 2014). This figure was then normalised against the average pixel intensity of 3 
300µm2 boxes placed in non-intestinal areas of each worm (distal portions of the tail and head). Net 
mean pixel intensity was calculated for each sample and median sought for each group. Statistical 
difference between day 1 and day 10 for each condition was independently calculated by 2-way Mann-
Whitney U to account for outliers. 
2.11.2. Motility Assay  
Motility assay was based on a modified protocol of Huang, Xiong and Kornfeld, (2004) used by Calvert 
et al., (2016). NGM agar plates were firmly tapped onto the microscope to stimulate movement. In 
responding worms, not impeded by OP501,  body bends (defined in Calvert et al., (2016)  as movement 
of the head in a half sigmoidal wave that propelled movement and/or resulted in a bend in the body that 
moved halfway down the length of the worm) were counted for 30 seconds in 10 worms for each condition 
at each time point (5, 10 and 15 days post-L4 moult) per trial across 3 independent trials to a total of 30 
worms per genotype and condition.  Mean deterioration in motility per genotype and/or condition was 
compared by 2- factor repeated ANOVA and Tukey post-hoc correction whilst individual time-point 
comparisons were tested by student’s T-test.  
  
 
1 Worms exhibit slowed and staggered locomotion when in the presence of OP50 
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3. Results: Rilmenidine Opposes the Transcriptional Direction of Ageing And 
Improves Survival in C. elegans  
3.1. Introduction 
Ageing has been previously defined as a vulnerability to disease and death characterised by 9 hallmarks 
(López-Otín et al., 2013). The molecular hallmarks of ageing both affect and are affected by 
transcriptional changes (Stegeman and Weake, 2017). As such, researchers have considered ageing to 
be a consequence of genomic instability manifesting itself as lack of dynamic control over the expression 
of genes (Tarkhov et al., 2019). Furthermore, the inability to effectively regulate homeostasis can be 
hypothesised to result in global dysregulation in gene expression, consistent across cell-type and 
represented by an ageing transcriptional signature or “fingerprint”.  
That said, the magnitude of such dysregulation is surprisingly small and targeted. Only 4% of genes show 
age-related changes in expression in either human brain or kidney tissue, or in monkey (Macaca mulatta) 
skeletal muscle; and meta-analysis of approximately 1500 human blood samples identified 12.5% of 
expressed genes as being differentially expressed with age (Berchtold et al., 2008; Kayo et al., 2001; Lu 
et al., 2004; Peters et al., 2015; Racette et al., 2017; Rodwell et al., 2004). Importantly, such specific 
changes reproducibly occur in stress-related pathways with noticeable upregulation of DNA repair and 
inflammatory pathways across multiple species, tissues and cell types (Stegeman and Weake, 2017).  
Thus, this more narrowed field of change offers reduced noise and heterogeneity which may be beneficial 
in identifying targetable pathways dysregulated by age-driven transcriptional changes. This is bolstered 
by evidence showing the power of human transcriptome changes as a robust metric for ageing which can 
be conveniently, quickly and reliably employed to test anti-ageing treatments before being validated in a 
laboratory setting (Fleischer et al., 2018; Peters et al., 2015).  
Previous work has identified that calorie restriction can elicit distinct and widespread changes in gene 
expression in a number of biological pathways, including growth hormone signalling, lipid metabolism, 
immune response, retinol metabolism, copper ion detoxification, and circadian rhythms (Swindell, 2009; 
Whitaker et al., 2014). Moreover, murine studies have suggested that CR might be able to reverse age-
associated gene expression changes (Lee et al., 1999). Specifically, mice initiated on CR at middle age 
demonstrate a profound transcriptional reprogramming that retards age associated gene expression 
changes in cardiac tissue (Lee et al., 2002). In murine hippocampal tissue excised from mice treated with 
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life-long CR demonstrated a reversal of age-associated changes in mitochondrial dysfunction, 
inflammation, and stress response gene expression patterns (Zeier et al., 2011).  
It is rational to propose that drugs which elicit a similar transcriptional profile to that of calorie restriction 
could reverse ageing signatures which may confer geroprotection. Indeed this was previously attempted 
using the connectivity map (cMAP) by our lab (Calvert et al., 2016). Initially developed by the Broad 
Institute, the cMAP is a database resource comprised of 6,000 transcriptomes of various compound 
treatments (drug perturbations) performed on a 5 different human cell lines (Lamb et al., 2006). Users 
upload 2 gene sets representing the top downregulated and the top upregulated genes of their chosen 
transcriptome. The CMap then implements a modified two-tailed non-parametric Kolmogorov–Smirnov 
statistical test to calculate the similarity of drug‐perturbed expression profiles to the gene sets used to 
query the database. The primary aim is to identify drugs which oppose or mimic a transcriptome, such 
that they may be repurposed to induce or reverse complex phenotypes. This bioinformatic approach has 
successfully identified a number of compounds that have subsequently been tested for the treatment of 
a number of conditions such as obesity (Liu et al., 2015), irritable bowel disease (Nair, 2013), and cancer 
(Wei et al., 2006). In the ageing field, the prototypical version of cMAP has been used numerous times 
to identify prolongevity drugs that might oppose a queried ageing signatures derived through various 
bioinformatic approaches (Dönertaş et al., 2018; Gillbro et al., 2015; Janssens et al., 2019). However, in 
collaboration with Library of Integrated Network-based Cellular Signatures consortium, the number of cell 
lines and compounds in the cMAP database was recently and dramatically expanded to include a total 
of 476,251 gene expression profiles generated using 27,927 perturbagens, including the loss of function 
(LOF) or gain of function (GOF) mutations across nine cell lines (Subramanian et al., 2017). The 
magnitude of this project is capacitated by the algorithmic reduced-representation prediction of genome-
wide transcriptional changes from a set of 1000 “landmark” genes. This next generation cMAP has now 
been cited over 200 times across broad disease biology fields.  
Only one paper, thus far, has utilised the updated cMap to find  anti-ageing compounds, wherein authors 
derived a C. elegans ageing signature to identify and validate heat-shock protein inhibitors as pro-
longevity compounds (Tarkhov et al., 2019). To date, no-one has published a CR gene set query to 
identify possible CR mimetics using the updated cMap. This could serve to re-validate allantoin as a 
potential CR mimetic whilst also offering a more detailed transcriptional analysis of imidazoline receptor 
agonists, such as rilmenidine, in relation to CR and ageing. 
Furthermore, upon the potential validation of bioinformatic insight garnered from the cMAP analysis, it is 
pertinent to assess the in-vivo propensity of any hit compounds, to ameliorate the ageing process. Indeed, 
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ageing is a complex phenotype manifesting in functional declines at many levels of biological 
organization. As such, measuring ageing, or indeed a rate of ageing, is a significant challenge.  Pathology 
and degeneration occurs at different times and rates, even within nematodes, making direct assessment 
even more challenging: however, any stochastic demise must eventuate in death and determine 
organismal lifespan (Ezcurra et al., 2018; Stroustrup et al., 2013). Thus, the measurement of lifespan, 
has for the last few decades, become the most common, robust and accepted metric of the ageing 
process, determining the consequence of ageing and death (Collins et al., 2006; Kirkland and Peterson, 
2009; Newell Stamper et al., 2018). Measurements of ageing by lifespan assays are critical for 
determining the geroprotective properties of a compound and often form the initial assessment any 
gerontological drug studies (Collins et al., 2006).  
Among the aforementioned benefits that have proliferated the use of C. elegans in the ageing research 
field, is its short lifespan, and large, manageable cohorts making it amenable to robust longitudinal study. 
The acquisition of statistical lifespan signatures has become a mainstay in defining the anti-ageing effect 
of chemical intervention (Stroustrup et al., 2013). This is commonly represented by means of survival 
curve: a monotonically decreasing function that quantifies the surviving fraction of a population vs time. 
Importantly, calorie restriction, in almost all model organisms, routinely elicits significant perturbations in 
survival (Liang et al., 2018). In C. elegans, survival/lifespan data is advisably processed by Kaplan-Meir 
analysis to demonstrate any significant efficacy an intervention may have in improving mean and/or 
maximum lifespan (Lionaki and Tavernarakis, 2013).  
3.2. Results 
3.2.1. Probing of the Connectivity Map With Age-Related and Calorie Restriction 
Transcripts Reveals Rilmenidine To Have a Significant Ageing and Senescence-
associated and Gene Expression Profile 
I probed the connectivity map with 8 different gene sets (Table 3). First, an ageing gene signature 
generated by our lab from a meta-analyses of 127 multi-tissue datasets of aged animals was used (Fabris 
et al., 2018) and from another meta-analysis of GTex ageing data (Mele et al., 2015). DEGs from both 
datasets were converted to Entrez IDs and filtered to generate a consensus gene list that was 
differentially expressed in both datasets. This represented our global ageing signature as well as the two 
individual meta-analyses being queried separately.  
Second, imidazoline receptor expression is most pronounced in the brain, corresponding to the centrally-
acting hypotensive effect of I1Ras (Bousquet et al., 2020; Ding et al., 2013). I1RAs may therefore elicit a 
brain-specific transcript, so I generated a gene set of DEGs from a sub-analysis using just brain tissue 
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samples within the selected datasets using the Fabris et al. meta-analysis gene-signature.  Then I further 
compartmentalised to include only Rostral Ventral Lateral Medulla (RVLM) gene expression changes with 
age. I harvested the only published and normalised gene expression data from the RVLM of young and 
old F344 rats using GSE90956 series matrix text files to produce a DEG set list defined by z-score. 
Rilmenidine and moxonidine are anti-hypertensives that exert their hypotensive effect through inhibition 
of the sympathetic nervous system. Rilmenidine acts primarily on imidazoline receptors in the RVLM to 
reduce sympathetic tone and to modulate sympathetic baroreflexes agonism (Head et al., 1998).  
Thirdly, given that cMAP works on an in-vitro level, I utilised a meta-analysis of publicly available datasets 
to identify a cellular senescence signature, which may represent more cell-specific ageing change 
(Chatsirisupachai et al., 2019). 
Lastly, I probed the cMAP with two separate dietary restriction profiles. We used the original 
transcriptional profile from published data in rat cells exposed to sera from rats or rhesus monkeys 
undergoing CR used in Calvert et al. (2016). However, this yielded a relatively low number of DEGs which 
would be vulnerable to noise and cross-species differences. Thus it was decided to upload an alternative 
CR gene set, derived using the same methods as for GSE90956, using human foreskin fibroblasts 
cultured in media supplemented with human sera obtained from: 1) healthy lean and weight-stable 
volunteers who were consuming calorie-restricted diets, for an average of 7 years, and 2) age-, sex-
matched individuals eating a Western Diet (Omodei et al., 2013). 
cMAP groups pharmocological classes which represent a collection of bioactive drugs with similar 
mechanism of action. Likewise, genetic perturbation classes represent GOF of LOF mutations that elicit 
a set ontology. Given that the purpose of this was not to identify new individual drugs but to validate 
process and the suitability of rilmenidine for further study, only the mean tau score “connectivity” of each 
perturbagen class was recorded corresponding to the fraction of reference gene sets with a greater 
similarity to the perturbagen class than the current query. We used a tau threshold of -90 for significantly 
opposing perturbagens and +90 for similar profiles as recommended by the database developers and as 
utilised elsewhere (Ferguson et al., 2018; Liao et al., 2019) . 
First and foremost, allantoin did not show significant connectivity to any of the signatures we queried; 
even the original de Cabo 2003 CR dataset used to initially identify the CRM properties of allantion. This 
highlights artefactual differences in perturbagen gene profiles between the prototypical and existing 
cMAP builds. An interesting pattern emerged from the data demonstrating that perturbagen classes that 
have been previously and routinely associated with amelioration of ageing phenotypes, were positively 
correlated with ageing and senescent signatures. Likewise, those age ameliorating classes were 
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negatively correlated to the DR transcripts used to query the cMAP. This further highlighted the 
unintuitively contrary results from the cMAP query. Specifically, mTOR inhibitors and IGF-1 inhibitors, 
classes of drugs which are routinely demonstrated to extend lifespan and confer geroprotection, 
appeared to elicit a significantly similar transcriptional profile to all 4 ageing and senescence signatures 
(Harrison et al., 2009; Mao et al., 2018). Moreover, mTOR inhibitor classes, despite their forerunning as 
CRMs, elicited a counterintuitive opposition to human CR gene expression patterns. With that said, using 
genetic perturbagens,  the queries reinforced previously published observations that ageing and 
senescence is associated with an activation of the NFκB pathway (Haustead et al., 2016; Helenius et al., 
1996). Both the universal ageing signature and also the gene signature derived from the senescence 
meta-analysis, resulted in significant connectivity of tau 94.3 and 99.24 with NF-κB activation. 
Furthermore, and validating the legitimacy of this bioinformatic approach, the senescence gene signature 
yielded a perfect and identical 100 score for cell-cycle LOF perturbations.  
Perturbagen classes that yielded a significantly dissimilar signature to the universal ageing signature and 
thus offered evidence of potential geroprotective properties, were bile acid and fibroblast growth factor 
receptor (FGFR) inhibitors. Bile acids have long been recognized as endocrine regulators beyond their 
role as emulsifiers in the gut lumen, through escapement into systemic circulation. Through interaction 
with farnesoid X receptors or by the G-protein coupled bile acid receptor (GPBAR1, formerly TGR5), bile 
acid supplementation interacts with ageing-relevant pathways involved in neuroprotection and glucose 
homeostasis (Ackerman and Gerhard, 2016; Shapiro et al., 2018).  Interestingly, FGFR inhibitors were 
the only pharmacological class that elicited significant (tau -92.59) opposition to the universal signature 
whilst offering significant similarity to long-term human CR gene expression changes. FGFR GOF 
mutations are oncogenic and are present in a number of human cancers; as such, FGFR inhibitors are 
routinely employed in chemotherapy (Katoh, 2016). However, relevantly, FGFRs are upregulated by 
fasting in the liver and adipose tissue, and FGFR have been demonstrated to increase bile acid secretion 
improve insulin resistance and glucose metabolism (Ge et al., 2014; Hagel et al., 2015; Katoh, 2016). 
Thus FGFR inhibitors represent a promising target for CRM identification in future research.  
To assess the prolongevity potential of I1RAs, we compared rilmenidine and moxonidine to the 8 gene 
sets. Moxonidine failed to have a significant connectivity to any of the queried gene sets. However, 
rilmenidine significantly opposed the all-tissue GeTex ageing signature (tau -93.24) and the gene 
signature of senescence (tau -99.68). Unfortunately, rilmenidine failed to elicit any significant 
transcriptional similarity to either of the CR gene sets, although some insignificant positivity was apparent 
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between rilmenidine (tau +74) and long-term human CR gene expression changes. Nonetheless, 
rilmenidine represents the more promising I1RA for anti-ageing intervention.  
Nischarin, is the only mammalian putative translated protein which expresses the I1RA binding site. LOF 
mutations significantly opposed the gene signature of hepatocytes exposed to CR serum. In theory, 
Nischarin LOF should correspond to a reduced I1RA agonism including those such as agmatine which 
are endogenously derived. Thus, it is plausible to hypothesise that I1RAs may play a part in some CR 
signalling. This is contrary to previous findings demonstrating Nischarin mutant mice to have better fasting 
insulin and glucose tolerance, eventuated by an increase in AMPK phosphorylation (Dong et al., 2017).  
Notably, both brain ageing signatures failed to generate any significant signals. Given the significant 
physiological consequences of rilmenidine activity on RVLM neurons, it was surprising to not observe a 
transcriptional overlap as seen in the universal ageing signature. This suggests that the potential 
suppression of an ageing signal by rilmenidine is lost in the brain and that this signal may be uncoupled 
from rilmenidine’s primary hypotensive effect. Thus, the potential anti-ageing transcriptional profile of 
rilmenidine warranted further bioinformatic investigation.
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Table 3. cMAP analysis reveals drug classes which share significantly opposing or similar transcriptional profiles to 8 queried gene sets. The top 150 upregulated 
and 150 downregulated differentially expressed genes (DEGs) for each of the 8 datasets (3 all-tissue ageing signatures, 2 brain-specific ageing signatures, 1 senescence 
signature and 2 CR signatures) were individually inputted to the online drug repurposing tool cMap. Those signature inputs were compared to a database of 27,927 
perturbagens, including the loss of function (LOF) or gain of function (GOF) mutations across nine cell lines. A numerical median connectivity or tau score was generated 
derived from a Kolmogorov–Smirnov enrichment statistical evaluation of each gene expression profile: Perturbational classes (grouped compounds or mutations by 
mechanism of action or ontology) were recorded based on a summary tau connectivity score. Perturbagens with a tau score >90 demonstrate a significantly similar 




  Ageing Genetic Sig. Brain ageing Sig. Senescence Genetic Sig. Calorie-Restriction Genetic Sig. 
Author Fabris (2018) Mele (2015) Combined Balivada (2017) Fabris (2018) Chatsirisupachai (2019) Omodei (2013) de Cabo (2003) 
No. Differentially Expressed Genes 1024 1573 583 540 580 1261 357 41 
Tissue All-Tissue All-Tissue All-Tissue RVLM Whole Brain All-Tissue Foreskin Fibroblasts Hepatocytes 
Perturbagen Class: Pharmacological                 
Bile Acid -59.16 -95.37 -72.95 6.58 -1.62 -98.13 79.82 -73.12 
Bromodomain Inhibitor 18.2 17.12 66.79 2.21 -0.26 99.57 -96.23 99.24 
CDK inhibitor 7.85 95.8 29.39 3.41 -0.03 99.83 -97.12 -89.54 
DNA dependent protein kinase inhibitor 95.7 97.47 94.23 -0.03 -0.01 99.32 -96.3 74.66 
FGFR inhibitor -58.91 -92.96 -92.59 -0.01 7.27 -19.51 97.72 -96.8 
FLT3 Inhibitor 74.74 95.74 93.83 0.57   99.7 -91.61 -76.87 
HMGCR Inhibitor 52.5 98.54 98.21 -4.6 1.25 96.65 -70.62 21.63 
IGF-1 Inhibitor  91.77 98.12 97.01 10.38 0.42 99.65 -94.6 -8.29 
IMPDH Inhibitor 81.28 96.25 80.63 2.39 38.93 97.89 -97.83 -88.12 
Jak Inhibitor 28.84 80.08 92.56 2.66 3.46 99.97 -93.8 -68.05 
MTOR Inhibitor 99.19 99.52 99.33 1.26 28.2 98.62 -96.75 -45.97 
PI3K Inhibitor 98.34 99.32 99.09 3.55 1.22 99.23 -97.63 -23.84 
PDGFR/KIT inhibitor 67.4 94.74 96.83 -0.05 1.11 84.32 -81.62 -92.71 
Protein Synthase Inhibitor 1.17 34.08 94.26 -57.77 2.38 94.08 12.36 -96.18 
Topoisomerase inhibitor 36.06 98.06 84.74 6.3 0 99.39 -94.48 -61.81 
T-type calcium channel blocker  94 90.59 96.05 -0.06 3.75 97.64 -54.92 -60.86 
Perturbagen Class: Genetic                  
 Cell Cycle Inhibition GOF  90.04 71.72 85.71 43.44 0.2 100 -96.37 -58.99 
NFKB Activation GOF 94.74 78.41 94.3 -18 7.39 99.24 -25.48 -80.81 
Perturbagen Class: Imidazoline Receptor 
Related                 
Rilmenidine -67.49 -93.24 -85.51 22.14 -10 -99.68 74 -32.61 
Moxonidine -10.66 -29.266 -7.29 -6.27 -3.95 -13.23 -1.11 21.39 
Nischarin GOF -0.93 14.11 -1.76 0 13.43 -0.49 5.79 16.61 
Nischarin LOF 2.87 -38.34 12.95 -46.92 -34.9 14.03 -2.73 -93 
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3.2.2. Meta-Analysis of In-vitro Imidazoline Receptor Agonist Treatment To Derive a 
Transcriptional Profile For Gene Set Enrichment Analysis 
To ascertain a consensus rilmenidine transcriptome for further study, a meta-analysis was performed to 
identify universally DEGs induced by in-vitro rilmenidine treatment. Using the L-1000 database (clue.io), 
normalised gene expression data was downloaded representing the gene expression changes (z-scores) 
of 61 cell lines treated with 10µM of rilmenidine for 6 hours in comparison to cell-line-matched, DMSO-
treated wells. In the L-1000 database, all cell lines were treated with 10 µM rilmenidine for either 6h or 
12h. 6h was chosen because it has been previously used as a time point for phenotype induction with 
rilmenidine in both human and rodent studies (De Visser et al., 2002; Perez et al., 2012). 
Meta-analysis was performed  via a value counting method as in de Magalhães et al., (2009), and is 
detailed in the methods section. In order to account for the subtilties of transcriptional change, a relaxed 
z-ratio threshold for differential expression was set at -1.96 and +1.96 (Cheadle et al., 2003). Overall, I 
identified 50 genes across the cell-lines consistently overexpressed with rilmenidine treatment, using an 
adjusted Benjamini–Hochberg cut-off of P <0.01. Conversely, we found 154 genes consistently 
underexpressed with rilmenidine treatment. SERPINA3 was the most consistently overexpressed gene, 
being differentially expressed in 15 of the 61 trials (adj. p-value 1.63E-09). SERPINA3 is a member of 
the serine protease inhibitors (SERPINs) superfamily. It is secreted as an acute phase protein to inhibit 
cathepsin G, limit inflammation and contribute to improved wound healing (Chelbi et al., 2012; Horvath 
et al., 2005; Whisstock and Bottomley, 2006). Importantly, gene expression of SERPINA3 has been 
reported to decrease with age (Glass et al., 2013). WIF1 is an inhibitory extracellular protein with a WNT 
inhibitory factor (WIF) domain and 5 epidermal growth factor (EGF)-like domains; this was the 2nd most 
consistently over expressed gene in response to rilmenidine, but is also known to be downregulated with 
ageing (Makrantonaki et al., 2012). Of the remaining top 10 expressed genes (SERPINA3, WIF1, MAL, 
FBXO11, SNX11, KYNU, SPP1, RRP8, RRS1, TLR4), all were landmark or well-inferred genes. 
Furthermore, a number of genes are involved in immune function (SPP-1, MAL, TLR-4) and a further 3 
were involved in protein processing (SNX11, FBXO11 and RRS1). 
Of the 154 genes consistently under-expressed in rilmenidine treated cell-lines, CHMP4A was the most 
significant, being differentially expressed in 13 of the 61 trials (adj. p-value 1.01E-10). CHMP4A belongs 
to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. Evidence 
suggests, CHMP4A is a key facilitator in degradation of surface receptor proteins and formation of 
endocytic multivesicular bodies (MVBs) (Tsang et al., 2006). Elsewhere, CHMP4A has been thought to 
accelerate cell cycle progression, and is accordingly differentially expressed during senescence 
(Rapisarda et al., 2017). Of interest, CHMP4a possesses a coiled coil domain, which has been 
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hypothesised to carry potential imidazoline receptor binding site (Katoh et al., 2003). The second most 
under-expressed gene was calpastatin (CAST). This gene encodes a calpain inhibitor, which supresses 
proteolytic activity of calpains (Mikosik et al., 2013). Dysregulation of calpains, key cleavage molecules, 
has been shown to influence cell migration and that calpain inhibition blunts tumour growth (Raimbourg 
et al., 2013). Thirdly, PPP2R5E was consistently underexpressed in 12 of the 61 trials (adj. p 1.44E-09). 
PPP2R5E is a gene that encodes a regulatory subunit of the tumor suppressing protein phosphatase 2A. 
Not only is its downregulation associated with cancer development and poor outcome, it’s downregulation 
is also shown in high-risk for AD APOE4 patients (Grochola et al., 2009; Theendakara et al., 2017). 
However, conversely, activated mTORC1 induces protein phosphatase 2A (PP2A)‐mediated 
dephosphorylation of the transcription factor forkhead box K1 (FOXK1) and thus its downregulation may 
be associated with reduced mTOR functioning (Nakatsumi et al., 2018). Of the other top ten most 
underexpressed genes, kinectin 1 was included. This gene is known to become overexpressed in ageing 
and its expression can be modulated by CR (Chang et al., 2015; Prolla et al., 2006). Moreover, included 
in the top ten was the consistent underexpression of C2CD5, a phospholipid binding and insertion protein. 
As such, C2CD5 contributes to insertion of GLUT4 into the plasma membrane and is thus associated to 
a “low glucose response” (Xie et al., 2011). 
To elucidate the collated effect of rilmenidine on cellular processes and gain some more functional insight, 
the differentially expressed gene lists of rilmenidine were enriched using a TopGO r-script and 
reclassification with Revigo (see materials and methods). This returned key processes affected by 
rilmenidine treatment. 166 biological processes (GO terms) were returned to be significantly enriched in 
the overexpressed rilmenidine gene list following TOPGO analysis using a weighted Fischer p value 
<0.05. This more relaxed threshold was employed to account for the focus on enriched functional 
categories rather than on individual genes. This resultant list was further filtered by Revigo, a software 
which summarises gene lists by removing redundant annotations to generate term subsets using a simple 
clustering algorithm that relies on semantic similarity measures (Supek et al., 2011).  Using a p value 
<0.01 threshold the analysis returned 22 GO terms that were enriched in the overexpression gene-list for 
rilmenidine (see Table 4). Results suggest that rilmenidine drives an overexpression in genes associated 
with development (GO:0060433: bronchus development, GO:0003179: heart valve morphogenesis, GO: 
0060231: mesenchymal to epithelial transition, GO:0035162: skeletal muscle tissue regeneration, 
GO0048701: Embryonic cranial skeleton morphogenesis). Furthermore, and relevant to calorie restriction 
and geroprotective properties, rilmenidine treatment appeared to reduce expression of inflammation 
associated genes (GO:0032689, negative regulation of interferon-gamma production; GO:1903556, 
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negative regulation of tumor necrosis factor superfamily cytokine production). Interestingly, rilmenidine 




Table 4. Gene Ontology (GO) terms for biological processes that are over represented in the lists of 
significantly underexpressed genes following meta-analysis of rilmenidine treated cell line transcripts. P-
values obtained using topGO to derive Fischer’s exact values and adj.p values following redundancy reduction 
using REViGO.      Shading pertains to extracellular matrix associated GO terms.    Shading pertains to immune 




GO Term Description REVIGO Log10 P-value  
GO:0070486 leukocyte aggregation -3.9586 
GO:1903543 positive regulation of exosomal secretion -3.7696 
GO:0022617 extracellular matrix disassembly -3.6383 
GO:0043312 neutrophil degranulation -3.4559 
GO:0042060 wound healing -3.2676 
GO:0045445 myoblast differentiation -3.1427 
GO:0033572 transferrin transport -3 
GO:0051093 negative regulation of developmental process -2.8996 
GO:0043062 extracellular structure organization -2.857 
GO:0050900 leukocyte migration -2.8539 
GO:0006027 glycosaminoglycan catabolic process -2.8447 
GO:0045214 sarcomere organization -2.8239 
GO:1902117 positive regulation of organelle assembly -2.7055 
GO:0048146 positive regulation of fibroblast proliferation -2.699 
GO:0042130 negative regulation of T cell proliferation -2.6498 
GO:0045600 positive regulation of fat cell differentiation -2.6326 
GO:0035722 interleukin-12-mediated signalling pathway -2.5884 
GO:0071230 cellular response to amino acid stimulus -2.5452 
GO:0098609 cell-cell adhesion -2.341 
GO:0071407 cellular response to organic cyclic compound -2.3344 
GO:0007160 cell-matrix adhesion -2.2967 
GO:0009894 regulation of catabolic process -2.2211 
GO:0001523 retinoid metabolic process -2.2147 
GO:0001657 ureteric bud development -2.1512 
GO:0006024 glycosaminoglycan biosynthetic process -2.0768 
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Table 5. Gene Ontology (GO) terms for biological processes that are over represented in the lists of 
significantly overexpressed genes following meta-analysis of rilmenidine treated cell line transcripts. P-
values obtained using topGO to derive Fischer’s exact values and adj.p values following redundancy reduction 
using REViGO.      Shading pertains to GO terms associated with developmental processes.     Shading pertains 
to anti-inflammatory associated GO terms. 
 
The pipeline was repeated for the rilmenidine underexpressed gene list. Again 138 GO terms were 
derived from TOPGO analysis of the underexpressed gene list which was further filtered to 25 GO terms 
by RIVIGO. In agreement with results demonstrated for the upregulated genes, biological processes that 
were significantly downregulated were immune related (GO:0070486, leukocyte aggregation; 
GO:0043312, neutrophil degranulation; GO:0050900, leukocyte migration; GO:0035722 interleukin-12-
mediated signalling pathway). Additionally, and again relevant to calorie restriction, rilmenidine causes a 
down regulation of genes that respond to amino acid stimulus (GO:0071230).  
To further clarify whether the transcriptional perturbations induced by rilmenidine treatment were 
symptomatic of imidazoline receptor activity, we repeated the meta-analysis to pool gene-expression data 
from 9 different known imidazoline receptor agonists (Table 6). Strikingly, despite rilmenidine being only 
1 of 9 imidazoline receptor agonists, every single overexpressed gene in rilmenidine treated cells was 
also overexpressed in the combined drug meta-analyses, with a total of 267 genes being overexpressed 
when all imidazoline receptor agonists were analysed together. Conversely, 586 DEGS were 
Overexpressed Rilmenidine 
GO Term Description REVIGO Log10 P-value 
GO:0030501 positive regulation of bone mineralization -3.7959 
GO:0060433 bronchus development -3.2676 
GO:0003179 heart valve morphogenesis -3.0862 
GO:0042447 hormone catabolic process -3.0706 
GO:0030277 maintenance of gastrointestinal epithelium -3.0132 
GO:0060231 mesenchymal to epithelial transition -2.8153 
GO:0035162 embryonic hemopoiesis -2.7721 
GO:2000311 regulation of  selective glutamate receptor activity -2.7721 
GO:0090303 positive regulation of wound healing -2.71 
GO:1904646 cellular response to beta-amyloid -2.6576 
GO:0045992 negative regulation of embryonic development -2.6216 
GO:0045671 negative regulation of osteoclast differentiation -2.4634 
GO:0032689 negative regulation of interferon-gamma production -2.4353 
GO:0043403 skeletal muscle tissue regeneration -2.382 
GO:0048701 embryonic cranial skeleton morphogenesis -2.3487 
GO:0042149 cellular response to glucose starvation -2.2848 
GO:0072160 nephron tubule epithelial cell differentiation -2.2434 
GO:1903556 negative regulation of TNF family cytokine production -2.2426 
GO:0001709 cell fate determination -2.2182 
GO:0030890 positive regulation of B cell proliferation -2.1979 
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underexpressed in the combined drug signature of which 129 were also significantly underexpressed in 
rilmenidine treatment; only 3 genes were not subsumed by combined treatment. Thus it can be 
reasonably concluded that imidazoline receptor activation is the likely cause of transcriptional 
perturbations by rilmenidine. 
Table 6. Imidazoline receptor agonists included in the combined drug gene expression meta-analysis. 
 
Next, it was important to establish whether rilmenidine was able to rescue any of the transcriptional 
alterations observed in ageing which might elucidate geroprotective mechanisms. Overlapping of DEGs 
in rilmenidine and DEGs from the Fabris et al. whole tissue ageing signature highlighted significantly 
opposing transcriptional direction, such that genes that became overexpressed in ageing were 
underexpressed in rilmenidine treatment (Fischer’s Exact; p= 7.72E-07). This suggested rilmenidine 
might be able to rescue transcriptional overactivity in ageing. To identify another potential transcriptional 
opposition, genes consistently underexpressed with ageing were compared to genes consistently 
overexpressed in rilmenidine, however this yielded no significance.  
It was important to establish which biological processes might be involved in the proposed rilmenidine 
induced rescuing of age-related overexpression. Firstly, rilmenidine did not match the transcription of the 
DR dataset in any direction (see supplementary; Fischer’s exact; over vs over p=1.0; under vs under 
p=0.7). Thus to gain further insight, gene enrichment as described above using TOPGO and REViGO 
was performed against the differentially expressed gene intersect for ageing overexpression and 
rilmenidine underexpression. 129 different biological processes were enriched in the intersect. Following 
reclassification by REViGO, 16 biological processes remained enriched and these are listed in Table 7. 
The most significantly enriched term was GO:0006027 glycosaminoglycan catabolic process. 
Glycosaminoglycans are abundant structural components of the extracellular matrix (ECM) and their 
catabolism forms part of a more global ECM breakdown in ageing (D. H. Lee et al., 2016). This GO term 
is related to 4 other GO terms associated with extracellular matrix function that are enriched in the ageing 
over/rilmenidine under gene list (GO:1903543 positive regulation of exosomal secretion; GO:0001523 
retinoid metabolic process; GO:1905048 regulation of metallopeptidase activity; GO:0022617 
extracellular matrix disassembly. Another collection of terms that were enriched were involved with 
immune response and inflammation (GO:0050900 leukocyte migration; GO:0035722interleukin-12-
mediated signalling pathway; GO:0016032 viral process; GO:0042060 wound healing; GO:0070486 
Drug Rilmenidine Moxonidine Clonidine Guanabenz Tizanidine Guanfacine Cimetidine Naphazoline Cirazoline Lofexidine
No. Cell Lines Tested 31 18 38 27 10 23 9 10 9 11
108 
 
leukocyte aggregation). In fact, ECM and immune function GO terms dominated more than half of the 
significantly enriched biological processes. When the same gene enrichment pipeline of gene list 
intersects was repeated for combined imidazoline receptor drugs, in lieu of rilmenidine, ECM terms and 






Figure 3. Venn diagrams demonstrating the combined overlaps of 3 different gene-sets. 1. Genes 
consistently overexpressed in ageing.  2. Genes consistently underexpressed in cells exposed to rilmenidine. 3. 
Genes consistently underexpressed following a meta-analysis of a range of cells exposed to 9 different known 





Table 7. Revigo recategorised GO terms derived from TOPGO gene enrichment of DEGS that intersect 






Underexpressed in Rilmenidine And Overexpressed In Ageing 
GO Term Description REVIGO Log10 P-value 
GO:0006027 glycosaminoglycan catabolic process 
-3.9586 
GO:0016032 viral process 
-3.7696 
GO:0042060 wound healing 
-3.6383 
GO:0070486 leukocyte aggregation 
-3.2676 
GO:1903543 positive regulation of exosomal secretion 
-3.1427 
GO:0097284 hepatocyte apoptotic process 
-3 
GO:0045445 myoblast differentiation 
-2.8996 
GO:0001523 retinoid metabolic process 
-2.857 
GO:0010988 regulation of low-density lipoprotein particle clearance 
-2.8539 
GO:1905048 regulation of metallopeptidase activity 
-2.8447 
GO:0033572 transferrin transport 
-2.699 
GO:0043687 post-translational protein modification 
-2.5884 
GO:0050900 leukocyte migration 
-2.5452 
GO:0035722 interleukin-12-mediated signalling pathway 
-2.2211 
GO:0022617 extracellular matrix disassembly 
-2.2147 




3.2.3. Rilmenidine and Other Imidazoline Receptor Agonists Improve Survival in C. 
elegans  
With the knowledge that rilmenidine and, more generally, imidazoline receptor agonists seemingly 
oppose the transcriptional direction of ageing, we exposed WT adult hermaphrodite C. elegans to varying 
concentrations of rilmenidine or moxonidine, to assess changes in survival. We utilised a popularised 
solid media NGM based lifespan assay using both FUDR and UV-killed OP50 E.coli (Sutphin and 
Kaeberlein, 2009). At L4/adult molt, worms that had previously developed on FUDR-free NGM and live 
OP50 E.coli were transferred to, and remained on thereafter, NGM plates that had been supplemented 
with both FUDR and a homogenously dissolved DMSO solution to 1% containing either rilmenidine (0µM, 
100µM, 150µM, 200µM, 300µM, 400µM), or moxonidine (0µM, 100µM, 150µM, 200µM, 250µM). 
Additionally, we reassessed the previously demonstrated pro-longevity dose of allantoin (250µM) as well 
as the oft-cited pro-longevity dosages of resveratrol (100µM) and rapamycin (100µM) to establish the 
reliability of the assay (J. Lee et al., 2016; Robida-Stubbs et al., 2012; Viswanathan et al., 2005; Wood 
et al., 2004).  
Dosages for I1RAs were established around the most efficacious dose administered by Calvert et al. 
when using the same solid media platform (Calvert et al., 2016). Given that guanidium compounds such 
as allantoin exhibit a more subtle agonistic affinity to I1RAs, we hypothesised a reduced dosage of 





Figure 4.  Improved survival of C. elegans treated with varying concentrations of imidazoline receptor 
agonists. A) Pooled survival curves of adult WT worms fed UV-killed OP50 also treated with increasing 
concentrations of rilmenidine (100uM-400uM) compared to control animals treated with a 1% DMSO vehicle. All 
tested concentrations except 400uM significantly improved survival (adj. p<0.001) as measured by log-rank test 
and Bonferroni corrections. n>90 animals across at least 3 independent trials.B) Pooled survival curves of adult 
WT worms fed UV-killed OP50 also treated with increasing concentrations of moxonidine (100uM-200uM) 
compared to control animals treated with a 1% DMSO vehicle. 100uM, 150uM, and 250uM. Moxonidine 
treatment significantly improved survival (adj. p<0.01) as measured by log-rank test and Bonferroni correction. 
n>190 animals across at least 2 independent trials. C)  mean lifespan (days\ of pooled trials measuring the 
survival of rilmenidine treated with increasing concentrations of rilmenidine (100uM-400uM) compared to control 
animals treated with a 1% DMSO vehicle. Error bars represent SEM; adjusted p-value derived from log-rank test 
and Bonferroni correction. D) % change in mean lifespan of the most potent concentration of each imidazoline 
receptor agonists (IRA) vs trial-specific control animals treated with a 1% DMSO vehicle. Data represented as 
means of at least three independent experiments (Bonferroni adjust ed log-rank test, *p < 0.05, **p < 0.01, and 




Table 8. Differences in mean and maximum lifespan of WT  C. elegans exposed to various compounds 
relative to the control within the same sets of trials.  Mean lifespan in days is the pooled mean of treatment 
cohort and the standard error (± S.E.M). Maximum lifespan defined as the day at which 90% cohort mortality was 
reached.  Lifespan assays performed at 20 °. Adjusted p-value was determined by log-rank test using the 
Kaplan-Meier survival analysis and subsequent bonferonni correction.  Pooled n = number of deaths observed 
across all respective trials.   
 
  
WT  WT worm treatment 
Pooled 
n= No. trials Mean lifespan (days) Std. error % Chg Vs. Ctrl. 90% Mortality (days) Adj. p-value 
DMSO               
WT  WT 651 6 24.03 0.19 0.00 30 n/a 
1% DMSO 806 6 23.84 0.17 0.01 30 n/s 
Rilmenidine               
0µM 374 6 21.85 0.26 0.00 29 n/a 
100µM 205 3 25.44 0.37 16.43 33 p<0.001 
150µM 92 3 24.72 0.58 13.14 31 p<0.001 
200µM 325 5 26.02 0.32 19.08 33 p<0.001 
300µM 222 3 23.83 0.44 9.06 33 p<0.001 
400µM 262 3 21.54 0.36 -1.49 30 n/s 
Moxonidine               
0µM 331 3 26.41 0.29 0.00 33 n/a 
100µM 196 3 28.31 0.36 7.19 33 p<0.01 
150µM 198 3 27.98 0.39 5.94 35 p<0.005 
200µM 372 3 25.58 0.30 -3.14 32 n/s 
250µM 61 1 27.48 0.93 4.05 36 p<0.05 
Allantoin               
0µM 238 3 25.05 0.32 0.00 32 n/a 
250µM 195 3 25.94 0.38 3.55 32 p<0.05 
Resveratrol               
0µM 100 1 20.97 0.50 0.00 27 n/a 
100µM 48 1 25.73 0.94 22.70 35 p<0.001 
Rapamycin               
0µM 109 3 22.07 0.49 0.00 28 n/a 
100µM 223 3 27.35 0.50 23.92 39 p<0.001 
Time Dependent Rilmenidine               
0µM 165 3 22.08 0.38 0.00 29 n/a 
Single Dose at Day 1 (200µM) 144 3 29.51 0.56 33.65 39 p<0.001 
Single Dose at Day 12 (200µM) 83 3 29.39 0.66 33.11 34 p<0.001 
Day 1 and Day 12 Dose (200µM) 68 3 29.15 0.78 32.02 38 p<0.001 
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Wild-type (WT) adult hermaphrodite C. elegans are reported to have an average lifespan of 23 days at 
20ºC when fed UV killed OP50 E.coli (Sutphin and Kaeberlein, 2009). In agreement, and under our 
standard laboratory conditions, control WT  animals had mean lifespan of 24.03 ± .19 days (n=651) and 
a maximum lifespan of 30 days. Furthermore, to address any confounding effects of DMSO on lifespan 
interventions, the post-developmental addition of 1% DMSO to the NGM media did not significantly affect 
the mean or maximum lifespan (p<0.43) of WT  worms (n=806). Confirmatively, both resveratrol (100µM) 
and  rapamycin (100µM) significantly extended lifespan similar to previously published observations (J. 
Lee et al., 2016; Robida-Stubbs et al., 2012; Viswanathan et al., 2005) (Table 9).  
Rilmenidine increased mean lifespan at all but the highest tested dosage (400µM); dosages increases 
were discontinued thereafter (Figure 4A). Lower dosages of 100µM and 150µM extended mean lifespan 
by +17% (p<0.001) and +13% (p<0.001) respectively (Figure 4C). Mean lifespan changes were most 
pronounced at 200µM with a +19% (p<0.001) increase. Higher dosages of 300µM increased mean 
lifespan, to a lesser extent, by 9% (p<0.001), and 400µM insignificantly reduced mean lifespan by -
1.42%. Lifespan extending dosages of rilmenidine unanimously increased maximum lifespan by 14% 
(p<0.001). Thus rilmenidine neither follows a dose-dependent curve nor a non-linear J-shaped hormetic 
curve. Instead rilmenidine elicited a somewhat gaussian function on lifespan with a peak at 200µM. 
Similarly, animals treated with moxonidine did not exhibit a dose-dependent curve nor a non-linear J-
shaped hormetic curve (Figure 4B). In fact, the largest increases in mean lifespan (+7.1%) was observed 
at the lowest concentration range (100µM) of moxonidine treatment (p<0.006), however this dosage 
failed to increase maximum lifespan. Both 150µM and 200µM elicited significant increases in mean 
lifespan of 7% (p=0.0047) and 5% (p=0.0105), and also maximum lifespan 6% and 9% respectively. 
200µM moxonidine failed to significantly alter mean or maximum lifespan in either direction.  
Despite a reported increase in mean lifespan of over 20% in our lab’s previous work, in this study, only a 
3.55% (p<0.05) change in mean lifespan was observed following 250µM allantoin treatment; and no 
change in maximum lifespan was elicited (Figure 4D). Taken together, these three compounds display a 
capacity to extend lifespan correlatively to their imidazoline binding site affinities. Rilmenidine exerts the  
most pronounced binding affinity in literature, whilst also displaying a largest increase in lifespan at the 
tested dosages (Nikolic and Agbaba, 2012). This is line with preceding evidence showing a more 
significant transcriptional correlation between rilmenidine and ageing in comparison to moxonidine and 
allantoin. Thus from hereon, rilmenidine will be tested as a potential geroprotective CRM.   
To confirm the efficacy of rilmenidine to extend lifespan in C. elegans, a multi-centred approach was 
taken. It is well established that inter-laboratory variation and idiosyncrasies can significantly affect 
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lifespan. To ascertain the validity of our initial findings, we invited an independent lab to test the pro-
longevity effect of rilmenidine without prior knowledge of our results. The lab of Colin Ewald tested our 
hypothesis using  an automated imaging and analysis platform called the C. elegans “lifespan machine” 
(Stroustrup et al., 2013), which has repeatedly been proven to be a reliable tool (Lin et al., 2018a; 
McEwan et al., 2016; Stroustrup et al., 2016). They followed the same solid agar NGM drug protocol as 
in our methods. Ewald’s lab independently reported significant lifespan extension by rilmenidine at the 
optimum dose (200µM) when treatment was initiated at L4/adult molt (Ewald lab: mean/max lifespan 
change p<0.05) (data not shown). 200µM was the dose, unless otherwise stated, administered to worms 
hereafter.  
Rilmenidine should ideally work when administered later in life. Although pharmacological interventions 
may prove to ameliorate the effects of ageing in humans when initiated in early adulthood, the application 
of this would present significant difficulties. Untenably protracted longitudinal survival-outcome clinical 
trials alongside, the ethical and compliance concerns of life-long administration precludes the clinical 
usage of any anti-ageing intervention for such times. Therefore, researchers have been keen to establish 
if potential compounds can extend lifespan when treatment is initiated later in life and the ageing process 
has considerably progressed (Cabreiro et al., 2013; Guha et al., 2014). This is particularly important given 
the difficulties of eliciting CR-mediated longevity in aged animals.  
WT worms grown throughout adulthood on NGM agar plates seeded only with UV killed OP50 E.coli were 
transferred, on day 12 adulthood, to NGM agar plates containing the most 200µM rilmenidine, or vice 
versa. At day 12, worms exhibit significant age-related deterioration. Specifically, by day 12 pharyngeal 
pumping, a routine measurement of animal health, has typically ceased alongside egg-laying (Collins et 
al., 2008). Furthermore, animals also exhibit dramatically altered metabolism, increased age-associated 
autofluorescence and proteostatic collapse: a key event in organismal ageing (Chapin et al., 2015; Collins 
et al., 2008; Rollins et al., 2017). Rilmenidine treatment initiated from day 12 significantly extended 




Figure 5. Effect of different rilmenidine administration times on C. elegans survival. A) Pooled survival 
curves of adult WT worms fed UV-killed OP50 also treated at different time points (day-1 or day-12 adulthood) 
with 200uM rilmenidine compared to control animals treated with a 1% DMSO vehicle from day-1 adulthood. 
Each lifespan experiment was repeated at least three independent times with similar results. Quantitative data 
and statistical analyses for the representative experiments are included in Table 9. B) % increase in mean 
lifespan of pooled trials measuring the survival of adult WT worms fed UV-killed OP50 also treated at different 
time points (day-1 or day-12 adulthood) with 200uM rilmenidine compared to control animals treated with a 1% 





Our solid media drug administration approach may lend to decompositional loss of potency towards the 
conclusion of a lifespan assay and thus an unrealised pro-longevity capacity of rilmenidine. However, the 
ability of rilmenidine to extend lifespan late in life is not additive to any pro-longevity effect exerted by 
early life treatment. Worms transferred from rilmenidine drug plates to fresh rilmenidine drug plates at 
day 12, lived no longer than worms grown exclusively on one rilmenidine drug plate from L4/adult molt. 
Therefore, it is possible any cellular mechanism by which rilmenidine exerts its geroprotection, is 
conserved through adulthood and ageing, and, it is unlikely that rilmenidine concentrations significantly 
erode during the lifespan assay. However, maximum lifespan was not as dramatically affected when 
treatment was initiated at day 12 (+17%) in comparison to complete lifespan exposure (+31.03%).   
3.3. Discussion  
In this chapter the recently updated cMAP was queried with 2 universal ageing signatures, a senescence 
signature and two dietary restriction signatures in a bid to identify potential calorie restriction mimetics 
which could show similarity to CR transcripts but opposition to ageing transcripts. This is the first recorded 
attempt to identify compounds that are significantly correlated to several simultaneously queried gene 
lists. The cMAP confirmed that rilmenidine was significantly opposed to the transcriptional direction of 
ageing, which was also mirrored in senescence. Specifically, the gene expression changes induced by 
in-vitro rilmenidine treatment, as recorded in the cMAP database, elicited a significantly negative tau 
connectivity score. Furthermore, rilmenidine displayed a transcriptional similarity to dietary restriction 
however this was not significant. Importantly, neither allantoin or moxonidine, I1RAs with a lower binding 
affinity, showed any directional connectivity with either ageing or dietary restriction.  
The confirmation that rilmenidine, as measured by the transcriptional connectivity of the cMAP, seemed 
to oppose the transcriptional direction of ageing, led to further investigation into specific gene changes. 
A meta-analysis of LINCS data containing 57 cell lines exposed to rilmenidine at a concentration of 10µM 
for 24h demonstrated rilmenidine to significantly overexpress genes related to developmental processes, 
as well as genes related to the downregulation of immune response. Additionally, rilmenidine treatment 
appeared to underexpress genes related to active immune response and inflammation, extracellular 
matrix function and response to amino acids. The gene expression changes identified by this meta-
analysis were indeed similar to the cMAP findings and clarified that rilmenidine likely rescues the gene 
expression perturbations of ageing, specifically those that become overexpressed in ageing. These 
genes correlated to immune hyperactivation in ageing and furthermore there was a strong enrichment of 
genes related to extracellular matrix disassembly. Moreover, these transcriptional relationships were 
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mirrored in all imidazoline receptor agonists, highlighting an imidazoline receptor agonist specific effect 
on ageing.  To test the potential geroprotection of rilmenidine in-vivo, WT C. elegans were fed increasing 
concentrations of rilmenidine to establish an optimum pro-longevity dose (200µM). This dosage extended 
mean and maximal lifespan in WT worms, when administered throughout life or once the worm had aged. 
This capacity demonstrates important translational potential that warrants further investigation.  
The identification of potential pro-longevity compounds is a popular endeavour within the gerontological 
community. DrugAge (Build 3), a database which I and other lab members have collated, lists 567 
different compounds purported to extend lifespan in model organisms (Barardo et al., 2017). Not only 
does this show a wide interest in the field but compendiously highlights the vast targetability of the 
heterogeneities and multiplicities of ageing, which had previously made the actual identification of 
translationally precise anti-ageing therapies difficult. Thus, researchers have turned to “omics” based 
approaches to aggregate such ageing pleiotropism into universal signatures of ageing which can help 
identify compounds that can more broadly oppose ageing in favour of individual pathway targeting. 
Transcriptional signatures using harvested dermal fibroblasts report to recapitulate biological ageing 
more precisely than other published metrics (Fleischer et al., 2018). The pattern of global transcriptional 
changes in ageing is conserved and an increase in age-associated expression of stress response and 
immune response pathways is reproducibly observed in ageing studies (Stegeman and Weake, 2017).  
Cell cycle inhibition also significantly correlated with the Fabris et al. ageing meta-analysis used from our 
lab. This added legitimacy to the ageing signature given this phenomenon is characteristic of cellular 
senescence which accumulates in aged tissue through replicative termination and stress induction. 
Accordingly, the transcriptional signature of senescence which was queried also revealed a perfect 
connectivity score to cell cycle inhibition. Thus, the similarity is potentially explained by aged tissue from 
the datasets used in the ageing meta-analysis being derived from heterogenous tissue that will contain a 
growing quantity of senescent and quiescent cells (Childs et al., 2015). Furthermore, a comparatively 
diminished stem cell pool in sample tissue may also contribute to a positive connectivity to cell cycle 
inhibition   
The above pattern observation may potentially explain why perturbagen classes that have been 
previously and routinely associated with amelioration of ageing phenotypes, were positively correlated 
with ageing and senescent signatures in the cMAP analysis. This contraindication to current ageing 
literature was apparent in several classes including a positive association to IGF-1 inhibition and also 
mTOR inhibition. Aged tissue that chronically accumulates damage prompts the accumulation of 
quiescent cells which display reduced AKT (Segrelles et al., 2014; Wei et al., 2016) and increased PTEN 
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phosphatase activity (Yue et al., 2017), which, in turn, suppresses mTOR signalling (Gan and DePinho, 
2009). Quiescent cells are transcriptionally active and downregulate proliferation-related genes and 
remain hyporesponsive towards growth factors and other external stimuli (Matsuda et al., 1992; Seshadri 
and Campisi, 1990; Yao, 2014). Hence the downregulation in growth factor signalling  is transcriptional 
hallmark of ageing (Frenk and Houseley, 2018). This is a similar notion to long-lived post mitotic cells 
such as neurons, myotubes, or cardiomyocytes that enable advanced mammalian function which will 
have been enriched in brain and muscle of aged tissue used to derive the aged signature. Transcriptional 
analysis has revealed post-mitotic tissue to be associated with reduced cell cycle gene expression and a 
reduced responsiveness to amino acid stimulation (Castillo-Morales et al., 2019). Thus, compared to the 
cancer cell lines used in the cMAP RNA-seq data acquisition of perturbagens, aged tissue is much more 
likely to show comparably reduced expression of mTOR, IGF-1 and PI3K stimulated genes which may 
mirror the effects of mTOR, IGF-1 and PI3K inhibitors in immortalised cell lines. 
Conversely, rilmenidine demonstrated a strong negative correlation to the ageing gene sets as well as 
the senescence signature, implying that rilmenidine is unlikely to significantly influence factors pertaining 
to cell cycle and proliferation. Nonetheless, it still showed significant transcriptional opposition to 
senescence implying that a relationship exists between the ancillary functions of senescence beyond 
mere cell cycle arrest. No significant connectivity was however observed in any aged brain tissue, even 
RVLM tissue which is primarily post-mitotic. Whilst one is keen to deduce that the age-related gene 
expression perturbations by rilmenidine are decoupled from its sympatholytic function in the brain and 
RVLM, it is more likely that given none of the cell lines used to generate the cMAP data originate from 
the brain, the results reflect a poorly transcriptional compatibility when querying brain tissue (Dönertaş et 
al., 2018).  
Additionally, cMAP analysis failed to demonstrate any significant connectivity to either gene lists of dietary 
restriction, and this was the same with moxonidine and also allantoin. Moreover,  a similar paradoxical 
pattern occurred whereby mTOR inhibitors and IGF-1 inhibitors, routinely touted as calorie restriction 
mimetics elicited, significantly opposing profiles to CR (López-Lluch and Navas, 2016). This is 
comparable to observations that long term CR restriction as seen in the datasets used herein, elicit an 
opposite gene expression profile to short-term starvation which is commonly used to provoke changes in 
mTOR and IGF activity (Whitaker et al., 2014). Strikingly, neither of the DR gene lists returned any 
perturbations which showed the same connectivity direction. This limits any inference that could be made, 
but excellently highlights the difficulty in applying gene expression-based approaches to a non-binary 
spectrumed phenomena vulnerable to external artefacts such as ageing and calorie restriction. To query 
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the cMAP, in-vitro calorie restriction datasets were explicitly chosen rather than tissue derived from 
calorie restricted model organisms specifically to minimise confounding factors. However, the translation 
of CR into in-vitro culture through the infusion of CR sera is likely to dilute the already modest global gene 
expression effects of calorie restriction (Gillespie et al., 2016). And, the fact that allantoin had been 
previously correlated to CR in preceding cMAP analysis on an outdated version, highlights artefactual 
differences in perturbagen gene profiles between the prototypical and existing cMAP builds.  
With that said, gene expression meta-analysis of rilmenidine treated cell lines revealed several enriched 
biological pathways that are conserved in CR. A 2012 meta-analysis of dietary restriction gene expression 
studies, using the same methods as in this thesis, equally revealed upregulation of retinol metabolism as 
seen in response to rilmenidine treatment in this chapter (Plank et al., 2012). The authors referenced 
another paper showing that physiological retinol levels are altered during CR, and also suggesting retinol 
to have anti-inflammatory properties (Berggren Soderlund et al., 2003). Also, rilmenidine treatment 
consistently overexpressed genes associated with glucose starvation whilst consistently underexpressing 
cellular response to amino acid stimulus; both processes are definitely tied to CR response (Soultoukis 
and Partridge, 2016).  
The rilmenidine meta-analysis produced a pattern of differential expression that was consistently 
enriched in both directions for downregulation of immune response and inflammation and also extra-
cellular matrix function. When this was overlapped with the ageing gene signature, these processes 
remained enriched. Notably, the relationship between ageing and rilmenidine was unidirectional and only 
genes that were overexpressed in ageing could be rescued by rilmenidine – overexpression of genes by 
rilmenidine did not significantly intersect genes underexpressed in ageing.  
Ageing has a complex phenotype likely reflected in its transcriptome, complicated by mutational and 
dysregulational epigenetic noise. This causes difficulty in differentiating between the targetable, 
detrimental effects which occur with age and the potentially beneficial responses to those changes 
enacted by cells to survive. Do maladaptive detrimental programmes become overexpressed in ageing? 
Indeed, global hypomethylation occurs with age that may give rise to pathological hyperfunctional 
overexpression but, it is likely that ageing interferes with the transcriptional machinery in multiple ways, 
increasing diversity and heterogeneities. There are numerous genetic pathways that become 
downregulated in ageing such as those encoding mitochondrial proteins and downregulation of the 
protein synthesis machinery (Frenk and Houseley, 2018).  
This accumulating evidence warranted survival analysis in C. elegans specifically aimed at testing 
imidazoline receptor compounds as a preliminary investigation into their CRM properties. Indeed, both 
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moxonidine, rilmenidine and allantoin all extended lifespan proportionally to their binding affinities which 
suggested that imidazoline receptor agonism may play a part in the lifespan extension of these 
compounds rather than a broader sub-lethal hormetic response. Importantly, this prolongevity effect was 
equally prominent when worms were fed rilmenidine in late life. Furthermore, moving worms treated from 
day 1 onto fresh plates containing rilmenidine at day 12 did not additively affect lifespan compared to 
worms exposed to the drug only from day 12. This suggests that rilmenidine may influence the same 
ageing programme in early and late life. This offers significant translation potential for the treatment when 
considering the preference for treatments starting in late life that can shorten longitudinal clinical trials 
alongside reducing the ethical and compliance concerns of life-long administration. When considering 
rilmenidine as a potential CRM, this late-life benefit significantly bolsters its preferential candidacy given 
that both mice and rats initiated on CR in late-life demonstrate negligible effects or indeed reductions in 
longevity (Ingram and de Cabo, 2017). This compounds concerns that dietary restriction in the elderly 
would contribute to the development of sarcopenia and bone loss, and likely precipitate the genesis of 
frailty in vulnerable individuals (Batsis et al., 2015). 
It could be argued that rilmenidine treatment was not started sufficiently late to qualify for a geriatric 
intervention. Treatment was started at day 12, 10 days prior to the mean age of mortality, which would 
translate to 15 months of age in C57BL/6J mice, 3 months premature of “old age” qualification (Fox, 
2007). However, ageing rates between taxonomical rank is diverse and ageing biomarkers such as 
proteostatic collapse are evident by day 3 in C. elegans (Ben-Zvi et al., 2009). Moreover, by day 12 
pharyngeal pumping, a routine measurement of animal health, has typically ceased alongside egg-laying 
(Collins et al., 2008). Furthermore, animals also exhibit dramatically altered metabolism, increased age-
associated autofluorescence and autophagic malfunction: a key event in organismal ageing (Chapin et 
al., 2015; Collins et al., 2008; Rollins et al., 2017). Practically, the transfer of worms between plates when 
significantly frail would confound the fitness of the animals.   
The ability for animals to survive is often dependent on their existential biome, which in the laboratory 
setting is dominated by the interaction with E.coli - their primary food source but also an infectious agent. 
Further work should confirm rilmenidine does not reduce the consumption of E.coli to mimic a completely 
upstream DR state and thus not meet Ingram’s criteria for a CRM. Secondly, despite worms grown in a 
pathogen free environment through the addition of nystatin and penicillin/streptomycin to all NGM plates 
as recommended, it is possible rilmenidine is still modulating the nematode’s innate immune response to 
prevent pathological infection (Lionaki and Tavernarakis, 2013; Stiernagle, 2006).  
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Future bioinformatic work should focus on delineating the expression changes induced by rilmenidine 
from ageing and senescence. Genes differentially expressed in senescence should be compared to 
rilmenidine to assess whether there is equal enrichment in comparison to ageing. Furthermore, given the 
utilisation of worms in this thesis as a model organism additional work comparing C. elegans specific 
transcriptional changes in ageing would be beneficial. Very recently, a paper has been published which 
developed a transcriptional age signature in C. elegans to probe the cMAP, but could also be compared 
to rilmenidine (Tarkhov et al., 2019). 
 
4. Results: F13E9.1 is an IRAS Ortholog Containing Similar Functional Domains 
and Potential Rilmenidine Binding Sites 
4.1. Introduction  
In order to assess the mechanisms by which rilmenidine may exert its prolongevity effect, we sought to 
identify a putative nematode receptor capable of binding rilmenidine and inducing bioactivity. At the time 
of writing, no imidazoline receptors have been characterised or indeed experimentally tested in C. 
elegans. Of course, clinically, rilmenidine is classified as a potent imidazoline type 1 receptor agonist. 
This is predicated by early radioligand‐binding studies in bovine brain membranes showing high‐affinity 
sites that recognized rilmenidine and other imidazoline adrenergic agents (Ernsberger et al., 1987). 
These imidazoline binding sites, when agonised in CHO cell lines, could induce specific cell-signalling 
responses such conversion of extracellular signal‐regulated kinase 1 (ERK1), ERK2, and c‐jun kinases 
to their active forms (Li et al., 2006). In 2000, a gene encoding an I1RA candidate protein, named 
imidazoline receptor antisera-selected protein (IRAS) was isolated (Piletz et al., 2000). The subsequent 
transfection of hIRAS cDNA into Chinese Hamster Ovary (CHO) and PC12 cells resulted in high-affinity 
I1-receptor like binding sites which induced greater ERK activation, when stimulated with rilmenidine than 
in transfected controls; this effect was repeated following overexpression of the hIRAS in HEK293 kidney 
cells (Piletz et al., 2003b). This relationship is confirmed by evidence that antisense inhibition of hIRAS 
in PC12 cells, reduced imidazoline binding affinity and moxonidine‐induced ERK1/2 activation (Sun et 




4.2.1. f13e9.1 is Orthologous to IRAS 
 It was logical to search for a potential IRAS homolog in C. elegans. Firstly, using a standard NCBI 
nucleotide megablast search with default parameters, the entire C. elegans genomic sequence was 
analysed for significant alignment homology. This returned no similar C. elegans sequences. Previously 
published work had hinted that the C. elegans genome may encode a putative IRAS  homolog, however, 
this has never been explored (Piletz et al., 2000). Specifically, Alahari et al (2000), when initially 
characterising IRAS, noted that the N-terminal sequence of IRAS displayed strong homology to a C. 
elegans protein coded for at the gene locus f13e9.1. Additionally, two other papers have assumptively 
referred to f13E9.1 as NISCH (the murine homolog of IRAS) in spite of any experimental evidence 
(Kinchen et al., 2008; Lu et al., 2011). Notwithstanding, using a direct approach, both the human IRAS 
and the f13e9.1 sequence were blasted against each other – this also returned no significant results. 
Finally, the protein sequence alignment was considered. F13E9.1 is a wholly uncharacterised 57.9kDa 
protein which has never been directly studied. The only seemingly available literature to date is at a 
genetic level in the form of a systematic RNAi screen which suggested the C. elegans protein may be 
involved in cell migration networks, although this was never validated in nematode models (Cram et al., 
2006). Lastly, a microarray to measure transcriptional response to heat-stress implicated f13e9.1 as a 
possible responsive element – again this was never followed up (Jovic et al., 2017).  
A NCBI BLASTp query was performed with parameters set to search all non-redundant GenBank CDS 
translations+PDB+SwissProt+PIR+PRF excluding environmental samples from WGS projects but limited 
to records that include: C. elegans (taxid:6239) (See Figure 7) (Johnson et al., 2008). IRAS is known to 
have a number of transcript variants encoding 4 different isoforms (Piletz et al., 2003a). The full-length 
human IRAS (167kDa and 1504aa) is poorly expressed in all examined tissues, suggestive of a normally 
fragmented protein (Piletz et al., 2003a). We therefore queried the BLAST server with isoform 3, the 3rd 
longest isoform. This isoform is a c-terminally truncated isoform of 63kDa and 583aa which is identically 
coded to the full sequence except for a small region 511-583 AAs IMFVQEEALA...PEVQVVPGSG → 
NRVCTLLLVE...CLLGEDSQLL, which does not contain any functional domains. It is a similar length to 
the suggested IRAS homolog, f13e9.1. The BLASTp query returned the strongest similarity and top-hit 
alignment to the translated full length f13e9.1 sequence (e-value 2e-80) with only 6% of residues not 
sharing physico-chemical similarity (See Supporting Figure 2) ; the full length IRAS sequence also returned 
significant similarity to F13E9.1 (e-value 2e-80). Additionally, two other proteins, T05H4.3 and K10D2.8 
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were reported to have similarity (e-value < 1e-5); therefore, we cannot exclude the existence of additional, 
even less conserved, IRAS orthologs in C. elegans.  
Secondary structure similarity between IRAS and F13E9.1 was then assessed using the Protein Structure 
Prediction (PSIPRED) Server, which predicts secondary structure based on an artificial neural network 
tested against the DSSP algorithm (Buchan et al., 2013) (Figure 7). In the N-terminal, F13E9.1 shared 9 
helices with IRAS, located in identical residues, including a 20 amino acid region (88-108) of exactly equal 
identity. Moreover, beta-sheets were commonly observed with IRAS in all but 1 location within the 
F13E9.1 250aa N-terminus. In the C-terminus, F13E9.1 shared large helical homology between aa438-
452, and again between aa462-495. Within the entire F13E9.1 sequence, all 12 beta-sheets were 
identically present within human IRAS isoform 3 (Figure 7).  
To define whether such secondary structure similarity corresponded to functional domain conservation 
we analysed both protein sequences using the web application InterproScan 75.0 (Jones et al., 2014). 
F13E9.1 revealed a PHOX domain, 5 leucine rich repeats and a coiled coil, all of which are conserved 
within isoform 3 human IRAS (Figure 8). Specifically, a PHOX binding domain was identified between 
amino acids 13-129. Likewise, in IRAS a PHOX binding domain differing in length by only 7 amino acids 
is present in the residues 11-121. Congruently, this domain shared 84% sequence identity to the F13E9.1 
PHOX domain, including 8 conserved areas of secondary structure. PHOX (PX) domains possess 
phosphoinositide-3-phosphate-binding capacity, likely enabling IRAS and, most likely, F13E9.1, to be 
anchored to the intracellular surface of the plasma membrane (Piletz et al., 2003b). Furthermore, a PHOX 
domain Is likely the necessary component that fulfils the sorting nexin function of IRAS, suggesting 
F13E9.1 may potentially exhibit such properties (Lim and Hong, 2004; Reddig et al., 2005). The murine 
NISCH homolog lacks the N terminal PHOX domain and is thus considered a cytosolic interacting protein 
involved in cytoskeletal organization (Reddig et al., 2005).  
Similarly, both human IRAS and F13E9.1 encode 5 leucine rich repeats which commence at 286/288 aa 
and ending at 397 and 425 aa respectively (Figure 8). Of the amino acids which encode the leucine rich 
repeats only two amino acids differed in F13E9.1 giving a 98% identity match between the two proteins. 
Leucine rich repeats are not necessary for the endosomal sorting nexin properties of IRAS, however it is 
likely they provide a versatile structural framework for the formation of protein-protein interactions 
between IRAS itself or between IRAS and its potential interacting partners such as integrin a5 (Lim and 
Hong, 2004). 
The last functionally recognised domain from the InterPro analysis was a coiled coil. This domain is 
predicted to sit at residue 455-482 in F13E9.1 (Figure 8). Likewise in the full length IRAS, a coiled coil is 
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present at residues 671-693 with a similar 27 amino acid length (e value 5e-04). The coiled coil is the 
predicted imidazoline binding site. For a ruthenium binding region is present in the coiled‐coil domain of 
IRAS, and addition of this dye, blocks imidazoline binding (Sun et al., 2007). Piletz et al (2000) deemed 
the aa 623–700 to be the imidazoline binding site, which is where the coiled coil domain sits containing 
an acidic domain rich in glu/asp. Indeed, F13E9.1 maintains a glutamic acid rich and acidic code in its 
coiled coil domain (See supporting figure 2). Thus, it is probable, F13E9.1 may have imidazoline binding 
capacity.  Additionally, IRAS homo-oligomerises via its coiled coil region and also this region is vital for 
its localization to endosomes (Lim and Hong, 2004). Of interest, murine Nischarin that lacks a Phox 
domain, retains a coiled-coil domain at aa 380–405 within the N terminus, enabling formation of vesicles.  
In total, F13E9.1 has significant homology to nishcarin and likely also possesses functional similarity. 
This is highlighted by gene ontology analyses showing both IRAS and F13E9.1 to have 
phosphatidylinositol binding (GO:0035091) which may facilitate membrane anchoring and participate in 
endosomal sorting and cell signalling, possibly involving leucine rich repeats.  
 
Figure 6. Native wild-type (WT) f13e9.1 gene expression analysed in 6 microarray datasets. Publicly 
available GEO datasets were mined (GSE8058, GSE16753, GSE54024, GSE34113, GSE32521, GSE39252) 
Each array probe was ranked according to its normalised mean gene expression value across all control WT 




To determine subcellular localisation and possible native expression pattern of f13e9.1, a transgenic 
reporter construct was developed (see chapter 2.5). The WRM0616C_F02 (f13e9.1) clone fosmid, 
expressing full length f13e9.1  with a 3’ end fused eGFP, driven by its native f13e9.1 promoter was 
coinjected with an mCherry co-marker and integrated onto an WT  background to generate 2 similar 
lines of PHX116 and PHX117 [f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry]. eGFP 
expression in day-1 adult transgenic animals was analysed under confocal fluorescent microscopy, 
however, endogenous expression levels were untraceable most likely being either under the detection 
limit or hidden by a super-thin bandpass green filter (520 +/- 20nm) required to overcome inherent 
autofluorescence within worms (See supporting figure 4). Marker co-injection with myo-2::mCherry 
produced predictable expression profiles (see supporting figure 4). Furthermore, there was also no 
detectable expression of F13E9.1:eGFP in transgenic non-integrated animals carrying the 
extrachromosomal array, ruling out chromosomal silencing as a factor.  Undetectable GFP fluorescence 
is a well-documented problem in the worm community (Sarov et al., 2012; Teuscher and Ewald, 2018). 
FLAG immunoblotting was also carried out in rescue lines PHX945 and PHX946 (See supporting figure 
3). No bands were detected for eGFP or x3FLAG in PHX946, and minimally visible bands were 
observed in PHX945. Therefore, to establish basal f13e9.1 expression in WT worms, microarray 
expression probes across 6 publicly available datasets were plotted by rank against their respective 
whole transcriptome (Figure 6). On the Affymetrix C. elegans genome arrays (used in all but GSE8058), 
3 probes correspond to f13e9.1; and on the University of Washington custom array (used in GSE8058), 
1 probe corresponds to f13e9.1. Probe expression had significant intra and inter-dataset variability, 
however, 12 of 16 probes sat within the upper half of the expression ranking. Such native expression 






Figure 7. Modified BLASTp Alignment of C. elegans F13E9.1 protein sequence (CELE_F13E9.1 – 
UniProtKB-K8F807) and truncated human NISCHARIN isoform 3 (HUMAN_NISCH – UniProtKB-Q9Y2I1-3) 
using BLASTp with default parameters. Sequence similarity measured by e-value >1e – 5. Identity = number 
of residues encoded by the same amino acid; positives corresponds to the number of amino acids that are either 
identical between F13E9.1 and the IRAS sequence or have similar chemical properties. Residues that do not 
correspond are represented by a -. Conserved secondary structure elements were analysed using PSIPRED and 
highlighted in colour; predicted alpha helices are highlighted in red and extended confirmation (beta-strand) are 
highlighted in blue. Functional protein motifs of human NISCH isoform 3 (PHOX domain and leucine rich repeats-





Figure 8. Schematic representation of InterPro domain architecture for the C. elegans F13E9.1 protein 
sequence and corresponding domains for the canonical full-length human Nischarin protein sequence 
(UniProtKB-Q9Y2I1-1). Human Nischarin and F13E9.1 encode, at proportionally similar residues, three key 
protein domains: PHOX binding domain, 5 leucine rich repeats (LRRs) and a coiled coil which is also the location 
of an imidazoline binding site in Human Nischarin (hIRAS) (Sun et al., 2007). Interpro also embeds a gene 
ontology application (InterPro2GO) with 34,213 GO terms mapped to InterPro entries. GO terms relevant to 




4.2.2. F13E9.1 is an Imidazoline Binding Protein That Mediates Rilmenidine-Induced 
Bioactivity  
To further examine the role of F13E9.1 as a functional homolog of IRAS that could mediate rilmenidine 
cell signalling, I designed a knockout mutant f13e9.1 -/-  strain (PHX893) which was generated by 
SUNYBiotech  using the CRISPR/Cas9 system (Figure 9) (See Chapter 2.5 for methodological detail). 
f13e9.1 is an 8 exon gene on the 4th chromosome: exon 2 and a large intronic site thereafter is overlapped 
at the 5’ end by the gene f13e9.11. Thus a 873bp homozygous deletion was initiated at the 3rd exon and 
replaced by a stop codon to prevent transcription of all subsequent exons. Admittedly, this resulted in a 
truncated f13e9.1 gene product which still contained a PHOX domain that may permit IRAS-associated 
functionality such as endosomal targeting (Figure 9). However, 3rd exon deletion and termination 
abrogates the key signalling domains of leucine rich repeats and the crucial imidazoline binding site in 




Figure 9.  Representation and genotyping of Crispr/CAS9 deletion of the C-terminus f13e9.1. A) schematic diagram illustrating WT f13e9.1 exons alongside translated 
protein motifs and the deleted regions in the homozygous mutant PHX893 (f13e9.1-/-). LRRs = leucine rich repeats (PFAM:PF13855); CC = coiled coil domain (ncoils) as defined 
by wormbase Jbrowse protein motif tracks B) End point single worm PCR genotyping of WT and PHX893 strain following x4 outcrossing. Using oligonucleotides flanking the 
deletion site (external primer pairs) generated either a 1968bp or a 1936bp amplicon depending on oligonucleotide pair in WT worms or a correspondingly 873bp reduced 
amplicon size in the genomic DNA of homozygous f13e9.1 -/- (PHX893) mutants (see chapter 2.5). Likewise, an oligonucleotide pair targeted to sequences within the Crispr 
deletion site produced a 1558bp amplicon in WT worms but no amplicon in homozygous f13e9.1 -/- (PHX893) mutants. Control amplifications were conducted on the lgc-37 
gene coded on 3rd chromosome.  
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Of course, rilmenidine has never been studied in C. elegans. Thus it is essential to establish that 
rilmenidine is indeed bioactive in C. elegans and that lifespan extension by rilmenidine is not merely a 
hormetic response, instead, eliciting key signalling pathways that are conserved in previously established 
cell models. Experiments to determine signalling in response to imidazoline agents have highlighted a 
number of pathways. One particularly well characterised pathway following interaction of rilmenidine with 
I1‐imidazoline receptor leads to activation of PC‐PLC and subsequent accumulation of the second 
messenger diacylglyceride (DAG) from phosphatidylcholine, and the release of phosphocholine. This 
causes downstream activation of MAPK/ERK1/2, with phosphorylation of ERK1/2 being a common read-
out for I1R activation by an I1R agonist (Edwards et al., 2008; Piletz et al., 2003b; Sun et al., 2007). C. 
elegans contains only one ERK gene (mpk-1), rendering it a more facile system to measure compared 
to the six isoforms of PLC. In order to assess if rilmenidine was bioactive in C. elegans and that such 
activity was likely specific to imidazoline receptor activation, the downstream activation of ERK (mpk-1) 
was measured, by way of pERK (mpk-1) to α-tubulin immunoreactivity, in response to 24h treatment with 
rilmenidine at varying concentration (200µM, 300µM and 40000µM) to establish a working concentration 
(Figure 10). Rilmenidine increased ERK phosphorylation most at the concentration of 200µM. 
Furthermore, 400µM produced an increase in ERK phosphorylation and 300µM did not significantly 
activate ERK (Figure 10). Researchers using in-vitro animal cell lines have also reported a comparable 




Figure 10. Effect of different concentrations on rilmenidine-induced MPK-1 phosphorylation as measured 
by Western Blotting. Phosphorylation of MPK-1 was assessed in wild-type (WT  ) in response to 24h 
pharmacological intervention, and subsequent western blotting using the primary antibody Phospho‐ERK (Cell 
Signalling Technology, Catalogue number: 9101) followed by the loading control, α-tubulin. All experiments were 
run in biological triplicate on separate western blots using different worm populations. Data is semi-quantified as 
log-fold densiometric ratio change relative to a-tubulin. Data is then expressed as log fold change compared to 
WT  control (1% DMSO). Coefficient of variation (%CV), defined as the percent standard deviation: mean ratio; 
significant difference in groups if  % fold change is x1.5* greater or x2** than % CV. WT  WT worms were treated 
with 3 different concentrations of rilmenidine for 24h. Rilmenidine at 200µM and 400µM significantly increased 





Rilmenidine increases lifespan most significantly at 200µM and also increases ERK phosphorylation in 
C. elegans most prominently at that concentration, hence it was necessary to elucidate the role f13e9.1 
may have in the transduction of a phosphorylative signal to ERK at life-extending concentrations.  
Again, when repeated in biological triplicate, 24h 200µM rilmenidine significantly increased ERK (MPK-
1) phosphorylation in comparison to 1% DMSO vehicle-treated WT worms by 103% mean fold change 
(%CV vs. FC = >1.5) (Figure 11A). To establish whether this increase in activity was mediated via 
rilmenidine binding to a I1‐imidazoline receptor, worms were co-incubated with rilmenidine (200µM) and 
efaroxan (2mM), an established selective I1‐imidazoline receptor antagonist. The efaroxan concentration 
used in worms was scaled to previously established ratios used in-vitro and in-vivo such that efaroxan 
concentration was x10 higher than the optimal rilmenidine dose (Dahmani et al., 2008; El-Mas et al., 
2009; Li et al., 2006). 24h efaroxan treatment alone did not significantly affect baseline ERK activity 
compared to 1% DMSO vehicle-treated WT worms; however, efaroxan significantly attenuated ERK 
activation by 200µM rilmenidine (Efar+Ril %CV vs. FC =<1.5) (Figure 11A). This suggests rilmenidine 
treatment most likely interacts with an endogenous imidazoline binding site in C. elegans to elicit 
increases in ERK activity.  
To further investigate whether the effect of rilmenidine on ERK stimulation in C. elegans was mediated 
by the putative IRAS ortholog F13E9.1, we also measured ERK phosphorylation in the mutant PHX893 
(f13e9.1-/-) strain (Figure 11B).  Importantly, f13e9.1 did not interfere with the functionality of ERK: 
baseline pERK activity was not significantly affected by deletion of f13e9.1 (%CV vs. FC = <1.5). 
However, critically, 24h treatment with 200µM of rilmenidine repeatedly failed to increase ERK activity in 
mutant PHX893 (f13e9.1-/-) worms, implying the necessity of f13e9.1 for rilmenidine induced ERK 
activation (Figure 11B).  
It is conceivable that f13e9.1 deletion might have led to off-site mutations in other genes that could affect 
rilmenidine bioactivity. Thus, to confirm the requirement of f13e9.1 to mediate rilmenidine induced ERK 
phosphorylation, PHX893 (f13e9.1-/-) worms were backcrossed with PHX116 and PHX117 
[f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-2::mCherry] strains to generate 2 new strains of full length 
gene rescues named PHX945 and PHX946 [f13e9.1::EGFP::3xFLAG, unc-119(+) + myo-2p::mCherry]. 
Whilst the co-injection marker was stably observable in both strains and genotype was confirmed by both 
sequencing and PCR, there was substantial difficulty in detecting a protein-level expression by western 
blot at ~100kD (F13E9.1 is a 57kD protein + the tag part including the eGFP, FLAG and the linker peptides 
accounts for a molecular mass of 35 kD = 92kD) (See supporting figure 3). This is likely attributed to the 
variable basal expression of f13e9.1 as documented in microarray analyses. Additionally, IRAS the 
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proposed human ortholog has numerous splice variants; all but the full-length transcript, which is the 
least expressed isoform, cleave the c-terminal end.  Both rescue lines did not interfere with ERK 
functionality as measured by insignificant changes to basal pERK activity (%CV vs. FC = <1.5) (Figure 
11C,D). Furthermore, reintegration of a full length f13e9.1 sequence in both PHX945 and PHX946 lines 
significantly restored the propensity of rilmenidine 200µM to increase ERK phosphorylation (%CV vs. FC 
= >2)(Figure 11C,D). Reintegration of fosmids often leads to increased expressible copy number in rescue 
lines. Hence it is possible, increased imidazoline binding sites may be available in PHX945 and PHX946 
lines, such that it might increase the potency of rilmenidine on ERK phosphorylation. However, neither 
PHX945 nor PHX946 strains exhibited increased ERK phosphorylation in response to rilmenidine than 
the WT  strain. This suggests PHX945 and PHX946 are suited to further rescue study following 





































Figure 11. Effect of different genetic backgrounds on rilmenidine-induced MPK-1 phosphorylation as 
measured by Western Blotting.  Phosphorylation of MPK-1 was assessed in wild-type (WT,WT ), homozygous 
f13e9.1 (PHX893) mutants, or PHX945 and PHX946 both carrying [f13e9.1::EGFP::3xFLAG, unc-119(+)+myo-
2::mCherry] in response to 24h pharmacological intervention, and subsequent western blotting using the primary 
antibody Phospho‐ERK (Cell Signalling Technology, Catalogue number: 9101) followed by the loading control, α-
tubulin. All experiments were run in biological triplicate on separate western blots using different worm 
populations. Data is semi-quantified as log-fold densiometric ratio change relative to a-tubulin. Data is then 
expressed as log fold change compared to WT  control (1% DMSO). ---- represents mean log-fold change 
between 3 biological replicates. Coefficient of variation (%CV), defined as the percent standard deviation: mean 
ratio; significant difference in groups if % fold change is x1.5* greater or x2** than % CV. A) WT  WT worms were 
treated with either rilmenidine (200µM), efaroxan (2mM) or in combination for 24h. Rilmenidine significantly 
increased MPK-1 phosphorylation *(%CV vs. FC = >1.5), however neither efaroxan alone nor rilmenidine and 
efaroxan in combination significantly increased MPK-1 phosphorylation n/s(%CV vs. FC = <1.5). B) f13e9.1 
(syb767) were treated with either 200 µM or a 1% DMSO vehicle for 24h. Rilmenidine failed to reproducibly 
increase phosphorylation of MPK-1 n/s(%CV vs. FC = <1.5). C and D) PHX945 and PHX946 worms were treated 
with either 200 µM or a 1% DMSO vehicle for 24h. Both strains significantly increased MPK-1 phosphorylation 




4.2.3. f13e9.1 Mutations Affect Body Size but not Development 
Three separate Nischarin transgenic mouse models have been reported, all demonstrating that murine 
Nischarin mutants are smaller than their wild-type counter parts. Firstly, in 2013, recessive mutants with 
deletion of the 4th exon with subsequent stop codon insertion were reported (Zhang et al., 2013). These 
mice were born smaller than WT littermates and at adulthood (12 weeks) remained 22% lighter than WT. 
Secondly, separate researchers identified a T to C substitution mutation (edsn) within exon 14 of Nisch, 
which was predicted to cause a Leu972Pro missense change in NISCH protein (Crompton et al., 2017). 
Importantly this mutation occurred further to the 5’ end than key protein motifs coding areas such the PX 
domain, LRRs and the coiled coil. Nonethess, both male and female Nischedsn/edsn mice were 35% smaller 
than WT littermates at 20wks of age. Finally, Dong et al. generated Nischarin-mutant mice with deletions 
in exons 7–10 (encoding 224–395 amino acids containing the five LRR domain) (Dong et al., 2017). 
Accordingly, these mice also exhibited dramatic growth defects showing a similar ~22% reduction in body 
weight, which was partly rescued in heterogenous mice.   
Comparably, f13e9.1 -/- mutants have a deletion and termination that spans predicted LRRs and also 
coiled coil domain. To further clarify whether f13e9.1 was a likely ortholog to NISCH, body phenotype 
was measured in f13e9.1 -/- worms in comparison to WT. Photographed day 1 adult worms were 
measured for length and width (see chapter 2.10.2). Day 1 adult WT  worms had a mean length of 881µm 
(±16.95 SEM) Figure 12A. The microscope available had a minimum objective of x10, causing a bias 
selection to potentially smaller WT worms which could be accommodated within the field of view. As 
such, WT  worms were moderately shorter than those routinely reported in literature (Li et al., 2018; 
Mörck and Pilon, 2006). Day 1 adult f13e9.1 mutants were 5.44% shorter that WT  worms (mean length 
at day 1: WT  881 ± 16.95 µm, n = 18; f13e9.1-/-, 833 ± 17.75 µm, n = 13; T-test: p<0.05) (Figure 12C). 
Similarly, day 1 adult f13e9.1 worms were 5.3% thinner than WT  worm counterparts when measured 
from posterior vulval peak to the corresponding outer edge of the intestinal cuticle (WT 71.28 ± 2.26 µm, 
n = 18; f13e9.1-/-, 67.32 ± 2.10 µm, n = 13; T-test: p<0.05) (Figure 12B). Of note, WT  width is 15% 
shorter than equally devised measurements in WT  worms published elsewhere (Mörck and Pilon, 2006). 
In total, day 1 adult f13e9.1 mutants had an estimated total body area 12.06% smaller (p<0.05) than WT  





Figure 12. f13e9.1 mutants exhibit reductions in body size at adulthood. Day 1 f13e9.1 and WT  adult 
animals were bleach synchronised and grown on NGM plates with adequate live E.coli OP50 until day 1 
adulthood. Images of animals were captured in brightfield at x10 objective on a Zeiss Axio Observer following 
paralysis in 20mM tetramisole. Body length and width was measured along the animal’s respective axes using 
NIH image J software. A) Body area quantification for adult WT  (n=18) and f13e9.1 (n=13) worms randomly 
selected from 3 separate trials. Body area defined as widthxlength at day 1 adulthood. The body area f13e9.1 
mutants was significantly reduced. 2-way t-test; asterisk (*) indicate p<0.05. B+C) Morphologic data for WT  
(N=18), f13e9.1 (N=13) animals randomly pooled from 3 separate trials. Length was measured from the head to 
the region of the tail where the diameter reaches 10 μm. The length of f13e9.1 mutants was significantly reduced 
Width was measured just behind the vulva region and was reduced in f13e9.1 worms (2-way t-test; asterisk (*) 
indicate p<0.05.) D) Representative pictures of WT  and f13e9.1 animals captured in brightfield at x10 objective 






Mutant Nischarin mice have previously exhibited comparatively lighter body weights and size consistently 
from embryos, through parturition and adulthood. Therefore, smaller body size was attributed to 
developmental abnormalities rather than delays in rate of development.   
To clarify that adult size defects in f13e9.1 -/- were not a cross-sectional artefact of slowed development, 
f13e9.1 -/- worms were compared to WT  animals to establish rate of development to adulthood. It is 
sensible to decouple measurement of development from metrics of body length, which may lead to 
confounding results. As such, categorical staging of vulval evolution and outgrowth, as advanced by 
Ludewig et al. (2017), was used to assess rate of development in worms. Cross-sectionally analysed 
F13e9.1-/- worms from a pooled analysis, developed at a similar rate to WT  worms and both strains had 
reached full vulval development and post L4 molt stage within 48h of bleach synchronised eggs being 
exposed to NGM seeded with OP50 (Figure 13). Neither strains exhibited any reproductive development 
abnormalities and staging speed was similar to that recorded in literature (Ludewig et al., 2017).  
The well-respected hyper-function theory of ageing suggests that developmental programmes essential 
for timely growth and maturation run on into adulthood and fundamentally drive ageing through 
hypertrophy-associated pathologies (Blagosklonny, 2006, 2013). Furthermore, the antagonistic 
pleotropic supplement to this infers that perturbations that increase reproductive potential early in life 
increase risk of disease and mortality later in life (Kuningas et al., 2011). de Magalhães, (2012) elegantly 
refers to this as the “short-sighted watchmaker”. Indeed, conversely improved longevity is routinely 
correlated to delayed fertility: Long-lived animals or those that are subjected to dietary restriction tend to 
display slow development. Specifically, down regulation of the insulin/IGF signalling in C. elegans as 
observed in DR, delays larval development and increases adult lifespan. Thus, interventions which 
increase lifespan through the supposed attenuation of “hyperfunctional” pathologies in ageing may be 
doing so through the down regulation of biosynthetic and proliferative processes that are important during 
development but detrimental during adulthood. It is logical that calorie restriction mimetics may intervene 
with such processes and manifest in delayed larval development. However, the exposure of rilmenidine, 
at a prolongevity dose (200µM) to WT worms after exit from L2 did not significantly affect reproductive 


















Figure 13. F13e9.1 -/- mutants and rilmenidine-fed WT worms do not exhibit delayed vulval development 
from the L3 stage. Animals were bleached and resultant eggs were time-synchronised in M9 buffer overnight. 
Arrested L1s were added to OP50 E.coli seeded NGM plates at 20°C for 24 hours. From then “hour 0” 
commenced, and all groups were maintained at 20°C. In the chart, developmental stages are listed on the Y-axis 
and were determined by the extent of vulval development. The no. of hours after a 24h exposure to food from L1 
is plotted on the x-axis. The areas of the circles in the chart reflect the percentage of the population at each 
stage of development; n≥30 from 3 independent pooled trials for each time point. Statistical difference 
established by way of 2-way anova wherein a mean development score could be ascertained through pre L3 
corresponding to a score of 0, Early L3 is 1 and Mid L3 a 3 etc. No groups displayed any significant difference in 











In this chapter a bioinformatic approach was taken to highlight a putative C. elegans orthlog to the human 
IRAS which could be phenotypically characterised to assess its candidacy as a potential imidazoline 
receptor that mediates rilmenidine bioactivity. Comparative protein sequence analyses showed that the 
predicted f13e9.1 sequence and IRAS share a similar overall structural organization with conserved 
PHOX domains, 5 contiguous leucine rich repeats, and a coiled coil domain that all occurred sequentially 
in both species. Previous research suggests the a type 1 imidazoline receptor is present in an acidic 
residues rich in glu/asp  within the coiled coil domain of IRAS (Piletz et al., 2000; Sun et al., 2007). 
Accordingly, F13E9.1 protein charge analysis revealed a series of acidic residues within the coiled coil 
domain reflective of a proposed imidazoline binding site.  
Initial comparative nucleotide sequence analysis revealed no significant alignment between IRAS and 
any C. elegans genes, however significant protein sequence alignment was noted between IRAS and 
F13E9.1, as well as two other uncharacterised proteins: T05H4.3 and K10D2.8 both are which are poorly 
annotated and lack characterisation.  
When comparing phylogenetically distant species such as humans and C. elegans nucleotide alignment 
becomes insensitive in identifying homology. First, DNA-DNA comparisons are largely based on 
straightforward text matching and thus evolutionary mutations in small nucleotides sequences make 
alignments rarely able to detect homology after more than 200–400 million years of divergence (Pearson, 
2013). Furthermore, long intronic sequences common in humans can easily “throw-off” alignment (Koonin 
et al., 2003). Contrariwise, the degeneracy of the genetic code, makes protein sequence alignment much 
better suited for homology searching. There is far less likelihood of different amino acid substitutions 
occurring during evolution in comparison to single base changes meaning protein:protein alignments 
routinely detect homology in sequences that last shared a common ancestor more than 2.5 billion years 
ago (e.g. humans to C. elegans) (Pearson, 2013). As such protein:protein alignment showed F13E9.1 to 
be significant to IRAS including three keys domain regions.  
The PHOX domain occurs within the first 20 amino acids of both IRAS and F13E9.1.  In humans, 49 
genes encode PHOX domains, of which the majority are sorting nexins (Chandra et al., 2019). PHOX 
domains have diverse functions including cell signalling (e.g., PLD1 and 2, PIKC2α, β, and γ), vesicle 
trafficking (e.g., SNXs 1, 2, 3, 5, and 6), protein scaffolding (e.g., SH3PXD2A and B), and cytoskeletal 
transport (SNX23/KIF16B) (Chandra et al., 2019). However, perhaps their most well characterised 
interaction involves its engagement with anchoring phosphoinositide lipids organelle membranes such 
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as endosomes (Viaud et al., 2016). The subsequent localisation of PHOX-domain proteins to cell 
membranes facilitates critical pathways in vesicular trafficking and cell signalling within the secretory and 
endocytic system (Chandra and Collins, 2018). The PHOX domain in IRAS,  has been demonstrated to 
target to sorting/recycling endosomes but must require co-interaction with the coiled coil to oligomerise 
and execute the function (Lim and Hong, 2004). This suggests that f13e9.1 likely localises to endosomal 
membranes. F13e9.1::eGFP expression could not be localised in C. elegans. Gene expression data 
suggests wildly variable expression patterns for f13e9.1 which could preclude observation. However, a 
number of datasets recorded extremely high expression levels of f13e9.1 probes but the exact binding 
site of these probes was not elucidated. IRAS undergoes a number of different splicing events, all of 
which result in removal of the 3’ end, and the full length transcript is rarely translated. Thus, the highly 
transcribed "189553_s_at" and "175226_at" probes may correspond to binding at the 5’ end of f13e9.1 
and the lowly transcribed “193781_at” probe may represent the frequently spliced 3’ end. Secondly, the 
fosmid integrated to generate the strains were tagged at the C terminus with a fluorescent and affinity 
cassette consisting of the Ty1 peptide, eGFP and 3xFLAG. As there are no known splice sites for f13e9.1 
it may be likely these reporters were spliced and degraded prohibiting in-vivo localisation of cleaved and 
functional F13E9.1. Lastly, integration into silenced areas of the chromosome is unlikely as the 
extrachromosomal fosmid strain also demonstrated no measurable eGFP fluorescence. 
Little mechanistic and functional information can be derived from PX interactions as the vast majority of 
IRAS study has been done in murine cell-lines which lack the N-terminus PX domain. However, STRING 
DB analysis the predicted functions partners of f13e9.1 to be sorting nexins (Szklarczyk et al., 2015). 
Nonetheless, the PX domain of IRAS has been demonstrated to target the vesicle formation of Mu opioid 
receptor (MOR) to ensure it recycling back to the membrane. Agonism of I1RAs has helped reduce opioid 
dependence and IRAS knockouts accelerate dependence (Li et al., 2016, 2009). 
Five contiguous leucine rich repeats have been functionally characterised in IRAS as well, and 
importantly F13E9.1 demonstrates a similar pattern of LRR expression. More than 60,000 proteins from 
viruses to eukaryotes contain LRRs, and are known to have diverse and broad functions through the 
enablement of protein:protein interactions. In 2017, a mutant mouse model was developed with targeted 
deletion of the LRR region (Dong et al., 2017). This model demonstrated interaction of IRAS LRRs with 
AMPK and importantly, LOF in LRRs resulted in defective Nischarin–AMPK interaction leading to 
increased AMPK activity. This implied that WT IRAS inhibited AMPK normally. As a result, mutant mice 
showed increased AMPK phosphorylation and decreased mTOR activity and enhanced sensitivity to 
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AMPK activators. This presents critical associative evidence between IRAS, F13E9.1 and calorie 
restriction.  
The coiled coil domain of IRAS appears conserved in F13E9.1. It is thought that the coiled coil co-
functions with the PHOX domain to permit oligomerised binding to endosomes and interaction with 
phosphatidylinositol 3-phosphate (PI3P) in PI3P-enriched endosomes (Lim and Hong, 2004). As 
discussed,  murine IRAS does not possess a PHOX domain but the coiled-coil region in the amino 
terminus of IRAS may be sufficient for regulation of translocation in mouse cells (Ding et al., 2008). A 
large number of other functions have been characterised in IRAS including interaction with integrin alpha 
5 however, their binding sites reside in the C-terminus of IRAS which is not conserved in C. elegans and 
thus are unlikely to play a role in the F13E9.1 functionality. Nonetheless, other N-terminal interactions 
have been reported including LKB1 PAK1 and LIMK1. Both PAK1 and LIMK are oncogenes that 
proliferate tumour growth, however, IRAS inhibited PAK1 and LIMK1 directly preventing cell migration 
whilst overexpression of IRAS inhibited breast tumour growth and metastasis (Baranwal et al., 2011). 
These benefits were shown to be due to association with LKB1 through their combined effect on cell-
cycle arrest, driven by inactivation of PAK1, and/or through the effect on actin-regulated  migration 
proteins such as PAK1, LIMK1, and cofilin (Jain et al., 2013).  
The next question was whether, in C. elegans, rilmenidine exhibited bioactivity characteristic of 
imidazoline receptor activation. Based on the genetic facileness of the ERK cascade in C. elegans, ERK 
phosphorylation was selected as an appropriate read-out for C. elegans imidazoline receptor activity. 
Increases in ERK phosphorylation are consistently observed following rilmenidine treatment in cell-lines, 
mediated through alterations in PKC (Li et al., 2006). Indeed, in C. elegans, rilmenidine increased ERK 
phosphorylation in a characteristic bi-phasic response (Piletz et al., 2000). However, a plethora of 
extracellular stimuli such as growth factors, cytokines, mitogens, hormones, and oxidative or heat stress 
are known to increase ERK phosphorylation (Mebratu and Tesfaigzi, 2009). Thus, it is not inconceivable 
that hormetic stress from rilmenidine administration may have upregulated ERK activity entirely 
independent from any imidazoline receptor activity. The co-incubation with the imidazoline receptor 
antagonist efaroxan went some way to refute this proposition in that whilst not altering basal pERK levels 
when administered alone, it abrogated the positive effect of rilmenidine in combination. However, 
efaroxan could indirectly block rilmenidine activity through interaction with a yet undiscovered signalling 
mechanism in worms.  
However, to mitigate that possibility, it was necessary to localise the ERK response to F13E9.1 the 
putative protein candidate for I1RA in C. elegans. As such, a mutant strain was generated by CRISPR 
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harbouring a homozygous deletion of f13e9.1 exons 3-8, encoding both the leucine rich repeats and the 
coiled coil domain. Preserving the sequence upstream of exon 3 was necessary to negate the mutation 
of the overlapping F13E9.11 gene in the sequence. Accordingly, this meant mutant strains could 
theoretically still transcribe the first 2 exons of f13e9.1 in which a PHOX domains resided. It must be 
assumed that this severely truncated gene product still maintains endosomal targeting capabilities 
characteristic of IRAS phosphoinositide lipid binding. However, f13e9.1 mutant strains abrogated 
rilmenidine induced ERK, increasing the likelihood a valid imidazoline binding site is expressed on 
f13e9.1. Moreover, this is strengthened by the observation that rescue with a full length integrated fosmid, 
restored rilmenidine-induced ERK phosphorylation. This provides substantial evidence that an 
imidazoline receptor is not encoded within the first 2 exons of f13e9.1 and that rilmenidine activates ERK 
signalling through an imidazoline receptor binding site coded in the C-terminus of F13E9.1. It is possible 
that f13e9.1 is merely necessary for rilmenidine induced ERK phosphorylation and that repression of 
rilmenidine-induced ERK activity in f13e9.1 worms is due to impaired capacity to increase ERK signalling 
above homeostatsis. Although a positive control of starvation was used in WT samples, future work would 
benefit from ensuring f13e9.1 mutants could reliably increase ERK activity when starved. Lastly, whilst 
f13e9.1 showed significant structural and functional similarity to IRAS, it is again conceivable that 
although f13e9.1 may have an imidazoline binding site, it may not function downstream in a similar 
manner to IRAS and elicits divergent cell signalling pathway which may coincidentally converge on ERK. 
To clarify this, research would benefit from upstream studies in C. elegans including repetition of 
rilmenidine-induced ERK phosphorylation in the presence of inhibitors of protein kinase A (PKA) (H-89 
and Rp-BrcAMPS) or protein kinase C (PKC) (calphostin C and staurosporine). Furthermore, DAG 
accumulation studies following rilmenidine administration to C. elegans would provide a clearer signalling 
map to implicate f13e9.1 as a bone fide IRAS homolog.  This would also provide a more targeted pathway 
to dissect when considering the pro-longevity or CRM effect of rilmenidine. 
Notwithstanding, f13e9.1 mutants displayed similar shortened body size to their murine counterparts 
suggesting the phenotypes and functionality of IRAS are conserved in f13e9.1. Researchers noted that 
size differences between WT and IRAS mutant mice were evident from embryonic development (Dong 
et al., 2017; Zhang et al., 2013). The Li lab likened the phenotype to Silver–Russell syndrome (SRS, 
OMIM: 180860), a genetic disease with disturbances of genes in insulin‐like growth factor pathway, such 
as GRB10, IGFBPs, IGFs, and so on (Zhang et al., 2013). Indeed, IRAS has been purported to associate 
with insulin receptor substrate, a receptor for IGF, and knockout of IRAS may reduce signal transduction. 
However, this association is enacted at the carboxyl terminus, which is not present in f13e9.1 and does 
not show any alignment to upstream F13E9.1 protein sequences. Alternatively, it is possible that 
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shortened body size is secondary to downregulated mTOR following AMPK activation in mutant IRAS 
mice, which would accordingly eventuate in prenatal growth defects and the postnatal growth retardation 
(Dong et al., 2017). Such prenatal growth defects manifested in reduced brain mass with abnormal 
organization of both the cerebrum and cerebellum and absence of the oral and nasal cavities. Also, the 
gastrointestinal tract failed to completely form in the mutant embryos. In C. elegans it is demonstrated 
that f13e9.1 mutants develop at a similar rate to WT, however investigation was limited to reproductive 
function. Whilst it could be argued that IRAS is only required for more complex tissue development such 
as the cerebellum and face in mice, more advanced phenotypical analysis of f13e9.1 mutant development 
is required including body length measurement during larval stages, to clarify the cause of the small 
phenotype. Another necessary point is the potential role IRAS may have as a sorting nexin which drives 
specific developmental processes and embryogenesis in mice, drosophila and C. elegans. A recent 
paper, published after the gathering of these results demonstrates sorting nexin mutants in C. elegans to 
exhibit a mix of developmental rates which were for the most part normal to WT (Vieira et al., 2018). 
However, importantly sorting nexin 3 caused significantly smaller body types in adulthood.  
The association of IRAS to body size and development places an interesting agenda towards the potential 
involvement of rilmenidine on longevity and CRM. It has not been fully elucidated whether rilmenidine’s 
agonism of the I1R affects IRAS and f13e9.1 in an inhibitory or activating manner. Thus it is plausible 
that rilmenidine may inhibit f13e9.1 to cause an upregulation of AMPK activity, subsequent mTOR 
repression, with a longevity phenotype. However, conversely whilst nishcarin LOF mutations may elicit 
developmental retardation, rilmenidine treatment in-vitro induces a gene ontology characteristic of 
accelerated growth including embryonic cranial skeleton morphogenesis, embryonic hemopoiesis, 
negative regulation of embryonic development and bronchus development (See chapter 3.2.1). In C. 
elegans, rilmenidine did not cause any significant effect on development, although this was again limited 
to reproductive function and the effect on body length with larval rilmenidine treatment should be 
recorded. This may provide additional evidence to suggest that the ageing programme which rilmenidine 
effects is decoupled from pathologically hyperfunctional developmental programmes hypothesised to 
cause ageing (Blagosklonny, 2013). More work needs to be done to decouple rilmenidine from 
developmental and also fecundity driven extension of lifespan, particularly through an assessment of 
fertility and brood size assay. This would help to further the pleiotropic mimicry rilmenidine may have on 
dietary restriction such that it may also reduce fecundity in adulthood – a metric which was not measured 
herein. With that said, toxicological studies in mice have revealed rilmenidine to not affect fertility, 




In summary, the C. elegans F13E9.1 protein encodes an acidic region within a coiled coil domain that 
displays conservation to the imidazoline binding site on human IRAS. Furthermore, F13E9.1 shares 
structural similarity and domain identity through the additional expression of a PHOX domain and leucine 
rich repeats. Rilmenidine was able to exert increases in ERK phosphorylation that was dependent on 
imidazoline receptor binding and also f13e9.1. Lastly, f13e9.1 mutants displayed morphological 
similarities to IRAS mutants, but lacked a similar developmental phenotype. It is possible the 
developmental and morphological phenotypes are associated with reduced mTOR functioning, although 
loss of sorting nexin capacity is also possible. Given the inexorable association between ageing, calorie 
restriction, body size and developmental rates, it is advisable the relationship between f13e9.1 and 




5. Results: Rilmenidine Improves Thermotolerance and Markers of “Healthspan” 
Dependent on f13e9.1 
5.1. Introduction 
Thus far this thesis has demonstrated rilmenidine to increase mean and maximum lifespan in C. elegans 
even if administered late in life. As highlighted in chapter 1.1.5 , ageing represents an accelerating 
vulnerability to disease and decreased adaptability to internal and external stress. The human body, 
model organisms and even individual organs, strive to maintain homeostasis and express the capacity 
to endure recurrently stressful conditions. Even in the absence of disease, one’s refractory capacity will 
erode, culminating in mortality (Fries, 2005). Ultimately, ageing can thus be defined by survival and 
mortality, and determines the longevity of an organism. The probability of death increases exponentially 
with advancing age and is inescapable for the cohort, proving survival a popular metric of ageing.  
However, lifespan is an ambiguous and loaded definition of ageing. Death rarely occurs as a result of 
ageing, and despite measures taken within experimental setting, incontrollable variables such as disease 
often eventuate death (Bronikowski, 2010; Pedro de Magalhães et al., 2018). Thus, lifespan is not 
sufficient in determining whether an intervention such as rilmenidine affects the ageing process or another 
age-independent factor. Researchers have hence looked for biomarkers that can eliminate the 
confounding influence of disease and measure underlying processes of ageing. As defined by Baker and 
Sprott, a biomarker “should reflect some basic biological process of ageing and certainly not the 
predisposition toward a disease state or some error in metabolism” (Moreno-Villanueva et al., 2015). That 
said, general patterns of age-change are common in certain tissue and moreover, such changes have 
been elucidated in most organ systems and serve as the source of many age-associated chronic 
diseases. These diseases are universal and inevitable manifestations of age that accelerate and can 
become symptomatic in line with functional decline, further compromising one’s stress resistance and 
vulnerability to death (Fries, 2005). The ability to compress the period of overt, symptomatic age-
associated disease, and maintain “healthy ageing” is one of the central tenants of anti-ageing research 
and a key target for pharmacological intervention (Stefánsson, 2005). Moreover, despite continued 
improvements in life expectancy, functional capacity and “healthspan” trajectories have not improved 
simultaneously, leading to a rapidly ageing population wherein, death is generally the result of chronic 
conditions, which develop over a long lifespan (Crimmins, 2015). Accordingly, intervention studies in 
model organisms have begun to shift the emphasis from calculating lifespan to measuring 
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healthspan (Keith et al., 2014). Biomarkers can be employed that can predict the general demise of 
ageing alongside the progressive enfeeblement characteristic of a prohibitively short healthspan including 
decreased adaptability to internal and external stress. This of course manifests in the phenotype of frailty, 
which is defined as having three or more of five physical components: unintentional weight loss, self-
reported exhaustion, weakness, slow walking speed and low physical activity (Fried et al., 2001). Recent 
evidence has demonstrated that frailty is the best indicator of remaining health and lifespan (Pyrkov and 
Fedichev, 2019). Although the exact pathogenesis remains elusive, frailty is accompanied by significant 
sarcopenia driven by muscle mitochondrial energy dysregulation and an accumulation of oxidative 
damage and aggregates in muscle cells (Angulo et al., 2016). Indeed, C. elegans exhibit a comparable 
age-associated deterioration in muscle function (Glenn et al., 2004; Herndon et al., 2002). Moreover, 
studies have shown that the rate of age-related decline in body movement is a good predictor of lifespan 
and that long-lived C. elegans mutants tend to exhibit prolonged locomotory capacity (Herndon et al., 
2002; C. Huang et al., 2004; Newell Stamper et al., 2018). Importantly, calorie restriction in C. elegans 
preserves body movement capacity with age, and putative CRMs are able to replicate this phenomena 
(Calvert et al., 2016; Onken and Driscoll, 2010).  
Secondly, lipofuscin accumulation is a routinely utilised biomarker of healthy ageing (Son et al., 2019).  
Lipofuscin is a heterogeneous mixture of cross-linked biomolecules that accumulates in the lysosomes 
of ageing cells (Yin, 1996). This post-mitotic phenomena, oft-cited as “the ageing pigment”, is well‐
conserved from humans to nematodes and correlates almost linearly with age and can be used to 
calculate the age of crustacean (Moreno-García et al., 2018) . Furthermore, it has been implicated in the 
development of neurodegenerative diseases by its triggering of neuronal loss, proliferation, and activation 
of glial cells. In normal brain ageing, intraneuronal deposits of lipofuscin significantly expand which 
correlates with altered neuronal cytoskeleton and cellular trafficking (Moreno-García et al., 2018). It is 
thought that accumulation may be driven by age-associated lysosomal impairment degradation failure 
which signals a more global proteostatic collapse. Thus, interventions which may preserve proteostatic 
function through a deceleration of the ageing process may manifest in reduced lipofuscin accumulation 
(Gerstbrein et al., 2005). Indeed, dietary restriction in murine models significantly reduces the prevalence 
of lipofuscin in the hippocampus, frontal cortex and retinal epithelium (Idrobo et al., 1987; Katz et al., 
1993).  
Whilst biomarkers may serve to calculate current age states, Butler et al., (2004)have also insisted 
biomarkers should predict the outcome of a wide range of age-sensitive tests, for which lifespan is 
inclusive. Following on from the position that stress resistance and homeostatic flexibility play a central 
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role in preventing mortality with age, it is conceivable that basal resistance to stress could predict the 
depth of reserve which an organism may harness to survive, and thus represents a viable biomarker of 
longevity. To that end, interventions that increase tolerance to multiple stressors, should in turn attenuate 
the diminishments in functional reserve.  
Stress resistance comprises two functions: the ability to prevent stress becoming malapropos and the 
resilience to recover from malapropos stress (Hamilton and Miller, 2016). Unsurprisingly, in C. elegans, 
long lived mutants exhibit high resistance to heat, oxidative, osmotic, hypoxic, ultraviolet, and heavy metal 
stresses, whereas progeric mutants exhibit greater sensitivity to these stressors (Dues et al., 2018; Keith 
et al., 2014) . In fact, when assessing the validity of a compound as a CRM beyond its inability to alter 
food intake, researchers propose that they must also activate stress response pathways, provide 
protection against stressors and lead to a preservation of healthspan (Ingram et al., 2006). 
It is imperative that the longevity effects of rilmenidine are indeed correlated to an attenuation of age 
biomarkers. Furthermore, as demonstrated, calorie restriction may delay ageing phenotypes through a 
preservation of homeostatic flexibility and improved resilience. For rilmenidine to be considered as a 
viable geroprotector it should extend healthspan and ideally, to qualify as a CRM, improve stress 
resistance. It would also be helpful to clarify whether these effects are mediated through f13e9.1 such 
that the pathways controlling rilmenidine-induced stress resistance are elucidated.   
5.2. Results 
5.2.1. Rilmenidine Attenuates Locomotory Decline But Not Autofluorescence Accrual 
During C. elegans Ageing via f13e9.1 
Initially, continuing with lifespan as an appropriate metric to assess the geroprotective properties of 
rilmenidine, it was necessary to establish whether lifespan extension was conferred via interaction with 
an endogenous imidazoline binding site in C. elegans, and furthermore, whether the putative IBS carrying 
gene, f13e9.1, was necessary for lifespan extension.  
Firstly, hypothesising that blockade of imidazoline binding sites in WT  worms would abrogate lifespan 
extension by rilmenidine, WT  worms were co-incubated from day 1 adulthood with rilmenidine (200µM) 
and efaroxan (2mM), an established selective I1‐imidazoline receptor antagonist. Importantly, efaroxan 
alone significantly increased mean lifespan by +12.5% in WT  worms compared a 1% DMSO vehicle 
control (efaroxan=24.5 days ± 0.5 S.E.M vs 1% DMSO 21.77days ± 0.64 S.E.M; log rank test w/ 
Bonferroni correction; p=0.013) (Figure 14). Furthermore, rilmenidine alone, as repeated in previous trials, 
significantly extended mean lifespan by +11.25% in WT  worms compared a 1% DMSO vehicle control 
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(rilmenidine=24.22 days ± 0.54 S.E.M vs 1% DMSO 21.77days ± 0.64 S.E.M; log rank test w/ Bonferroni 
correction; p=0.05). However, whilst rilmenidine and efaroxan combination therapy increased mean 
lifespan in WT  worms compared to controls, there was no additive effects, and co-treatment with 
rilmenidine and efaroxan failed to impart further mean lifespan extension than worms treated with either 
rilmenidine or efaroxan monotherapy (Ril vs. Ril & Efar p=0.202; Efar vs. Ril & Efar p=0.391).  
It was hypothesised that an IBS, through which the prolongevity effect of rilmenidine is derived, is 
encoded within the f13e9.1. Thus, lifespan assays were performed on f13e9.1 mutants. This would 
establish the contributions of f13e9.1 to a normal lifespan, the ageing process, and furthermore whether 
f13e9.1 was a longevity associated gene. Lastly, and ideally, the necessity of f13e9.1 for the prolongevity 
effect of rilmenidine should be assessed. As such, employing the previously described solid media NGM 
based lifespan assay (see chapter 2.7), adult lifespan was measured in WT  (WT), f13e9.1 (-/-)  and two 
nominally identical strains of rescue mutants PHX945 and PHX946 (syb767) IV; 
sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+) + myo-2p::mCherry]. At L4/adult molt, worms that had 
previously developed on FUDR-free NGM and were transferred to, and remained on thereafter, NGM 
plates that had been supplemented with 400µM FUDR and seeded with x10 concentrated live E.coli. 
Survival analysis demonstrated that f13e9.1 mutants had modest but significantly +6.3% increased mean 
lifespan in comparison to WT animals (WT =23.01 days ± 0.37 S.E.M vs f13e9.1 24.46days ± 0.41 S.E.M; 
log rank test w/ bonferroni correction; p=0.01) (Figure 15). Rescue mutants did not give a consistent 
lifespan phenotype. The second rescue strain PHX946(syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, 
unc-119(+) + myo-2p::mCherry) lifespan did not significantly differ to that of f13e9.1 mutants (log rank; 
p=0.22), and as such was statistically more long-lived than WT (WT =23.01 days ± 0.37 S.E.M vs 
PHX946 25.50days ± 0.38 S.E.M; log rank test w/ bonferroni correction; p<0.001) (Figure 15). Conversely, 
PHX945(syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+) + myo-2p::mCherry) rescues 
seemingly restored lifespan that did not significantly differ to WT (WT ) (log rank; p=1), and as such were 
modestly but insignificantly short-lived in comparison to  f13e9.1(sybIs62) mutants (PHX945=23.43 days 
± 0.30 S.E.M vs f13e9.1 24.46days ± 0.41 S.E.M; log rank test w/ bonferroni correction; p = 0.09). 
Experimental failures owing to a broken incubator prohibited the completion of a final set of lifespan 








Figure 14. Rilmenidine- Induced Lifespan Extension is Mediated By an Imidazoline Receptor Binding in 
C. elegans. Pooled survival curves of adult WT  worms fed UV-killed OP50 also treated with rilmenidine 
(200µM) and efaroxan (2mM) independently, or in combination, compared to control animals treated with a 1% 
DMSO vehicle. Both rilmenidine and efaroxan increased lifespan independently, but these effects were not 
additive when tested in combination. Kaplan Meir survival analysis performed on pooled data from at least 2 
independent trials in no less than 90 animals per condition. Groups tested by Log-rank with Bonferonni 




Table 9. Summary lifespan data of WT  WT worms exposed to various compounds. Differences in mean 
and maximum lifespan of WT  C. elegans exposed to various compounds relative to the control within the same 
sets of trials. Mean lifespan in days is the pooled mean of treatment cohort and the standard error (± S.E.M). 
Maximum lifespan defined as the day at which 90% cohort mortality was reached.  Lifespan assays performed at 
20 °. Adjusted p-value was determined by log-rank test using the Kaplan-Meier survival analysis and subsequent 















WT  (Live OP50 E.coli)               
Live OP50 E.coli 179 3 23.01 0.37 N/A 30 N/A 
WT  (UV Killed OP50 E.coli)               
1% DMSO 93 2 21.77 0.17 0.01 29 N/A 
2mM Efaroxan 155 2 24.50 0.50 12.54 34 0.057 
200µM Rilmenidine 125 2 24.22 0.54 11.25 32  0.013 
Rilmenidine and Efaroxan 177 2 25.57 0.51 17.46 34 0.001  
f13e9.1(sybIs62)               
Live OP50 E.coli 180 3 24.46 0.41 N/A 32 N/A 
PHX945 (f13e9.1 (syb767) 
IV; sybIs62[f13e9.1+]) 
              
Live OP50 E.coli 187 3 23.43 0.39 N/A 30 N/A 
PHX946 (f13e9.1 (syb767) 
IV; sybIs62[f13e9.1+]) 
              




















Figure 15. Effects of a f13e9.1 mutation and transgenic rescues on C. elegans lifespan. WT , f13e9.1 
mutants, and two transgenic rescue lines PHX945 and PHX946 (syb767) IV; sybIs62[f13e9.1::EGFP::3xFLAG, 
unc-119(+) + myo-2p::mCherry), were bleach synchronised and arrested in L1 overnight. All strains were 
transferred to NGM plates seeded with live OP50 E.coli until L4/adult Molt. Day 1 commenced upon the transfer 
of strains onto NGM plates containing 400µM FUDR and seeded with live OP50 E.coli. Worms remained on the 
same plates until completion. Kaplan Meir survival analysis performed on pooled data from at least 3 
independent trials in no less than 170 animals per genotype. Groups tested by Log-rank with Bonferonni 




Thus, to expand on the geroprotective and CRM properties of rilmenidine, it is essential to establish that 
rilmenidine can also prolong healthspan in C. elegans and can attenuate metrics of frailty. Using the 
common assay of sigmoidal motility as a surrogate marker for frailty we measured body bends in WT 
worms exposed to rilmenidine at 3 different concentrations (200µM, 300µM, 400µM) (see chapter 
2.11.2). Worms were observed at days 5,10,15 to straddle proposed window of muscular decline that 
becomes significant at around day 8 in WT worms  (Glenn et al., 2004). Results correlated with lifespan 
somewhat, in that, 200µM was the only concentration that significantly ameliorated deterioration in WT 
animal motility over the three time points (p<0.05; 2-way anova and Tukey post-hoc); however when time 
points were individually compared, at day-15 the difference did not reach statistical significance (WT  
w/1% DMSO = 10.1±1.21 bends/min vs. WT  w/200µM = 13.2±1.30 bends/min; p=0.057) (Figure 16A). 
Concentrations of 300 and 400 µM did not affect motility decline in either direction over the 3 time points 
(Figure 16B,C) 
Next it was important to assess whether preservation of healthspan by rilmenidine may be dependent on 
the putative IRAS homolog, f13e9.1. First of all, f13e9.1 mutants, treated with only a vehicle (1% DMSO) 
exhibited significantly accelerated declines in motility compared to WT  which is suggestive of a shortened 
healthspan (p<0.05; 2-way anova and Tukey post-hoc); this difference was significant at all time points 
(Figure 16D). The supplementation of f13e9.1 mutant worms with 200µM rilmenidine from day-1 failed to 
improve motility (Figure 16E). Rescue of f13e9.1 mutant using either the PHX945 or PHX946 strains failed 
to significantly restore age-related declines in motility to that observed in WT (Figure 13E). However, 
PHX945 was able to reinstate the preservation of motility into age by rilmenidine as observed in WT 
worms. This provides some evidence that rilmenidine may preserve healthspan in C. elegans, which is 










Figure 16. Quantification of motility deterioration with age in WT (WT,WT ), f13e9.1 (-/-) mutants, and two 
f13e9.1 rescue mutants (PHX945 and PHX946) in the presence or absence of rilmenidine. Motility was 
measured as number of stimulated sigmoidal body bends on solid NGM over a 1 minute period at day 5, 10 and 
15. Data is represented as a pooled mean (X) of 10 animals per time-point and condition/genotype repeated over 
3 independent trials (n=30) overlaid on a box plot representing quartiles. Error bars, upper:Q3 + 1.5*IQR; 
minimum: Q1 -1.5*IQR. A) Effect of differing concentration of rilmenidine (200, 300 and 400µM) on motility over 
time compared to 1% DMSO vehicle controls in WT worms. Only rilmenidine at 200µM significantly reduced age-
related deterioration in animal motility in WT worms (adj. p<0.05; 2-way ANOVA and Tukey post-hoc). B) Effect 
of differing genotypes on motility over time on NGM agar without 1% DMSO. f13e9.1 (-/-), f13e9.1(-); f13e9.1(+)1 
PHX945 and f13e9.1(-);f13e9.1(+)2 PHX946 all showed significantly different age-related deterioration in motility 
(adj. p<0.05; 2-way ANOVA and Tukey post-hoc). C) Quantification of body bends f13e9.1 (-/-), f13e9.1(-); 
f13e9.1(+)1 PHX945 and f13e9.1(-);f13e9.1(+)2 PHX946 transgenic animals fed from Day 1 of adulthood with 
200µM rilmenidine or a 1% vehicle control. Rilmenidine significantly affected motility deterioration in f13e9.1(-); 
f13e9.1(+)1 PHX945 rescue worms but not in f13e9.1 (-/-) or f13e9.1(-);f13e9.1(+)2 PHX946 worms (adj. p<0.05; 




As worms age, it is suggested they accumulate lipofuscin in the intestinal cells from base of the pharynx 
to rectum. Lipofuscin generates a measurable autofluorescence which can be visualised and quantified 
using a DAPI channel filter (Rollins et al., 2017). This pigment increases in a time-dependent fashion in 
line with ageing from day 5 to day 10 (Keith et al., 2014). Undoubtedly, researchers seemingly prefer to 
measure age-related autofluorescence through the DAPI channel, and indeed this wavelength is 
advocated in guidelines (Bansal et al., 2015; Collins et al., 2008; Keith et al., 2014; Rollins et al., 2017). 
Work from the Gems lab has sought to overturn the commonly held belief that autoflourescence emitted 
through the UV spectrum signifies lipofuscin. Instead, it is argued that the DAPI signal is due to 
anthranilate acid esters originating from gut granules and furthermore, that this signal intensified 
preceding the animal’s ensuant death. This likens DAPI autofluorescence to survival in that, rather than 
predicting the biological age of an animal, it actually demarcates the mortality risk of the cohort (Coburn 
et al., 2013). Nonetheless, well-cited papers, in highly ranked journals, have continued to image 
autofluorescence in the DAPI channel to measure an already ill-defined concept of healthspan (Bansal 
et al., 2015; Chen et al., 2019; Dehghan et al., 2017; Hsieh et al., 2017; Kwon et al., 2016; Lee et al., 
2015; Rollins et al., 2017).  To monitor this process and assess the effect of rilmenidine to attenuate 
lipofuscin accumulation, synchronised adult day 1 worms were cultivated on NGM agar supplemented 
with FUDR in the presence or absence of prolongevity dose of rilmenidine (200µM) (see chapter 2.11.1). 
A cross-sectional cohort of worms were imaged at day 2 to establish baseline autofluorescence and an 
additional separate cross-sectional cohort were measured at day 10 to establish rate of accumulation in 
line with previous methods (Pluskota et al., 2009). Firstly, the rate of lipofuscin accrual of no different 
between WT and f13e9.1; neither of the two groups had a significant accumulation of lipofuscin over the 
10 day period Figure 17.   
In the WT cohorts, median accumulation in pixel intensity between day 1 and day 10 was less in the 
rilmenidine treated group compared to the control group, however this did not reach statistical significance 
(Figure 17). This is owing to the fact that WT (WT ) worms did not significantly accumulate lipofuscin over 
10 days in either the control (1% DMSO) group or the rilmenidine-treated group (Mann-Whitney U; p>0.05 
for both treatments). In the f13e9.1 mutant cohort, rilmenidine treated worms had a more significant 
accrual of lipofuscin over the day 10 period compared DMSO treated worms suggesting rilmenidine 
worsened lipofuscin accumulation with age in f13e9.1 mutants (f13e9.1 DMSO Day 1 vs. DMSO Day 10, 
p=0.34; f13e9.1 Ril Day 1 vs. Ril Day 10, p=0.01). Given the poor induction of phenotype by rilmenidine 





Figure 17. Effect of rilmenidine treatment on lipofuscin accumulation in WT and f13e9.1 mutants. L4/Adult 
moult worms were transferred to NGM plates seeded with UV killed OP50 E.coli  containing either 200µM 
rilmenidiine or a 1% DMSO control. On day 2 and 10 they were imaged for age-related lipofuscin accumulation.  
A)  Lipofuscin was quantified by autofluorescence as measured by mean pixel intensity in the DAPI channel (ext 
on Zen Blue with background subtraction. N>28 per condition and genotype across 3 independent trials. Median 
Pixel intensity was calculated for each cohort and compared to respective control; *p<0.05, no indicator = not 
significant; two-tailed Mann-Whitney U. PI= pixel intensity through DAPI channel in Zen Blue Error bars, 
upper:Q3 + 1.5*IQR; minimum: Q1 -1.5*IQR B) Representative images of lipofuscin fluorescence in DMSO-
treated nematodes and rilmenidine-treated nematodes are shown. Animals were immobilized and mounted onto 
glass slides in 20mM solution of tetramisole hydrochloride before being imaged through both brightfield and 




5.2.2. Rilmenidine Improves Thermotolerance But Not Oxidative Stress Resistance 
Lastly, it was necessary to assess the hypothesis that rilmenidine may be a CRM due its capacity to 
improve stress resistance. Upon consultation with various stress-resistance assay guidelines, 
thermotolerance and oxidative stress were selected based on frequency of adoption (Keith et al., 2014; 
Lionaki and Tavernarakis, 2013) (Park et al., 2017). Furthermore, each would separately recapitulate an 
aspect of ageing. Heat-shock response is critical to proteome fidelity and the same machinery used to 
improve resilience is implicated in proteostatic collapse in ageing. Secondly, oxidative stress assays in 
which worms are exposed to high levels of ROS can aggressively recapitulate DNA damage and mutation 
accumulation proposed in organismal ageing.  
The thermotolerance assay was started at day 1 adulthood, to avoid premature age-related proteostastic 
collapse (Ben-Zvi et al., 2009) and to negate the need for FUDR which has been shown to interfere with 
thermotolerance and proteotoxic stress (Angeli et al., 2013). After 24h of respective drug exposure, 
worms were added to an incubator preset to 37⁰C to induce heat-shock whilst still exposed to the 
respective drugs (Zevian and Yanowitz, 2014) (see chapter 2.92). After 3 hours, worms were removed 
from the incubator and being kept on the same drug plates, shifted to 20⁰C  and scored for survival after 
a ~20h “recovery period” (Kumsta et al., 2017). We validated the assay demonstrating proline to improve 
survival to the above protocol, as previously reported (data not shown) (Edwards et al., 2015a). 
Rilmenidine at a prolongevity dose (200µM) significantly improved survival in comparison to WT worms 
(one way ANOVA p<0.05) (Figure 18B). To establish whether this effect might be mediated by the putative 
IRAS orthology f13e9.1 we exposed F13E9.1(syb767) mutant worms to the same heat stress in the 
presence or absence of rilmenidine. F13E9.1(syb767) worms were not anymore sensitive to heat-shock 
than WT worms; however 24h treatment with rilmenidine significantly reduced their survival, implying that 
rilmenidine required f13e9.1 to improve thermotolerance. To clarify the relationship further, I exposed 
PHX945 and PHX946 rescue strains to equivalent heat shock (Figure 15B). Survival was improved in 
comparison to WT and F13E9.1(syb767) worms, but this did not reach significance. Furthermore, 24h 
pre-incubation with rilmenidine (200µM) did improve survival by ~19% in both PHX945 and PHX946, but 
this failed to reach significance. Whilst this may suggest that f13e9.1 does not mediate the 
thermotolerance effects of rilmenidine, it is likely the high survival observed by rescue strains masked the 
benefits of rilmenidine.  
To assess oxidative stress response in C. elegans, treated with rilmenidine, we used the popular pro-
oxidant hydrogen peroxide H2O2 in a routinely used solid media based assay (Ludewig et al., 2013; 
Oláhová and Veal, 2015). Again, adult day 1 worms were exposed to rilmenidine or 1% DMSO for 24h 
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before being transferred to freshly prepared NGM plates containing 200µM rilmenidine and 2mM H2O2  
(see chapter 2.9.1). A subset of worms were removed from drug exposure whilst incubated on H2O2 
plates in order to account for any confounding external reactivities of H2O2 and rilmenidine not related to 
endogenous superoxide scavenging (see supporting table). Survival was then scored every 2 hours for 
10 hours as in previous assays (Jansen et al., 2002; Senchuk et al., 2017). A prolongevity dose of 
rilmenidine failed to affect survival in response to H2O2 induced oxidative stress. To establish whether 
this was due to an insufficient dosing, neither 300µM or 400µM significantly altered survival (see 
supporting table 3). To clarify that this was not a ubiquitous phenomena, 5-10mM NAC (+ve control) 
supplementation significantly improved survival in oxidatively stressed WT  worms (see supporting table 
3). Interestingly, F13E9.1(syb767) mutants were more sensitive to oxidative stress than WT worms and 
their demise was significantly more accelerated (log rank; p<1.70E-07) (Figure 18A). Moreover, treatment 
with rilmenidine additively worsened the response. Rilmenidine treated f13e9.1 mutants died significantly 
quicker than f13e9.1 worms treated with just a 1% DMSO vehicle (log rank; p<2.40E-05) (Figure 18A). 





Figure 18. Rilmenidine increases thermotolerance but not oxidative stress resistance dependent on f13e9.1. Survival of Day 1 Adult WT (WT,WT ), f13e9.1 (-/-) 
mutants, and two f13e9.1 rescue mutants (PHX945 and PHX946) in the presence or absence of rilmenidine following exposure to either heat-stress or oxidative stress. A) 
Oxidative stress: survival of WT  WT worms and f13e9.1 (-/-) worms exposed to 2mM H2O2 plates seeded with dead OP50 E.coli, following 24h treatment with either 200µM 
rilmenidine or a 1% DMSO vehicle.  Survival curves are a representative composite of 3 experiment with a total n>170 animals per condition measured at 2, 4, 6, 8 and 10 h. 
Kaplan-Meier log rank analysis was used to compare survival curves; Bonferroni adjusted p-value <0.05 considered significant. Complete, raw experimental data, with 
replicates, statistics, and percent changes in survival time provided in Table S2. B) Thermotolerance: Survival of day 1 adult WT  WT, F13e9.1 (-/-), f13e9.1(-); f13e9.1(+)1 
PHX945 and f13e9.1(-);f13e9.1(+)2 PHX946 worms exposed to 37⁰C for 3 hours and ~20h recovery period measured by single-time point % survival.  Drug-treated animals 
were placed on NGM plates supplemented w/ 200µM rilmenidine 24 hours prior to heat exposure and remained on the same plates through recovery. Data are represented as 
mean %survival ± S.E.M from three independent trials of at least 150 animals per strain and/or condition. *p<0.05 (one-way ANOVA with Tukey post hoc comparisons). See 





Whilst rilmenidne extends lifespan, the metric of survival is somewhat limited and does not define 
rilmendinie as a longevity molecule. As such it was necessary to determine if rilmenidine could improve 
any biomarkers of ageing alongside an improvement in stress resistance which together may confer 
increases in healthspan. Indeed, in worms rilmenidine improved two ageing biomarkers, a metric of frailty 
and the accumulation of intestinal autofluorescence, both of which were dependent on a functioning 
F13E9.1. Furthermore, rilmenidine treated worms appeared more resistant to heat stress, but were 
equally sensitive to oxidative stress as WT worms. Improved thermotolerance by rilmenidine in C. elegans 
was also dependent on f13e9.1, and strikingly, rilmenidine treatment increased sensitivity to oxidative 
stress in f13e9.1 mutant worms. When examining the healthspan of f13e9.1 worms, despite living longer 
than WT couterparts, they were counterintuitively frail at younger ages and accumulated lipofuscin faster 
than WT. Together these findings further uncover a complex and potentially dynamic relationship 
between rilmenidine and it’s putative C.eleagns receptor f13e9.1. Moreover, it bolsters evidence that such 
a relationship is associated with a dietary restricted phenotype.  
The data presented herein sought to establish whether the longevity effect of rilmenidine correlated to an 
ncrease in healthspan which may translate to longer periods of frailty-free, healthy years in clinical trials. 
Locomotory decline has been routinely employed in C. elegans ageing research as a surrogate marker 
of frailty owing to their shared sarcopenic aetiology (Bansal et al., 2015; Collins et al., 2008; Keith et al., 
2014; Rollins et al., 2017). In particular, body bends in response to stimulation represents a popular and 
easily implemented metric for ascertaining locomotive potential within a nematode which correlates to 
lifespan and tissue deterioration (Collins et al., 2008; Herndon et al., 2002; C. Huang et al., 2004). This 
metric becomes more appealing upon the realisation that environmentally induced  CR and also CRMs 
appear to attenuate reductions in body bends with age (Calvert et al., 2016; Lüersen et al., 2014; Onken 
and Driscoll, 2010). 
In this research, only 200µM rilmenidine significantly attenuated locomotory decline in C. elegans, which 
is also the dosage that increased lifespan the most. Such correlation shows that rilmenidine may act on 
ageing processes rather the deferment of mortality, whilst also reinforcing the utility of locomotion analysis 
as a predictor of lifespan. Rilmenidine treated worms demonstrated improved stimulated motility at day 
10, and day 15 when tested individually: these are both time points where significant increases in “frail” 
individuals are expected (Herndon et al., 2002). This is in agreement with a particularly relevant clinical 
trial looking to measure objective and subjective improvements in quality of life in perimenopausal women 
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with mild to moderate hypertension following rilmenidine monotherapy (Kawecka‐Jaszcz et al., 2006). 
They had previously noted that rilmenidine treatment reduced weakness and fatigue in women (Polskie 
Towarzystwo Nadciśnienia Te ̨tniczego et al., 1999).  
Biochemical perturbations underlie the very deterioration of age driven by a lifelong accumulation of 
molecular damage (Engelfriet et al., 2013). Whilst behavioural changes in processes such as locomotion 
provide an integrated and cumulative metric for functional decline, it does not characterise any cellular 
pathologies driving tissue ageing. The investigation of lipofuscin accumulation in ageing C. elegans, 
provided a platform to assess whether rilmenidine may fundamentally ameliorate cellular abnormalities 
at the foundation of an ageing phenotype. Indeed, rilmenidine attenuated the accumulation of 
autofluorescence in the intestine however this did not reach statistical significance. It is tempting to 
speculate that differences between rilmenidine and DMSO treated groups would become significant if a 
later end-point was defined. This is bolstered by evidence that, whilst median intestinal autofluorescence 
accumulated from day 2 to day 10 in control worms, the time-points were not significantly different, 
suggesting 10 days was not long enough for the worms to age. In our hands, WT  worms, grown on UV 
killed E.coli, have longer lifespans than WT  worms from comparable studies where autofluorescence 
accumulation was quantified at day 10 (Dehghan et al., 2017; Mi et al., 2018). Nonetheless, lipofuscin 
accumulation is clearly apparent in younger animals, including day 2 animals herein, and statistically 
different timepoints in pharmacological intervention studies have been as early as day 4  (Asthana et al., 
2015; Pant et al., 2014).  
Hence it is implied these organelles may harbour lipofuscin-like garbage. Given that the lipofuscin cannot 
be effectively degraded or exocytosed, it is likely interventions that attenuate lipofuscin accumulation do 
so through prevention rather than clearance (Moreno-García et al., 2018; Terman and Brunk, 1999). Such 
prevention is mostly initiated through efficacious protein homeostasis, a deferment of mitochondrially-
induced oxidative stress or conservation of lipid metabolism (Moreno-García et al., 2018). Lipofuscin is 
accepted to consist of oxidized proteins (30–70%), placing onus on effective  autophagic machinery to 
prevent the polymerisation of oxidised protein in lipofuscin formation (Höhn and Grune, 2013). Indeed 
rilmenidine has been demonstrated in a number of models to improve the clearance of aggregated 
proteins including synuclein and polyglutamate expansions (Rose et al., 2010; Williams et al., 2008). 
Thus, further exploration into the appealing signal of rilmenidine attenuating lipofuscin accumulation is 
warranted especially given the implication that treatment may have been too short to exact statistical 
difference: time-points extending to day 12, 15 and 17 may clarify the current uncertainty.   
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Deterioration in locomotory rates correlates with in-vivo DAPI autofluorescence, which has been validated 
in long-lived mutants, suggestive of a physiological ageing rate (Gerstbrein et al., 2005). However, 
despite a plethora or multi-taxonomical investigations demonstrating calorie restriction to improve 
measures of healthspan including locomotory metrics, repeatedly it has been shown to not elicit 
significant changes in DAPI autofluorescence with age (Bansal et al., 2015; Gerstbrein et al., 2005). 
Afterall this thesis searches not to reinvent measures of healthspan but to mimic age-associated 
phenotypes induced by dietary restriction. And, to that end, rilmenidine continues to mimic certain trends 
induced by calorie restriction, by matching attenuations in both locomotion and autofluorescence and 
ensuring worms do not exhibit periods of protracted frailty and burden.   
This chapter also set out to establish whether rilmenidine might be able to improve stress resistance as 
required for its qualification as a CRM (Ingram et al., 2006). Resistance to heat-stress is routinely found 
to correlate to increased lifespan: ∼80% of genes that promote thermotolerance also increase lifespan 
by >15%. Thermal adaption to heat stress is conserved in all eukaryotes and serves to prevent 
consequential proteostatic collapse in the face of heat-induced protein destabilisation and unfolding 
(Higuchi-Sanabria et al., 2018).  An extremely recent paper, released as I write my discussion, has 
showed a strong positive correlation between longevity and resistance to high thermal stress (Benedetto 
et al., 2019). The authors argued that severe thermal stress (>40⁰C) better tested heat-shock response 
by denying animals the ability to adapt to the stress as would be possible in the moderate stress and 
recovery assay employed herein. It was demonstrated that autophagy is required to mediate this 
response, linearizing a relationship between increased autophagy, thermotolerance and decelerated 
ageing. 
Another relevant finding by Benedetto et al. (2019) revealed lifespan was not correlated to oxidative 
stress resistance, casting further doubt on the necessity of improved oxidative stress as a determinant of 
lifespan (Gems and Doonan, 2009; Magalhães and Church, 2006). This a somewhat comforting 
reassurance when considering the inability of rilmenidine to rescue worms exposed to hydrogen peroxide. 
To answer why this might be the case, Benedetto et al. (2019) again provide some exceptional insight: 
autophagic machinery is not necessary for oxidative stress resistance and indeed it may in fact worsen 
sensitivities to oxidative stresses, especially at young adulthood. If rilmenidine does increase autophagy 
to improve thermotolerance it is unlikely to offer any great resistance to animals faced with oxidative 
stress. Furthermore, gene signatures from rilmenidine treated cells do not appear to be enriched for any 
ROS scavenger or detoxifying terms which may mitigate oxidative stress in animals. However, it must be 
noted that oxidative stress assays in this chapter were limited to acute stresses derived from one agent. 
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It is possible that rilmenidine may improve oxidative stress, as demonstrated by other CRMs, when 
different agents and exposure times are used (Onken and Driscoll, 2010; Robida-Stubbs et al., 2012; 
Schulz et al., 2007).  
It was still essential to clarify how rilmenidine might signal improvements in frailty indices and 
thermotolerance. It was hypothesised these effects were meditated through imidazoline receptor binding. 
In a brief return to lifespan analysis as a confirmative prologue, rimenidine was administered to worms 
already being treated with, the imidazoline type 1 receptor antagonist, efaroxan. Rilmenidine was unable 
to further extend lifespan in comparison to efaroxan or rilmenidine monotherapy, suggesting a common 
binding site. Efaroxan has long been used to block imidazoline binding sites, so its prolongevity effect 
was somewhat surprising: if rilmenidine extends lifespan through an interactional direction with the 
imidazoline receptor, the opposite effect of that should at the very least fail to confer lifespan. However, 
efaroxan has binding affinities to other receptors which may eventuate “off-site” prolongevity effects. 
Efaroxan is a selective agonist for at the I3 receptor (Clews et al., 2004). Research has shown that I3R 
binding may be insulinotropic in pancreatic β-cells through intracellular increases in Ca2+ concentrations 
and blockade of K-ATP channels (Soldatov et al., 2018). Attempts to characterize the associated IBSs 
have been unsuccessful making speculation on how efaroxan may confer lifespan extension difficult 
(Nikolic and Agbaba, 2012). However, a pharmacological lifespan screen by Ye et al. (2014), implied 
interaction with potassium and calcium channels may lead to, an undiscovered, mechanism of pro-
longevity. Thus, it is probable, rilmenidine signals through an imidazoline binding site in C. elegans to 
extend lifespan which can be effectively blocked by efaraxan; however given efaroxan itself may similarly 
increase lifespan through independent mechanisms, the resultant dual-therapy response is similar to that 
exacted by either of the imidazolines alone. Ideally, this would have been confirmed in knockout-rescue 
studies using the putative imidazoline receptor, f13e9.1, however, as discussed incubator failures 
precluded data acquisition. Nonetheless, initial longevity phenotype characterisation had been 
established in mutants. 
Unexpectedly, f13e9.1 mutants had extended lifespans in comparison to wild-types - a somewhat 
surprising result given the agonism of binding sites on f13e9.1 by rilmenidine increased lifespan. 
Additionally, maximum lifespan was also increased suggesting a deferral of mortality was an unlikely 
cause. To better explain the role f13e9.1 may play in rilmenidine-induced prolongevity, healthspan and 
stress resistance was re-examined. Despite, f13e9.1 mutants living longer, they displayed accelerated 
signs of frailty and autofluorescence, whilst also being more sensitive to oxidative stress in comparison 
to WT. This paradox represents a disturbing manifestation of the Tithonian error. Furthermore, rilmenidine 
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treatment further worsened lipofuscin accumulation, oxidative stress resistance, thermotolerance and 
motility; although the latter two failed to reach significance. Whilst, an abrogation of successful ageing 
biomarkers was expected in f13e9.1 mutants treated with rilmenidine, through ablation of a potential IBS, 
a worsening was not hypothesised.  Moreover, while lipofuscin accumulation and oxidative stress 
resistance metrics insignificantly improved responses in rilmenidine-treated WT worms, in f13e9.1 there 
was a reversed response in that they now were significantly worsened effects observed in WT.  
In previous chapters, based on results from mutant murine studies, an activation of AMPK and 
subsequent downregulation of mTOR was hypothesised to result from a deletion of IRAS. Thus, f13e9.1 
mutations might lead to a phenocopy of IRAS mouse knockouts, which had been demonstrated in 
observed growth defects. Phenotypes of shorter body size and catabolic AMPK/mTOR alterations are 
reminiscent of CR such that one questioned whether deletion of f13e9.1 may be a genetic CRM (Mörck 
and Pilon, 2006). When looking at genetic models of CR in C. elegans, in particular eat-2, a healthspan 
and stress resistance phenotype may also be comparable. Numerous papers have shown eat-2 mutants 
to display accelerated locomotory decline in comparison to WT, alongside increased lipofuscin 
accumulation (Bansal et al., 2015; Hansen et al., 2008; Lüersen et al., 2014). Furthermore, eat-2 worms 
are often more sensitive to heat-stress however, this is not consistent with oxidative stress (Bansal et al., 
2015; Houthoofd et al., 2002a, 2002b). It has also been hypothesised that IRAS and thus potentially 
f13e9.1 additionally function as sorting nexins. Mutations in sorting nexins in C. elegans dramatically 
decreased stress resistance, which may be linked to the reduced size of the amphid sensory 
compartment: nexins are required for the morphogenesis of sensory compartments, which if improperly 
developed my led to altered stimulus regulation (Oikonomou et al., 2012; Vieira et al., 2018)  
When analysing this pattern in association with rilmenidine treatment, a DR phenocopy could again be 
argued. Metformin, a potent CRM, drastically, reduces the lifespan of eat-2 mutants which would 
presumably affect healthspan parameters such as frailty and lipofuscin (Onken and Driscoll, 2010). 
Authors suggested that metformin might induce a starvation-like state from excessive metabolic 
shutdown, which toppled the delicate life-extending metabolic balance of eat-2 mutants (Onken and 
Driscoll, 2010). However, how rilmenidine might still be able to elicit further “DR-states” in f13e9.1 is 
difficult to answer. One possibility is that f13e9.1 mutants maintain some functionality in the 1st and 2nd 
non-deleted exons which may have potential binding affinity. This may then lead to inverse agonism of a 
dysfunctional f13e9.1 protein which may begin inappropriately interacting with binding partners such as 
LKB-1. Furthermore, f13e9.1 mutants, maintaining PHOX domain interactivity in 5’ exons may lack 
regulation from a deleted coiled coil domain such that it triggers unregulated membrane binding, and 
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deleterious outcomes for healthspan and stress resistance, which becomes even more deleterious upon 
activation by rilmenidine. Or f13e9.1 functionality is significantly downregulated by its mutagenesis, which 
is then completely shut down by rilmenidine treatment. Alternatively, rilmenidine may weakly bind to other 
receptors in the absence of f13e9.1 leading to harmful signalling related to oxidative stress, which may 
cause accelerations in lipofuscin accumulation. Whilst, conclusions on adverse reactions in f1e9.1 are 
difficult to make, results do suggest that rilmenidine requires f13e9.1 to attenuate locomotory declines 
and heat stress and that rescue strains PHX945 preferentially restores these proclivities. Despite 
locomotion still declining quicker in PHX945 in comparison to WT, it did rescue the ability of rilmenidine 
to attenuate such deteriorations, implying that a potential healthspan benefit signals through interactions 
with f13e9.1. Furthermore, improved thermotolerance can be restored to levels observed in WT, however 
this did not quite reach significance. This failure to reach significance is only apparent following multiplicity 
correction and individual analysis assumes rilmenidine to improve heat stress in both rescue lines. The 
difficulty in observing statistically clear survival improvements is likely potentiated by an increase in basal 
survival in fosmid rescues. Fosmid derived f13e9.1 is highly tagged which may disturb function as 
previously documented. This may lead to moderate downregulation of f13e9.1 mimicking moderate 
f13e9.1 inhibition by rilmenidine, leading to improved thermotolerance. 
When assessing how f13e9.1 binding interactions with rilmenidine may transduce improved 
thermotolerance, experimental evidence in this thesis only provides ERK signalling as an option. 
Fortunately, heat-shock induces two major signalling events: the transcriptional induction of HSPs and 
the activation of ERK (Petrocchi et al., 2010). Furthermore, recent studies reported that there was a 
correlation between protective HSP70 expression and activation of the MAPK pathway. Thus rilmenidine, 
which increases pERK via f13e9.1, may improve heat-shock response via ERK signalling. As example, 
epicatechin modulates stress-resistance in C. elegans through increases in ERK. It is also important to 
note that the ERK-MAPK pathway regulates longevity and knock-down of its function shortens lifespan 
(Okuyama et al., 2010). Together, this provides an interesting link between rilmenidine treatment, ERK 
activation, thermotolerance and lifespan. This is especially relevant since ERK activation following heat 
stress is also diminished as a function of age, providing opportunity for rilmenidine to improve functionality 
into age, which may in turn improve markers of healthspan such as locomotion. Indeed, cells derived 
from long-lived animals exhibit a prolonged low level ERK activation following heat-stress which is 
suggested to contribute to improved stress resistance and longevity (Elbourkadi et al., 2014; Sun et al., 
2009). Imidazolines also induce prolonged moderate increases in ERK activity, which may be able to 
mimic a response to stress characteristic of long-lived animals (Edwards et al., 2008; Li et al., 2006; Piletz 
et al., 2003b; Sun et al., 2007).  
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These results suggest rilmenidine to effectively attenuate frailty indices in C. elegans and improve 
thermotolerance which is dependent on f13e9.1, thus continuing its growing qualification as a bone fide 
CRM. Conversely, f13e9.1 mutants, whilst living longer, exhibit shorter time to frailty and diminished 
stress resistance. This highlights f13e9.1 as potential Tithonian mutant similar to some long-lived strains. 
Furthermore, oxidative stress resistance and lipofuscin are worsened by rilmenidine treatment in f13e9.1 
mutants which is overwise unaffected in WT. This suggests a sensitising effect in f13e9.1 mutants that is 
decoupled from rilmenidine’s interaction with an IBS on F13E9.1. However, making any such claims is 
difficult in the face of poor signalling characterisation of f13e9.1 or indeed it’s homolog IRAS. It is 
hypothesised that rilmenidine may improve heat-stress through an efficacious increase in pERK although 
this stands to be tested using ERK knockdown models exposed to heat-stress and rilmenidine. In 
summary, these results show a promising potential of rilmenidine to mimic CR through the improvement 
of thermotolerance in worms, although potentially separately through ERK activation and autophagic 
responses which sets the scene for greater resistance to life stressors. Such improved capacity 
represents greater organ reserve characteristic of “healthspan” which may prolong this period as 




6. Results: Rilmenidine Extends Lifespan Through Dietary Restriction Associated 
Signalling Pathways 
6.1. Introduction 
This thesis has so far presented evidence demonstrating rilmenidine to improve lifespan in C. elegans 
when administered throughout adulthood or agedness. This corresponded to delayed manifestations of 
age associated phenotypes of lipofuscin accumulation and nematodal frailty. Furthermore, rilmenidine 
treated worms have improved stress resistance which corelates to extended healthspan. Indeed, these 
characteristics are shared with calorie restriction. Specifically, DR in worms, whether by bacterial 
restriction or genetically induced obstruction of food consumption, attenuates age-associated lipofuscin 
accumulation and motility impairments (Gerstbrein et al., 2005; Son et al., 2019). Moreover, DR in worms 
leads to greater resistance to thermal and oxidative stress (Houthoofd et al., 2005). Whilst such effects 
are mimicked by rilmenidine, transcriptional analysis revealed no similarity between DR and rilmenidine 
treatment. However, previously published transcriptional profiles of DR have been contradictory and gene 
expression effects vary in magnitude between studies (Gillespie et al., 2016). Furthermore, calorie 
restriction is vastly pleiotropic and heterogeneity through secondary effects likely leads to such ambiguity. 
This may mask more targeted gene expression changes elicited by rilmenidine, which whilst altered by 
DR, are diluted within “off-site” gene expression upstream by DR.  
As previously highlighted, two key nutrient responsive gene products, AMPK and TOR, have been 
considered “master regulators” of dietary restriction. The ability of potential CRMs to affect the activity of 
these pathways specifically may offer a more orthogonal approach to CR mimicry without superfluously 
auxiliary effects. Classical genetic epistasis analysis reasons that if two interventions result in an additive 
phenotypic response their mechanism of induction must differ. Thus if rilmenidine acts through the 
mimicry of DR, animals already undergoing DR could not further respond in a synergistic manner to 
rilmenidine. This logic is applicable to downstream mutational targeting of DR-associated genetic 
pathways. Pre-set downregulation of mTOR activity would make mTOR inhibitors unable to elicit further 
lifespan extension, and in a similar vein, AMPK loss of function would preclude its geroprotective 
activation. Thus, to clarify current uncertainty surrounding the relationship of rilmenidine to CR, the 
interactive pathway of rilmenidine should be followed to isolate potential genetic targets which could be 
mediating a CRM pro-longevity function.  
169 
 
However, whilst, lifespan offers a most convenient and holistic metric for ageing deceleration, it is an 
insufficient, indirect and resultant read-out for the activation of numerous longevity mechanisms within a 
cell. Any overlapping processes between dietary restriction and rilmenidine ideally should also be defined. 
It is demonstrated hereafter that rilmenidine likely signals through both dietary restriction and additionally 
through AMPK and TOR signalling. Dietary restriction, AMPK activation and TOR inhibition, unanimously 
converge one distinct process: autophagy. 
CR is routinely cited as the most robust physiological inducer of autophagy and nutrient depletion is the 
gold-standard for autophagic induction in culture (Kroemer et al., 2010). Thus, autophagy is a vital 
component of CR-induced longevity. Multiple models have demonstrated that the longevity benefits of 
dietary restriction are abrogated following the knockdown of autophagic machinery (Hansen et al., 2008; 
Jia and Levine, 2007; Rubinsztein et al., 2011). As such, researchers often seek to demonstrate that their 
CRM of interest upregulates autophagy and that this upregulation mediates its lifespan extension 
(Eisenberg et al., 2009; Pietrocola et al., 2018; Shintani et al., 2010). In fact, the relationship between 
calorie restriction and autophagy is so inexorable that researchers have proposed a CRM criteria solely 
pertaining to how a compound upregulates autophagy (Madeo et al., 2019).  
In 2008, an in-vitro screen for autophagy enhancers returned rilmenidine as a hit (Williams et al., 2008). 
Rilmenidine was able to clear A30P α-synuclein, a known autophagy substrate, in stable inducible PC12 
cells, and furthermore, increased LC3-II levels (autophagic protein markers) in a dose-dependent manner 
(Williams et al., 2008). Subsequent exploration within the same paper revealed rilmenidine to upregulate 
autophagy via an mTOR independent cAMP mediated manner. Importantly, clonidine, another 
imidazoline receptor agonist, upregulated autophagy in a similar manner (Williams et al., 2008). 
Rilmenidine has since been administered in a number of disease models to assess its capacity to 
ameliorate neurodegeneration. Firstly, in a Huntington’s murine model, rilmenidine decreased levels of 
mutant huntingtin and improved motor phenotypes, yet failed to improve survival (Rose et al., 2010). 
More recently, in a murine model of ALS, generated through transgenic expression of a G93A mutant 
form of human SOD1, rilmenidine elicited significantly upregulated in-vivo autophagy and clearance of 
soluble mutant SOD1 (Perera et al., 2018). However, the autophagic potential for rilmenidine has never 
been explored in C. elegans and more importantly, no efforts have been made in any model to associated 
this to ageing or calorie restriction. Thus this chapter serves to explore the pathways by which rilmenidine 
might mimic CR, whether any mimicry culminates in a change in autophagy, and finally whether that is 




6.2.1. Rilmenidine Extends Lifespan Mediated By Established Calorie Restriction 
Nexuses 
Starting with an upstream evocation of CR, the eat-2 (ad1116) strain was employed. eat-2 mutants lack 
the encoded nicotinic acetyl-choline receptor which renders the pharyngeal muscle unresponsive(Avery, 
1993). Animals are unable to efficiently grind the bacteria, providing a bona fide genetic surrogate for DR 
on regular media plates. eat-2 live around 30% longer than their WT  counterparts, comparable to other 
long-lived mutants and represent the most long-lived of the eat gene family (Lakowski and Hekimi, 1998). 
This lifespan extension is similar to that observed in mammals and both exhibit a correspondingly pale 
and thin morphology. As such, this has popularised the use of eat-2 and specifically the ad1116 allele in 
renowned ageing labs (Crawford et al., 2007; Hansen et al., 2008). Lifespan assays were performed in 
eat-2 (ad1116) worms treated from adulthood with either a 1% DMSO control or rilmenidine a 200µM 
pro-longevity dose. Confirmatively, eat-2 (ad1116) worms grown on 1% DMSO NGM plates lived 14.63% 
longer than condition matched WT  controls (Figure 19F). Although, eat-2 worms are the most consistently 
long-lived lifespan variability is still apparent, potentially explaining the more modest results observed in 
this thesis  (Lakowski and Hekimi, 1998). The administration of rilmenidine to eat-2 worms not only failed 
to additively increase lifespan, it significantly reduced lifespan in a toxic manner (log rank test; p=2.90E-
08) (Figure 19F).  Rilmenidine treated eat-2 worms lived 16.94% shorter lives than those treated with only 
a 1% DMSO vehicle (Figure 19F). This is strikingly reminiscent of the effect of metformin on eat-2 mutants, 
wherein  pro-longevity doses of metformin are reproducibly detrimental to the viability of eat-2 mutants 
(Onken and Driscoll, 2010). Thus, given the similarity in response it was imperative to assess the 
necessity of AMPK to mediate the prolongevity effect of rilmenidine. Of note, the Lifespan Machine at the 
Ewald lab was utilised to verify these findings; they found rilmenidine to not significantly affect lifespan of 
eat-2 worms in either direction.  
Onken and Driscoll (2010), demonstrated that metformin, the most renowned putative CRM, was unable 
to additively extend lifespan in an AMPK mutants (aak-2) at prolongevity doses. C. elegans aak-2 
encodes one of two homologs of the catalytic α subunit of the AMPK heterotrimeric complex, and 
nematode AAK-2 is activated by AMP, as occurs for mammalian AMPK (Onken and Driscoll, 2010). Aak-
2 is the preferred catalytic subunit to mutagenize owing to ability to elicit specific longevity phenotypes 
unlike aak-1 (Apfeld et al., 2004). Three mutant allele strains are available for aak-2; allele gt33 harbours 
the largest deletion of the alleles available (606bp) (Cordero and Viollet, 2016). Hence, lifespan assays 
were performed in akk-2 (gt33) worms treated from adulthood with either a 1% DMSO control or 
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rilmenidine a 200µM pro-longevity dose. Accordingly, and as reported similarly elsewhere, aak-2 mutants 
lived 11.33% longer than condition matched WT  controls (WT 23.84 ± 0.17 mean days; aak-2 26.54 ± 
0.33 mean days S.E.M, log rank test: p<0.05) (Figure 19E). Whilst rilmenidine treatment did result in 
significant mean lifespan extension in aak-2 mutants, the effect was far more tempered and modest to 
that elicited in WT: rilmenidine increases mean lifespan in WT  wildtype by 19% whereas, in aak-2 
mutants, this effect was only 5.43% (Figure 19E). Seemingly, some prolongevity benefit from rilmenidine 
may be in some way derived from interaction with AMPK. It is thus likely, rilmenidine interacts with other 
longevity associated pathways as well. 
As highlighted in chapter 1.3.1, mTOR inhibition is one the proposed mechanisms of DR induced lifespan 
extension and geroprotection; and key downstream transcription factors of TOR: S6K, eIF2 and eIF4G, 
all increase lifespan in C. elegans when suppressed (Hansen et al., 2007). Furthermore, Hansen et al. 
(2008) showed CR and TOR inhibition in combination does not further extend lifespan in C. elegans, thus 
highlighting an overlap in their pro-longevity signalling. Downstream targets of nematode DR are similar 
to that of TOR inhibition and include FOXO types, SKN-1 and HIF-1 (Yanase et al., 2019). CeTOR exists 
in two distinct complexes: TORC1 containing the principle TOR component, the coactivator DAF-
15/Raptor and TORC2 including RICT-1/Rictor. TOR in worms is coded for by let-363, and its 
homozygous deletion causes dauer-like larval arrest, limiting it’s use for translational lifespan assays (Jia 
et al., 2004). Additionally, daf-15 homozygous mutants show larval arrest (Jia et al., 2004). Heterozygous 
strains have been developed to lessen the developmental penetrance, resulting in a gain in lifespan. 
Thus researchers routinely use this model, which is often crossed with a phenotypical marker gene, when 
assessing if an anti-ageing interventions signal via the TOR pathway (Han et al., 2017; Honda et al., 
2015; Sanchis et al., 2019). The strain daf-15(m81)/unc-24(e138) IV, developed in the Riddle lab, was 
utilised owing to its natural selection pressure to heterozygotes given homozygous lethality of the unc-24 
gene (Jia et al., 2004). Confirmatively, daf-15(m81)/unc-24(e138) IV worms grown on 1% DMSO NGM 
plates lived 11.28% longer than condition matched WT  controls (WT 23.84 ± 0.17 mean days; daf-15     
24.56   ± 0.95 mean days S.E.M, log rank test: p<0.05)  Figure 19B. I further validated the model by 
demonstrating that, at concentrations, previously shown to extend lifespan in C. elegans, rapamycin 
(100µM) failed to significantly affect the basal mean lifespan of daf-15(m81)/unc-24(e138) heterozygotes 
(log rank test: p>0.05) (Robida-Stubbs et al., 2012) (Figure 19B). Importantly rilmenidine also elicited an 
insignificant change in lifespan, suggesting that lifespan extension by rilmenidine is dependent on TOR 
functionality (log rank test: p>0.05) (Figure 19A). 
172 
 
Due to a poor sample size (n<50 per condition), precipitated by difficulty in identifying penetrant 
heterozygotes for hand-picking onto small drug plate, an alternative approach was sought after to confirm 
epistatic observations. Accordingly, WT  worms  were co-incubated from day 1 adulthood with rilmenidine 
(200µM) and rapamycin (100µM), an established CeTOR inhibitor (Robida-Stubbs et al., 2012). 
Importantly, rapamycin alone significantly increased mean lifespan by +23.92% in WT  worms compared 
to a 1% DMSO vehicle control (1% DMSO=22.07 days ± 0.5 S.E.M vs rapa 27.35days ± 0.49 S.E.M; log 
rank test w/ Bonferroni correction; p=0.000) (Figure 19A). Likewise, rilmenidine alone, as repeated in 
previous trials, significantly extended mean lifespan by +36.16% in WT  worms compared a 1% DMSO 
vehicle control (rilmenidine=30.05 days ± 0.61 S.E.M vs 1% DMSO=22.07 days ± 0.5 S.E.M; log rank 
test w/ Bonferroni correction; p = 0.05) (Figure 19A).. However, whilst rilmenidine and rapamycin 
combination therapy increased mean lifespan in WT  worms compared to controls, there was no additive 
effects, and co-treatment with rilmenidine and rapamycin failed to impart further mean lifespan extension 
than worms treated with either rilmenidine or rapamycin monotherapy (Ril vs. Ril & Rapa p=0.703; Rapa 
vs. Ril & Rapa p=1) (Figure 19A).  
It is also well established in worms, that AMPK activation and TOR inhibition by genetic or 
pharmacological intervention, like in mammals leads to activation of key longevity transcription factors 
such as skn-1 and daf-16 (Robida-Stubbs et al., 2012; Templeman and Murphy, 2018). Moreover, on 
solid media, daf-16 is indispensable for CR-induced longevity. To explore whether rilmenidine induced 
some of its longevity effects, a daf-16 mutant model was employed, specifically the commonly used daf-
16(mgDf50) null allele due to the presence of a large deletion within the gene. It has been routinely used 
when assessing the signalling pathways of potential longevity compounds (Hunt et al., 2011; Wilson et 
al., 2006). Lifespan assays on daf-16 were employed using the lifespan machine by the Ewald lab, and 
found rilmenidine did not significantly affect lifespan in either direction (daf-16 w/DMSO 19.37± 0.21 days; 





Figure 19. Effects of rilmenidine treatment on survival of CR associated mutants. Pooled survival curves 
of f) eat-2 e) aak-2 b) daf 15 +/- g) daf-16 worms fed UV-killed OP50 also treated either a prolongevity dose of 
rilmenidine (200µM) or a 1% DMSO vehicle. Statistical data analysis of survival curves between treatments and 
not genotype was performed using log-rank testing and bonferonni correction; statistical data available in table. 
C) Pooled survival curves of adult WT  worms fed UV-killed OP50 also treated with Rilmenidine (200µM) and 
rapamycin (100µM) independently, or in combination, compared to control animals treated with a 1% DMSO 
vehicle. Statistical data analysis of survival curves between treatments and not genotype was performed using 
log-rank testing and Bonferroni correction; statistical data available in table. D) mean lifespan (days) of pooled 
trials measuring the survival curves of panel C.  Error bars represent SEM; adjusted p-value derived from log-
rank test and Bonferroni correction. F) Artistic representation of possible prolongevity signalling of rilmenidine. 





6.2.2. Rilmenidine Induced Lifespan Extension is Mediated by Autophagic Upregulation  
To assess the capacity of rilmenidine to increase autophagy, reference was made to published guidelines 
(Chen et al., 2017; Papandreou and Tavernarakis, 2017; Zhang et al., 2015). Therein, authors 
recommend monitoring the appearance of distinct autophagic puncta in response to interventions. In C. 
elegans, autophagy is a highly conserved process, and autophagosomes are formed by the proteins 
LGG-1 and LGG-2, homologous to Atg8/mammalian LC3B (cytosolic microtubule-associated protein 1 
light chain 3-MAP1LC3), however their mechanism remains largely elusive (Papandreou and 
Tavernarakis, 2017). Nonetheless, it is known that LGG-1/LGG-2 are conjugated to a 
phosphatidylethanolamine (PE) lipid during autophagosome formation and these lipoproteins decorate 
the outside of the membrane (Wu et al., 2012). When an autophagosome has engulfed its requisite target, 
it subsequently fuses with a late endosome or lysosome to form an autophagolysosome (or autolysome) 
for degradation (Meléndez et al., 2008). The congregation and lipidation of LGG-1 during autophagosome 
causes the diffuse cellular distribution pattern to become distinctively punctate (Papandreou and 
Tavernarakis, 2017). Researchers have utilised this phenomena by generating a number of transgenic 
reporter strains carrying fluorescent tags of LGG-1, which can visualise and quantify autophagic induction 
to assess response to environmental conditions and potential anti-ageing compounds (Chen et al., 2017).  
The transgenic worm (vkEx1241) expresses an extrachromosomal N-terminally fused mCherry::LGG-1 
construct driven off an intestinal nhx-2 promoter and is recommended for implementation in guidelines 
(Palmisano and Meléndez, 2016; Zhang et al., 2015). It has been routinely used to identify compounds 
which upregulate autophagy (Gosai et al., 2010; Li et al., 2014). Furthermore, the pro-longevity effect of 
DR is primarily regulated by intestinal autophagy (Gelino et al., 2016). 
Autophagosome formation was observed in the transgenic autophagy reporter strain vkEx1241 by 
fluorescence microscopy. Autophagic activity was quantified by the number of LGG-1:mCherry puncta 
cross-sectionally present per mm2 of fluorescent posterior intestine (See chapter 2.8.1). 24h incubation 
with rilmenidine in 2 day adults significantly increased mCherry::LGG-1 puncta formation in a dose-
dependent manner (Figure 20B). Specifically, the pro-longevity dose of rilmenidine produced the most 
modest, but still significant, increases in puncta formation (one-way ANOVA; adj. p<0.01). 300µM 
incubation further increased median puncta number by a magnitude of 2-fold, and 400µM incubation 
increased median puncta number by 2.5 fold in comparison to a 1% DMSO vehicle (300µM vs DMSO 
p=0.001; 400µM vs DMSO p=0.001) (Figure20B). Increases in autophagy in LGG-1 positive punctae can 
be attributed to either activation of autophagy or decreased autophagosome clearance due to a block in 
autophagosome-lysosome fusion. Given the hypothesis that rilmenidine increases autophagic induction, 
it is essential to infer the turnover of autophagosomes in the presence and absence of lysosomal 
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degradation. Confirmatively, rilmenidine continued to increase LGG-1 positive puncta in adult day 2 
worms co-incubated with chloroquine, at previously utilised doses (20mM) to stall autophagic clearance 





Figure 20. Induction of autophagy by rilmenidine and efaroxan in a synergistic manner. A) Representative 
Images of well-fed day 2 adult transgenic animals, expressing the intestinal specific autophagy reporter gene   
Pnhx-2mCherry::lgg-1 and exposed to varying concentrations of rilmenidine or a 1% DMSO vehicle for 24h. 
Worms were immobilized and mounted onto glass slides in 20mM tetramisole prior to imaging at x10 objective on 
a Zeiss Axio Observer with a 150ms exposure. Grey triangular arrows highlight characteristic puncta to guide 
Scale bar, 20 μm. B) Graph shows the interquartile distribution of mean number of mCherry::LGG-1 puncta in 
the posterior intestine of the animals in each condition. Error bars, upper:Q3 + 1.5*IQR; minimum: Q1 -1.5*IQR.  
mCherry::LGG-1 puncta were counted in each of three rectangular boxes of 1mm2; they were placed in tandem 
beginning with the most posterior region of the intestinal and extended toward the vulva; mean number per mm2 
was calculated for each animal.   N>25 animals analysed per treatment in at least 3 independent trials . 
**P<0.01, *P<0.05; one-way ANOVA followed by a Tukey’s post hoc test.  
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Having previously demonstrated that rilmenidine-induced ERK activation is abrogated by the blockade or 
deletion of the imidazoline binding site, it was hypothesised that autophagy may be upregulated via 
interaction with this binding site. Conversely, blockade of the imidazoline binding site by efaroxan 
increased median autophagosome formation in VkEx1241 strains 2-fold (adj. p=0.002) (Figure 20B). 
Moreover, co-incubation with rilmenidine synergistically and significantly increased autophagosome 
formation in comparison to worms treated with either rilmenidine or efaroxan monotherapy (Ril vs. Ril & 
Efar p=0.001; Efar vs. Ril & Efar adj. p=0.026).  
Next, it was prudent to determine whether upregulated autophagy was required for the prolongevity effect 
of rilmenidine. Autophagy is an essential component of development and autophagy mutants exhibit 
divergent lifespans. Furthermore, the effects of rilmenidine on lifespan are measured from adulthood, so 
thus the inhibition of autophagic machinery is best done via RNAi using a feeding protocol (see 
chapter2.8.2) that allows knockdown commencement from adulthood (Meléndez et al., 2008). Selection 
of autophagy genes to knockdown is also important to ensure complete coverage of the pathway. Using 
the Ahringer library, E.coli strains transformed with either the plasmids CUUkp3301P034Q (lgg-1) or 
CUUkp3303WT 02Q (bec-1) were used to knockdown different stages of the autophagy pathway as 
performed in previous research (Schmeisser and Parker, 2018; Seo et al., 2018). Bec-1 is involved in the 
vesicle nucleation, whereas, lgg-1 participates in vesicle elongation (Meléndez and Levine, 2009). 
Knockdown by dsRNA was validated by measuring autophagy inhibition of vKEx1093(nhx-
2::mCherry::lgg-1) worms in the presence of rapamycin rather than RT-PCR; a decision based on 
previous methods (Figure 21D) (Miedel et al., 2012; Pietrocola et al., 2018; Schipanski et al., 2013) . 
Knockdown of bec-1 RNAi modestly decreased the lifespan of WT worms as previously demonstrated 
(Figure 21A) (Jia and Levine, 2007). Given the necessity for live E.coli to be used in RNAi experiments, 
concerns were raised that live bacteria may metabolise rilmenidine and reduce its bioavailability. 
Nevertheless, worms treated with a prolongevtiy dose (200µM) of rilmenidine from adulthood on plates 
seeded with live HT115 vector E.coli continued to demonstrate a significant 8% lifespan extension (log 
rank; adj. p=1.40E-05). It is likely the lessened prolongevity effect is due to some degree of bacterial 
metabolization as referenced in other pharmacological intervention studies (Zheng et al., 2013). 
Importantly, bec-1 RNAi prohibited lifespan extension in WT worms treated with a prolongevity dose 
(200µM) of rilmenidine, and treated worms exhibited similar lifespans to bec-1 RNAi WT  worms (log 
rank; p=1). 
Lgg-1 knockdown alone significantly reduced lifespan in WT  worms as previously reported (Hashimoto 
et al., 2009b; Schmeisser and Parker, 2018). As demonstrated in bec-1 knockdown, lgg-1 RNAi 
178 
 
prohibited lifespan extension in WT worms treated with a prolongevity dose (200µM) of rilmenidine, and 
treated worms exhibited similar lifespans to lgg-1 RNAi WT  worms (log rank; adj. p=0.482) (Figure 21B). 





Figure 21. Inhibition of autophagy abrogates the prolongevity effect of rilmenidine. Survival curves of WT  
animals fed either HT115 E.coli expressing an empty vector or HT115  E.coli  expressing  (A) bec-1 dsRNA (B) 
lgg-1 dsRNA from day 1 adulthood in the presence or absence of 200µM rilmenidine. C) Quantification of mean 
lifespan (days) and % change in WT  worms under different RNAi and rilmenidine treatment.  Statistical 
analyses performed using the log-rank test and Bonferroni correction against pooled data of 3 independent 
trials. N>150 worms per pooled condition. Rilmenidine significantly increased lifespan by 8.29% in WT  
animals fed HT115 E.coli expressing an empty vector (p<0.001), however failed to significantly affect lifespan 
in worms fed HT115  E.coli  expressing  bec-1 or lgg-1 dsRNA; n/s = p>0.05). D) quantification of RNAi 
knockdown validation. Adult vKEx1093(nhx-2::mCherry::lgg-1) worms were fed either HT115  E.coli 
expressing an empty vector or HT115  E.coli  expressing bec-1 dsRNA lgg-1 dsRNA from day 1 adulthood in 
the presence or absence of an autophagy inducing dosage of rapamycin (100µM). After 3 days the no. of 
visible lgg-1::mcherry puncta were counted in at least 12 worms across 3 independent trials. Bec-1 and lgg-1 
RNAi significantly reduced the number of lgg-1::mcherry puncta in rapamycin-treated worms (Kruskal-Wallis; 




6.2.3. Rilmenidine Attenuates PolyQ Aggregation 
One important hallmark of neurodegenerative diseases is the accumulation of protein aggregates, which 
should typically be degraded via autophagy. Age-related protein aggregation and misfolding is evident in 
routine C. elegans ageing and precipitates a pronounced, widespread decline in proteostasis, which 
some argue is a programmed event (Labbadia and Morimoto, 2014). Neurodegenerative diseases are 
therefore often symptomatic of an accelerated functional decline during ageing. As such, researchers 
have been continually using models of neurodegeneration in C. elegans to elucidate molecular aspects 
of disease. The inexorable tie between proteostatic collapse and ageing means many interventions that 
extend lifespan in worms also alleviate phenotypes of aggregative transgenic worms (Devagi et al., 2018; 
Keowkase et al., 2018; Kim et al., 2019; Marcellino et al., 2018; Negi et al., 2017; Zhang et al., 2012). 
Moreover, researchers often demonstrate that potential pro-longevity compounds upregulate autophagy 
alongside a conferred amelioration of aggregation phenotypes in worms, whilst also increasing lifespan 
in wild-type worms (Boasquívis et al., 2018; Denzel et al., 2014).  
As introduced in this chapter, rilmenidine has already been shown to alleviate neurodegenerative 
phenotypes in a mouse model of Huntington’s disease through a autophagy driven attenuation of 
polyglutamine expansions (Rose et al., 2010). It thus seemed logical to utilise a similar model in C. 
elegans to observe in-vivo attenuation  of PolyQ aggregations which could demonstrate the autophagy 
upregulated by rilmenidine was indeed productive and not an idiosyncratic off-site artefact. Differing 
dosages of rilmenidine (200,300,400µM) were administered to L1 transgenic polyQ model AM141, which 
expresses polyQ40::YFP fusion proteins in body wall muscle cells and shows a discrete fluorescent 
aggregate phenotype when reaching adulthood (See chapter 2.9.5). Rilmenidine, at all treatments 
significantly delayed the accumulation of YFP aggregates, but by 96h, aggregates matched that observed 





Figure 22. Reduction of polyQ40 aggregation by differing rilmenidine concentrations in C. elegans 
AM141. (a) Fluorescent micrographs of AM141 nematodes expressing polyQ40::YFP in body-wall muscle cells 
at the indicated times and  treatment for L1. Scale bars = 100µm.  B) quantification of Q40::YFP aggregates per 
entire nematode after treatment with differing rilmenidine concentrations for the indicated times from L1. At least 
30 worms were quantified for each treatment and time-point across 3 independent trials. Data represented as the 
pooled mean no. aggregates per worm. Error bars are ±S.E.M. Significance derived from 2-way repeated 




Table 10.  Differences in mean and maximum lifespan of different C. elegans genotypes exposed to 
various perturbations relative to the control within the same sets of trials.  Mean lifespan in days is the 
pooled mean of treatment cohort and the standard error (± S.E.M). Maximum lifespan defined as the day at 
which 90% cohort mortality was reached.  Lifespan assays performed at 20 °C. Adjusted p-value was determined 
by log-rank test using the Kaplan-Meier survival analysis and subsequent bonferonni correction.  Pooled n = 
number of deaths observed across all respective trials. 













WT                
1% DMSO 109 3 22.07 0.5 N/A 28 N/A 
Rilmenidine (200µM) 150 3 30.05 0.61 36.16 39 0.00E+00 
Rapamycin (100µM) 223 3 27.35 0.49 23.92 39 0.00E+00 
Rilmenidine and Rapamycin 231 3 28.28 0.5 28.14 39 0.00E+00 
WT                
1% DMSO    268    4    23.67       0.32    n/a    32      
Rilmenidine (200µM) 119 3 27.37 0.53 16.6 36 5.40E-08 
Forskolin (100µM)    272    3    20.18       0.43    -14.74    32    0.0014 
cAMP (5mM)    165    2    21.19       0.36    -10.48    27    5.20E-06 
DDE (1mM)    81    1    26.73       0.65    12.9    36    2.60E-05 
Rilmenidine and Forskolin    275    3    22.38       0.40    -5.45    32    1 
Rilmenidine and cAMP    154    2    23.12       0.37    -2.32    29    1 
DDE and Forskolin    123    1    18.76       0.38    -20.74    25    0.00E+00 
DDE and cAMP    156    1    19.09       0.22    19.35    22    0.00E+00 
eat-2               
1% DMSO    102    2    27.33       0.71    N/A    35    N/A 
Rilmenidine (200µM)    120    2    22.57       0.56    -16.94    33    2.90E-08 
aak-2               
1% DMSO    281    2    26.54       0.33    N/A 34 N/A 
Rilmenidine (200µM)    465    2    27.98       0.34    5.43 39 0.0001 
daf-15 (+/-)               
1% DMSO    34    2    24.56       0.95    N/A    32    N/A 
Rilmenidine (200µM)    31    2    23.26       0.88    -5.29    30    1 
Rapamycin (100µM)    49    2    22.43       0.86    8.67    27    0.9 
daf- 16               
1% DMSO 766 4 19.37 0.21 N/A 27 N/A 
Rilmenidine (200µM) 716 4 18.59 0.22 -4.03 27 0.15 
RNAi w/WT                
Empty Vector 244 3    28.01       0.35    N/A 36   
Empty Vector and Rilmenidine 
(200µM) 
240 3    30.33       0.39    8.28 39 4.80E-06 
bec-1 and 1% DMSO    225    3    26.82       0.35    -4.25 34 0.0325 
bec-1 and Rilmenidine (200µM)    189    3    26.22       0.43    -6.39 34 0.0252 
lgg-1 and 1% DMSO 298 3 25.82 0.28 -7.82 32 6.60E-07 




Figure 23. Induction of autophagy by rilmenidine is independent of cAMP signalling. Well-fed day 2 adult 
transgenic animals, expressing the intestinal specific autophagy reporter gene (Pnhx-2mCherry::lgg-1), were 
exposed to rilmenidine or a 1% DMSO vehicle for 24h in the presence or absence of cAMP accumulation by 
forskolin (500µM) or exogenous cAMP (5mM). Worms were immobilized and mounted onto glass slides in 20mM 
tetramisole prior to imaging at x10 objective on a Zeiss Axio Observer with a 150ms exposure. Graph shows the 
interquartile distribution of mean number of mCherry::LGG-1 puncta in the posterior intestine of the animals in 
each condition. Error bars, upper:Q3 + 1.5*IQR; minimum: Q1 -1.5*IQR.  mCherry::LGG-1 puncta were counted 
in each of three rectangular boxes of 1mm2; they were placed in tandem beginning with the most posterior region 
of the intestinal and extended toward the vulva; mean number per mm2 was calculated for each animal.   N>25 
animals analysed per treatment in at least 2 independent trials. **P<0.01, *P<0.05; one-way ANOVA followed by 




6.2.4. Rilmenidine Increases Autophagy Independent of cAMP Signalling   
Williams et al. have previously posited that rilmenidine upregulates autophagy in-vitro through the 
reduction of cAMP (Williams et al., 2008). This furthers preceding evidence that rilmenidine and other I(1) 
receptor-selective imidazolines decrease forskolin-stimulated cAMP level in PC12 cells (Greney et al., 
2000). Forskolin is a naturally occurring diterpene compound that has been shown to directly activate 
adenylyl cyclase (AC): an enzyme responsible for the conversion of adenosine triphosphate into cAMP 
(reviewed in Insel and Ostrom, 2003). As such, forskolin is frequently used in-vitro and in-vivo to increase 
intracellular cAMP levels (Greney et al., 2000; Urosevic et al., 2004). In 2008, Williams et al., posited that 
if rilmenidine cleared synuclein, and forskolin worsened clearance, rilmenidine must increase autophagy 
via cAMP reductions. Furthermore, exogenous cAMP supplementation produced a comparable 
worsening of synuclein aggregation to forskolin (Williams et al., 2008). This was validated by the 
observation that 2',5'-Dideoxyadenosine (DDA), an adenyl cyclase inhibitor, could effectively clear 
synuclein and increase autophagy proportional to rilmenidine (Williams et al., 2008). Downstream, it is 
hypothesised that decreased cAMP prohibits increased IP3 generation by PLCε-mediated hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2): this reverses the homeostatic IP3 mediated mobilisation of 
ER Ca2+ stores that inhibit autophagy (Renna et al., 2010). 
To assess whether rilmenidine-induced autophagy was mediated by cAMP levels, an extension of 
William’s reductionist approach was employed. In theory, rilmenidine should increase C. elegans 
autophagy whilst forskolin should not increase autophagy. Moreover, if rilmenidine signals through the 
downregulation cAMP levels, the enzymatic increase of cAMP production by forskolin should block 
autophagy signalling by rilmenidine - and this effect should be mirrored by exogenous cAMP 
supplementation. Throughout this thesis, drugs have been administered by dissolving them in NGM agar. 
To continue that approach, it was necessary to find an appropriate dosage using an NGM medium, to 
effectively and non-toxically increase cAMP levels by forskolin or exogenous cAMP. Fortunately, this 
method has been employed elsewhere. Liu et al., (2017) added 500µM of forskolin to NGM or 5mM 
exogenous cAMP to rescue cAMP reduction caused by cold stress in C. elegans. Accordingly, that 
dosage seemed appropriate and was followed hereafter.  
vKEx1093(nhx-2::mCherry::lgg-1) worms were assessed for puncta accrual in response to alteration in 
cAMP levels as previously described (see chapter 2.8.1). First, it was re-established that rilmenidine at a 
prolongevity dose (200µM) increases autophagy in vKEx1093 worms (One-way ANOVA adj. p<0.008) 
(Figure 23). Forskolin and cAMP both modestly increased median punta accrual, 1.22 fold and 2 fold 
respectively, however this failed to reach significance when corrected for multiplicity (One-way ANOVA; 
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FOR adj. p=0.12, cAMP adj. p=0.90). Strikingly, co-administration of rilmenidine with forksolin, failed to 
abrogate the autophagy inducing effects of rilmenidine, and FOR+RIL increased no. of mCherry::LGG-1 
positive puncta by 3 fold (Figure 23) (One way ANOVA; 1%DMSO vs. FOR+RIL p=0.01). This effect was 
replicated through cAMP treatment. Transgenic vKEx1093(nhx-2::mCherry::lgg-1) worms treated with 
exogenous cAMP did not demonstrate any statistical difference in no. of mCherry::LGG-1 positive puncta, 
whereas rilmenidine and cAMP combination significantly increased no. of mCherry::LGG-1 positive 
puncta (One way ANOVA; 1%DMSO vs. cAMP p=0.9; 1%DMSO vs. cAMP+RIL p=0.001) (Figure 23). 
Together these results provide evidence that rilmenidine increases autophagy independent of cAMP, 
contrary to previous hypotheses.  
A wealth of previous evidence has inexorably tied rilmenidine to downregulation of cAMP: Rilmenidine 
and other imidaozline receptor agonists have been shown to reduce cAMP levels alone, to reduce 
forskolin-stimulated cAMP levels in cell culture and inhibit isoproterenol stimulated cAMP accumulation 
in rabbit iris-ciliary bodies (Chu et al., 1996; Edwards et al., 2012; Urosevic et al., 2004) . However as 
demonstrated in this chapter, this does not necessitate its involvement in rilmenidine induced autophagy. 
Nevertheless, the downregulation of cAMP may still be essential to the pro-longevity effect of lifespan, 
independent of autophagy. Thus, if homeostatic cAMP levels normally seen in OP50 fed WT worms were 
disrupted to abnormal levels, it should cause significant difficulty for rilmenidine to increase lifespan if 
mediated through cAMP. In replication of the autophagy experiments, cAMP levels were increased by 
500µM forskolin administration to lifespan assay plates on which adult WT  worms were assayed for 
survival. It would be reasonable to assume that forskolin integrity and concentration within the agar would 
diminish throughout the assay. However, forskolin addition produced a crystallization effect in the NGM 
indicative of its presence which could be monitored for bioavailability throughout the experiment. 
Forskolin addition to plates, significantly reduced WT  lifespan by 15% (log rank; adj. p=0.001) (Figure 
24A). Interestingly, co-treatment with rilmenidine was able to rescue the forskolin induced lifespan 
phenotype which corresponded to statistically indifferent lifespan to WT  worms fed a 1% DMSO vehicle 
(log rank; adj. p=1). To assess whether this rescuing was due to a refraction of forksolin induced cAMP 
levels by rilmenidine and not an off-site toxicity mediated by forskolin, we exogenously increased cAMP 
levels using 5mM cAMP. As expected, results were reflected and cAMP significantly reduced WT lifespan 
which was rescued by rilmenidine combination (log rank test; DMSO vs cAMP p<0.001; DMSO vs. 
cAMP+RIL adj. p=1) (Figure 24B). This presented an interpretive dilemma: was rilmenidine actually 
normalising cAMP levels or merely extending lifespan independently of cAMP signalling? To answer this 
question, the adenyl cyclase inhibitor DDE was co-administered to forskolin and cAMP treated worms to 
definitely normalise cAMP, using dosages previously used to do so (Müller et al., 2015). DDE failed to 
186 
 
rescue both forskolin and cAMP lifespan phenotypes, and in fact shortened lifespan further than just 
forskolin or cAMP by -7 and -10% respectively (log rank; FOR vs. FOR+DDE p=0.02; cAMP vs. 
cAMP+DDE p=1.00E-07) (Figure 24C,D). Lastly, to confirm that this was not due to inappropriate dosing 
of DDE and subsequent toxicity, WT  WT worms were treated with DDE. WT  WT lifespan was increased 
12.9% by DDE (log rank; adj. p<0.001), confirming no toxicity and assisting in the conclusion that 





Figure 24. Rilmenidine- Induced Lifespan Extension is Independent of cAMP Signalling. A+B) Pooled 
survival curves of adult WT  worms fed UV-killed OP50 also treated with Rilmenidine (200µM) and Forskolin 
(500µM)/cAMP (5mM) independently, or in combination, compared to control animals treated with a 1% DMSO 
vehicle. C + D) Survival curves of WT  adult worms treated with 1mM DDE in the absence or presence of 
cAMP or Forskolin.Kaplan Meir survival analysis performed on pooled data from 3  independent trials in no 
less than 100 animals per condition. Groups tested by Log-rank with Bonferonni correction; p<0.05 
considered significant; detailed analysis available in table. E)  mean lifespan (days\ of cohorts of WT  
animals derived from survival curves represented in A,B,C and D. Error bars represent SEM; adjusted p -
value derived from log-rank test and Bonferroni correction. F Schematic diagram of rilmenidine increasing 
lifespan independently of cAMP signalling. On the right panel, forskolin activates ACY-1 to increase cAMP 





This thesis thus far has unravelled an intriguing relationship between dietary restriction and rilmenidine 
that appears associative yet unmasked. Rilmenidine can indeed increase lifespan and induce gene 
expression changes in functions also affected by CR. Similarly, protection against environmental stresses 
by CR are mirrored in rilmenidine treatment that be involved in the observed improvement in a loosely 
defined metric of “healthspan”. Therefore, the candidacy of rilmenidine as a CRM required definitive 
testing.  
Epistatic interactions between rilmenidine and CR in the form of reduced swallowing capacity (eat-2) 
demonstrated the inability of rilmenidine to extend lifespan in an additive manner; instead, rilmenidine 
doses that normally benefit wild-type were actually deleterious to eat-2, possibly through a hyper-
induction of CR signalling. Downstream genetic signalling pathways of CR, AMPK, DAF-16 and TOR, 
contributed to the ability of rilmenidine to extend lifespan, although AMPK was not critical to the pro-
longevity effect. Given that both AMPK and TOR converge on autophagic pathways, it seemed sensible 
to test autophagy in worms treated with rilmenidine, especially given previous evidence showing mice 
treated with rilmenidine have increased autophagy (Rose et al., 2010). Reassuringly, rilmenidine not only 
increased autophagy in a dose-dependent manner, but it demonstrated functionality by improving the 
clearance of polyglutamine expansions. Furthermore, functioning autophagic machinery was essential to 
rilmenidine lifespan increases, suggesting the vast majority of rilmenidine’s geroprotective properties are 
derived from increased autophagy, similar to that observed by CR. Lastly, a previously proposed cAMP 
dependent mechanism was tested for its necessity for rilmenidine induced autophagy and longevity. 
Indeed, rilmenidine was able to increase lifespan and autophagy in spite of severe cAMP aberrations 
casting new doubt on how rilmenidine might increase autophagy.  
This chapter started by administering a prolongevity dose of rilmenidine to eat-2 worms. It was 
hypothesised that worms already undergoing geroprotective CR could not experience further longevity 
gains by rilmenidine; a hypothesis tested in myriad publications qualifying the CRM candidacy of their 
own compounds (Calvert et al., 2016; Kim et al., 2018; Onken and Driscoll, 2010; Shintani et al., 2017 - 
to reference a pertinient few). In a similar response to that elicited by metformin, rilmenidine actually 
significantly shortened eat-2 lifespan (Onken and Driscoll, 2010). This is an intriguing result which 
suggests rilmenidine may mimic CR so directly, that it sends CR signals already upregulated in eat-2 into 
overdrive, eliciting a deleterious “extreme CR response” (Gillespie et al., 2016). Indeed, extreme calorie 
restriction, as seen in the Minnesotta Starvation Experiment as well as in Anorexia Nervosa patients, 
increases mortality risk as well as causing chronic weakness and reduced aerobic capacity (Most et al., 
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2017). However, humans cannot delve into a Dauer response which should have theoretically formed, 
but did not, following metabolic shutdown from both rilmenidine and metformin.  
When rilmenidine pro-longevity was assessed in key genetic pathway mutations of DR, a more modest 
response was found. Rilmenidine did significantly increase lifespan in aak-2 mutants however this was 
far more nuanced than that seen in WT, suggesting that AMPK activation, as in CR, likely contributed to 
the prolongevity effect of rilmenidine – although this should be clarified by protein phosphorylation 
studies. Research suggests that several CR regimes, including eat-2 models, similarly don’t require aak-
2 for their pro-longevity effect (Greer et al., 2007). However, rilmenidine lifespan extension was entirely 
dependent on normalised TOR function (whether that be pharmaceutically or genetically downregulated), 
implying that rilmenidine signalling likely converged on TOR to elicit most of its geroprotective properties. 
How rilmenidine might interact with TOR remains to be seen. Given that rilmenidine also required daf-16 
to elicit lifespan extension it is possible that rilmenidine causes TOR inhibition leading to daf-16 activation 
and transcription of longevity and importantly heat-shock genes (Robida-Stubbs et al., 2012). This 
provides a potential mechanism of rilmenidine-induced geroprotection and thermotolerance. This would 
differentiate rilmenidine from rapamycin in its mechanism, which is daf-16 independent, owing to its 
interaction with TORC2 (Robida-Stubbs et al., 2012). Chronic administration of rapamycin is associated 
with activation of mTORC2 which supposedly causes detrimental effects on metabolism, including 
hyperglycaemia, hyperlipidaemia, and insulin resistance in mice, and thus if rilmenidine can precisely 
downregulate mTORC1 signalling, without affecting mTORC2 it may present a more tolerable and 
durable CRM than rapamycin (Lamming et al., 2012; Robida-Stubbs et al., 2012). Future work would 
greatly benefit from immunoprecipitation analyses of the changes in mTOR signalling elicited by 
rilmenidine. Nonetheless, these lifespan analyses provide more evidence supporting the hypothesis that 
rilmenidine is an inverse agonist to IRAS which causes an upregulation of AMPK activity and TOR 
inhibition, in line with murine IRAS-/- models (Dong et al., 2017). However, this does not explain the ability 
for rilmenidine to increase lifespan despite aak-2 mutations. Hence, it is also reasoned that rilmenidine 
may have dual roles, and it may also interact with IRAS or f13e9.1 to increase tumour suppressive 
interaction with LKB1 and reduce TOR activity (Jain et al., 2013; Shaw et al., 2004).  
Given that rilmenidine seemingly signalled through dietary restriction pathways, it was rationed that it 
might increase autophagy. In-vitro and murine work has confirmed rilmenidine can induce autophagy, 
however this has never been conceived in C. elegans or in the ageing arena (Perera et al., 2018; Rose 
et al., 2010). Accordingly, rilmenidine increased autophagy in a dose-dependent manner. This is 
important because prolongevity doses of rilmenidine did not increase autophagy as much as larger toxic 
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and potentially progeroid doses. Whilst plenty of evidence has demonstrated autophagy induction to 
increase a multitude of ageing markers, it represents a sharp double-edged sword, whereby overactive 
autophagy may actually precipitate cellular pathology  (Benedetto et al., 2019; Benedetto and Gems, 
2019; Kubli and Gustafsson, 2014; Qiu et al., 2018; Rubinsztein et al., 2011). Hence dosages around 
200µM provides a beneficial upregulation, but dosages exceeding 300µM may induce pathological 
amounts of autophagy. Dosages of 200µM rilmenidine were tested for autophagic induction in the 
presence of the imidazoline receptor blocker efaroxan. Again, mirroring lifespan experiments, efaroxan 
increased autophagy in C. elegans, but critically differed in the fact rilmenidine and efaroxan 
synergistically increased autophagy to levels higher than rilmenidine or efaroxan alone. This result defied 
expectation and previous lifespan and imidazoline binding site mechanisms elucidated in this study. 
Unfortunately, it is seemingly assumed amongst the scientific community that rilmenidine increases 
autophagy dependent on an imidazoline receptor, and as such no literature exists testing this hypothesis. 
Given that rilmenidine is a highly specific imidazoline receptor agonist it is highly unlikely an ulterior 
binding would elicit such marked cell changes. A plausible explanation lies in the duplicity of efaroxan 
being a ligand for both imidazoline and α2‐adrenergic receptors (Lehner et al., 2012). Efaroxan and its 
analogue, idazoxan (also with the same duplicity)  were recently shown to increase autophagy in murine 
macrophage cell-lines (Nakagawa et al., 2018). The authors suggested this autophagic induction was 
independent of the imidazoline receptor, albeit based on a single read out of downstream Jun activity. 
Activation of the α2‐adrenergic receptors also been associated with increased autophagy and it is 
reasonable to inductively deduce that efaroxan may increase autophagy via α2‐adrenergic binding rather 
than imidazoline receptor binding (Han et al., 2018; Oh et al., 2019). Furthermore, whilst efaroxan 
significantly attenuated rilmenidine induced ERK activation in chapter 4, signalling remained more 
elevated with combination rather than efaroxan mono-treatment, suggesting efaroxan may have only 
partially blocked the IBS. Together, efarxoan may increase autophagy via α2‐adrenergic binding but only 
partially block the IBS such that rilmenidine might still modestly upregulate autophagy, leading to an 
additive autophagic effect. Nonetheless, establishing the necessity of an IBS for autophagy induction by 
rilmenidine is critical. It would perhaps be advisable to cross f13e9.1 mutants with vkEx1241 transgenic 
mCherry::LGG-1 strains to identify possible abrogation of autophagy induction by rilmenidine in f13e9.1 
-/- reporter strains. 
In assessing the functional relevance of autophagic induction, it was shown rilmenidine attenuated the 
build-up of polyglutamine expansions in a transgenic overexpression C. elegans model. This reconfirms 
evidence from Huntington’s disease mouse models showing rilmenidine to attenuate in-vivo 
polyglutamine expansions (Rose et al., 2010).  Furthermore, this adds to a catalogue of evidence 
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demonstrating rilmenidine to clear age-associated pathological protein aggregates including synuclein, 
misfolded forms of SOD1, TARDBP, tau, as well as poly-q aggregates and implicates rilmenidine as a 
robust autophagy inducer with a capacity to mitigate a number of age-associated proteinopathies 
(Moreau et al., 2014; Perera et al., 2018; Williams et al., 2008). Loss of proteostatsis, represents a 
conserved hallmark of ageing across species including C. elegans (Ben-Zvi et al., 2009; López-Otín et 
al., 2013).  Additionally, loss of proteostasis underlies the onset of many diseases of ageing, including 
neurodegenerative diseases, meaning the deferment of its collapse is critical for maintaining disease-
free living into later life. As such, when evaluating potential compounds for “healthspan” benefits, 
researchers are keen to utilise the genetic tractability of C. elegans to assess resistance to acute 
perturbation of proteostasis (Boasquívis et al., 2018; Denzel et al., 2014; Rollins et al., 2017). Thus, the 
clearance of toxic aggregates by rilmenidine serves not only as a demonstration of autophagic efficiency, 
but as an additional marker of health-span preservation alongside the attenuation of locomotory decline 
and improved thermotolerance.  More recently, however, researchers have begun querying the 
phenotypical consequences of rilmenidine-induced autophagy. Whilst, Rose et al. (2010) found an 
attenuation of symptoms in their murine Huntington’s model, other researchers have found rilmenidine to 
exacerbate neurodegenerative phenotypes in SOD1 mutant mice (Perera et al., 2018). Furthermore, 
when under proteostatic challenge by either chloroquine or aggregative protein models, lysosomal 
efficiency following autophagy induction by rilmenidine appears dysfunctional (Button et al., 2017; 
Civiletto et al., 2018). Thus, particularly in geriatric populations, whom are likely burdened with sub-clinical 
or overt aggregative phenotypes, the potential contraindications could limit the translative potential of 
rilmenidine (Serrano-Pozo et al., 2011).  
The results demonstrate not only the presence, but the necessity of functional autophagy for rilmenidine 
to extend lifespan. This study followed a similar schema to that implemented by Hansen et al. (2008) 
when assessing the same dependency in dietary restriction. Utilising the practical RNAi feeding method 
(see chapter 2.8.2), Hansen et al. (2008) knocked down autophagic function using dsRNA against bec-1 
and vps-34. Given the role vps-34 has in endocytic cargo transport, a  function shared by IRAS, it was 
decided the autophagy-specific gene lgg-1 should be used, as in other studies (Jia et al., 2009; 
Samokhvalov et al., 2008). Knockdown of these genes prevented rilmenidine from extending lifespan 
supporting the hypothesis that rilmenidine mimics dietary restriction in the geroprotective upregulation of 
autophagy. Disrupting autophagy genes from adulthood does not perturb other phenotypes normally 
associated with dietary restriction, including morphological, spectrofluorimetric or reproductive changes, 
and whilst it is likely this is replicated in rilmenidine-treated worms, this cannot be ruled out (Hansen et 
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al., 2008). Nonetheless, it is likely autophagy is specifically required for the prolongevity benefits of 
rilmenidine, and upregulated autophagy defers the proteostatic collapse in C. elegans ageing.   
Finally, this chapter sought to establish a mechanism elicited by rilmenidine to signal an increase in 
autophagy in C. elegans. It has been tentatively proposed that in-vitro, rilmenidine upregulates autophagy 
by reducing intracellular cAMP levels, prohibiting IP3 mediated Ca2+ release from the ER (Renna et al., 
2010). Indeed, it is mechanistically proven that in-vitro, rilmenidine can reduce both basal and forskolin-
stimulated cAMP levels (Greney et al., 2000). Thus it is logical to hypothesise, rilmenidine may increase 
autophagy via downregulation of cAMP signalling in C. elegans as well. However, a direct mechanistic 
link between cAMP modulation and autophagy induction by rilmenidine has never been proven. In this 
thesis, pharmacologically increasing levels of cAMP with either exogenous cAMP or forskolin, did not 
prohibit the ability of rilmenidine to increase autophagy levels indicating that rilmenidine acts 
independently of the cAMP pathway to upregulate autophagy. There is a possibility that the remissive 
properties of rilmenidine outweighed the augmentation by either cAMP or forskolin. However, these 
experiments were performed at the lowest autophagy inducing concentrations of rilmenidine and 
furthermore, the degree of autophagic induction was proportional in cAMP/forskolin treated worms to 
control worms. Of course, confirmative quantification of cAMP levels would be preferential, however, this 
is precluded in the notoriously difficult and noisy C. elegans (Kashyap et al., 2014).  
Given that autophagy is critical to lifespan extension by rilmenidine, prohibition of the requisite signalling 
by forskolin or cAMP supplementation, should abrogate any lifespan extension. However, it was also 
found that rilmenidine increased lifespan independently of cAMP levels. This corroborates our autophagy 
results to support the likelihood that rilmenidine increases autophagy through a cAMP independent 
mechanism. As rilmenidine and forskolin (or cAMP) co-administration did not significantly affect WT 
lifespan, it can be assumed any increases in autophagy observed during cotreatment were legitimately 
beneficial and not responses to toxicity manifesting in autophagy mediated survival and apoptotic 
response.  
However, the explicit confirmation of mTOR independent autophagy induction by rilmenidine is lacking 
specifically in C. elegans. Further work is needed to establish whether rilmenidine inhibits Ce.TOR 
leading to autophagy induction. This would provide a sophisticated pathway demonstrating rilmenidine to 
inhibit ceTOR leading to autophagy induction and lifespan extension. Conversely, it is possible that 
ceTOR is required for alternative pathways necessary for longevity that depend of autophagy. For 
example, rilmenidine may not only clear cellular waste, but help in the generation of new raw material for 
protein synthesis that requires functioning ceTOR.  Taken together, it can be concluded that rilmenidine 
193 
 
mimics genetic dietary restriction and the key CR nexuses, ceTOR, AMPK and daf-16 function in the 
prolongevity effect of rilmenidine. Furthermore rilmenidine increases autophagy in C. elegans 
independent of cAMP, which is necessary for its prolongevity effect. However it is not possible to 
conclude, at present, which pathway rilmenidine signals through to induce autophagy, but it is likely the 




7. Conclusions  
7.1. Rilmenidine Is Likely A Calorie Restriction Mimetic 
Ageing is, by definition, a time-dependent increase in disease susceptibility and mortality. However, 
despite its universality, and clear perceptibility, it remains the most elusive and least well-understood 
aspect of human biology (Kirkwood, 2005). I have argued herein that ageing should be considered a 
disease which routinely imparts dramatic physiological and psychological suffering. The ageing process 
imposes limitations and reductions in liberty through enfeeblement, frailty and pathology and thus, a 
failure to advocate and fund scientific research into ageing not only violates one’s right to health but 
prevents the translation of immediate strategies urgently needed to curtail growing healthcare costs and 
late-life suffering. However, the deceleration of ageing that provides protection against the full spectrum 
of diseases of ageing thereby assuring late-life health extension, unfortunately comes with an incidental 
corollary of increased lifespan. With that said, the propensity of moderate lifespan extension strategies 
to outspread health through a suppression of age-related pathology already exists and the pursuit of its 
viable translation fascinates many leading scientists in the field.  
At present, calorie restriction offers the most feasible and robust intervention to decelerate ageing.  
However, as highlighted, several concerns surrounding the applicability, tolerability and safety of calorie 
restriction currently precludes its adoption. Thus, the search for a viable alternative that could recapitulate 
the phenotype of calorie restriction without dietary implementation has greatly accelerated in the last 
decade. Calorie restriction mimetics have led the way in easily translatable alternatives with two 
compounds at the forefront. Both rapamycin and metformin have shown promise and at least 
demonstrated potential in mimicking the geroprotective properties of CR. However, they both come with 
substantial criticism: metformin may provide a still unsubstantiated pleotropic effect whilst rapamycin 
appears to aggressively downregulate one pathway associated with CR. Thus, much work is still required 
to identify compounds which provide a safe and tolerable profile that extends lifespan and healthspan in 
a manner similar to CR.  
I set out to identify and conduct an introductory exploration into the repurposing of a clinically approved 
drug for the deceleration of ageing and compression of morbidity mediated through a mimicry of calorie 
restriction. It should bypass the pleiotropy of CR to modulate specific downstream pathways of CR in a 
hope it might provide a more precise and directed evocation of the beneficial aspects of CR without any 
adverse associations. Furthermore, when assessing the validity of a compound as a CRM it must also 
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activate stress response pathways, provide protection against stressors and lead to a preservation of 
healthspan (Ingram et al., 2006). 
In the knowledge that allantoin, a weak imidazoline receptor agonist, could increase lifespan in WT  
worms but not in eat-2, it was hypothesised that more specific imidazoline receptor agonists such as 
rilmenidine might possess prolongevity qualities. Transcriptomic analysis revealed rilmenidine gene 
expression to share significant connectedness to a number of age-related gene signatures. Moreover, 
rilmenidine gene expression significantly opposed ageing signatures, such that rilmenidine treatment 
seemingly rescued age-associated hyperfunctional over-expression that was enriched for immune 
response, inflammation and extra-cellular matrix function. Whilst the transcriptome of rilmenidine 
treatment lacked direct overlap with any assessed CR signatures, gene lists from both CR and rilmenidine 
were both functionally enriched for inflammation and extra-cellular matrix integrity. The American 
Academy of Anti-Ageing medicine, as written by Holt (2011), defines a calorie restriction mimetic as “a 
pharmaceutical…which has the ability to reproduce one or more of the principal biological effects of 
calorie restriction” and the reduction of inflammation and modulation of metabolism expression represents 
two of those effects. To that end alone, rilmenidine mimics calorie restriction, however, this thesis seeks 
to repurpose rilmenidine as an intervention to decelerate ageing and compress morbidity. 
The most comprehensive and well-cited definition and criteria for a calorie restriction mimetic was 
established in 2006 by Donald Ingram et al. (Ingram et al., 2006; Ribarič, 2012; Testa et al., 2014). 
Therein, he requested all CRMs should fulfil the following: 1) extend life span and reduce or delay the 
onset of age-related diseases, 2) activate stress response pathways observed in CR and provide 
protection against a variety of stressors similar to CR 3) elicit metabolic, hormonal and physiological 
effects similar to CR. 4) not require a significant reduction in long-term food intake. Lastly, researchers 
have called for autophagy induction capacity to be an essential component of CR mimicry and thus it 
should be assessed when analysing the candidacy of rilmenidine  (Madeo et al., 2019).  
Firstly, rilmenidine extended lifespan in C. elegans not only when administered from early adulthood but 
also when the ageing process was already considerably advanced. Lifespan extension, when 
commenced from early adulthood was comparable to that observed through the treatment of C. elegans 
with metformin or rapamycin (Onken and Driscoll, 2010; Robida-Stubbs et al., 2012). Furthermore, 
rilmenidine delayed the onset of frailty in C. elegans as measured by the well-established surrogate 
marker, locomotory decline. Additionally, rilmenidine was able to delay the rate of poly-q aggregation in 
a transgenic worm model. Indeed, both the locomotory assay and the transgenic polyQ model used 
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herein have been assessed previously in response to CR and found to be ameliorated as a result (C. 
Huang et al., 2004; Lüersen et al., 2014; Moroz et al., 2014; Raynes et al., 2012).  
Secondly, rilmenidine was able to improve stress resistance, specifically acute thermotolerance. Survival 
from stress is one of the key suggestions by Ingram to infer CR candidacy (Ingram et al., 2006). Whilst 
rilmenidine failed to improve oxidative stress, novel research has suggested that oxidative stress 
resistance may be dispensable for increased lifespan and is uncorrelated to longevity in C. elegans 
(Benedetto et al., 2019). Moreover, debate still exists in literature regarding the way in which CR may 
modulate oxidative stress in conferring lifespan extension. Although diet-restricted worms show 
increased oxidative stress resistance, knockout of antioxidant capacity does not reduce lifespan in two 
different types of DR. This suggests that enhanced antioxidant defence may not be essential for DR-
induced longevity. Conversely, in eat-2 models of CR, a functioning heat-shock response is indispensable 
for longevity effects  (Hsu et al., 2003). It must be noted that activation of key stress response pathways 
was not assessed in this thesis, and thus, at present, rilmenidine cannot be deemed to activate key stress 
response pathways and does not entirely meet the second clause of the CRM criteria. Nonetheless, this 
research highlights the indispensability of daf-16, a key stress pathway modulator for lifespan, which 
increases the likelihood that rilmenidine induces daf-16 nuclear localisation. Future work should assess 
nuclear localisation using the well-cited daf-16::GFP reporter strain.  
Thirdly, I sought to assess whether rilmenidine signalled through key CR pathways that may affect 
conserved metabolic and physiological effects seen in CR. Whilst C. elegans is continuing to emerge as 
a useful model to assess physiological metabolism, the primary utility of C. elegans lies in the genetic 
dissection and assessment of nutritional and metabolic signalling pathways rather than the physiological 
consequences thereafter. AMPK and TOR are two key metabolic pathways critical to DR-induced 
metabolic changes. Rilmenidine required complete functionality of both AMPK and TOR to elicit the 
extensiveness of its longevity effect, suggesting rilmenidine converged on key signalling pathways critical 
to metabolic regulation. Moreover, in the setting of global CR, rilmenidine failed to additively extend 
lifespan, highlighting a converging prolongevity mechanism between CR and rilmenidine.  It was not 
attempted in this thesis, but the exploration of fat metabolism that could be expeditiously assessed using 
Nile-red straining of fat deposits. Ingram et al (2006) also highlights the importance of modifying body 
temperature and insulin control when assessing CRM candidacy. Whilst these metrics were not assessed 
in C. elegans, mammalian evidence supports this line of enquiry. Imidazoline receptor agonists have 
been shown to reduce body temperature in mice, rats, cats, sheep and goats (Bhalla et al., 2011; Lomax 
and Foster, 1969; Maskrey et al., 1970; Thorn et al., 2012). The advocacy of imidazoline receptor 
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agonists for metabolic normalisation is decades old, yet has received little attention (Krentz and Evans, 
1998). This was based on observations that in animal models of insulin resistance, such as the fructose-
fed rat and the obese spontaneously hypertensive rat, moxonidine might also have favourable effects on 
other features of the metabolic syndrome (Krentz and Evans, 1998). Although amelioration of 
vasoconstriction is a plausible mechanism, improvements in skeletal-muscle glucose transport and 
insulin-receptor autophosphorylation with increased expression of insulin-receptor substrate-1 suggest 
direct effects on insulin action at cellular level (Krentz and Evans, 1998). This research led to more 
modernised clinical studies into the effects of common I1R agonists. Controlled double blind study over 
a 6 month period demonstrated that rilmenidine could significantly lower plasma fasting and 2-h glucose 
levels and insulin concentration after an oral glucose tolerance test in hypertensive patients with 
metabolic syndrome (Luca et al., 2000). Similarly, moxonidine improved insulin resistance as indicated 
by an increase in the glucose infusion rate and the insulin sensitivity index (Haenni and Lithell, 1999). 
More recently, 37 hypertensive non-diabetic patients were treated with rilmenidine to access potential 
metabolic improvements  (Konrady et al., 2006). A sub group were treated with atenolol. The two groups 
were treated for 26 weeks. Whilst both drugs produced similar BP reductions, the atenolol group showed 
deterioration in oral glucose tolerance whilst rilmenidine maintained healthy oral glucose tolerance 
through reducing hyperinsulinemia and hyperglycaemia.  
Fourthly, I sought to explore the propensity of rilmenidine to increase autophagy. Not only did rilmenidine 
increase autophagic induction in C. elegans, but the prolongevity benefit of rilmenidine was dependent 
on autophagy. This pattern is mirrored in eat-2 worms who require intact autophagy to extend lifespan 
(Hansen et al., 2008). However, Madeo and colleagues suggest that the criterion of mere autophagic 
induction is insufficient, and instead, CRM candidates should specifically induce autophagy via a 
reduction in protein acetylation and the inhibition of EP300 acetyltransferase activity(Madeo et al., 2019). 
Thus, further work should explore whether rilmenidine may induce such effects.  
According to Ingram and Roth, CRMs by definition, must not exert their benefit through a reduction in 
food intake and any doing so would constitute an induction of CR rather than a de facto mimicry (Ingram 
and Roth, 2015). However, this is unlikely the case as numerous reports have concluded absolutely no 
difference in body weight or food intake in animals treated with imidazoline receptor agonists including 
rilmenidine (Aubertin et al., 2019; Mukaddam-Daher et al., 2008; Parkin et al., 2016; Rose et al., 2010).  
Beyond elucidating the similarity of rilmenidine to CR to affirm its CRM candidacy, it was essential that 
rilmenidine could present an orthogonal alternative to the pleotropism of CR. The oft-cited unsuitability of 
CR in many human subpopulations is in part driven by the pleiotropic nature of CR that induces a 
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catalogue of physiological effects. The numerous and largely undefined pathways potentiated by CR, do 
of course, also involve themselves in the regulation of immunity, tissue repair, thermoregulation and 
reproduction (Le Couteur et al., 2012). Furthermore, the restriction of energy in elderly or 
immunocompromised individuals presents a significant risk for morbidity, frailty and hospitalisation. Whilst 
CRMs have sought to overcome these limitations, it is well established that, metformin and rapamycin 
both elicit adverse side-effects themselves which rilmenidine should avoid.  
Principal concerns surrounding the applicability of calorie restriction derive from observations that CR 
may lead to frailty in that unintentional weight loss is part of the frailty syndrome and also represents an 
important susceptibility trait (Fried et al., 2001). Ageing, of course, is associated with an increase in 
sarcopenia, reserve capacity diminishment, malnutrition, and hence, the addition of caloric restriction is 
likely to rapidly accelerate that process. As such, both mice and rats initiated on CR in late-life often 
demonstrate negligible effects or indeed reductions in longevity (Forster et al., 2003; Lipman et al., 1998, 
1995; Ross, 2009). Conversely, this thesis found rilmenidine treatment to elicit lifespan extension even 
when initiated in later-life after the development of age-associated phenotypes. Granted, assessments 
of “healthspan” were not made during late-life administration trials, however, lifelong treatment with 
rilmenidine significantly attenuated locomotory decline in C.elegan; a valuable surrogate frailty 
assessment. Thus, given that late-life and whole-life rilmenidine treatment yields similar lifespan gains, it 
is reasonable to assume metrics of frailty may be comparable. As evidence in this thesis suggests 
autophagy to be the driving force behind the longevity effect of rilmenidine, there is a strong likelihood 
that autophagic inductive capacity by rilmenidine is preserved during ageing. Furthermore, CR has been 
recently found to attenuate the age-related sarcopenic impairment of autophagy in rodent skeletal 
muscle, and therefore presents a possible mechanism by which rilmenidine may be able to preserve 
autophagic induction capacity into old-age and defer the development of frailty in C. elegans. This is 
supported by transcription data in this thesis showing rimenidine to promote muscle tissue regeneration. 
Clinical evidence proves imidazoline agents including rilmenidine to be tolerable and safe in elderly 
populations whilst also ineffective at changing body weight, supporting its potential implementation later 
in life and in murine models (Kirkendall, 1986; Martin et al., 2005; Nowak et al., 2005; Rose et al., 2010). 
Notably, rilmenidine did not precipitate musculoskeletal decline in old age.  
In addition, concerns have been raised regarding the immunological function of animals under CR. 
Gardner et al. (2005; 2011), in a series of papers, first provided experimental evidence that CR mice 
exhibited CR impaired responses to the influenza virus resulting in a much higher risk of mortality. These 
concerns were compounded by increased colonisation of various nematode infections following 
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inoculation in CR mouse strains, which additionally proliferated an aberrant t-cell response (Kristan, 2007; 
Shi et al., 1998). In C. elegans, harmane, an endogenous imidazoline receptor agonist, improves immune 
response and survival in pathogenic environments (Jakobsen et al., 2013). Moreover, recently, 
rilmenidine and other imidazoline receptor agonists were demonstrated to have an inhibitory effect on the 
replication of various influenza virus strains, which translated to improved survival in mice inoculated with 
lethal influenza (Matsui et al., 2018). Gene expression data derived from this thesis supports a general 
downregulation in inflammatory pathways which contributes to infection pathophysiology and may 
contribute to the improved immune function in rilmenidine-treated animals. Adjunctly, CR is associated 
with poor wound healing. In contrast, research in this thesis shows rilmenidine to upregulate genes 
associated with wound healing and regenerative processes.  
Lastly, it would be beneficial to further explore  the extent that rilmenidine mimics CR pleotropism, and 
specifically whether rilmenidine may also reduce fecundity in adulthood – a metric which was not 
measured herein. With that said, toxicological studies in mice have revealed rilmenidine to not affect 
fertility, suggesting rilmenidine may not completely phenocopy the undesirable consequences of DR 
(Verbeuren et al., 1990). 
Whilst, these results may suggest rilmenidine to elicit more orthogonal prolongevity effects in comparison 
to CR, the lifespan results were far more modest than commonly observed in CR animals. Thus, in an 
attempt to target other longevity pathways potentially missed by rilmenidine, it is possible additive effects 
by compound/treatment combinations may be beneficial. Interestingly, it is suggested in chapter 5 that 
rilmenidine may function as an inverse agonist to IRAS and hence may mimic effects induced by IRAS-
/- mutants. Dong et al. (2017) demonstrated that IRAS -/- mutants had increased phosphorylation of 
AMPK, which is similar to the increase in phosphorylation observed by imidazoline receptor agonist 
treatment in WT mice (Aubertin et al., 2019; Dong et al., 2017). Importantly, IRAS LOF enhanced 
sensitivity to AMPK activators including metformin which suggests rilmenidine may be able to synergise 
with metformin to provide even greater CR mimicry (Aubertin et al., 2019; Dong et al., 2017). Allantoin, 
the CR mimetic with established imidazoline receptor affinity and the stimulus for this thesis, was recently 
demonstrated to fail in synergising with metformin and did not induce additive lifespan effects (Admasu 
et al., 2018) . However, allantoin is a far weaker imidazoline receptor agonist and elicits no significant 
gene expression changes which may not truly represent the synergistic potential of metformin and more 
specific imidazoline receptor agonists (Admasu et al., 2018; Nikolic and Agbaba, 2012). Rilmenidine and 
metformin combination therapy is not clinically contraindicated and may provide synergistic 
antihypertensive and antihyperglycemic roles which could be invaluable in the treatment of metabolic 
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syndrome highly prevalent in ageing populations whilst also decelerating the ageing process.  Admansu 
et al. (2018) also demonstrated allantoin to lack synergy with rapamycin for lifespan extension, which is 
in agreement with research conducted in chapter 5 of this thesis, that showed rilmenidine to not synergise 
with rapamycin. However, despite the high likelihood of rilmenidine converging on TOR in competition 
with rapamycin, rilmenidine may do so in a more nuanced way making it a more preferential CRM to 
rapamycin. Chronic administration of rapamycin is associated with activation of mTORC2 which 
supposedly causes detrimental effects on metabolism, including hyperglycaemia, hyperlipidaemia, and 
insulin resistance in mice (Lamming et al., 2012; Robida-Stubbs et al., 2012). In C. elegans, TORC1 
inhibition is daf-16 dependent whereas TORC2 inhibition is daf-16 independent (Robida-Stubbs et al., 
2012). Given that rapamycin extends lifespan independently of daf-16 and rilmenidine extends life 
dependent on daf-16, although both signal through the TOR complex, it is likely that rilmenidine bypasses 
any TORC2 inhibition and thus is unlikely to elicit the aforementioned mTORC2 side-effects (Robida-
Stubbs et al., 2012). Conversely, clinical evidence seemed to demonstrate an improvement in glycaemic 
and lipemic control following rilmenidine treatment (Nowak et al., 2005) 
In sum, this research presents a strong novel case for rilmenidine to be considered a calorie restriction 
mimetic through its prolongevity and health preserving effects, increased stress resistance and increased 
autophagy. However, whilst the profound effect on ageing and associated pathologies by DR are still 
being elucidated, it is extremely difficult to target molecular study beyond pathways known to be affected 
by CR. The problem is further compounded by a great heterogeneity in CR definitions which hinders the 
development of consensus protocols. This is no better exemplified in C. elegans research, whereby 
different dietary restriction regimes elicit varying effects on lifespan, age-associated biomarkers, and even 
signal via different mechanisms (see for review Zhang and Mair, 2017). Future work should assess the 
prolongevity effect of rilmenidine in epistatic lifespan assays under different DR regimes.   
7.2. Prolongevity Signalling by Rilmenidine is Mediated Through F13E9.1 
The aim of the thesis was to identify a drug which decelerated ageing through the mimicry of calorie 
restriction without necessarily recapitulating the entirety of CR induced effects. To entertain that 
possibility, it was essential to begin unravelling the signalling mechanisms of rilmenidine which co-
ordinated the favourable phenotype of increased lifespan, improved “healthspan” and stress resistance. 
Indeed, this thesis provided a number of pieces in the jigsaw. Firstly, rilmenidine is bioactive in C. elegans 
and increases ERK activity via an imidazoline binding site encoded on a novel and uncharacterised IRAS 
homolog f13e9.1. Thereafter it was confirmed that the phenotypes of improved healthy longevity, 
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including thermotolerance and attenuated frailty were modulated via f13e9.1. Further work confirmed that 
rilmenidine increased lifespan via AMPK, CeTOR and DAF-16 signalling. Downstream, rilmenidine 
increased autophagy, which was essential for lifespan extension, and was induced independently of 
cAMP signalling. In association with a number of congruent findings published elsewhere in the field, the 
potential geroprotective signalling mechanisms of rilmenidine can be rationally proposed herewith. 
If rilmenidine elicits improved markers of longevity dependent on F13E9.1, a protein with significant 
homology to that of rilmenidine’s characterised mammalian receptor IRAS, it is highly likely that 
rilmenidine signals via f13e9.1 to elicit geroprotective effects. This is bolstered by the characterisation of 
f13e9.1 as a modulator of rilmenidine induced ERK activity, a canonical signal elicited in cell lines upon 
IRAS binding with rilmenidine (Li et al., 2006). That alone may be sufficient to extend lifespan in C. 
elegans. Work from Okuyama et al. (2010) identified MPK-1 as a key longevity factor and knockdown of 
mpk-1 significantly shortened WT lifespan. More recently, researchers established that the prolongevity 
effect of resveratrol was modulated via MPK-1 activity (Yoon et al., 2019). Furthermore, resveratrol 
increased constitutive MPK-1 phosphorylation and was able to defer declining  MPK‐1 activity during 
ageing (Yoon et al., 2019). Given that rilmenidine increased MPK-1 activity in young adult nematodes, it 
suggests increased activity may mediate the prolongevity effect of the drug. However, the lifespan effects 
of resveratrol are mediated through MPK-1 and SKN-1, a pathway not examined in this thesis. 
Nonetheless, regulation of lifespan by MPK-1 is dependent on daf-16, a gene which controls rilmenidine-
induced lifespan extension (Okuyama et al., 2010). Thus, it could be suggested that rilmenidine increases 
lifespan through activating MPK-1 which leads to increased DAF-16 activity: however, there is not the 
experimental evidence to confirm or refute this. Nonetheless, this pathway could legitimately programme 
the upregulation of autophagy. Infection with P.aeruginosa PA14 triggers the phosphorylation of MPK-1 
which is essential for the consequent autophagic induction, and that this response is dependent on daf-
16 (Zou et al., 2014). 
Therefore, rilmenidine may be geroprotective through the upregulation and preservation of longevity-
associated MPK-1 signalling in ageing that activates daf-16 to increase autophagy and stress resistance.  
However, such linear upregulation of DAF-16 activity would normally confer a more wholesale stress-
resistance that would include improved protection against hydrogen peroxide (Lin et al., 2018b; Weinkove 
et al., 2006). Specific thermotolerance is primarily regulated by HSF-1 in metazoans, working in concert 
with Daf-16 - even in permissive temperature HSF-1 appears to regulate DAF-16 activity to extend 
lifespan (Douglas et al., 2015). f13e9.1 expression appears highly regulated by HSF-1 and rilmenidine 
increases autophagy, thermotolerance and delays the formation of polyQ aggregations, processes 
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controlled by HSF-1. Therefore there could be an alternative signalling route, whereby MPK-1 activation 
is an unrelated signalling process to rilmenidine induced-longevity (Hesp et al., 2015). 
Rilmenidine induced prolongevity was also partially dependent on aak-2, implying rilmenidine may 
increase longevity through increasing AMPK signalling. Indeed, as this thesis was being completed, 
experimental murine work demonstrated a rilmenidine-like, highly specific, imidazoline receptor agonist, 
to increase AMPK phosphorylation and improve metabolic markers of increased AMPK activity (Aubertin 
et al., 2019). These effects were strikingly similar to models of I1R IRAS -/- murine models. Specifically, 
IRAS knockouts displayed a phenocopy of imidazoline receptor agonism including improved glucose 
tolerance, HOMA-index, and lipid metabolism (Dong et al., 2017). Thus, this heightens the likelihood that 
rilmenidine may function as an inverse agonist to f13e9.1/IRAS to repress IRAS binding and inhibition of 
AMPK. Consequent increased AMPK activity leads to inhibition of mTOR which is reflected by ceTOR 
dependent rilmenidine-induced lifespan extension. Both Reduced ceTOR activity alongside AMPK 
activation would independently lead to DAF-16 activation, upregulation of autophagy and improved stress 
resistance and longevity (Tullet et al., 2014). However, rilmenidine has been demonstrated to increase 
autophagy independent of mTOR, therefore, it may be possible that AMPK alone can increase autophagy 
in response to rilmenidine through mTOR-independent mechanisms such as ULK1 (Perera et al., 2018; 
Roach, 2011; Rose et al., 2010). The necessity of ceTOR for rilmenidine induced longevity is then 
reconciled with the requirement of  alternative pathways that depends of autophagy. For example, 
rilmenidine may not only clear cellular waste, but may also help in the generation of new raw material for 
protein synthesis that requires functioning ceTOR. Such alternative autophagic induction pathways are 
necessary in the new light that, at least in C. elegans, rilmenidine does not increase autophagy or lifespan 
via an TOR independent cAMP pathway including activation of the Ca++/calmodulin-dependent kinase 
CaMKKβ and AMPK phosphorylation, but rather through an, as yet, undiscovered pathway (Aubertin et 
al., 2019). 
However, this model Is challenged by the characteristics unravelled in the f13e9.1 mutant model. If 
rilmenidine inversely agonised f13e9.1 to induce its inhibition and ensuant AMPK activation, a knockout 
of f13e9.1 should theoretically manifest in a mimicry of prolongevity models such as aak-2 overexpression 
or metformin treatment (Greer et al., 2007). Although lifespan extension was observed, and stunted 
growth was similar to IRAS -/- mice, mutant worms were rendered more sensitive to oxidative stress and 
reached frailty quicker; both phenotypes were further exacerbated by rilmenidine. Indeed, this may 
represent a hyperactivation of longevity pathways that become detrimental as seen in metformin treated 
eat-2 worms (Onken and Driscoll, 2010). Additionally, such a Tithonian phenotype is not uncommon of 
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DR worms as models often display poor stress resistance and accelerated markers of ageing (Bansal et 
al., 2015; Hansen et al., 2008; Lüersen et al., 2014). 
Increased autophagy may also explain or at least correlate with transcriptional signature of ECM 
preservation by rilmenidine. Of course, diverse genetic, nutritional, and pharmacological pro-longevity 
interventions delay an age-related decline in collagen expression (Ewald et al., 2015). Furthermore, 
autophagy inhibition accelerates age-dependent loss of total collagen in worms, and thus its upregulation 
may serve to preserve ECM into ageing (Chen et al., 2019). But, the modulation of this effect is currently 
obscure. Heat shock also upregulates genes associated with the extracellular matrix and HSF also 
appears to regulate genes associated with collagen biogenesis (Brunquell et al., 2016). This implicates 
a possible mechanism by which rilmenidine may preserve extracellular matrix in the face of heat-shock 
to mimic an HSR, providing a convergent mechanism shared by both HIF-1 and also rilmenidine. 
In summary, it is hypothesised that rilmenidine is geroprotective through the inverse agonism of f13e9.1 
such that it leads to MPK-1 and AMPK activation, both of which converge on autophagy, likely through 
DAF-16. Such signalling can recapitulate many of the beneficial hallmarks of CR and may provide a more 







Figure 25. Schematic illustration of potential signalling cascades elicited following rilmenidine binding to 
f13e9.1. Rilmenidine may function as an inverse agonist of f13e9.1 such that the inhibition of AMPK is abrogated 
and MPK-1 is activated. This leads to downstream activation of DAF-16 and subsequent autophagy induction, 




7.3. Future Work:  
C. elegans ageing research serves as a reasonable and low-cost platform to screen potential 
interventions to expedite their translation into clinical use. Following the establishment of rilmenidine as 
a legitimate calorie restriction mimetic with geroprotective properties, it is prudent to assess the 
translatability of this drug. Rilmenidine, and its analog moxonidine, are in the fortunate position of already 
being clinically approved drugs, widely prescribed for the treatment of resistant hypertension. In the UK, 
between Jul '18—Jun '19, 393,356 prescriptions were dispensed for imidazoline receptor agonists to treat 
hypertension or heart failure, at a cost of £657,940 (Curtis and Goldacre, 2018). 
7.3.1. The Translational Potential of Rilmenidine as an Anti-Ageing Intervention  
NICE recommends treatment of hypertension should involve the prescription of an Angiotensin 
Converting Enzyme (ACE) inhibitors (<55 years) and calcium channel blockers (CCB) (>55 
years)(McCormack et al., 2013). However, In referral for specialist treatment for resistant hypertension, 
NICE suggests the initiation of centrally acting hypertensive drugs such as rilmenidine or moxonidine: 
their efficacy is well established and they appear as equally effective in treating mild-moderate 
hypertension as diuretics, CCBs and ACEs (Materson et al., 1995; Reid, 2000). 
Additionally, moxonidine and rilmenidine are well tolerated through their selective binding to I1RAs as 
has been shown in ample clinical studies (reviewed in Reid, 2000). Specifically, double blind studies 
found no discernible adversity between rilmenidine vs placebo and moxonidine vs placebo (Ostermann 
et al., 1988; Scemama et al., 1995). Furthermore, moxonidine appeared to produce less adverse effects 
than other commonly prescribed antihypertensives drugs (Prichard, 1994; Schachter et al., 1998). These 
drugs must be tolerated for long periods of time. Indeed, in a study of over 18,00 patients prescribed 
rilmenidine, only 3.6% of participants withdrew following adverse effects (Luccioni, 1995). In studies of 
moxonidine, no significant adverse side effects were noted (Gaponova et al., 2011).   
Moreover, rilmenidine and moxonidine may also have auxiliary clinical benefits beyond their 
antihypertensive properties. Imidazoline receptor agonists suppresses the sympathetic activation in 
ischemic heart disease and chronic heart failurehas proven effective in reducing SNA in chronic heart 
failure patients (Graham et al., 2004; Swedberg et al., 2002). Furthermore, although evidence in normo- 
and prehypertensives is absent, rilmenidine is able to reduce LVH, improve arterial distensibility, and 
prevent arrhythmia in hypertensives (Koldas et al., 2003; Roegel et al., 1998; Trimarco et al., 1995) 
The sympatholytic mechanisms of these drugs may also alleviate the detrimental effects of sympathetic 
hyperactivity in ageing. At base resting levels of sympathetic activity change, a generalised sympathetic 
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tone increase can be observed during ageing measured by plasma noradrenaline and burst discharge 
rate on the muscle sympathetic nerve fibres (Iwase et al., 1991; Wallin et al., 1981). Importantly, 
sympathetic hyperactivity is not just an artefact of ageing, rather an active determinant of mortality and 
ympathetic hyperactivity is associated with poor prognosis in community dwelling elderly individuals 
(Reuben et al., 2000). Furthermore, whilst most neuromodulator receptors decline in ageing, it is 
particularly important that imidazoline receptor numbers increase with age (García-Sevilla et al., 1995). 
This puts a special emphasis on the increasing role that inverse agonism of imidazoline receptors may 
have in defining age-related changes in the brain and the body. Rilmenidine produces no increase in 
adverse effects in the elderly (Galley et al., 1988). One clinical trial looked to test the effect of rilmenidine 
on cognitive function in elderly hypertensive patients. Nedogoda et al., (2006), treated 30 patients with 
24 weeks of rilmenidine monotherapy. Blood pressure was reduced by 25.3% alongside significant 
improvements in Wechsler Adult Intelligence Scale scores by 15%. At the same time significant increase 
in vocal activity of patients is noted: number of words at free associations tests, verbs and plants 
denomination increased by 5.8%, 5.1% and 6.3% respectively (p<0.05). Moxonidine administration on 
10 elderly hypertensive patients for 2 weeks significantly reduced BP and significantly improved memory 
and thinking (Ostroumova et al., 2001). 
Hypertension is a substantial and growing epidemic that burdens healthcare systems, society and the 
economy. High blood pressure affects more than 1 in 4 adults in England, around 12.5 million people in 
2015 (Public Health England, 2017). This is compounded by the ever-increasing proportion of elderly 
people who have an almost intractable predeterminancy to the development of hypertension defined by 
vascular calcification, sympathetic hyperactivity and left ventricular hypertrophy. 63.7% of an English 
cohort had hypertension between the ages of 60-80, and estimates have suggested by the age of 75, 
73% of English adults will suffer from hypertension (Joffres et al., 2013; MacDonald and Morant, 2008). 
Thus, the sheer prevalence of such a condition provides a significant platform for the preferential 
consideration of imidazoline receptor agonists such as rilmenidine, for hypertensive populations which 
would provide a safe, tolerable and cheaper2 method to improve cardiovascular risk whilst also presenting 
a method of CR mimicry to over 25% of the population. Furthermore, it warrants substantial clinical 
investigation as to the auxiliary benefits which may underly their overt purpose as anti-hypertensives.  
 
2 Cost based on (Total Cost/Total Prescriptions) in 2019 NHS OpenPrescribing data between calcium 
channel blockers (estimated £2.58) and moxonidine (estimated £1.67) 
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7.3.2. Translatability of Rilmenidine in Healthy Normotensive Populations 
One of the greatest issues with the analysis of antihypertensive drugs, is that the vast majority of all large-
scale clinical trials, have studied the drug in hypertensive or morbid individuals. Very few studies have 
tested the effects of antihypertensive drugs in a normotensive and healthy populations. If antihypertensive 
drugs were to be considered for mass-market, far larger and inclusive studies would be needed to be 
conducted across all demographics. However, the availability, established supplier manufacture and 
clinical tolerability of rilmenidine makes the task of mass distribution more appealing than other purported 
geroprotectors. Rilmenidine has a good clinical profile and chronic administration is rarely a problem in 
hypertensives. But very few studies have assessed the effects of rilmenidine on adult populations to 
address concerns that sympatholytic anti-hypertensive treatment in normotensives may drive a 
hypotensive crisis. Upon its clinical introduction, rilmenidine was tested in a small normotensive healthy 
cohort and it did not induce orthostatic hypotension, a significant decrease in heart rate or a significant 
dryness of mouth (Dollery et al., 1988). However, given the substitutive use of moxonidine in US and UK, 
far more data is available pertaining to healthy subjects, which will likely mirror that seen in rilmenidine. 
Moxonidine given to otherwise healthy overweight young adults decreased clinic systolic BP, but did not 
significantly affect ambulatory BP, as assessed over the 24‐hour period, nor did it improve the average 
BP over the night or the day (Lambert et al., 2017). Furthermore, moxonidine treated groups reported no 
adverse side effects or abnormal metabolic effects (Lambert et al., 2017). Similarly, otherwise healthy 
and normotensive poly-cystic ovary syndrome patients were treated with moxonidine and experienced 
no significant changes to BP, heart rate or metabolism (Shorakae et al., 2018).  
In normotensive older populations, the evidence of long-term IRA treatment is severely lacking. 
Nonetheless, following the promising results of rilmenidine in a mouse model of Huntington’s, an open 
label clinical trial was initiated to assess the feasibility and tolerability of rilmenidine for the treatment of 
Huntington’s disease (Underwood et al., 2017). 16 patients received 1 mg rilmenidine daily for 6 months 
and then 2mg daily for the next 18 months of the study. The study reported no drug-related serious 
adverse events or withdrawals, and, there was no significant effect on Huntington’s clinical or 
metabolomic outcomes (Underwood et al., 2017). However, promisingly, mean age was 53 (range 37–
69) and may suggest a potential suitability for later life rilmenidine geroprotective treatment initiation.  
These results must be weighed against some concerning findings in murine models. Perera et al., (2018) 
noted that in a murine model of ALS, generated through transgenic expression of a G93A mutant form of 
human SOD1, rilmenidine significantly exacerbated neurodegeneration. Furthermore, when under 
proteostatic challenge by either chloroquine or aggregative protein models, lysosomal efficiency following 
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autophagy induction by rilmenidine, appears dysfunctional (Button et al., 2017; Civiletto et al., 2018). The 
results in this thesis suggest that rilmenidine might continue to improve lifespan even when administered 
following age-associated autophagic dysfunction, however murine models suggest rilmenidine continues 
to increase autophagy despite post-inductive malfunction. Thus, in normal populations, as age-
associated protein aggregates naturally accumulate, rilmenidine treatment may lead to exacerbation, yet 
to be unmasked in clinical trials, limiting its translative potential (Serrano-Pozo et al., 2011). However, it 
must be noted that these pathological models serve to overwhelm the autophagic machinery far quicker 
and more aggressively than would be experienced in ageing. Furthermore, SOD1 aggregation is not 
typical of normal human ageing (Paré et al., 2018). Accumulation of tau and amyloid dominate the 
aggregative landscape of normal brain ageing, and mammalian intervention studies with rilmenidine are 
necessary to clarify the effect on these aggregates (Reas, 2017).  
In conclusion, rilmenidine is a safe, efficacious and tolerable anti-hypertensive which may have beneficial 
effects on fasting plasma glucose, insulin sensitivity, atherosclerosis and cardiac remodelling. However, 
these studies have been almost exclusively performed in hypertensive populations. Whilst this provides 
a large potential cohort to trial the CR mimicking effects of rilmenidine, the safety profile of rilmenidine is 
not sufficiently substantiated in healthy populations. In addition to concerns regarding the exacerbation 
of neurodegeneration alongside potential autophagic aberrancies, further murine work is required before 
considering clinical trials in healthy older patients.  
7.4. Future Directions 
Although specific follow-up work has been recommended throughout this thesis in relevant chapters, it is 
important to identify the themes of future study to direct the progress of this project. There are three 
themes that require continued exploration and tackle three pertinent models: 1) the mechanistic 
unravelling of rilmenidine-induced prolongevity signalling in C. elegans 2) ascertaining whether 
rilmenidine ameliorates biomarkers of ageing in mice and improves survival 3) computationally led clinical 
assessment of retrospective survival outcomes and biomarkers of longevity in hypertensive patients 
treated with rilmenidine. 
7.4.1. Mechanistic Unravelling of Rilmenidine-induced Prolongevity Signalling in C. 
elegans 
The extension of C. elegans led mechanistic studies is beneficial and can continue to profit from the 
genetic tractability and short life-cycle of the model organism. Several questions were left unanswered 
and centred around the signalling pathway induced by rilmenidine that drives autophagic upregulation 
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and how this might affect lifespan and its control by f13e9.1. Thus, the continuation of study in vkEx1093 
[nhx-2p::mCherry::lgg-1] is advisable if paired with genetic crossing of key signalling pathways. Firstly, 
vkEX1093 worms should be crossed with f13e9.1 mutants or knocked down with f13e9.1 RNAi. 
Replication of autophagic induction methods as in (see chapter 2.8.1) of this thesis is necessary to 
decipher the dependency of f13e9.1 to mediate rilmenidine induced autophagy. Furthermore, lifespan 
analysis in f13e9.1 mutants, and respective rescues, in response to rilmenidine treatment is critical to 
target f13e9.1 as the key mediator of rilmenidine-induced lifespan extension and autophagic induction. 
Additionally, ERK pathway RNAi as in Okuyama et al., (2010) would help to elucidate the relative 
necessity of this pathway for the induction of autophagy by rilmenidine in the vkEX1093 worms, and for 
lifespan extension and thermotolerance in WT worms. Lastly, in C. elegans, although this thesis exposed 
the dependency of aak-2 and daf-16  for rilmenidine-induced lifespan extension, this does not insinuate 
their activation. Immunoblotting for increased AMPK phosphorylation following rilmenidine treatment in 
both WT  and f13e9.1 strains would help replicate work observed in mammalian models which may 
provide a more nuanced hypothesis for rilmenidine-induced longevity. Moreover, the observation of DAF-
16 nuclear localisation following rilmenidine treatment in WT , f13e9.1 and aak-2 mutants would be 
invaluable for providing an elegant mechanistic longevity pathway whereby rilmenidine signals through 
f13e9.1, the putative IRAS homolog, leading to AMPK activation, and DAF-16 mediated longevity.  
Whilst evidence in this thesis strongly implicates f13e9.1 as the nematodal ortholog of IRAS, confirmative 
work is necessary. If possible, IRAS knockout lines should be generated in PC12 cells, although IRAS -
/- lines can be readily purchased in HAP1 lineage. PC12 is preferred owing to an inherent lack of α-2 
adrenergic receptor expression which would negate an off-site interactivity with rilmenidine despite its 
low affinity for the receptor (Edwards et al., 2012). The functional homology of f13e9.1 could then be 
explored following its transfection into IRAS knockout PC12 cell lines and assessing the subsequent 
restoration of rilmenidine-mediated ERK activation or DAG accumulation (Li et al., 2006).  
Rilmenidine may recapitulate many of the effects of CR, but epistatic interaction was only observed in 
eat-2 mutants. CR in worms varies depending on the method of induction and therefore, rilmenidine 
should be tested in the presence of other regimes to establish whether its mimicry is specific to only 
certain regimes.  Furthermore, it was unconfirmed whether rilmenidine induced a CR state through the 
downstream regulation of CR-associated pathway or whether it merely reduced food consumption in C. 
elegans. Whilst rilmenidine does not affect food intake in mammals, it would be beneficial to confirm this 
in C. elegans using a food clearance assay.    
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7.4.2. Ascertaining the Effects of Rilmenidine Treatment on Ageing in Mouse Models 
The examination of the physiological effects induced by calorie restriction is limited in C. elegans. Thus, 
the exploration of rilmenidine-induced phenotypes is better suited in mammalian models. Specifically, in 
endeavouring to fulfil Ingram’s CRM criteria, rilmenidine should ideally mimic the metabolic, hormonal, 
and physiological effects of CR. Using UM-HET3 mice, to replicate the ITP protocols, intraperitoneal 
rilmenidine treatment (10 mg/kg body weight) four times a week, as in Rose et al. (2010) should be 
assessed to confirm the effect on CR markers including fasting adiponectin, growth hormone, SHBG, 
insulin levels and plasma levels of glucose after oral glucose load. Furthermore, given the intriguing anti-
inflammatory gene expression profile of rilmenidine which rescued the ageing signature, it would be 
beneficial to establish whether rilmenidine can reduce markers of inflammation in mice through the 
measurement of cytokine profiles as well as pNF-κB and pJNK. Researchers must be aware of any 
potential sexual dimorphism in response to rilmenidine treatment which may mimic that seen in IRAS 
mutant mice and also CR (Dong et al., 2019; Ingram and de Cabo, 2017).  
Ideally, large longitudinal lifespan assays with rilmenidine should be developed whereby sub-populations 
of mice are cross-sectionally scarified for histopathological, and gene expression data. However, even 
murine lifelong intervention testing programmes would take over 2 years to complete. Thus, it might be 
expedient to utilise a “pre-aged” C57BL/6J cohort sold by the Jackson Laboratory to initiate a more 
translational rilmenidine administration regime started in later life; a strategy which was shown in this 
thesis to increase lifespan in C. elegans. Alternatively, the utilisation of a progeroid mouse model may 
also accelerate the accrual of insightful data. Specifically, the Hutchison Gilford progeria mouse models 
may be an avenue to explore. ZMPSTE24-null mice, mimic clinical phenotypes of HGPS including 
metabolic abnormalities, bone and joint abnormalities, subcutaneous fat loss, growth defects and severe 
atherosclerosis and cardiomyopathy (Gonzalo et al., 2017; Piekarowicz et al., 2019). Some of the 
aforementioned phenotypes are likely driven by high expression of ECM proteins and low expression of 
ECM remodelling enzymes, which can result in aberrant ECM deposition (Gonzalo et al., 2017). It could 
be hypothesised that this segmental ageing disease model may exhibit improved survival following 
treatment by rilmenidine, especially considering the transcriptional signature of ECM preservation elicited 
by rilmenidine.  
7.4.3. Computationally Led Clinical Assessment of Retrospective Survival Outcomes and 
Biomarkers of Longevity in Hypertensive Patients Treated with Rilmenidine 
During this thesis I had begun to explore the clinical effect of rilmenidine on ageing. However, with no 
access to my own cohort, I sought to repurpose current clinical databases. I gained access to the 
epigenetic data of a large cohort of patients from TwinsUK, many of whom had hypertension (Moayyeri 
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et al., 2013). I hypothesised that hypertensive patients, taking centrally-acting anti-hypertensives may 
exhibit a lesser age acceleration residue as measured by Hovarth’s clock that would indicate an anti-
ageing effect by rilmenidine or moxonidine (Horvath, 2013). However, within the cohort, only 3 patients 
were taking centrally-acting antihypertensives, thus precluding any further study. Therefore, in 
continuation of this project, I would suggest collating data from other cohorts to increase numbers of 
patients taking rilmenidine or moxonidine; whole-genome methylation 450k datasets from LifeLines-deep 
167,000 individual cohort or the Lothian Birth Cohorts would be an advisable starting point (Horvath, 
2013; Tigchelaar et al., 2015)  .  
Likewise, a routinely documented metric such as mortality is valuable to assess the effect of rilmenidine 
on retrospective survival outcomes in longitudinal datasets. Using a repository such as the Clinical 
Practice Research Datalink (CPRD), hypertensives taking I1RAs could be compared to hypertensives 
taking other antihypertensive medications while controlling for the effects of the different therapies on 
blood pressure. Therefore, any difference in outcomes could be reasonably to be attributed to 
rilmenidine/moxonidine therapy beyond hypertensive control. 
Whilst highly generalisable and vulnerable to residual confounding factors which could obscure any true 
effects, both epigenetic clock analysis and retrospective cohort survival provide convenient, accessible 
and cheap means to quickly assess the clinical potential of rilmenidine that will help in the justification of 
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Supporting Table 1. Revigo recategorised GO terms derived from TOPGO gene enrichment of DEGS that 
intersect both combined imidazoline receptor agonist-induced underexpression and age-induced 
overexpression. Log10 -200 considered significant.  
Underexpressed in Combined I1R Agonists + Underexpressed in Ageing 
GO Term Description 
REVIGO Log10 P-
value 
GO:1903543 positive regulation of exosomal secretion -3.80 
GO:0033209 tumor necrosis factor-mediated signalling pathway -3.27 
GO:0098609 cell-cell adhesion -3.09 
GO:0042060 wound healing -3.07 
GO:0007160 cell-matrix adhesion -3.01 
GO:0043312 neutrophil degranulation -2.82 
GO:0002931 response to ischemia -2.77 
GO:0022617 extracellular matrix disassembly -2.77 
GO:0009611 response to wounding -2.71 
GO:0043062 extracellular structure organization -2.66 
GO:0048146 positive regulation of fibroblast proliferation -2.62 
GO:0070486 leukocyte aggregation -2.46 
GO:0097284 hepatocyte apoptotic process -2.44 
GO:1902117 positive regulation of organelle assembly -2.38 
GO:0060712 spongiotrophoblast layer development -2.35 
GO:0030214 hyaluronan catabolic process -2.28 
GO:0008360 regulation of cell shape -2.24 
GO:0072574 hepatocyte proliferation -2.24 
GO:0016050 vesicle organization -2.22 





Supporting Table 2. Statistical overlap of perturbagen DEGs and Ageing DEGs. P values from Fischer’s 








Perturbagen DEGs Ageing DEGs p value 
adjusted p value 
(Bonferroni) 
Rilmenidine Over Age Under 0.492 1.000 
Rilmenidine Under Age Over 0.000 0.000 
Combined Over Age Under 1.000 1.000 




Supporting Figure 1. Pairwise comparison of genes differentially expressed in cell treated with 






Supporting Figure 2. Charge distribution analysis of F13E9.1 protein. The protein sequence of F13E9.1 was 
inputted into the Statistical Analysis of Protein Sequences, SAPS, to compute the charge distribution of amino 






Supporting Figure 3. Verification of 2 transgenic worm rescue lines of PHX945 and PHX946 (syb767) IV; 
sybIs62[f13e9.1::EGFP::3xFLAG, unc-119(+) + myo-2p::mCherry. A)  Representative western blot of the 
FLAG-tagged F13E9.1 protein in C. elegans lysates derived as in material and methods section. Lanes from left 
to right are marker, recombinant FLAG vector from E.coli, lysate from WT worms, f13e9.1 mutant worms, and 
two rescue strains carrying the WRM0616C_F02 (f13e9.1) clone which should theoretically express a c-fused 
::EGFP::3xFLAG sequence.3 Immunofluorescent bands can be seen at ~90kD for rescue one and may 
represent isoforms. F13E9.1 is a 57kD protein + the tag part including the EGFP, FLAG and the linker peptides 
accounts for a molecular mass of 35 kD = 92kD B) End point PCR representing amplification of 1.16kbp 





Supporting Figure 4. Expression of f139.1::GFP in transgenic strains under homeostatic conditions. WT  
WT strains, PHX116 and ExPHX116 worms were paralysed in 10mM tetramisole solution and imaged under a 
Zeiss 710 confocal microscope at 20 °C with a Fluar 20x/0.75 lens. Images were acquired as in 
Teuscher and Ewald, (2018) which recommends a super-thin bandpass green filter (520 +/- 20nm) to 
overcome inherent autofluorescence within worms. No significant difference was observed between 





Supporting Table 3. Survival of WT worms exposed to 2mM H2O2 plates seeded with dead OP50 E.coli, 
following 24h treatment with either 200µM rilmenidine or a 1% DMSO vehicle. Kaplan-Meier log rank 
analysis was used to compare survival; Bonferroni adjusted p-value <0.05 considered significant. 
 
  
Genotype/Ril Con. No. Trials n= Mean Survival Hours Std Err p vs. Control
N2 0µM 2 118 7.68 0.16 N/A
N2 200µM 2 70 7.94 0.27 0.10
N2 300µM 2 89 7.10 0.27 1.00
N2 400µM 2 99 7.72 0.21 0.50
 N2 NAC 5mM 2 128 8.39 0.19 0.00
N2 0µM 1 32 6.56 0.45 N/A
N2 200µM 1 51 8.20 0.29 0.01
N2 300µM 1 23 9.65 0.20 0.00
N2 400µM 1 43 8.09 0.36 0.01
 N2 NAC 5mM 1 62 9.19 0.24 0.00
N2 1% DMSO 3    174      5.43      0.19   N/A
   N2 Ril 200µM 3    181      5.50      0.18   1.00
 f13e9.1 3    246      4.14      0.13   0.00
f13e9.1  Ril 200µM 3    249      3.30      0.12   0.00
24h Treatment With Different Conentrations of Rilmenidine (Rilmenidine Includ. During 10h H2O2 Exposure)
24h Treatment With Different Conentrations of Rilmenidine (Rilmenidine Omitted During 10h H2O2 Exposure)




Supporting Figure 5. Graph shows the interquartile distribution of mCherry::LGG-1 puncta in the 
posterior intestine of the animals in grown on NGM agar supplemented with 20mM chloroquine in the 
presence or absence of 200µM rilmenidine. Error bars, upper:Q3 + 1.5*IQR; minimum: Q1 -1.5*IQR.  
mCherry::LGG-1 puncta were counted in each of three rectangular boxes of 1mm2; they were placed in tandem 
beginning with the most posterior region of the intestinal and extended toward the vulva; mean number per mm2 
was calculated for each animal.   N>24 animals analysed per treatment in at least 3 independent trials. 
 
